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4OHT: 4-hydroxy tamoxifen  
53BP1: tumor protein p53 binding protein 1 
9-1-1: Rad9-Hus1-Rad1 complex 
aa: amino acid 
Abraxas/CCDC98: BRCA1-A complex subunit 
Abraxas 
AID: activation-induced cytidine deaminase 
Alt-NHEJ: alternative NHEJ 
AP: apurinic-apirimidic 
APE1: apurinic-apirimidic endonuclease 
APH: aphidicolin 
APLF: aprataxin-PNK-like factor 
APOBEC: apolipoprotein B mRNA editing enzyme, 
catalytic polypeptide 
AR: androgen receptor 
ASF/SF2: serine/arginine-rich splicing factor 1 
AT: ataxia telangiectasia  
ATLD: AT-like disorder 
ATM: ataxia telangiectasia mutated 
ATMi: ATM inhibitor 
ATMIN: ATM interacting protein 
ATP: adenosine triphosphate 
ATR: ataxia telangiectasia and Rad3-related protein 
ATRIP: ATR-interacting protein 
BARD1: BRCA1-associated ring domain protein 1 
BCL10: B-cell CLL/lymphoma 10 
BER: base excision repair 
BLM: bloom syndrome, RecQ-helicase-like 
BMI1 : murine leukemia viral (Bmi-1) oncogene 
homolog 
bp: base pair 
BRCA1: breast cancer 1 
BRCA2: breast cancer 2 
BRCC36: BRCA1/BRCA2-containing complex 
subunit 36 
BRCC45: BRCA1/BRCA2-containing complex 
subunit 45  
BRCT: breast cancer C-terminal domain 
Bru: bromouride  
BrUTP: 5-bromouridine triphosphate 
CAND1: cullin-associated NEDD8-dissociated 1 
CCT6A: chaperonin containing TCP1, subunit 6A 
Cdk: cyclin-dependent kinases 
CENPA:	  centromere protein A 
CENPF: centromere protein F 
CFTR: cystic fibrosis transmembrane conductance 
regulator 
CHD3: chromodomain helicase DNA binding 
protein 3 
CHFR: checkpoint with forkhead and ring finger 
domains 
ChIP: chromatin immunoprecipitation 
ChIP/DNA: chromatin/DNA immunoprecipitation  
ChIP-Seq: ChIP-sequencing 
Chk1: checkpoint kinase 1 
Chk2: checkpoint kinase 2 
CK2: caseine kinase 2 
CPD: cyclobutane pyrimidine dimers  
CPT: camptothecin  
CS: cockayne syndrome 
CSB: cockayne syndrome group B protein 
CSN: COP9 signalosome	  
CSR: class switch recombination  
CTD: carboxy-terminal domain  
CtIP: carboxy-terminal binding protein-interacting 
protein 
Cul: cullin  
DDR: DNA damage response 
DDRNA: DNA damage response RNAs 
DHFR: dihydrofolate reductase 
DNA-PK: DNA-dependent protein kinase  
DNA-PKcs: DNA-dependent protein kinase 
catalytic subunit 
DNA-PKi: DNA-PK inhibitor 
DRB: 5,6-Dichloro-1-β-D-
ribofuranosylbenzimidazole 
DSB: double-strands break 
dsDNA: double-strand DNA 
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DSEs: double-strands ends 
DSS1: deleted in split hand/split foot protein 1 
DUB: deubiquitylating enzyme  
E1: ubiquitin-activating enzyme 
E2: ubiquitin-conjugating enzyme 
E3: ubiquitin ligase 
ENL: myeloid/lymphoid translocated 
ERCC1: excision repair cross-complementing group 
1 
eRNAs: enhancer RNA 
Et743: ecteinascidin 743 
FA: Fanconi anemia  
FACT: facilitates chromatin transcription 
FDA: US food and drug administration  
FEN1: flap structure-specific endonuclease 1 
FHA: forkhead-associated domain 
FK2: ubiquitinylated proteins 
FLV: flavopiridol  
FRDA: Friedreich ataxia  
FXN: frataxin  
GFP: green fluorescent protein 
GO: gene ontology  
HDAC: histone deacetylase 
HECT: homology to E6AP C-terminus 
HERC2: HECT and RLD domain containing E3 
ubiquitin protein ligase 2 
HIF-1α: hypoxia-inducible factor 1-alpha	  
HIRA: histone regulator A	  
HMGN1: high mobility group nucleosome binding 
domain 1 
hMOF: human ortholog of drosophila males absent 
on the first 
HP1: heterochromatin-binding protein 1 
HR: homologous recombination 
ICC-FISH: immunocytochemistry staining followed 
by fluorescence in situ hybridization 
IgH: immunoglobulin heavy chain 
IKZF1: IKAROS family zinc finger 1 
IR: ionizing radiation 
IRIF: ionizing radiation induced foci 
ISG15: interferon-stimulated gene 15 
JMJD: jumonji domain containing protein 
KAP1: KRAB-associated protein-1 
KD: kinase dead 
L3MBTL1: lethal(3) malignant brain tumour-like 
protein 1 
LCR: locus control region  
LEDGF: lens epithelium-derived growth factor 
LET: linear energy transfer 
Lig3: DNA ligase 3 
Lig4: ligase 4 
MCSZ: microcephaly with early-onset, intractable 
seizures and developmental delay 
MDC1: mediator of DNA-damage checkpoint 1 
MDM2: mouse double minute 2 
MERIT40: mediator of RAP80 interactions and 
targeting subunit of 40 kDa	  
MIU: motifs interacting with ubiquitin domain 
MR: mental retardation  
Mre11: meiotic recombination protein 11 
MRN: Mre11-Rad50-Nbs1 complex 
mRNP: messanger ribonucleoprotein particles  
mTOR: mammalian target of rapamycin 
Mus81: Mus81 endonuclease homolog (yeast) 
NAE1: NEDD8 activating enzyme 
NBS: Nijmegen breakage syndrome  
NBSLD: NBS-like disorder 
ncRNA: non-coding RNA 
NCS: neocarzinostatin 
NEDD8: neural precursor cell expressed 
developmentally downregulated 8 
NER: nucleotide-excision repair  
NHEJ: non-homologous end-joining  
nt: nucleotide 
NuRD: nucleosome remodelling and deacetylase 
OTUB1: OTU deubiquitinase, ubiquitin aldehyde 
binding 1 
P-TEFb: positive transcriptional elongation factor b	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p53: tumor protein p53	  
PA200: proteasome activator 200 
PA28: proteasome activator 28 
PARG: PAR-glycohydrolase 
PARP: poly [ADP-ribose] polymerase 
PARPi: PARP inhibitor	  
PAXX: paralog of XRCC4 and XLF	  
PCNA: proliferating cell nuclear antigen 
PI3K: phosphoinositide 3-kinase 
PIAS: protein inhibitor of activate STAT protein  
PIKK: phosphatidylinositol-3-kinase-like kinase 
family  
PLD: phospholipase D  
PNKP: polynucleotide kinase phosphatase 
POH1: 26S proteasome-associated PAD1 homolog 1 
POMP: proteasome maturation protein	  
PP: protein phosphatase 	  
PR-Set7: PR/SET domain-containing protein 07 
PRC: Polycomb repressive complex  
PROMPTs: promoter upstream transcripts 
PSF: protein-associated splicing factor 
PSMD4: proteasome 26S subunit, non-ATPase, 4 
PTIP: PAX transcription activation domain 
interacting protein 1 like 
PTM: post-translation modifications 
Rad: radiation sensitivity abnormal  
Rap80: receptor associated protein 80 
RBM8A: RNA binding motif protein 8 
RBR: ring between ring 
RBX: ring box 1  
rDNA: ribosomal DNA  
REV7: REV7 homolog 
RFC: replication factor C 
RIDDLE: radiosensitivity, immunodeficiency, 
dysmorphic features, and learning difficulties 
RIF1: rap1-interacting factor 1 homolog 
RING: really interesting new gene 
RNAP: RNA polymerase 
RNF: ring finger protein  
ROS: reactive oxygen species 
RC-DSB: replication-coupled DSB  
RPA: replication protein A 
Rpb1: RNA polymerase II subunit B1 
RS-SCID: radiosensitive T-B- severe combined 
immunodeficiency 
SAE1: SUMO1 activating enzyme subunit 1 
SCAN1: spinocerebellar ataxia with axonal 
neuropathy  
SCC1: SCC1 homolog 
SENP: SUMO-specific protease 
Seq: sequencing 
SET2: SET domain containing 2 
SIM: SUMO-interacting motif 
siRNA: small interfering RNA 
SIRT: sirtuin  
SLX: SLX structure-specific endonuclease subunit 
SMARCA2: SWI/SNF related, matrix associated, 
actin dependent regulator of chromatin, subfamily A, 
member 2 
SMG1: suppressor of mutagenesis in genitalia 1  
Sp1: specificity protein 1 
Spo11: sporulation protein 11 
SR: serine arginine rich protein 
SSA: single-strand annealing 
SSB: single strand break  
ssDNA: single strand DNA 
SUMO1/2/3: small ubiquitin-related modifier-1, -2 
or -3 
suv39h1: suppressor of variegation 3-9 homolog 1 
Suv4-20: suppressor of variegation 4-20 homolog 1 
TALEs: transcription activator-like effectors 
TBP: TATA box binding protein 
tBRCT: tandem BRCT domains 
TC-DSB: transcription-coupled DSB 
TCR: transcription-coupled repair 
Tdp1: tyrosyl-DNA phosphodiesterase 1 
TERT: telomerase reverse transcriptase 
TF: transcription factor 
	   	   	   5 	  
TIP: type 2A-interacting protein 
Tip60: tat interacting protein, 60kDa 
TOBP1: topoisomerase-binding protein 1  
Top1: topoisomerase I  
Top1cc: Top1 cleavage complexes  
Top2: topoisomerase II 
Topors: topoisomerase I-binding RS proteins 
TRF1/2: telomere repeat factor 1 / 2  
TRRAP: transformation/transcription domain-
associated protein 
TSS: transcription start site 
TTF2: transcription termination factor, RNA 
polymerase II 
tTudor: tandem Tudor domains 
Ub: ubiquitin 
UBA: ubiquitin-like modifier activating enzyme  
Ubc: uquiquitin-containing enzyme  
UBD: ubiquitin-binding domains  
UBE: ubiquitin-conjugating enzyme  
UBLs: ubiquitin-like proteins  
UDR: ubiquitylation-dependent recruitment motif 
UIM: motifs interacting with ubiquitin domain-
related ubiquitin-binding domain 
UNG: uracil-DNA glycosylase 
UPS: ubiquitin-proteasome system 
USP: ubiquitin-specific protease  
UV: ultraviolet 
VCP/p97: valosin containing protein 
WIP1: wild-type P53-induced phosphatase 1 
WRN: Werner syndrome, RecQ helicase-like  
WSTF: Williams syndrome transcription factor 
XLF: XRCC4-like factor 
XPA/B/C/D/F/G: xeroderma pigmentosum group-
A/B/C/D/F/G complementing protein 
XRCC: X-ray repair cross-complementing protein  
ZFNs: site-specific zink-finger 
Zn1/2: zinc finger domain 1 / 2  
γH2AX: H2AX phosphorylated 
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I.1 DNA Topoisomerases  
 
DNA topoisomerases are ubiquitous and highly conserved enzymes that relax DNA (Champoux, 
2001; Schoeffler and Berger, 2008; Wang, 2002).  
DNA topoisomerases are molecular machines that regulate the topological state of the DNA in the 
cell. The interest in DNA topoisomerases in recent years derives not only from the recognition of 
their crucial role in managing DNA topology, but also from the wide variety of topoisomerase-
targeting drugs that have been identified. These topoisomerase poisons include both antimicrobials 
and anticancer chemotherapeutics, some of which are approved by US Food and Drug 
Administration (FDA) to treat human cancers or infectious diseases. 	  
Human somatic cells encode six topoisomerases (Table 1). A seventh topoisomerase is Spo11 but 
its expression is restricted to germ cells (Bergerat et al., 1997). Bacteria tend to have a simpler 
organization, with only four topoisomerases in Escherichia coli (Pommier et al., 2010). 
All topoisomerases cleave the DNA phosphodiester backbone by nucleophilic attack from a 
catalytic tyrosine residue that becomes transiently linked to the phosphate end (P-Y) of the DNA 
break. On the base of the number of strand cleaved (I, II) and the polarity of the cleavage, DNA 
topoisomerases are divided into different classes and subfamilies.  
 
Table 1: Classification of human topoisomerases* 
Type Polarity Mechanism Genes Proteins Drugs 
IA 5'-PY Strand passage TOP3A Top3α none 
TOP3B Top3β none 
IB 3'-PY Rotation 
TOP1 Top1 anticancer 
TOP1MT Top1mt none 
IIA 5'-PY Strand passage ATPase TOP2A Top2α anticancer 
TOP2B Top2β anticancer 
       *(Pommier, 2013) 
 
Topoisomerases that cleave only one strand of the DNA are defined as type I. In particular, if the 
protein is attached to the 5’ phosphate of the DNA (5’ P-Y), it is a type IA subfamily member. If it 
is attached to the 3’ phosphate (3’ P-Y), the enzyme is a type IB subfamily member. Moreover, 
these enzymes also differ for their catalytic mechanisms. Type IA topoisomerases work by passing 
one strand through the single-strand break (SSB) generated by the enzymes (Viard and de la Tour, 
2007) (Figure 1). These topoisomerases are able to relax highly negatively supercoiled substrates 
and to efficiently unknot and decatenate DNAs containing single-stranded regions or nicks 
(hemicatenanes and double-holiday junctions) (Wu and Hickson, 2003). Type IB topoisomerases 
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use a “controlled rotation” mechanism by letting the broken strand rotate around the intact one (see 
section I.2.3) (Champoux, 2001) (Figure 1). These enzymes catalyse the relaxation of both 
negatively and positively supercoiled DNAs (Koster et al., 2005). 
In humans, topoisomerases 3α and 3β (Top3α, Top3β) belong to type IA subfamily whereas the 
nuclear topoisomerase I (Top1) and the mitochondrial topoisomerase I (Top1mt) are members of 
the type IB subfamily (Table 1). 
Topoisomerases that cleave both strands to generate a double-strand break are grouped together in 
the type II family of topoisomerases. Type II topoisomerases are multi-subunit enzymes, and form 
double-strand breaks with enzyme subunits covalently linked to 5’ ends at the DNA cleavage site. 
The enzymes work by passing a second DNA duplex through the cleavage of the first DNA 
segment with a mechanism dependent on ATP and Mg2+ (Liu et al., 1983; Nitiss, 2009) (Figure 1). 
Those topoisomerases act as full decatenases, unlinking pre/catenanes, interlinked DNA products of 
replication (Nitiss, 2009). Type IIA topoisomerases are widespread in nature. Topoisomerase 2α 
and 2β (Top2α, Top2β) are the human type IIA topoisomerase (Table 1). Type IIB enzymes are 
confined to Archaea, plants, and some algae.  
  
                    	  
Figure 1: Different catalytic mechanisms of topoisomerases. Type IA and IIA enzymes act by strand passage with one single-
strand break or one double-strand break, respectively. Type IB acts by controlled rotation. (Pommier, 2013) 
  
Type IA 
Type IB 
Type IIA 
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I.2 Human DNA Topoisomerase I (Top1) 
 
All eukaryotes harbor at least one type IB topoisomerase (Top1). Top1 is a nuclear enzyme, which 
is essential in vertebrates and in Droshophila (Lee et al., 1993) but not in yeast (Goto and Wang, 
1985; Uemura and Yanagida, 1984), probably because it can be substituted by other topoisomerases. 
Top1-null mouse embryos fail to develop (Morham et al., 1996). Cell lines expressing low levels of 
Top1 exist, for example the murine cell line (p388/CPT45) selected for resistance to camptothecin 
(CPT) (Eng et al., 1990; Tuduri et al., 2009) or the human cancer cell lines stably expressing siRNA 
against Top1 (HCT116-siTop1 and MCF-7-siTop1) (Miao et al., 2007). Features of those cells are 
genomic instability, replication defects and altered gene expression (Miao et al., 2007; Tuduri et al., 
2009).  
Top1 expression is constitutive throughout the cell cycle, similar in cycling and non-cycling cells 
(Baker et al., 1995). Although it is expressed throughout the nucleus, it is enriched in the nucleolus 
where it supports high rate of ribosomal DNA (rDNA) transcription (Muller et al., 1985; Zhang et 
al., 1988).  
 
I.2.1 Structural domains of Top1 
 
The human TOP1 gene is located on chromosome 20q11.2-13.1 and encodes a 91 kDa protein that 
has been subdivided into four distinct domains (Figure 2) (Champoux, 1998; Pourquier and 
Pommier, 2001; Stewart et al., 1996): 
- N-terminal domain: It is composed of 214 amino acids and it is the most variable region. 
This domain is dispensable for relaxation activity in vitro. It contains four putative nuclear 
localization signals, from which only two are functional (Mo et al., 2000). This domain also 
possesses sites for interaction with other cellular proteins such as nucleolin, SV40 T-antigen, certain 
transcription factors (TF), p53 and WRN (Werner syndrome, RecQ helicase-like). 
- Core domain: Constituted by 421 amino acids, it is a conserved domain that is required for 
enzyme activity. It contains all the residues required for the catalytic activity of Top1 except the 
active site tyrosine. It can be divided into three subdomains (I, II, III). 
- Linker domain: It is composed of 77 amino acids and it is dispensable for enzyme activity. It 
connects the core domain to the C-terminal domain. 
- C-terminal domain: It possesses 53 amino acids. It is the most conserved domain and it 
contains the active site T723, which covalently binds to DNA end it is essential for relaxation 
activity of Top1.  
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Figure 2: Schematic of Top1 domains. The four main domains of Top1 and catalytic tyrosine (pink) are illustrated. NTS indicates 
the nuclear translocation signals. Arrows correspond to Top1 mutations that are responsible for resistance to Top1 inhibitors (see 
section I.4.1 for details). Adapted from (Pourquier and Lansiaux, 2011). 
 
Several crystal structures of different fragments of the human Top1 covalently or not covalently 
bound to DNA are available (Lesher et al., 2002; Redinbo et al., 2000; Redinbo et al., 1998; Stewart 
et al., 1998). These structures show that Top1 is a bi-lobed protein that tightly encircles the DNA 
like a clamp (Figure 3). One of the lobes represents the “cap” of the protein and it comprises core 
subdomains I and II. Core subdomain III and the C-terminal domain constitute the second lobe that 
forms a base around the DNA. The two lobes are connected by a long α-helix (“connector”). The 
“lips” are pairs of opposing loops positioned on the opposite side to the connector: they allow non-
covalent interactions of the cap with the base of the protein. The break of this interaction and lifting 
of the cap results in the opening and closing of the protein clamp during the catalytic cycle. Finally, 
the linker domain forms a coiled-coil structure protruding from the base of the protein (Champoux, 
2001; Redinbo et al., 2000). 
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Figure 3: Two views of the structure of the human Top1 non-covalently complexed with DNA. The structure of the enzyme 
(PDB entry 1A36) is viewed from the (A) side with the DNA axis horizontally oriented and (B) looking down the axis of the DNA. 
The N-terminal domain is missing from the structure. The cap is composed of core subdomain I (yellow) and core subdomain II 
(blue). The base is composed of core subdomain III containing the long α-helix connector (red) and the C-terminal domain (green) 
containing the active site tyrosine represented in (A) in black and ball stick. The linker forms a coiled-coil structure protruding from 
the base (gold). Lips are indicated in (B) and they are the regions where the protein opens during DNA binding and unbinding. 
Adapted from (Champoux, 2001). 	  
I.2.2 Substrate specificity 
 
The substrate specificity of Top1 has been determined in relation to both DNA sequence and DNA 
structure. A preference was observed for nucleotides that extend from positions -4 to -1, 5’-
(A/T)(G/C)(A/T)T-3’ with the enzyme covalently attached to the -1 thymine residue (Been et al., 
1984; Bonven et al., 1985; Tanizawa et al., 1993). Occasionally a cytosine residue is found at the -1 
position. 
Based on structural data, the only identified contact Top1-DNA is the interaction by hydrogen-bond 
between K532 of the Top1 and the oxygen in position 2 of the thymine base located at the -1 
position (Redinbo et al., 1998). It appears that additional protein-DNA interactions play an 
important role in cleavage site selection (Champoux, 2001). 
Several studies reveal that Top1 has a preference for binding to double-stranded DNA (Been and 
Champoux, 1984) and most efficiently supercoiled over relaxed DNA in vitro (Camilloni et al., 
1988; Madden et al., 1995; Muller, 1985). Since the enzyme preferentially binds to positive and 
negative supercoiled DNA, it seems likely that the structural feature recognized by Top1 in the 
DNA is a bent DNA segment. Alternatively, the enzymes may recognize the node where two 
duplexes cross; this is the case of replication (Zechiedrich and Osheroff, 1990). 
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I.2.3 Catalytic cycle 
 
The catalytic cycle of Top1 can be divided in four steps (Pommier et al., 1998; Pourquier and 
Pommier, 2001) (Figure 4): 
1) Non-covalent DNA binding. Top1 non-covalently binds DNA at preferred sites (see section 
I.2.2). Before binding, the enzyme is in an open conformation, with the cap and the catalytic Y723 
spreading apart. As Top1 binds to DNA, these domains adopt the clamp configuration around the 
duplex (Redinbo et al., 1998). The binding footprint is approximately 20 bp (base pair) with the 
cleavage site centrally located (Stevnsner et al., 1989). 
2) Cleavage of one strand of the DNA duplex: DNA and Top1 are covalently linked by 
transesterification between the hydroxyl group of the catalytic tyrosine (Y723) and the phosphate of 
the DNA strand (Champoux, 1981). These DNA-Top1 covalent complexes are referred to as “Top1 
cleavage complexes” (Top1cc). 
3) Controlled rotation: Top1 relaxes supercoiled DNA changing its linking number, a 
parameter indicating the number of times the two helical strands are interwound, by step of one. To 
relax DNA, the enzyme allows the rotation of the broken strand around the intact one. A “controlled 
rotation” mechanism has been proposed on the base of biochemical and structural data indicating that 
the structural domains of the Top1 likely control over the rate of rotation (Stewart et al., 1998). In fact, 
rotation is slowed by contacts of DNA with the inner cavity of the enzyme and with the linker.  
4) Religation: Top1 religates the single-strand break by reversing its covalent binding in the 
absence of energy cofactors. This transesterification reaction occurs between the free 5’-OH of the 
broken strand that mediates the nucleophile attack and the Top1-DNA bond. Religation requires the 
alignment of the 5’ end of the cleaved strand with the tyrosine-DNA bond. Under normal conditions, 
Top1cc are transient as religation is favoured (Pourquier and Pommier, 2001). 
The catalytic cycle of Top1 is very fast, up to 6000 cycles per minute (Seol et al., 2013). 
Top1 can also religate exogenous DNA strands harbouring a 5’-OH free end (Christiansen et al., 
1993; Christiansen and Westergaard, 1994; Pourquier et al., 1997a). Misalignment of the 5’-OH 
with the scissile-phosphodiester bond by drugs or by DNA modification results in stabilized Top1cc 
(see section I.4) and increases the probability of illegitimate recombination (Christiansen et al., 
1993; Christiansen and Westergaard, 1994; Pourquier et al., 1997a). 
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Figure 4: Topoisomerase I catalytic cycle. DNA relaxation by Top1 can be divided in four steps: 1) Non-covalent DNA binding, 2) 
Cleavage of one DNA strand, 3) Relaxation by controlled rotation and 4) Religation. See text for details. Figure adapted from 
(Pourquier and Lansiaux, 2011). 
 
I.3 Biological functions of Top1 
 
I.3.1 Relaxation of DNA supercoiling during transcription and replication 
 
The main function of Top1 is to relax DNA supercoiling generated during transcription and 
replication (Champoux, 2001; Wang, 2002). In normal relaxed B-DNA, each strand crosses the 
other once every 10.4 bp with a right-handed turn, therefore DNA twisted in a right-handed fashion 
generates positive supercoiling (crossing < 10.4 bp) whereas DNA twisted in a left-handed fashion 
(crossing > 10.4 bp) generates negative supercoiling (Wang, 2002). 
Top1 is efficient to relax both positively and negatively supercoiled DNA with a preference for 
positive supercoiling (Koster et al., 2007; McClendon and Osheroff, 2006; Wang, 2002). 
 
Replication 
As the replication fork advances during replication, the replication machinery forces the helical 
interwines of the DNA ahead of it and DNA becomes overwound; behind the advancing fork, the 
replicated bubble becomes progressively larger (Wang, 2002). If the replication machinery is 
allowed to rotate around the helical axis of the unreplicated DNA, positive supercoils ahead of the 
ongoing fork are redistributed into the region behind it, leading to the intertwining of the pair of 
duplicated double helix (Wang, 2002). However, because of the size of replication machinery, it is 
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plausible that this complex does not rotate freely around DNA helix consequently leading to 
positively supercoiled DNA upstream of the replication fork.  
Not surprisingly, in the absence of Top1, replication forks are slower (0.7 kb/min in HCT116 
shTop1 cells compared to 1.1 kb/min in HCT116 shControl cells) and pause or stall more 
frequently (Tuduri et al., 2009). 
 
Transcription 
Similarly to replication, during transcription elongation, the transcription complex cannot 
continuously rotate around the DNA helix, which forces the DNA strand to rotate around its own 
helix axis. As a result, positive supercoiling accumulates ahead of the advancing transcriptional 
complex, and negative supercoiling behind it. This is the “twin-supercoiled-domain” model 
proposed by Liu and Wang in 1987 (Liu and Wang, 1987) and further supported by several studies 
(Cook et al., 1992; Leng and McMacken, 2002; Lodge et al., 1989; Lynch and Wang, 1993). Left 
unresolved, this supercoiled DNA can impact transcription in different ways (Blot et al., 2006; 
Drolet, 2006; Gartenberg and Wang, 1992; Peter et al., 2004). For instance, high levels of positive 
supercoiling can inhibit transcription (Drolet, 2006; Gartenberg and Wang, 1992) whereas negative 
supercoils may enhance transcriptional initiation at promoters either by helping RNA Polymerase 
(RNAP) to form an open complex or by helping to recruit transcription factors (Hatfield and 
Benham, 2002; Ma and Wang, 2014; Mizutani et al., 1991a; Mizutani et al., 1991b). In addition, 
negative supercoiling favours the formation of R-loop (Drolet et al., 1994; Drolet et al., 2003; 
Higgins and Vologodskii, 2015) and non-B DNA structures such as Z-DNA (Nordheim et al., 1982), 
both affecting transcription (see section I.5.2.5). 
By removing DNA supercoiling, Top1 is required for proper transcription. This may explain why 
Top1 has been found to bind and cleave preferentially transcribing genes (Gilmour et al., 1986; 
Khobta et al., 2006; Kroeger and Rowe, 1992; Stewart et al., 1990; Zhang et al., 1988). Despite its 
important role in transcription, works in yeast indicate that neither Top1 nor Top2 are essential for 
RNAPII transcription, while ribosomal RNA synthesis is highly reduced in the absence of both 
enzymes (Brill et al., 1987). 
Another source of torsional stress is nucleosome remodelling in active transcribed regions and Top1 
has been implicated in. It has been shown that either Top1 or Top2 is required for efficient 
transcription of a chromatin template, but not for in vitro transcription of naked DNA (Mondal and 
Parvin, 2001; Mondal et al., 2003). Interestingly, repression of transcription was detected without 
topoisomerases when RNA transcripts were above 200 bp (Mondal et al., 2003). Evidences in 
literature suggest that Top1 can affect gene expression through regulation of chromatin structure 
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and histone modifications. For example, a genome-wide analysis in S. pombe reveals that 
topoisomerase activity promotes transcription by modulating histone density. Indeed, absence of 
Top1 and Top2 leads to higher H3 occupancy in the promoter regions of highly transcribed genes 
correlating with reduced RNAPII occupancy and reduced expression profile (Durand-Dubief et al., 
2010).	  Negative supercoiling left by transcribing RNAP favours nucleosome incorporation. Thus, 
authors suggested a function of Top1 (in concert with the chromatin remodeller Hrp1) in 
maintaining a low histone density at promoters to allow for efficient RNAPII recruitment. In 
addition, Top1-Top2 double mutants exhibit increased transcriptional levels in the 3’ transcription 
terminator region of the genes compared to wild-type (Durand-Dubief et al., 2011). These findings 
indicate that Top1 activity also controls supercoiled DNA at 3’ end of the genes thereby 
contributing to nucleosome disassembly and transcriptional termination. Figure 5 illustrates the 
model proposed by the authors for the function of Top1 and Top2 in regulating DNA topological 
state and chromatin structure during transcription initiation, elongation and termination (Durand-
Dubief et al., 2011). Oppositely to this report, another work shows that Top1 activity negatively 
regulates transcription at telomere-proximal regions in S. cerevisiae by favouring a repressed 
chromatin organization (Lotito et al., 2008).  
 
Figure 5: Model of transcriptional regulation in all steps by Top1 and Top2 activity. In the initiation phase and pre-initiation 
complex formation, Top1 removes negative supercoils facilitating nucleosome disassembly at promoter. In the elongation phase, 
Top1 and Top2 act in concert to resolve topological tension generated by ongoing RNAP as predicted by the “twin-supercoiled-
domain” model. Then in transcription termination, topoisomerase activity is required for histone disassembly and transcription 
termination (Durand-Dubief et al., 2011). 
Wild Type!
Top1-Top2 
double mutant!
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Top1 regulates transcription also by acting at enhancer regions (Puc et al., 2015; Rosenberg et al., 
2013). The main mechanism by which enhancers are thought to regulate transcription is through 
DNA looping that brings distant enhancers in contact with promoters (Lam et al., 2014). Enhancers 
are also transcription units that can generate noncoding RNA transcripts identified as eRNAs 
(enhancer RNAs) (De Santa et al., 2010). eRNAs appear to be functionally important for the proper 
formation of chromosomal looping between enhancers and transcription start site (TSS) of 
regulated genes (Lam et al., 2014). DNA looping and eRNA transcription are potential source of 
topological stress. First evidences of Top1 involvement on enhancers’ regulation come from 
chromatin immunoprecipitation experiments (ChIP) showing an enrichment of Top1 at the β-
globulin locus control region (LCR) (Rosenberg et al., 2013). Then, ChIP-Seq (ChIP-sequencing) 
analysis reveals that Top1 is rapidly recruited to several AR (androgen receptor)-regulated 
enhancers in prostate cancer cells (Puc et al., 2015). Top1-depleted cells or cells complemented 
with a catalytically inactive Top1 mutant exhibit reduced production of eRNAs and coding gene 
RNAs for most of these AR-regulated genes. Authors showed that Top1 recruitment to enhancers 
occurs at the same regions of AR in proximity of TSS and causes a SSB that is necessary for eRNA 
synthesis and enhancer activation. This study identifies a novel function of Top1 dependent on its 
catalytic activity in the control of the cell-specific transcriptional program by ligand-driven 
enhancer activation (Puc et al., 2015). 
 
I.3.2 Transcriptional roles of Top1 independent of its nicking-closing activity 
 
Top1 regulates transcription independently of its nicking-closing activity by acting in concert or by 
interacting with transcriptional activators and general transcription factors. Non-canonical Top1 
functions include: 
- Activation/repression of transcription: 
 In vitro studies show that Top1 is able to either repress basal transcription as well as to co-activate 
transcription (Kretzschmar et al., 1993; Merino et al., 1993; Shykind et al., 1997). Top1 seems to 
activate transcription by enhancing the formation of the TFIID-TFIIA-DNA complex at promoters 
(Shykind et al., 1997). This function of Top1 does not require its nicking-closing activity since a 
catalytically inactive Top1 mutant can stimulate transcription as the wild type.  
- Recruitment of RNAP: 
Top1 may also favour the recruitment of RNAPII at transcription sites either directly by its ability 
to bind the C-terminal region of Rpb1 (Carty and Greenleaf, 2002; Rose et al., 1988) or indirectly 
by interacting with Topors (topoisomerase I-binding RS proteins), small nuclear RING-finger 
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proteins harbouring E3 ubiquitin- and SUMO1 (small ubiquitin-related modifier-1)- ligase activities 
(Haluska et al., 1999). A similar model has been proposed for RNAPI recruitment at 
transcriptionally active ribosomal genes either by its direct interaction with Top1 (Rose et al., 1988) 
or nucleolin (Bharti et al., 1996).  
- RNA splicing: 
In higher eukaryotes, Top1 has a specific kinase activity and it can phosphorylate splicing factors 
such as SR proteins (serine/arginine-rich protein, like ASF/SF2) (Rossi et al., 1996), thus promoting 
the formation of messenger ribonucleoprotein particles (mRNPs) and the maturation of nascent 
RNA (Rossi et al., 1996; Soret et al., 2003). The interaction between Top1 and ASF/SF2 seems to 
inhibit Top1 relaxation activity (Andersen et al., 2002). Top1 has also been reported to interact with 
PSF (protein-associated splicing factor), a co-factor of RNA splicing, which in complex with the 
RNA-binding protein p54 stimulates Top1 relaxing activity (Straub et al., 1998). In Drosophila, 
Top1 associates with and phosphorylates the SR protein B52 (Juge et al., 2010). This interaction is 
important to target Top1 to RNAPII-active chromatin loci. Furthermore, a proteomic analysis of 
Top1-containing complexes reveals that 10 out of the 36 proteins identified as Top1 partners are 
involved in RNA splicing (Czubaty et al., 2005).  
- Suppression of transcription-associated replication stress: 
A function of Top1 in mammalian cells, which is dependent on both its nicking-closing activity and 
its kinase activity, is to suppress the transcription-associated replication stress in an ASF/SF2-
dependent manner (Tuduri et al., 2009). Top1 and mRNPs biogenesis avoid interference between 
replication and transcription and the formation of R-loop-mediated genome instability in S-phase 
(Tuduri et al., 2009). 
 
I.3.3 Roles of Top1 in DNA damage signalling/repair  
 
As Top1 can be trapped by a number of DNA modifications (see section I.4.2), it has been 
speculated that Top1 could play a role in DNA damage signalling and/or repair in response to DNA 
lesions. For instance, ultraviolet (UV) -induced DNA damage stimulates Top1cc formation in vivo 
(Subramanian et al., 1998). The authors suggested that UV-induced Top1cc may result from (i) 
cyclobutane pyrimidine dimers (CPD) and photoproducts, which alter the DNA local conformation 
causing a misalignement of the 5’ broken end impeding the religation step or (ii) active recruitment 
of Top1 at DNA lesions. Two hypothesis, mutually not exclusive, have been proposed for the 
possible roles of trapped Top1 at DNA lesions (reviewed in (Leppard and Champoux, 2005; 
Pourquier and Lansiaux, 2011)):  
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1) Targeting repair proteins to DNA damage:  
Top1 may act as a “sensor” of DNA damage, which recruits repair proteins to damaged chromatin. 
Accordingly with this possibility, Mao et al. show Top1’s involvement in nucleotide-excision repair 
(NER) (Mao et al., 2000a). Indeed, the repair of UV lesions and the recruitment of the NER factor 
PCNA (proliferating cell nuclear antigen) are reduced in Top1 depleted cells. Another evidence 
suggesting a role of Top1cc in DNA repair is its ability to interact with DNA damage response 
proteins (DDR) such as p53 (Albor et al., 1998; Mao et al., 2000a; Smith and Grosovsky, 1999) and 
PARP1 (Poly [ADP-ribose] polymerase 1) (Czubaty et al., 2005; Drew and Plummer, 2009). In 
particular, the interaction of Top1 with p53 stimulates Top1 catalytic activity and Top1 recruitment 
at UV-induced lesions (Mao et al., 2000a). Finally, a recent report shows that the recruitment of 
Top1 at AR-regulated enhancers is kinetically accompanied by the recruitment of the MRN 
complex (Mre11-Rad50-Nbs1 complex, see section II.5.1.1) and ATR (ataxia telangiectasia and 
Rad3-related protein, see section II.3.2), followed by additional components of the DDR (Puc et al., 
2015). 
2) Induction of apoptosis:  
Top1 may promote apoptosis when DNA damage persists and cannot be repaired. Accordingly with 
this hypothesis, Top1 depletion reduces some apoptotic nuclear features and it has been suggested 
that Top1 might act as a nuclear effector of apoptosis (see section I.4.3). Furthermore, the 
association of Top1 trapped at UV-lesions with p53 might support a possible role for Top1 in the 
p53-dependent apoptosis in response to DNA damage (Mao et al., 2000a). 
 
I.4 Trapping of Top1 
 
Despite their frequency throughout the genome, in physiological conditions, Top1cc are extremely 
transient and almost undetectable. These complexes can be stabilized generally by 5’-OH DNA-end 
misalignment that prohibits religation. Top1cc can be stabilized by camptothecins and non-
campthotecins Top1 inhibitors (Pommier, 2006; Pommier, 2013), by DNA alterations (Pommier et 
al., 2006), by ribonucleotide misincorporation (Kim et al., 2011) and during apoptosis (Sordet and 
Solier, 2012). 
 
I.4.1 Trapping of Top1 by Top1 inhibitors 
 
Camptothecin and Camptothecin-like Top1 inhibitors 
Camptothecin (CPT) and CPT-like inhibitors block the religation step of the Top1 catalytical cycle. 
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More precisely, they inhibit the second transesterification reaction (Hsiang et al., 1985) (Figure 
6A). CPT is an alkaloid compound isolated from the bark of the Chinese tree Camptotheca 
acuminata in 1966 (Wall, 1966). CPT was tested clinically in the 1970s, showing anticancer 
activity and SSB induction that rapidly disappear as the drug is removed (Gottlieb et al., 1970; 
Horwitz et al., 1971; Kessel, 1971; Kessel et al., 1972; Muggia et al., 1972; Spataro and Kessel, 
1972). However, the severe side effects discouraged the clinical development. The discovery that 
Top1 is the cellular target of CPT came 10 years after (Eng et al., 1988; Hsiang et al., 1985; Nitiss 
and Wang, 1988) and led to the development of CPT derivatives. 
A key feature of CPT is that Top1 is its only cellular target (Pommier, 2006; Pommier et al., 2010): 
(i) only the natural 20-S enantiomer is active (Hsiang et al., 1989b; Jaxel et al., 1989), (ii) yeasts 
deleted for TOP1 (Top1Δ) are completely resistant to CPT (Eng et al., 1988; Nitiss and Wang, 
1988), (iii) cells selected for CPT resistance bear single point mutations in the TOP1 gene 
(Pommier et al., 1999), (iv) plants producing CPT harbour a point mutation in TOP1 gene 
(Sirikantaramas et al., 2008) that renders Top1 refractory to the drug (Fujimori et al., 1995). 
Chemically, CPT is a 5-ring heterocyclic containing a α-hydroxylactone within its E-ring (Figure 
6A). 
Mechanistically, CPT traps Top1cc by docking at the enzyme-DNA interface (Figure 7A). Hence, 
it represents a paradigm for “interfacial inhibitors” (Jaxel et al., 1991; Marchand et al., 2006). The 
formation of this ternary complex (DNA-CPT-Top1) was initially suggested by DNA-sequencing 
experiments (Capranico and Binaschi, 1998; Capranico et al., 1990; Jaxel et al., 1991; Pommier et 
al., 1991) and by the stereospecific nature of CPT activity. Then, it was confirmed by 
crystallographic data (Ioanoviciu et al., 2005; Staker et al., 2005; Staker et al., 2002). CPT binds 
simultaneously both to DNA by hydrophobic stacking interaction and to Top1 by three hydrogen 
bonds involving R364, D533 and N722 (Marchand et al., 2006). CPT traps only a subset of Top1cc, 
those with a thymine at the -1 position and a guanine at the +1 position (Jaxel et al., 1991). Another 
key feature of CPT is the reversible nature of its binding to Top1cc (Covey et al., 1989). 
Some of the characteristics that render CPT a powerful pharmacological tool are also the causes of 
its clinical limitations (Pommier, 2006; Pommier, 2013; Tomicic and Kaina): (i) long infusions as 
Top1cc are rapidly reverted upon drug removal, (ii) chemical instability due to its inactivation at 
physiological pH by lactone E-ring opening (Figure 6A), (iii) relatively low potency and despite its 
selectivity, CPT has to be applied at µM concentration, (iv) dose-limiting side effects because of the 
destruction of bone narrow progenitors, (v) cross-resistance in cells expressing the drug efflux 
membrane ABC transporters. 
Three water-soluble CPT derivatives are approved for clinical use: topotecan, irinotecan and 
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belotecan (in South Corea) (Figure 6A). Topotecan is approved for ovarian cancer and recurrent 
small cell lung cancer. Irinotecan, which is a prodrug converted to its active metabolite SN-38 by 
plasma and cellular carboxylesterases, is used in colon and rectal cancer. Both drugs are also used 
in glioblastomas, sarcomas and cancer of the cervix (Pommier, 2013).  
Different modifications of CPT and water-soluble CPT derivatives have been produced to improve 
solubility, clinical tolerability and allow oral administration (such as gimatecan, lurtotecan and 
exatecan). Two approaches have been used to overcome the chemicals instability of CPTs: the 
addition of a methylene group as in homocamptothecins (Lavergne et al., 1998) or the substitution 
of the E-ring with a five-member ring as S39625 (Takagi et al., 2007). 
 
 
Figure 6: Structures of some Top1 inhibitors. (A) Camptothecins. (B) Non-camptothecin Top1 inhibitors in clinical trials. 
Adapted from (Pommier, 2013). 
 
Non- Camptothecin Top1 inhibitors 
After the discovery that Top1 is the selective target of CPT, the search for Top1 inhibitors not based 
on the structure of CPT began. Screening of chemical library and natural products led to the 
discovery of various compounds (Meng et al., 2003). There are three classes of non-CPT Top1 
inhibitors (Teicher, 2008) (Figure 6B):  
- Indolocarbazoles: Edotecarin reached Phase III clinical trials but like other 
indolocarbazoles, it has been found unselective (Urasaki et al., 2001)  
- Phenanthridine derivatives: ARC-111 compound has been entered in Phase I clinical trials  
- Indenoisoquinoline derivatives: they are selective for Top1, chemically stable, they trap 
Top1cc at different sites of CPT, they are not substrate of ABC transporters and they show the same 
antiproliferative activity of CPT (Antony et al., 2007a; Antony et al., 2003; Antony et al., 2005; 
Tanizawa et al., 1994). Indotecan (LMP400) and indimitecan (LMP776) are in Phase I clinical 
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trials.  
 
Top1 catalytic inhibitors  
Unlike Top1 poisons, catalytic inhibitors do not trap the Top1cc. They interact with free enzyme or 
with DNA impeding Top1 to bind or cleave DNA (for review see (Bailly, 2000)) (Figure 7B). 
Those inhibitors are generally unselective and they need to be used at elevated concentration (> 1 
µM) (Pourquier and Lansiaux, 2011). Currently, there is no specific Top1 catalytic inhibitor known.  
 
Figure 7: Mechanism of action of CPTs and non-CPT Top1 inhibitors and Top1 catalytic inhibitors. (A) CPTs and non-CPTs 
inhibitors trap Top1cc by blocking DNA religation. (B) Top1 catalytic inhibitors block the binding and/or the cleavage of DNA by 
Top1. Adapted from (Pourquier and Lansiaux, 2011). 
 
I.4.2 Trapping of Top1 by DNA modifications 
 
Top1 may encounter damage and alternative structures of DNA with high frequency by virtue of its 
abundant and ubiquitous nature. Table 2 summarizes different lesions and DNA alterations from 
endogenous or exogenous sources that can trap Top1cc (reviewed in (Pommier et al., 2006; 
Pommier et al., 2014; Pourquier and Pommier, 2001)). Top1cc trapping is likely to be frequent and 
biologically important, in particular in neurons that are characterized by high oxidative metabolism 
and long transcripts (Huang et al., 2012; Powell et al., 2013). Spontaneous abasic sites have been 
estimated at a frequency of ≈ 104 per cell per day (Lindahl and Nyberg, 1972). The accumulation of 
Top1cc is generally associated to religation inhibition because of 5’-OH- end misalignment (see 
section I.2.3) but it can also be due to an enhancement of Top1 binding or of its cleavage reaction 
(Pommier et al., 2006). The localization of the DNA alteration is another parameter determining 
Top1 outcome (reviewed in (Pourquier and Pommier, 2001)). In general, single lesions at position 
Topo1 
CPTs !
Non-CPT Top1 inhbitors!Topo1 + 
Topo1 
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+1, +2 or +3 from the cleavage site lead to Top1cc accumulation whereas lesions at position -1, -2 
and -3 (and to lesser extent abasic sites at -4, -5 and -6) suppress Top1-mediated DNA cleavage.  
Moreover, DNA modifications can produce reversible or irreversible Top1cc. Irreversible Top1cc 
are constituted by a break on one or both strands in association with Top1 covalently bound to the 3’ 
DNA-end. These complexes are termed “suicide complexes”.   
Recently, different works investigated a special form of abortive Top1cc related to the RNA nicking 
activity of Top1 (Kim et al., 2011; Sparks and Burgers, 2015; Williams et al., 2013). This 
endoribonuclease activity has been at first described in vitro (Sekiguchi and Shuman, 1997) and it 
consists in the conversion of a ribonucleotide embedded in cellular DNA into a 2’-3’-cyclic 
phosphate nick by Top1 (Kim et al., 2011; Sparks and Burgers, 2015). This activity of Top1 could 
represent an alternative repair pathway to RNaseH2 for misincorporated ribonucleotides during 
DNA replication. However, it can also promote genomic instability. The endoribonuclease activity 
of Top1 has been linked to Top1-mediated mutations in yeast by initiating short base deletions and 
by creating nicks or cyclic phosphate intermediates (Kim et al., 2011; Sparks and Burgers, 2015).  
 
Table 2: Endogenous and exogenous factors able to produce Top1cc (Pommier et al., 2006) 
Type of DNA modification Mechanism(a) Reversibility(b) References 
Endogenous factors 
Single base mismatches T(c) r(f) (Pourquier and Pommier, 2001; Pourquier 
et al., 1997b) 
Mismatched loops  T ir(g) (Pourquier et al., 1997b)  
Abasic sites  T Ir (Pourquier et al., 1997b) 
8-oxoguanosine B(d) R (Lesher et al., 2002) 
5-hydroxycytosine ? R (Lesher et al., 2002) 
SSB T Ir (Pourquier et al., 1997a; Wang et al., 1998) 
Cytosine methylation F(e)+T R (Leteurtre et al., 1994) 
Triple helix formation F+T R (Antony et al., 2004a) 
Apoptotic chromatin fragmentation B+T Ir (Sordet et al., 2003; Sordet et al., 2004a; Sordet et al., 2004b; Sordet et al., 2004c) 
Exogenous factors 
UV lesions ? ? (Lanza et al., 1996; Subramanian et al., 1998) 
IR lesions T Ir (Pourquier et al., 1997a) 
O6-methylguanine T R (Pourquier et al., 2001) 
O6-dA-benzo[a]pyrene adducts T R (Pommier et al., 2000b) 
O6-dG-benzo[a]pyrene adducts F Ir (Pommier et al., 2000a) (Pommier et al., 2002)  
O6-dG-benzo[c]phenantrhrene adducts T R (Pommier et al., 2002)  
N6-Ethanoadenine T R (Pourquier et al., 1998) 
N2-dG-ethyl adducts T R (Antony et al., 2004b) 
N2-dG-crotonaldehyde adducts T Ir (Dexheimer et al., 2008) 
(a)Mechanism for Top1cc accumulation: (c)T, Inhibition of religation; (d)B, enhancement of binding; (e)F, enhancement of cleavage. 
(b)Reversibility of Top1cc: (f)r, reversible; (f)ir, irreversible. 
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I.4.3 Trapping of Top1 during apoptosis 
 
Top1cc are also stabilized in cells undergoing apoptosis. These complexes, referred to as “apoptotic 
Top1cc”, have been described in different mammalian cell lines exposed to various apoptotic-
inducing agents that do not have direct effect on Top1 (Table 3) (Ganguly et al., 2007; Rockstroh et 
al., 2007; Soe et al., 2004; Sordet et al., 2006; Sordet et al., 2008a; Sordet et al., 2004a; Sordet et al., 
2004c). Apoptotic-Top1ccs are found on the genome with an average of approximately 1/100 kbp 
in early phases and 1/10 kbp in late phases of apoptosis (Rockstroh et al., 2007; Sordet et al., 
2008a). 
 
Table 3: Agents known to induce apoptotic Top1cc (Sordet and Solier, 2012) 
Agents Cellular target(s) References 
Etoposide  
Doxorubicin   
m-AMSA 
Stabilization of Top2 cleavage complex (Sordet et al., 2006) 
Vinblatin  
Taxol  
Colcemid 
Insertion at the interface of the tubulin heterodimer (Sordet et al., 2006) (Rockstroh et al., 2007) 
TRAIL Activates the plasma memebran receptors DR4 DR5 
(Rockstroh et al., 2007) 
(Sordet et al., 2008a) Fas ligand Activates the plasma membrane receptor Fas 
TNF-α Activates the plasma membrane receptor TNFR1 
Antimycin 
 BH3I-2' 
BH3 mimetics that bind to and inhibit the antiapoptotic 
effect of Bcl-xL at the mitochondria (Sordet et al., 2008a) 
Arsenic trioxide Induces the intracellular accumulation of ROS (Sordet et al., 2004c) 
Staurosporine Inhibitor of protein kinases: Chk1, Chk2, PDK1, PKC 
(Sordet et al., 2004a) 
(Ganguly et al., 2007; Sen et 
al., 2007) 
UV radiation Production of pyrimidine dimers, 4,6-photoproducts and 
oxidative DNA lesions (Soe et al., 2004) 
 
In the current model, the common mechanism to trap Top1cc during apoptosis is the ROS (reactive 
oxygen species)-dependent formation of oxidative DNA lesions (Sordet et al., 2006; Sordet et al., 
2008a; Sordet et al., 2004a; Sordet et al., 2004b). Most apoptotic stimuli activate the apoptotic 
mitochondrial pathway and subsequently caspase-3, both responsible for ROS intracellular 
accumulation. Along with its contribution to ROS production, caspase-3 also cleaves Top1 
generating an 80 kDa-truncated form that is still able to form Top1cc (Samejima et al., 1999) and 
rather it is the preferred form producing apoptotic-Top1cc (Sordet et al., 2008a). 
Several studies, in particular experiments performed in cells depleted for Top1 (by siRNA or 
shRNA), show that Top1 participates in the execution of apoptosis by contributing to the apoptotic-
associated nuclear modifications, such as nuclear fission, apoptotic body release and chromatin 
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condensation (Ganguly et al., 2007; Sordet et al., 2008a; Sordet et al., 2004a; Sordet et al., 2004c). 
Currently it is not clear if the role of Top1 in apoptosis is dependent or not on its catalytic activity.  
Taken together these finding propose a role for Top1 in the apoptotic program. It remains to be 
elucidated if Top1 participates to apoptosis like an apoptotic endonuclease, if it functions 
amplifying the apoptotic process or if it contributes to the proper recognition and elimination of 
apoptotic cells (for review see (Sordet et al., 2003; Sordet et al., 2004b; Sordet and Solier, 2012)). 
 
I.5 Cellular consequences of CPT-mediated trapping of Top1cc 
 
The cellular consequences of CPT-mediated trapping of Top1 are related to (i) the induction of 
protein-linked DNA nicks (Covey et al., 1989) and (ii) the inhibition of Top1 activity and 
topological stress (Duann et al., 1999; Koster et al., 2007). 
CPT-stabilized Top1cc are normally rapidly reversed, as CPT does not cause directly a 
misalignment of the 5’-OH DNA-end. Early experiments demonstrated that short exposures (less 
than 60 minutes in cell culture) to CPT are relatively non-cytotoxic (Holm et al., 1989; Horwitz et 
al., 1971; O'Connor et al., 1991). The cytotoxicity of CPT is not the direct consequence of Top1 
inhibition, it is rather associated to the conversion of the reversible Top1cc into irreversible 
complexes and DNA damage after processing by replication and transcription machineries 
(Pommier, 2006). These observations are consistent with a time-dependent production of Top1-
suicide complexes and cytotoxicity. The probability for forming irreversible Top1cc is enhanced by 
CPT treatment because Top1 religation activity is slowed down.  
The relative contribution of DNA replication and transcription depends on CPT concentration, cell 
type and proliferation status. In highly proliferative cancer cells, replication-induced DNA damage 
(notably DNA double-strand breaks, DSBs, see section I.5.1) is the main responsible for 
cytotoxicity, which is achieved at low CPT doses (Holm et al., 1989). In contrast, transcription 
contributes to cytotoxicity at high doses of CPT in slowly and non-proliferating cells (Hsiang et al., 
1989b; Huang et al., 2010). Exceptions are given by non-dividing neurons and lymphocytes that can 
be killed in a transcription-dependent manner at pharmacological concentrations (Morris and Geller, 
1996; Stefanis et al., 1999). 
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I.5.1 Replicational consequences of CPT-mediated trapping of Top1cc 
 
The two main replicational consequences of CPT-mediated stabilization of Top1cc are (i) inhibition 
of DNA synthesis and (ii) production of replication-coupled DSBs (RC-DSBs). 
After CPT treatment, inhibition of DNA synthesis is intense (≥80%), rapid (within minutes) and 
persistent (up to 8h) after drug removal (Shao et al., 1999). The mechanisms leading to DNA 
duplication arrest may include: (i) collision between replication machinery and Top1cc that directly 
blocks fork progression (Snapka, 1986; Strumberg et al., 2000; Tsao et al., 1993), (ii) inhibition of 
thymidine kinase (Voeller et al., 2000) and (iii) S-phase checkpoint activation (Shao et al., 1999) 
(Seiler et al., 2007).  
Top1cc can be converted in RC-DSBs by its collision with the ongoing replication forks (Pommier, 
2006). Such RC-DSBs are the primary cytotoxic mechanism of Top1 inhibitors in proliferating cells. 
Indeed, cells tend to be immune to CPT when they are outside of S-phases or when replication is 
arrested by aphidicolin treatment (Borovitskaya and D'Arpa, 1998; Horwitz and Horwitz, 1973). At 
least two mechanisms have been described for the production of RC-DSBs by Top1cc: (i) the 
“replication run-off” (Hsiang et al., 1989a; Strumberg et al., 2000) and (ii) the Mus81-Eme1 
cleavage (Regairaz et al., 2011) (Figure 8). 
Analysis of the broken ends by ligation-mediated PCR in the ribosomal RNA gene cluster in 
mammalian cells shows the extension of the leading strand up to the last nucleotide at the 5’ end of 
the Top1cc resulting in 5’ phosphorylated blunt-ended DSBs (also called DNA double-strands ends, 
DSEs) by “replication run-off” (Strumberg et al., 2000) (Figure 8A). Since the 5’-OH terminus 
enables the reversibility of the Top1cc, the 5’ phosphorylation should prevent religation by Top1 
itself (Strumberg et al., 2000).  
RC-DSBs can also be mediated by the 3’ flap endonuclease Mus81-Eme1 (Regairaz et al., 2011). 
Mus81-deficient cells have a reduced level of CPT-induced DSBs. Regairaz and coworkers 
proposed that DSEs could be the result of the Mus81-Eme1-dependent cleavage of replication fork 
stalled by trapped Top1cc. Although Mus81-Eme1-cleaveage leads to DSBs production, the 
primary function of this pathway is to dissipate the excess of positive supercoils resulting from 
CPT-induced Top1 inhibition and to promote replication fork recovery and cell survival. Indeed, 
Mus81-deficient cells are hypersensitive to CPT (Figure 8B). 
CPT-induced RC-DSBs initiate a pleiotropic DDR with checkpoint activation, DNA repair and 
apoptosis (reviewed in (Pommier et al., 2006; Sordet et al., 2003; Tomicic and Kaina)). This DDR 
includes the activation of the ATR-Chk1 (ataxia telangiectasia Rad3-related protein - checkpoint 
Kinase 1), ATM-Chk2-p53 (ataxia telangiectasia mutated - checkpoint kinase 2 - tumour protein 
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P53) pathways, the DNA-dependent protein kinase (DNA-PK) and the phosphorylation of H2AX 
(γH2AX) and RPA (replication protein A) (see Chapter II). Defects in these pathways sensitize 
cancer cells to Top1-mediated DNA damage (reviewed in (Pommier et al., 2006; Tomicic and 
Kaina)). Although both Chk1 and Chk2 are rapidly activated upon exposure to low doses of CPTs, 
it seems that the ATR-Chk1 axis is the predominant pathway in response to RC-DSBs (Furuta et al., 
2003; Huang et al., 2010), which are the predominant lesions in replicating cells treated with 
pharmacological doses of CPT. ATR-Chk1 activation induces Cdc25A degradation and consequent 
S-phase delay and G2/M arrest (Xiao et al., 2003).  
 
	  
Figure 8: Mechanisms of production of replication coupled DSBs (RC-DSBs) by Top1cc. (A) Replication run off (Strumberg et 
al., 2000). (B) Mus81-Eme1 cleavage of the stalled replication fork (Regairaz et al., 2011). Adapted from (Regairaz et al., 2011). 
 
I.5.2 Transcriptional consequences of CPT-mediated trapping of Top1cc 
 
Since Top1 is enriched at transcribed regions (Gilmour et al., 1986; Khobta et al., 2006; Kroeger 
and Rowe, 1992; Stewart et al., 1990; Zhang et al., 1988) where it exerts several functions that are 
both dependent- and independent- of its catalytic activity (see section I.3.1 and I.3.2), Top1 
poisoning may occur primarily in actively transcribed regions and can uncouple transcriptional 
regulation processes leading to multiple cellular consequences. 
 
I.5.2.1 General transcription downregulation and alteration of gene expression patterns 
 
An immediate effect of CPT in cultured cells is the broad and general inhibition of both 
nucleoplasmic (mRNA) and nucleolar (rRNA) transcription elongation (Alagoz et al., 2013; Desai 
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et al., 2003; Horwitz et al., 1971; Kann and Kohn, 1972; Lin et al., 2013). In vitro studies suggested 
that this inhibition can result from the physical blockage of the RNAPII elongation complexes by 
Top1cc (Bendixen et al., 1990) and/or by the accumulation of DNA supercoils by ongoing 
transcription (Darzacq et al., 2007; Garg et al., 1987). 3(H)uridine incorporation measurements 
show that transcription is reduced to 20%, within 10 minutes of CPT treatment (Desai et al., 2003; 
Horwitz et al., 1971).  
Although the overall level of transcripts decreases quickly after CPT treatment, topoisomerase 
inhibition differently affects the gene expression. One of the first evidences of the alteration of gene 
expression patterns is given by the study of Collins et al. (Collins et al., 2001). The authors showed 
that CPT enhances the expression of C-FOS, downregulates C-MYC and does not impact the 
transcription of the HSP70 and GADPH genes. Later works have allowed the measurements of 
global changes in gene expression patterns induced by CPT-stabilized Top1cc by using microarray 
technology (Lotito et al., 2009; Solier et al., 2013; Zhou et al., 2002). Zhou et al. highlighted the 
different changes in gene expression profiles associated with high and low concentrations of CPT 
(Zhou et al., 2002). Low CPT concentrations are associated with the downregulation of cell cycle-
related genes whereas high CPT concentrations induce up-regulation of p53-related stress genes 
(Zhou et al., 2002). Lotito and coworkers analysed the CPT-induced alteration of gene expression in 
yeast (Lotito et al., 2009). 73 genes, mainly related to Gene Ontology (GO) components such as 
vesicle-mediated transport, organelle and cell wall organisation and protein modifications, were 
downregulated by CPT. The authors also reported the up-regulation of 22 genes mainly related to 
cell cycle, mitosis and DNA replication which are regulated by the transcription factors Mbp1 and 
Swi4 (Lotito et al., 2009). In human cells, the genome-wide transcriptional response to CPT has 
been recently characterized by two independent groups employing different technologies. The 
group of Pommier performed the genome-wide analysis of CPT-treated cells at exon resolution by 
using the exon array platform (Solier et al., 2013). They found that in response to CPT, 20% of the 
analysed genes are downregulated while 5% are upregulated (by at least 2-fold). CPT-induced 
Top1cc preferentially downregulate genes highly expressed at basal level and upregulate lowly 
expressed genes. The probability for a gene to be downregulated increases with the increasing of 
both the gene length and the exons’ number. Interestingly, downregulation of a large number of 
genes is mediated by the upregulation of at least one specific miRNA, miR-142-3p, in response to 
CPT. Among the most significant GO category for the downregulated genes, the authors found the 
ubiquitin- and RNA degradation-related pathways genes (Solier et al., 2013). The importance of 
gene length was confirmed by Ljungman’s group employing the Bru-Seq method, which consists in 
the metabolic labelling of RNA using bromouridine (Bru) followed by specific isolation of Bru-
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labeled nascent RNA and genome-wide analysis (Veloso et al., 2013). The authors reported also 
that CPT affects transcriptional termination by stimulating transcriptional read-through past the 3’ 
end of small genes and it enhances the expression of eRNA from certain enhancer elements. In 
addition, this work highlights the effect of CPT in shifting the balance of apoptosis-regulated genes 
by reducing the relative transcription rate of large anti-apoptotic genes and enhancing the 
expression of a set of smaller pro-apoptotic genes (Veloso et al., 2013).  
Another recent RNA-Seq analysis has been performed to survey changes in gene expression in mice 
cortical neurons after a 3-day topotecan treatment (King et al., 2013). This study shows that, like in 
cancer cells (Solier et al., 2013; Veloso et al., 2013), topotecan reduces the transcription of long 
genes (>200 kb) in post mitotic neurons by impairing transcription elongation (King et al., 2013). 
Importantly, the topotecan-downregulated genes are related to GO components of synapses, cell 
adhesion and neurotransmission and a number of these genes are associated with autism (King et al., 
2013). The transcriptional downregulation of these genes is accompanied by the depletion of 
multiple synaptic proteins and the suppression of the excitatory and inhibitory synaptic activity in 
topotecan-treated neurons (Mabb et al., 2014). These studies highlight the role of Top1 in post-
mitotic neurons in maintaining proper synaptic function. For instance, a de novo Top1 mutation has 
been found in individuals with autism spectrum disorder (Iossifov et al., 2012; Neale et al., 2012). 
By contrast to replication, transcription inhibition recovers rapidly. The transcriptional recovery 
starts after 15 min of CPT exposure and continues gradually during the next 4h (Desai et al., 2003). 
Following removal of CPT, the rate of RNA synthesis reaches the 90% of the control sample within 
minutes (Horwitz et al., 1971). Indeed, transcription spreads as a wave in a 5’ to 3’ direction with 
no recovery of transcription apparent from RNAPII stalled in the body of genes (Ljungman and 
Hanawalt, 1996; Veloso et al., 2013). The inability of cells to resume elongation from within the 
body of genes suggested that blocked RNAPII are discarded rather than recycled.  
However, transcription recovers with a reduced elongation rate (around 1.1-1.3 kb/min after CPT 
removal compared to 2 kb/min in untreated cells). It is possible that this reduced elongation rate is 
due to a requirement for repair of Top1cc-associated DNA damage to take place before 
transcription can resume (see section I.5.2.7) (Veloso et al., 2013). 
Importantly, the recovery of RNA synthesis depends on Top1 degradation (see section I.5.2.4) 
(Alagoz et al., 2013; Desai et al., 2003). The requirement of transcription-coupled nucleotide 
excision repair (TCR) for transcription resumption is controversial. Some studies have shown that 
Cockayne syndrome (CS) cells that are deficient in TCR (CSB factor) are hypersensitive to CPT 
and have defects in RNA synthesis recovery (Desai et al., 2003; Squires et al., 1993), while others 
studies have found no defects (Sakai et al., 2012; Veloso et al., 2013). 
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I.5.2.2 Effects on RNA Polymerase II  
 
CPT-induced Top1cc have immediate and specific effects on RNAPII: 
- Hyperphosphorylation of RNAPII: 
Within few minutes, CPT triggers the hyperphosphorylation of the largest subunit (Rpb1) of 
RNAPII in both primary and transformed cancer cells (Amente et al., 2009; Desai et al., 2003; 
Dutertre et al., 2010; Khobta et al., 2006; Sordet et al., 2008b). Indeed, the conserved heptapeptide 
repeats of the carboxy-terminal domain (CTD) of Rpb1 (YSPTSPD) is 
phosphorylated/dephosphorylated during the transcription cycle and the hyperphosphorylated form 
of the RNAPII corresponds to the transcriptionally active polymerase (Sims et al., 2004). RNAPII 
phosphorylated at serine 5 (S5) peaks early in the transcription cycle and decreases towards the 3’ 
end of the gene correlating with transcription initiation and early elongation (promoter clearance). 
By contrast, phosphorylation at serine 2 (S2) predominates in the body and toward the 3’ end of the 
gene correlating with productive elongation (Sims et al., 2004). 
CPT produces selectively hyperphosphorylation on the S5 that is mediated by Cdk7, a component 
of the transcription factor TFIIH (Sordet et al., 2008b). Although Cdk9 mainly induces S2 
phosphorylation, the implication of Cdk9 in CPT-induced S5 hyperphosphorylation cannot be 
completely excluded. Indeed, Cdk9 can phosphorylate RNAPII at S5 (Ramanathan et al., 2001) and 
CPT triggers the activation of the P-TEFb complex containing the Cdk9 kinase activity (Amente et 
al., 2009). The hyperphosphorylation of Rpb1 on S5 is consistent with others studies proposing that 
CPT-induced Top1cc block elongation and stimulate RNAPII transcription initiation (Khobta et al., 
2006; Ljungman and Hanawalt, 1996). However, the study of Dutertre et al. reports that 1 h of CPT 
induces also hyperphosphorylation of RNAPII on S2 and that this form of hyperphosphorylated 
RNAPII is slightly enriched at the 3’ end of the MDM2 (mouse double minute 2) gene (Dutertre et 
al., 2010). 
- Redistribution of chromatin-bound RNAPII: 
A second immediate effect of CPT on RNAPII is the redistribution of chromatin-bound RNAPII 
along transcribed genes in human cells in a manner dependent on Cdk activity (Baranello et al., 
2010; Khobta et al., 2006). The Capranico’s group reported that RNAPII levels are reduced at 
promoter pause site and are transiently increased at internal exons in response to CPT (Capranico et 
al., 2007; Khobta et al., 2006). The authors provided evidences that CPT-induced Top1cc trigger 
the escape of RNAPII from promoter-proximal pause site of the HIF-1α (hypoxia-inducible factor 
1α) gene and suggested a new role for Top1 in regulating RNAPII pausing (Baranello et al., 2010; 
Capranico et al., 2010). Before starting the productive elongation, RNAPII synthesizes a short RNA 
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and pauses partially at 20-50 bases from TSS. This pausing step functions as checkpoint for 
elongation and assures the recruitment of the capping and splicing factors to promote RNA 
processing (Sims et al., 2004). The proposed model is that Top1 facilitates the polymerase pausing 
thus; Top1 inhibition by CPT activates PTEF-b, which in turns phosphorylates the CTD of RNAPII 
favouring pausing escape (Baranello et al., 2010; Capranico et al., 2010). Others studies are 
consistent with this model. 3(H)uridine pulse labelling and nuclear run-on measurements of the 
transcription rate in the rodent DHFR (dihydrofolate reductase) gene and genome-wide Bru-Seq 
data in human cells show that CPT enhances transcription signal from the 5’ ends of the genes 
while reduces transcription signal at promoter-distal sequences (Ljungman and Hanawalt, 1996; 
Veloso et al., 2013). A kinetic analysis of RNAPII transcription at a gene-array locus reveals that 
RNAPII often pauses during elongation. CPT increases the efficiency of intragenic pausing without 
affecting the pausing time that results in a reduction of the elongation rate (to ¼ of the normal rate) 
but not in a complete inhibition of elongation (Darzacq et al., 2007). The authors explained the 
effect of CPT by the slower DNA unwinding related to the inhibition of Top1 activity rather than to 
the physical block of RNAPII by Top1cc (the collision model).  
- RNAPII degradation: 
Another effect of CPT on RNAPII that has been described by Desai et al. is the proteasomal 
degradation of Rpb1 (Desai et al., 2003). UV light, cisplatin, ecteinascidin 743 (Et743) and 
hydrogen peroxide also induce RNAPII degradation (Aune et al., 2008; Inukai et al., 2004; Jung 
and Lippard, 2006; Somesh et al., 2005) suggesting that, in a similar manner, Top1cc-induced 
stalled RNAPII complexes are targeted to degradation. However, CPT induces 
hyperphosphorylation of CTD at S5 (Sordet et al., 2008b) and this phosphorylation, but not 
phosphorylation on S2, has been described to protect RNAPII from ubiquitylation in response to 
UV (Somesh et al., 2005). Furthermore, compared to RNAPII degradation-induced by UV, Et743 
or hydrogen peroxide that is a rapid and massive event, CPT-induced RNAPII degradation is a 
relatively late (6h) and modest event. Stalled RNAPII may be recognized and ubiquitinated 
differentially depending on the types of DNA lesions. Hence, further studies are needed to 
characterize mechanistically the fate of RNAPII stalled by transcription-blocking Top1cc. 
 
I.5.2.3 Alteration of mRNA splicing  
 
Several studies have involved Top1 in splicing because of its catalytic activity and its ability to 
interact with and phosphorylate splicing factors (see section I.3.2). Thus, it is not surprising that 
CPT profoundly affects splicing events. CPT blocks the SR-kinase activity of Top1 (Rossi et al., 
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1996). However, two different studies suggest that the splicing effects of CPT are unrelated to 
defects of Top1 relaxation and/or kinase activity (Dutertre et al., 2010; Solier et al., 2010).   
Different studies have reported that CPT alters the splicing of single genes resulting in alternative 
splicing (Baranello et al., 2010; Dujardin et al., 2014; Dutertre et al., 2010; Eisenreich et al., 2009; 
Listerman et al., 2006; Shkreta et al., 2008; Solier et al., 2010; Solier et al., 2008; Solier et al., 
2004). Alternative splicing is the regulation of splice-site selection and it seems to occur in 50%-
70% of human genes resulting in the transcriptome diversity produced by a limited number of genes 
(Stamm et al., 2005).   
Listerman et al. studied the impact of CPT in the Fos pre-mRNA (Listerman et al., 2006). CPT 
enhances splicing factors accumulation on the FOS gene but not on intronless genes and this 
accumulation correlates with higher levels of cotranscriptional splicing. The authors suggested that 
CPT, by slowing down RNAPII elongation, allows more time for the splicing factors to bind to the 
nascent RNA. The decrease in RNAPII elongation rate by CPT has also been described to promote 
the skipping of exon 9 (E9) of the CFTR (cystic fibrosis transmembrane conductance regulator) 
gene by opening a time window to the negative splicing factor ETR-3 to be recruited (Dujardin et 
al., 2014). Interestingly, this study shows that the changes in the E9 splicing induced by CPT are 
not caused by an alteration of the abundance or phosphorylation of the SR proteins, likely excluding 
an effect dependent on the kinase activity of Top1 (Dujardin et al., 2014). Another example of 
alternative splicing driven by CPT is given by MDM2 (Dutertre et al., 2010). In unstressed cells, 
MDM2 expression is positively regulated by p53 and then, MDM2 negatively regulates p53 by 
suppressing p53-transcriptional activity (Oliner et al., 1993) or by targeting p53 for proteasomal 
degradation (Haupt et al., 1997). CPT induces cotranscriptional skipping of several MDM2 exons 
leading to numerous alternative transcripts that do not give rise to stable protein isoforms. However, 
CPT removal suppresses alternatively spliced variants of MDM2 and the protein is expressed again. 
In response to CPT, p53 is activated (Ljungman and Lane, 2004; Ljungman et al., 2001). Hence, the 
CPT-induced MDM2 exon skipping may be a mechanism to prevent the accumulation of the 
MDM2 protein thus avoiding p53 degradation (Dutertre et al., 2010). 
In addition to the study of the effects of CPT in the alternative splicing of some specific genes, two 
reports analyse the consequences of CPT on splicing at global genome level in human cells 
(Dutertre et al., 2010; Solier et al., 2010). Both studies agree that CPT is able to induce both exon 
skipping and exon inclusion. Solier et al. describe a time-dependent effect of splicing in response to 
CPT (Solier et al., 2010). While the appearance of novel exons is an early (1 h, 2 h and 4 h) and a 
late event (15 h and 20 h), the exons skipping is mostly a late event. Splice events occur all along 
the transcripts and tend to augment with the length of the transcript (Solier et al., 2010). Genes that 
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are downregulated in response to CPT have a higher probability to be spliced compared to 
unchanged and upregulated genes (Solier et al., 2013). Three genes categories are more affected by 
the CPT-induced alternative splicing: genes encoding splicing factors, genes related to mitosis and 
genes related to methylation (Solier et al., 2010). These data open the possibility that the splicing 
alterations of several genes in response to Top1cc could be due to the effect of CPT on genes 
encoding splicing factors. Solier et al. proposed that CPT-induced RNAPII hyperphosphorylation 
could trigger alternative splicing by affecting RNAPII pausing and splicing site selection and/or 
modulating the interaction with splicing factors. Accordingly to this hypothesis, DRB (5,6-dichloro-
1-β-D-ribofuranosylbenzimidazole), which inhibits Cdk9 and RNAPII phosphorylation, prevented 
CPT-mediated alternative splicing of RBM8A (RNA binding motif protein 8) and caspase-2 genes 
(Solier et al., 2010). By contrast, Dutertre et al. found that DRB does not suppress CPT-induced 
alternative MDM2 transcripts indicating that RNAPII phosphorylation-independent mechanisms 
also exist in response to CPT (Dutertre et al., 2010). The authors suggested that exon skipping 
induced by CPT could be caused by the de-coupling of transcription and splicing. In particular, they 
showed that CPT disrupts the interaction between the transcriptional coregulator EWS and the 
spliceosome-associated factor YB-1. The depletion of those factors reproduces the exons skipping 
induced by CPT in eight genes, including MDM2 (Dutertre et al., 2010).   
In addition to these two mechanisms, a recent paper shows that CPT treatment causes selective 
chromatin displacement of late-stage spliceosomes in non-replicating cells (Tresini et al., 2015). 
This spliceosome displacement may be another mechanism by which CPT promotes alternative 
splicing. 
 
I.5.2.4 Top1 downregulation 
 
Top1 downregulation corresponds to the reduction of Top1 cellular content during prolonged CPT 
treatment and it has been described for the first time by Beidler and Cheng in 1995 (Beidler and 
Cheng, 1995). The protein level of Top1 is strongly reduced in a time-dependent manner in less 
than 6 h of CPT treatment (Desai et al., 2003) with Top1 half-life dropping from 10-16 h down to 1-
2 h (Desai et al., 1997). CPT-induced Top1 downregulation correlates with Top1cc formation 
(Beidler and Cheng, 1995; Desai et al., 2003) suggesting that Top1 trapping triggers Top1 
downregulation (Desai et al., 2003). 
Top1 downregulation is part of the transcriptional response to CPT since it is selectively dependent 
on transcription and independent on replication. Indeed, it is suppressed by the transcription 
inhibitors DRB and α-amanitin but not by the replication inhibitor aphidicolin (Beidler and Cheng, 
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1995; Desai et al., 1997; Desai et al., 2003; Huang et al., 2010; Lin et al., 2008; Sakasai et al., 
2010a; Sordet et al., 2008b). Similarly, cycloheximide, that inhibits protein synthesis, does not 
prevent CPT-induced Top1 downregulation excluding the involvement of a reduced de novo 
synthesis (Desai et al., 1997). Top1 downregulation appears to be specific of CPT-induced Top1cc, 
since UV-trapped Top1 is not downregulated (Subramanian et al., 1998). 
The Liu’s laboratory has shown that CPT-induced transcriptional Top1 downregulation is the result 
of Top1 K48-polyubiquitylation and degradation by the 26S proteasome (Ban et al., 2013; Desai et 
al., 2001; Desai et al., 1997; Desai et al., 2003; Lin et al., 2008). Several evidences support this 
conclusion: 
1- Proteasome inhibitors (MG132, lactacystin) prevent Top1 downregulation and Top1cc 
decreasing after prolonged CPT exposure (Desai et al., 2001; Desai et al., 1997; Desai et al., 2003; 
Huang et al., 2010; Lin et al., 2008; Sordet et al., 2008b). 
2- siRNA against POMP (proteasome maturation protein), a factor which promotes the 20S 
proteasome assembly (Fricke et al., 2007), abolish Top1 downregulation (Ban et al., 2013; Lin et al., 
2009). 
3- siRNA against ATPases and non ATPases 19S components hinder Top1 degradation  (Ban 
et al., 2013). 
4- CPT induces the formation of Top1-ubiquitin conjugates (Ban et al., 2013; Desai et al., 
2001; Katyal et al., 2014; Kerzendorfer et al., 2010; Lin et al., 2008; Lin et al., 2009; Zhang et al., 
2004) in a transcription-dependent manner (Lin et al., 2008). 
5- The ubiquitin isopeptidase inhibitor G5, which depletes the free ubiquitin pool (Aleo et al., 
2006), blocks Top1 downregulation (Lin et al., 2008). 
6- Top1 downregulation is inhibited in the temperature-sensitive E1 activating enzyme mutant 
cell line ts85 (Finley et al., 1984) at the restrictive temperature that triggers UBA1 (ubiquitin-like 
modifier activating enzyme 1) degradation (Ban et al., 2013; Desai et al., 1997). 
7- Transfection of cells with the dominant-negative mutant, K48R-Ub (K48 is mutated to R on 
HA-Ub) but neither K29R-Ub nor K63R-Ub, suppresses Top1 downregulation (Ban et al., 2013; 
Lin et al., 2008). 
More recently, the same laboratory has reported a new ubiquitin-independent mechanism for the 
degradation of etoposide-induced Top2β-DNA cleavage complexes colliding with elongating 
RNAPII (Ban et al., 2013). Degradation of Top2β roadblocks requires only 19S ATPases and 20S 
proteasome (Ban et al., 2013). Based on the new findings on Top2β and on previous studies 
demonstrating that 19S ATPases are associated with elongating RNAPII (Ferdous et al., 2001; 
Ferdous et al., 2002; Gillette et al., 2004; Gonzalez et al., 2002; Muratani and Tansey, 2003), the 
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authors speculated about a possible new model for Top1 degradation depending on Top1cc polarity 
(Ban et al., 2013) (Figure 9): (i) Top1cc in the non-template strand could be unfolded by 19S 
ATPases leading elongating RNAPII to read-through Top1cc and Top1 to be ubiquitinated or (ii) 
Top1cc in the template strand could arrest elongating RNAPII leading to Top1 degradation by the 
same ubiquitin-independent pathway as for Top2β. Even if authors suggested that ubiquitin-
dependency may simply reflect a higher rate of ubiquitin-dependent degradation of Top1; currently 
there is no evidence supporting a possible ubiquitin-independent degradation pathway for Top1cc.   
 
	  
Figure 9: Proposed model for CPT-induced Top1 degradation based on Top1cc polarity. Top1cc on the non-template strand are 
proposed to be degraded by an ubiquitin-dependent mechanism whereas Top1cc on the template strand could be degraded by an 
ubiquitin-independent mechanism similarly to Top2β degradation in response to etoposide (Ban et al., 2013). 
 
Top1 ubiquitination  
The ubiquitination cascade is carried out by the sequential action of three enzymes: E1 (ubiquitin-
activating enzyme), E2 ubiquitin-conjugating enzyme and E3 ubiquitin-ligase (see section II.5.3.4 
and Figure 29). Defects in Top1 downregulation in ts85 cells treated with CPT (Ban et al., 2013; 
Desai et al., 1997) suggest that the E1 enzyme responsible for Top1 ubiquitylation is UBA1 as in 
these cells, UBA1 is rapidly degraded at restrictive temperature (Baugh et al., 2009). Four E3 
ligases have been described as potential E3 candidates for Top1 ubiquitylation: Cullin 3 (Cul3) (Lin 
et al., 2009; Zhang et al., 2004), BRCA1 (breast cancer 1) (Sordet et al., 2008b), Cullin 4A (Cul4A) 
and Cullin 4B (Cul4B) (Kerzendorfer et al., 2010). Depletion of one of these E3’s activity is able to 
prevent, at least partially, Top1 downregulation in response to CPT. Modulating the protein level of 
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Cul3, Cul4A or Cul4B by overexpression or depletion is able to reduce or enhance Top1cc and 
Top1 ubiquitin-conjugates, respectively (Kerzendorfer et al., 2010; Zhang et al., 2004). 
Interestingly, Cul4B is one of the most commonly mutated genes in X-linked mental retardation 
(MR) patients (Tarpey et al., 2007). Those patients present some clinical features similar to SCAN1 
(spinocerebellar ataxia with axonal neuropathy) patients and MR-derived cells show increased level 
of CPT-induced SSBs similar to that of SCAN1 cells (Kerzendorfer et al., 2010). Although 
published data suggest that all four E3 ligases can act on Top1 ubiquitylation, additional studies are 
needed to show whether those E3 ligases can directly ubiquitylate Top1 in vitro and in vivo and on 
which residues.  
Top1-ubiquitin conjugates are discernible after DNAse treatment of cell lysates following Top1 
immunoprecipitation, suggesting that Top1cc are ubiquitylated on the DNA (Desai et al., 2003). 
However, it is not known whether ubiquitylated Top1 is degraded on DNA and/or it is released 
from chromatin and then degraded away. The first possibility is supported by the action of Tdp1 
(tyrosyl-DNA phosphodiesterase 1), which removes Top1 from DNA more efficiently when it is 
proteolysed (Debethune et al., 2002) and by recent finding showing that etoposide treatment 
induces the accumulation of 19S factors into chromatin in a transcription-dependent manner (Ban et 
al., 2013).  
 
Impact of ubiquitin-like modifications of Top1 on Top1 downregulation  
In addition to ubiquitin, two others ubiquitin-like proteins (UBLs), SUMO1/2/3 (see section 
II.5.3.6) and ISG15 (interferon-stimulated gene 15), has been proposed to influence Top1 
downregulation (Desai et al., 2008; Kanagasabai et al., 2009; Mao et al., 2000b). UBLs are post-
translational modifications of target protein substrates and have been described on the base of their 
structural similarity and sequence homology to ubiquitin (for review see (Streich and Lima, 2014)). 
UBLs are conjugated to target proteins in a way similar to ubiquitin but using distinct E1, E2 and 
E3 enzymes (Streich and Lima, 2014). 
The SUMO-conjugates of Top1, have been originally visualized, but erroneously interpreted as 
ubiquitin-conjugates, by Desai et al. (Desai et al., 1997) and later characterized by Mao et al. (Mao 
et al., 2000b). Similarly to ubiquitylation, Top1 is SUMOylated in response to CPT and it has been 
proposed that the Top1cc, rather than Top1 undergoes SUMO-conjugation (Desai et al., 2003; Mao 
et al., 2000b). Unlike Top1 ubiquitination, Top1 SUMOylation is transcription- and replication-
independent (Mao et al., 2000b). Top1 can be conjugated to SUMO1 (Desai et al., 2001; Desai et al., 
2003; Horie et al., 2002; Katyal et al., 2014; Mao et al., 2000b) or to SUMO2/3 (Kanagasabai et al., 
2009). Horie et al. proposed that SUMO1 conjugation to Top1 amplifies the formation of Top1cc in 
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response to CPT (Horie et al., 2002). SUMO1 conjugation to substrates has been suggested to 
antagonizes their ubiquitination and to prevent their proteolysis by the 26S proteasome (Muller et 
al., 2001). Thereby, it is possible that SUMO1 may serve to prevent Top1 ubiquitination. Another 
group showed that purified CPT-induced Top1cc are enriched in SUMO2/3 chains and ubiquitin 
(Kanagasabai et al., 2009). Since SUMO2/3 polychains serve as a signal for polyubiquitylation and 
proteasome-dependent proteolysis (Weisshaar et al., 2008) and since SUMOylation and 
ubiquitylation coexist in Top1cc, SUMOylation with SUMO2/3 has been proposed to target Top1cc 
for ubiquitylation and proteolysis (Kanagasabai et al., 2009). However, further studies are needed to 
clearly show the role of SUMOylation in Top1 downregulation.  
Desai et al. showed that ISGylation is elevated in many tumours and interferes with the 
ubiquitin/26S proteasome pathway, leading to altered degradation of many cellular targets likely by 
hampering ubiquitylation through substrate competition at the E2/E3 level (Desai et al., 2006). 
Accordingly to these finding, depletion of ISG15 or UbcH8 (retinoic acid-induced gene B protein, 
the major E2 for ISG15) in breast cancer ZR-75-1 cells results in increased rate of Top1 
downregulation without affecting the level of CPT-induced Top1cc (Desai et al., 2008).  
 
Impact of DDR/Repair proteins on Top1 downregulation  
In addition to BRCA1, other DDR and repair proteins have been described to promote Top1 
downregulation in response to CPT (Alagoz et al., 2013; Christmann et al., 2008; Katyal et al., 
2014; Tomicic et al., 2005). Failure of Top1 degradation in response to topotecan was observed in 
cells deficient for WRN (Tomicic et al., 2005) or for p53 (Christmann et al., 2008). Both WRN 
(Laine et al., 2003) and p53 (Mao et al., 2000a) can directly interact with Top1. However, the 
physical interaction Top1-p53 is unlikely the regulator of Top1 downregulation because inhibition 
of p53 transcriptional activity by pifithrin-α also blocks Top1 degradation suggesting that p53 may 
control the transcription of a factor, which mediates Top1 degradation (Tomicic et al., 2005). 
Recently, the DDR kinase ATM (see section II.3.1) has also been implicated in Top1 
downregulation (Alagoz et al., 2013; Katyal et al., 2014). Human and mouse cells knockout for 
ATM accumulate CPT-induced Top1cc, are defective for Top1 downregulation and fail to recover 
transcription after CPT removal (Alagoz et al., 2013; Katyal et al., 2014). ATM deficiency leads to 
a marked reduction of Top1-ubiquitin and -SUMO1 conjugates induced by CPT (Katyal et al., 
2014). How ATM deficiency impairs Top1 ubiquitylation and SUMOylation in response to CPT 
remains to be established. However, AT (ataxia telangiectasia) cells, that are deficient for ATM, 
also display elevated expression of the ISG15 conjugation pathway that correlate with impaired 
proteasome-mediated protein degradation (Wood et al., 2011). 
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Cellular function of Top1 downregulation  
The functional meaning of Top1 downregulation has been linked to: (i) repair of Top1cc and then 
recovery of RNA synthesis by exposing the Top1-DNA binding to be processed by Tdp1 (see 
section I.6.2) (Debethune et al., 2002; Desai et al., 2003; Lin et al., 2008); (ii) decrease of the total 
cellular pool of Top1 consequently limiting further trapping of Top1 and Top1cc-induced DNA 
damage (see section I.5.2.7) (Beidler and Cheng, 1995; Desai et al., 2001).   
In agreement with these possibilities, CPT-induced downregulation of Top1 appears to be a 
mechanism of cellular resistance to avoid accumulation of Top1cc and DNA damage. Indeed, cell 
lines selected for CPT resistance have reduced amount of Top1 (Chang et al., 1992) and the extent 
of CPT-induced Top1 downregulation correlates with CPT resistance in some cancer cells (Desai et 
al., 2001). Moreover, modulating factors that influence Top1 downregulation (Figure 10) results in 
altered CPT sensitivity: 
- Proteasome inhibition, which blocks Top1 degradation, increases tumour cell sensitivity to 
CPT (Desai et al., 2001), particularly in S-phase (Zhang et al., 2004). 
- Overexpression of Cul3, which increases Top1 downregulation, confers resistance to CPT 
(Zhang et al., 2004). 
- BRCA1-deficient cells are defective for Top1 degradation and hypersensitive to CPT 
(Fedier et al., 2003; Sordet et al., 2008b).  
- Cell lines from patients with CUL4B mutations exhibit reduced Top1 ubiquitylation and 
increased CPT sensitivity (Kerzendorfer et al., 2010). 
- siRNA depletion of Cul4A decreases Top1 downregulation and enhances CPT sensitivity 
(Kerzendorfer et al., 2010) 
- Cell lines selected for CPT resistance downregulate ISG15 expression and siRNA depletion 
of ISG15 or UbcH8 increases Top1 downregulation and decreases CPT sensitivity (Desai et al., 
2008). 
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Figure 10: Model of Top1cc degradation. The diagram depicts factors described to promote (green arrows) or to inhibit (red 
arrows) Top1 degradation and cellular consequences of Top1 downregulation. Adapted from (Sordet et al., 2008b). 
 
CPT-induced Top1 downregulation occurs in normal cells but it is defective in many tumour cells 
(Desai et al., 2001). Cancer cells with impaired Top1 downregulation are hypersensitive to CPT 
(Desai et al., 2001). Similarly, in a nude mouse model, topotecan treatment causes Top1 
downregulation in many normal tissues (as blood, brain, kidney, liver, and skin) but not in 
xenografted MDA-MB-435 breast cancer cells (Desai et al., 2003). Furthermore, patients receiving 
topotecan therapy also display reduced Top1 levels in normal peripheral blood cells but not in 
leukemic cells (Hochster et al., 1997; Rubin et al., 1995). Most tumour cells are defective in CPT-
induced Top1 downregulation, which could explain in part the increased sensitivity of tumour cells 
to CPT (Desai et al., 2001). The molecular basis for the defective degradation of Top1 in many 
cancer cells is not clear. It could be related to BRCA1 inactivating mutations that occur frequently 
during tumorigenesis (Silver and Livingston, 2012) or to mutations in cullins and cofactors proteins 
(Carlucci and D'Angiolella, 2015). 	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I.5.2.5 Topological stress and R-loops 
 
According to the “twin-supercoiled-domain” model (see section I.3.1), RNAP would generate 
approximately seven supercoils per second depending on the rate of transcription, the length of the 
transcribed unit and the arrangement of promoters (for example, divergent transcription) (Darzacq 
et al., 2007). These supercoils are resolved by DNA topoisomerases, and if not dissipated, they 
create a torsional stress (Kouzine et al., 2013). Several studies in bacteria, yeast and human cells 
have shown that deletion of Top1 increases supercoiling in front of the elongating RNAP and leads 
to melting of the DNA and the formation of R-loops behind the RNAP (Drolet, 2006; Drolet et al., 
1994; El Hage et al., 2010; Masse and Drolet, 1999a; Tuduri et al., 2009). Less works have 
investigated the topological stress induced specifically by CPTs. Koster and colleagues measured 
the real-time uncoiling rate of human Top1 in the presence of topotecan in the context of a single-
molecule (Koster et al., 2007). They reported both in vitro and in cellulo (yeast) that topotecan 
significantly hinders Top1-dependent DNA uncoiling, with a more important impact on the removal 
of positive versus negative supercoils thus showing that topotecan induces an accumulation of 
positive supercoils (Koster et al., 2007). More recently, the Levens’s lab mapped transcription-
dependent dynamic supercoiling in human cells by using psoralen photobinding and they clearly 
demonstrated that both Top1 and Top2 prevent the build-up of negative supercoiling in promoter 
regions in cellulo (Kouzine et al., 2013). Five min of CPT treatment strongly increases negative 
supercoils at the TSS and upstream of all genes, indicating a broad requirement for Top1 activity at 
promoters, but the effect of CPT is stronger in moderately expressed genes than in highly expressed 
genes. Effectively, moderately expressed genes depend only on Top1 whereas highly expressed 
genes recruit Top2 additionally to Top1 (Kouzine et al., 2013). Interestingly, Bru-Seq in response to 
CPT reveals a strong enrichment in PROMPTs (promoter upstream transcripts) (Veloso et al., 2013), 
that are a product of divergent transcription (Kapusta and Feschotte, 2014). The activity of 
divergent promoters may be mechanically coupled through dynamic supercoiling thus, a possible 
scenario is that the negative supercoiling induced by CPT at promoter could facilitate DNA melting, 
open complex formation and divergent transcription (Kouzine et al., 2013). 
The accumulation of negative supercoiling can promote the formation of non-B DNA structures 
such as Z-DNA, cruciforms and most likely R-loops that can affect gene expression (Drolet, 2006). 
R-loops are three-stranded structures formed by an RNA-DNA hybrid plus a displaced single strand 
DNA (ssDNA), identical to the RNA molecule (Aguilera and Garcia-Muse, 2012) (Figure 11).  
The first R-loops were characterized in vitro in 1976 (Thomas et al., 1976), in cellulo in bacteria in 
1994 (Drolet et al., 1994) and then showed in different organisms (reviewed in (Aguilera and 
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Garcia-Muse, 2012; Groh and Gromak, 2014; Hamperl and Cimprich, 2014; Skourti-Stathaki and 
Proudfoot, 2014)). In living cells, R-loops can form in cis during transcription (co-transcriptional R-
loop). The first model for R-loop formation envisages that R-loops are a direct extension of the 
RNA-DNA hybrid within the transcription bubble (“extended RNA-DNA hybrid” model) but this 
scenario is not consistent with the crystallographic structure of RNAPII (Westover et al., 2004). The 
most accepted mechanism is the “thread back” model, in which the nascent RNA transcript passes 
through the exit pore of the RNA polymerase before threading back to anneal with the template 
DNA (Roy et al., 2008). However, recently the Konsland’s laboratory has shown that R-loops can 
be formed in trans (away from the initial transcription point) since RNA transcribed at one locus 
can invade an homologous DNA at another locus and this mechanism is dependent on Rad51 
(Wahba et al., 2013). 
 
	  
Figure 11: Inhibition of Top1 activity by CPT promotes R-loop formation. Trapping of Top1 by CPT results in SSB formation 
and accumulation of positive supercoils ahead of transcribing RNAPII and negative supercoils behind it. Negative supercoiling 
triggers partial unwinding of the DNA double helix, thereby facilitating the intrusion and the annealing of the nascent RNA with the 
complementary DNA strand (Adapted from (Hamperl and Cimprich, 2014)). 
 
Transcription-dependent topological state and DNA sequence are important features controlling R-
loop generation. The initial formation of an R-loop is facilitated in vitro by G clusters and DNA 
nicks downstream of the promoter on the non-template DNA strand, whereas negative supercoils 
and high G density promote the stabilisation and the elongation of the RNA-DNA hybrid (Roy et al., 
2010). Once formed, R-loops are particularly stable since RNA-DNA hybrids are 
thermodynamically more stable than double-strand DNA (dsDNA) (Roberts and Crothers, 1992).  
R-loops can be both beneficial and deleterious to cells. The programmed formation of R-loops is 
implicated in important biological processes, such as immunoglobulin class switch recombination 
(CSR) (Yu et al., 2003), regulation of gene expression (Tous and Aguilera, 2007), transcription 
termination (Skourti-Stathaki et al., 2011) and epigenetic mechanisms (Ginno et al., 2012). 
However, unscheduled R-loops can be a dangerous source of DNA damage because of the exposure 
of the ssDNA resulting from the RNA-DNA hybridization. ssDNA is chemically more unstable and 
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vulnerable to DNA-damaging agents than duplex DNA, thereby R-loops can promote genome 
instability or change the transcriptional landscape (for review (Aguilera and Garcia-Muse, 2012; 
Hamperl and Cimprich, 2014; Sollier and Cimprich, 2015)). Topoisomerases and RNA processing 
factors (such mRNA biogenesis factors) prevent R-loop formation while the RNaseH enzymes and 
RNA-DNA helicases act to remove R-loops (Hamperl and Cimprich, 2014; Skourti-Stathaki and 
Proudfoot, 2014). 
The role of Top1 in preventing R-loop has been initially investigated in E. coli (Drolet, 2006; 
Drolet et al., 1994; Drolet et al., 1995; Masse and Drolet, 1999a; Masse and Drolet, 1999b). In E. 
coli the topology of its circular DNA is regulated by the concerted action of DNA gyrase that 
introduces negative supercoils and Topoisomerase 1 (TopA) that relaxes them. Transcription-
dependent supercoils accumulate in TopA mutants and are responsible for defects in full-length 
RNA synthesis, metabolism and growth (Drolet et al., 1995). The phenotype of E. coli TopA 
mutants is reversed by RNAseH1 overexpression (Drolet et al., 1995). In yeast, the role of Top1 has 
been analysed in the highly transcribed ribosomal DNA cluster (El Hage et al., 2010). Yeast Top1 
mainly resolves negative supercoils behind RNAPI, whereas Top2 resolves positive supercoils in 
front of it. Chromatin/DNA immunoprecipitation (ChIP/DNA) experiments by using the 
monoclonal antibody S9.6 directed against RNA-DNA hybrids reveal that R-loops form in the wild 
type yeast, in particular over the 18S 5’ region. Those R-loops are significantly increased in yeast 
mutants lacking Top1 and/or Top2. The sites where R-loops accumulate correlate with truncated 
fragments of pre-rRNA and with piled up RNAPI in Top1 mutants (El Hage et al., 2010). Finally, 
human and murine cells expressing low to undetectable levels of Top1 display replication 
impairment at gene-rich regions. RNaseH overexpression suppresses this phenotype indicating that 
Top1 avoids R-loops accumulation coordinating supercoils relaxation and splicing thus preventing 
interference between replication and transcription (Tuduri et al., 2009). 
CPT, by inhibiting the activity of Top1 and by triggering the accumulation of negative supercoiling, 
may have the same effect as Top1 downregulation in R-loop formation. RNaseH1 overexpression 
decreases the induction of γH2AX following CPT treatment in post-mitotic primary rat neurons and 
in replication-blocked and replicating HeLa cells (Sollier et al., 2014; Sordet et al., 2009). The 
direct impact of CPT treatment in accumulating and stabilizing R-loops in cellulo has also been 
shown by recent studies (Groh et al., 2014; Marinello et al., 2013; Powell et al., 2013; Stuckey et al., 
2015). In response to CPT, R-loops, visualized by immunofluorescence with the S9.6 antibody, are 
rapidly stabilized at nucleoli and mitochondria in human cells with a kinetic that closely correlates 
with Top1cc formation (Marinello et al., 2013). By using ChIP/DNA Powell et al. show that 
topotecan increases R-loop levels over the Snord116 paternal locus (Powell et al., 2013) (Figure 
	   	   	   45 	  
12). This R-loop accumulation causes chromatin decondensation and inhibition of RNAPII 
elongation resulting in the inhibited expression of the non-coding RNA (ncRNA) Ube3a-ATS and 
the expression of the paternal Ube3a gene, which is normally silenced by Ube3a-ATS. This study 
holds promise for using topotecan to treat Angelman syndrome, a neurodevelopmental disorder 
characterized by the loss of function of the expressed maternal Ube3a (Powell et al., 2013). CPT 
also enhances R-loop formation over expanded GAA in frataxin (FXN) gene in cells from 
Friedreich ataxia (FRDA), another neurodegenerative disorder (Groh et al., 2014). These R-loops 
are responsible for FXN transcriptional repression and promote formation of repressive H3K9me2 
marks suggesting a molecular mechanism of the FRDA pathology (Groh et al., 2014).  
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	   	  
Figure 12: Topotecan-dependent reactivation of paternal Ube3a allele. ncRNA Ube3a-ATS expression represses paternal Ube3a 
in cis. Topotecan inhibits Top1 catalytic activity leading to R-loops accumulation over the Snord116 locus that results in chromatin 
decondensation, inhibition of Ube3a-ATS transcription and reactivation of paternal Ube3a expression (Groh and Gromak, 2014; 
Powell et al., 2013). 
 
I.5.2.6 Induction of antisense transcripts 
 
A number of works from Capranico’s laboratory have described a transcriptional response to 
prolonged CPT treatment (4 h) likely linked to sustained CPT interference with RNAPII regulation 
(for review see (Capranico et al., 2010)). This response involves a more accessible chromatin 
conformation and the induction of low-abundance antisense transcripts (Baranello et al., 2010; 
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Bertozzi et al., 2011; Marinello et al., 2013). CPT triggers an increase of antisense transcripts at the 
5’ and 3’ ends of the human HIF1α gene. These antisense transcripts overlap with the primary sense 
transcript of HIF1α gene and their expression correlates with a reduction of the mRNA (Baranello 
et al., 2010). The 5’ antisense HIF1α localizes mainly at the nuclear membrane close to the nuclear 
pore protein Nup62 suggesting a role in the nucleus-cytoplasm transporting machinery (Bertozzi et 
al., 2011). Although antisense transcripts have been suggested to trigger silent chromatin assembly 
(Grewal and Moazed, 2003), the increasing level of HIF1α antisense transcripts is not associated 
with H3K9me2 repressive chromatin mark, but to a more accessible chromatin structure (Baranello 
et al., 2010). Those observations have suggested that CPT induces an imbalance of sense/antisense 
transcripts.  
More recently, RNA-sequencing analysis in response to CPT (4 h) has revealed that Top1cc 
specifically enhance antisense transcripts at CpG island promoters of intermediate activity in 
different human cell types (Marinello et al., 2013). Those promoter-associated antisense transcripts 
have features of divergent promoters: symmetrical chromatin architecture with two peaks of paused 
RNAPII, and two domains of the active H3K4me3 and H3K27ac marks. CPT-induced antisense 
transcripts are Cdk9-dependent and replication-independent. Since bidirectional promoters have a 
higher rate of transcription-generated negative supercoils, it is possible that the accumulation of R-
loops and/or torsional stress at CpG island promoters of moderately expressed genes may lead to 
antisense transcript accumulation. However, the torsional stress generated by the inhibition of Top1 
activity is not sufficient to explain the induction of antisense transcripts by CPT because depletion 
of Top1 by siRNA or shRNA decreases the levels of antisense transcripts indicating that their 
induction is dependent on Top1cc (Baranello et al., 2010; Marinello et al., 2013). Indeed, K+SDS 
immunoprecipitation to map Top1cc at TSS-proximal regions of active divergent promoters shows 
a rapid burst of Top1cc that correlate with a transient RNAPII block at promoter (Marinello et al., 
2013). 
 
I.5.2.7 Induction of DNA damage and DDR activation 
 
Similarly to replication, Top1cc stabilized by CPT can be converted into irreversible Top1cc upon 
collision with the transcriptional machinery, which determines DNA end misalignement and 
precludes end religation (Pommier, 2006; Wu and Liu, 1997). This collision results in the 
production of (i) Top1-linked SSBs (Hsiang et al., 1985) (Figure 13A), for review see (Ashour et 
al., 2015) and (ii) DSBs (Sordet et al., 2010; Sordet et al., 2009) (Figure 13B). 
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The Liu’s laboratory initially demonstrated the involvement of transcription in CPT-induced DNA 
damage (Wu and Liu, 1997). They showed that the conversion of reversible Top1cc into 
irreversible Top1cc by transcription occurs primarily on the template strand within the transcribed 
region with a maximal frequency near the promoter (Wu and Liu, 1997). This is in agreement with 
a gradual decrease in transcriptional activity at sites distal from the promoter (Bendixen et al., 1990; 
Khobta et al., 2006) (see section I.5.2.2). However, the authors also reported the generation of a 
number of transcription-dependent irreversible Top1cc in the non-template strand located upstream 
of the promoter (Wu and Liu, 1997). 
In non-proliferative cells, CPT induces SSBs that can be visualized by alkaline comet assay in a 
replication-independent but transcription-dependent manner (Huang et al., 2010; Katyal et al., 2014; 
Lin et al., 2008). Those CPT-induced SSBs can be enhanced by inhibition of PARylation (Lin et al., 
2008). 
The other type of transcription-dependent lesions produced by CPT-stabilized Top1cc are 
transcription-coupled DSBs (TC-DSBs) (see Chapter II for description of DSBs). The production 
of TC-DSBs was first reported by Sordet et al. in post-mitotic primary neurons and lymphocytes 
and in EdU-negative cycling cells (cells outside of S-phase) (Sordet et al., 2010; Sordet et al., 2009) 
and then confirmed by several studies in different cellular models (Das et al., 2009; Huang et al., 
2010; Katyal et al., 2014; Regairaz et al., 2011; Sakai et al., 2012; Sakasai et al., 2010a; Tian et al., 
2009; Zhang et al., 2011). The nature of transcription-mediated DNA damage and downstream 
cellular responses is less well characterized than that of replication-induced damage. 
The presence of DSBs can be monitored by the induction of comet tail moment in neutral condition 
and by the activation of DDR. In post-mitotic primary neurons and lymphocytes, CPT produces 
DSBs and activates DDR leading to the formation of large nuclear DDR foci containing activated 
ATM, γH2AX, activated Chk2, MDC1 (mediator of DNA-damage checkpoint 1) and 53BP1 (tumor 
protein p53 binding protein 1) (Sordet et al., 2009). Those replication-independent DSBs are 
dependent on RNAPII transcription as inhibition of transcription by DRB, flavopiridol (FLV) or α-
amanitin suppresses DSB induction and the activation of the ATM-DDR pathway (Sordet et al., 
2009). In addition, those TC-DSBs are located inside transcription factories since they colocalize 
with the euchromatin marker H3K9ac and S5-phosphorylated RNAPII (Sordet et al., 2009). 
CPT-induced TC-DSBs form foci that have specific characteristics that make them different from 
replicational foci. In asynchronously growing cancer cells, Sakasai et al. distinguish 53BP1 foci 
associated to TC-DSBs from 53BP1 foci associated with RC-DSBs (Sakai et al., 2012; Sakasai et 
al., 2010a). The transcriptional 53BP1 foci are large foci compared to the smaller replicational foci 
characteristic of S-phase, they are completely dependent on ATM, they do not colocalize with RPA 
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and they appear only at CPT concentration > 1 µM. In addition, these foci are formed with a slower 
kinetic compared to replicational foci but are repaired more rapidly (Sakai et al., 2012). 
The other key feature of CPT-induced TC-DSBs is the strong activation of ATM and the ATM-
dependent DDR pathway (Huang et al., 2010; Katyal et al., 2014; Lin et al., 2008; Sakai et al., 
2012; Sakasai et al., 2010a; Sordet et al., 2010; Sordet et al., 2009; Tian et al., 2009). In non-
replicating cells, CPT-induced ATM activation is dependent on transcription (Huang et al., 2010; 
Katyal et al., 2014; Lin et al., 2008; Sakasai et al., 2010a; Sordet et al., 2009) and on proteasome 
activity (Huang et al., 2010; Katyal et al., 2014; Lin et al., 2008) and independent of replication. 
The DDR response to TC-DSBs is also dependent on ATM: γH2AX (Katyal et al., 2014; Sordet et 
al., 2009), 53BP1 (Sakasai et al., 2010a; Sordet et al., 2009), p53 (Tian et al., 2009) and Chk2-T68 
(Sordet et al., 2009). This CPT-induced ATM-dependent DDR pathway can be enhanced by 
inhibition of PARylation (Lin et al., 2008; Sakai et al., 2012; Zhang et al., 2011) or depletion of 
Tdp1 (Das et al., 2009; Katyal et al., 2014). 
In CPT-treated post mitotic cells, the induction of γH2AX foci has been described to be completely 
dependent of ATM (Katyal et al., 2014; Sordet et al., 2009) but independent of Nbs1 (Katyal et al., 
2014), a component of the MRN complex, which acts as ATM cofactor (see Table 6 and section 
II.5.1.1). In those cells, the kinase DNA-PK (see section II.3.3) is also activated in an ATM-
dependent manner (Sordet et al., 2009) but the role of this activation is not known yet. DNA-PK 
inhibition does not impact CPT-induced γH2AX foci in post mitotic neurons (Katyal et al., 2014; 
Sordet et al., 2009). However, the maintaining of γH2AX foci after CPT removal is dependent on 
DNA-PK activity indicating a role for DNA-PK in the response to TC-DSBs that remain to 
characterize (Katyal et al., 2014). By contrast, the ATR kinase (see section II.3.2) is likely not 
implicated in the response to TC-DSBs since it is not or only weakly expressed in post mitotic cells 
(Jones et al., 2004; Sordet et al., 2009). 
Mechanistically, the production of TC-DSBs involves R-loops (see section I.5.2.5) as RNaseH1 
overexpression reduces the CPT-induced γH2AX foci in both post mitotic neurons treated with CPT 
as well as in HeLa cells in which replication was blocked before treatment with CPT (Sordet et al., 
2009).  
As discussed above, R-loops may form as negative supercoiling accumulates behind the 
transcription complexes arrested by Top1cc (Drolet et al., 1994) or by a possible interference with 
splicing regulated by the SR-kinase activity of Top1, which is also known to promote R-loops (Li 
and Manley, 2005; Soret et al., 2003). How DSBs arise from a transcription-blocked Top1cc and an 
R-loop remains to be established. Recently, it has been reported that R-loops can be converted in 
DNA damage by the TCR through the activity of the endonucleases XPF and XPG (xeroderma 
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pigmentosum group-F/G complementing protein) and the participation of the NER factors XPA, 
XPB, XPD and CSB (Sollier et al., 2014). Indeed, XPG depletion reduces γH2AX foci in 
replicating cells treated with CPT (Sollier et al., 2014). Further studies will be necessary to 
elucidate the mechanism of production of TC-DSBs and the role of R-loops and R-loop processing 
factors in TC-DSB production. 
The R-loop-dependent nature of CPT-induced TC-DSBs raises the question whether TC-DSBs 
occur at specific genomic sites with features that promote R-loop formation. The co-staining of 
γH2AX foci and IgH locus by ICC-FISH experiments (immunocytochemistry staining followed by 
fluorescence in situ hybridization) shows an enrichment of γH2AX at those sites in unstimulated 
splenocytes treated by CPT (Sordet et al., 2010). IgH corresponds to immunoglobulin heavy chain 
locus where CSR occurs (Petersen et al., 2001). CSR is a process enabling mature B cells to change 
antibody isotypes and it involves transcription, R-loops and DSB production (Chaudhuri and Alt, 
2004). Therefore, authors suggested that CPT-induced TC-DSBs may form at specific genomic 
sites (Sordet et al., 2010). 
 
	  
Figure 13: Schematic representation of the conversion of CPT-stabilized Top1cc in DNA damage by transcription. Top1cc 
trapped by CPT in the template strand collides with transcribing RNAPII. The collision converts reversible Top1cc into irreversible 
Top1cc resulting in the production of (A) Top1-linked SSBs or (B) DSBs by an R-loop dependent mechanism and activation of the 
ATM-DDR pathway (Adapted from (Sordet et al., 2009)).  
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In addition to replication-associated cytotoxicity, transcription-induced DNA damage can 
participate to CPT cytotoxicity (Katyal et al., 2014; Morris and Geller, 1996; Morris et al., 2001; 
Sakasai et al., 2010a; Stefanis et al., 1999). In cancer cells, CPT cytotoxicity becomes not only 
dependent on replication at high (>1 µM) concentrations (Holm et al., 1989; O'Connor et al., 1991). 
However, CPT induces cell-death in post-mitotic cells by inducing apoptosis in a transcription-
dependent manner (Morris and Geller, 1996; Morris et al., 2001; Stefanis et al., 1999). In neurons, 
CPT-induced cell death is mediated by the activation of a Cdk5-ATM-p53 pathway, which triggers 
cell-cycle re-entry and expression of the p53 target genes related to death such as Puma and Bax 
(Tian et al., 2009). Although the ATM-dependent pathway controls cell fate, the ATM-mediated 
response appears to be different in post mitotic and cycling cells treated with CPT. Indeed, ATM 
promotes cellular survival in G1-phase cells exposed to CPT by activating the G1/S and S-phase 
checkpoint and by protecting cells from DNA-PK-induced cell killing (Sakasai et al., 2010a). The 
authors suggested two possible explanations for their observations: (i) the ATM-dependent 
checkpoint activation in G1 limits the number of DSBs by avoiding the entering of damaged cells in 
S-phase and the replication-dependent conversion of SSBs in DSBs that massively activate DNA-
PK in S-phase or (ii) a complex cross-regulation between the two kinases exists (Sakasai et al., 
2010a). In any case, transcription-dependent processing of the Top1cc may lead to the generation of 
an intermediate that is lethal to cells but the nature of this intermediate is not known. 
It appears clearly that ATM signalling coordinates the response to DNA damage induced by 
transcription-dependent Top1cc by controlling Top1 degradation (Alagoz et al., 2013; Katyal et al., 
2014), by promoting the activity of Tdp1 (Das et al., 2009), by regulating the level of ROS (Guo et 
al., 2010; Ito et al., 2004; Okuno et al., 2012) that can further trap Top1 (Daroui et al., 2004; 
Pourquier and Pommier, 2001), by regulating transcription in presence of damaged DNA (Alagoz et 
al., 2013; Shanbhag et al., 2010), by activating DDR response to transcriptional DSBs (Sordet et al., 
2009) and by controlling cell’s fate (Sakasai et al., 2010a; Tian et al., 2009). 
 
I.6 Repair of irreversible Top1cc 
 
As mentioned above, a trapped Top1cc creates a SSB associated with a covalently-linked Top1 
molecule at the 3’ end of the break and a free 5’ end generally associated with a complementary 
strand. In the case of transcription-mediated Top1cc, the resulting double-strand termini are DNA-
RNA hybrids, whereas in the case of replication-mediated Top1cc, the DNA-DSEs are composed of 
the DNA template and the newly synthesized leading strand. In the case of Top1cc formed by an 
SSB or by a neighbouring Top1cc on the opposing strand from the Top1 scissile strand, a staggered 
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DSB is formed. Those DNA termini are not suitable for repair as the proper substrate for DNA 
ligases are a 3’-hydroxyl and a 5’-phosphate. 
Thus, the “cleaning” of DNA ends by removing Top1 covalent complexes is the requirement to 
repair the DNA damage associated with irreversible Top1cc and to allow transcription and 
replication restart. Deciphering the biochemical pathways involved in the repair of Top1 suicide 
complex started in yeast. The human orthologs of many of the yeast genes identified for Top1 repair 
are mutated in hereditary diseases predisposing to cancer and sensitize cells to CPT (for gene list, 
see (Pommier, 2006; Pommier et al., 2006)). The three main pathways (reviewed in (Ashour et al., 
2015; Pommier et al., 2006; Pommier et al., 2003; Xu, 2015)) for irreversible Top1cc repair are: (i) 
the helicase pathway, (ii) Top1 excision by Tdp1, (iii) Top1 excision by nucleases. The apparent 
redundancy of the Top1 repair pathways is consistent with the formation of irreversible Top1cc 
under physiological conditions (Pourquier and Pommier, 2001). It seems that each pathway is 
preferentially used for a particular Top1cc (for example transcription mediated-Top1cc or 
replication-mediated Top1cc), and in a specific cellular context (for example replicating or post-
mitotic cells). The choice of the pathway is at least in part determined by the nature of the DNA 
lesion. Further studies are necessary to clarify this point but the working model is: the preferential 
repair of transcriptional-Top1cc by the Tdp1 excision pathway and the preferential repair of 
replicational-Top1cc by the helicases or the endonucleases pathway. 
 
I.6.1 Helicase pathway 
 
This pathway is not possible for Top1cc produced by lesions affecting the 5’ end of the broken 
DNA, since it relays on the efficacy of Top1 in religating a 5’-OH to the Top1cc. Top1 religation 
becomes possible in the case of replication- or transcription- dependent Top1cc following 
regression of the replication or transcription complexes (Pommier et al., 2006). 
Replication fork regression leads to the formation of a “chicken foot” DNA structure by newly 
synthesized strands, which is topologically equivalent to a Holiday junction. These structures can be 
resolved by RecQ helicases, such as BLM (bloom syndrome, RecQ-helicase-like) and WRN, and 
Top3α (for review see (Pommier et al., 2006; Pommier et al., 2003)). WRN deficient cells are 
hypersensitive to Top1 inhibitors, show enhanced DNA replication block and S-phase arrest and 
accumulate DSBs suggesting a role of WRN in the resolution of stalled replication forks induced by 
trapped Top1 (Christmann et al., 2008). Recently, it has been shown that CPT-induced fork slowing 
and reversal is promoted by PARP1 activity, which inhibits the helicase RECQ1 locally, thereby 
restraining the restart of reversed forks until Top1cc repair is complete (Berti et al., 2013; Ray 
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Chaudhuri et al., 2012) (Figure 16A). 
A similar mechanism may be also hypothesized for transcription following RNAP backtracking.   
Top1 can also religate a non-homologous DNA strand bearing a 5’-hydroxyl end, which results in 
non-homologous recombination (Pommier et al., 1995). 
 
I.6.2 Excision by Tdp1 pathway 
 
I.6.2.1 Structure and function of the Tdp1 enzyme 
 
Tdp1 was discovered in 1996 by Nash and coworkers in Saccharomyces cerevisiae as the enzyme 
capable of hydrolysing the covalent bond between the Top1 catalytic tyrosine and the 3’ end of the 
DNA (Pouliot et al., 1999; Yang et al., 1996). This activity was named tyrosyl-DNA 
phosphodiesterase 1. Tdp1 generates a 3’-phosphate, which is further processed by a 3’-
phosphatase, such as PNKP (polynucleotide kinase phosphatase) (Whitehouse et al., 2001). 
Tdp1 is highly conserved in eukaryotes and belongs to the phospholipase D (PLD) superfamily 
(Interthal et al., 2001), which comprises a heterogeneous group of enzymes that catalyse phosphoryl 
transfer reaction. Human Tdp1 is a 68-kDa polypeptide ubiquitously expressed. Human Tdp1 has 
an analogous 3’-phosphotyrosyl processing activity to its yeast counterpart (Interthal et al., 2001), 
while having only about 15% sequence identity (Cheng et al., 2002). Human Tdp1 is constituted by 
608 amino acids organised in two domains (Interthal et al., 2001; Pommier et al., 2014) (Figure 
14A): 
- N-terminal domain (1-148 aa): It is the poorly conserved domain or absent in lower 
eukaryotes. It is dispensable for enzymatic activity, yet it regulates Tdp1 recruitment and protein 
stability by receiving post-translational modifications (see section I.6.2.3). 
- C-terminal domain: It is the catalytic domain belonging to the PLD family as it contains two 
catalytic HKN motifs (amino acids 262-289 the first HKN and 492-522 the second HKN), the most 
conserved regions among the Tdp1 orthologs, separated from each other by 210 amino acid 
residues. Differently from the other PLD family members, the aspartates in the HKD motifs are 
replaced by asparagines (HKN motifs) in Tdp1. Mutations of histidine (H263A) or lysine (K265S) 
in the first HKN motif results in complete loss of Tdp1 activity, whereas analogous mutations 
(H493A/R/N or K495S) in the second HKN motif lead to a strong decrease in Tdp1 activity 
(Interthal et al., 2001; Raymond et al., 2004). 
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Figure 14: Schematic of Tdp1 and Tdp1 physiological substrates. (A) Representation of N-Terminal (white) and C-terminal 
(pink) domains of Tdp1. HKN motifs and the sites of phosphorylation (S81) and SUMOylation (K111) are indicated. Adapted from 
(Pommier et al., 2014). (B) Some DNA adducts that can be processed by Tdp1 are represented. Adapted from (Ashour et al., 2015).  
 
Crystal structures demonstrate that Tdp1 acts as a monomer with the two HKN motifs in close 
proximity to form the catalytic site located inside an asymmetric substrate-binding channel (Davies 
et al., 2002a; Davies et al., 2002b; Davies et al., 2003). This “binding channel” is relatively narrow 
and positively charged to bind the single-stranded DNA substrate. The DNA substrate is stabilized 
by hydrophobic or polar interactions thereby the binding of Tdp1 to DNA is not restricted to 
particular base sequences. This is consistent with the ubiquitous nature of Top1cc on the genome 
and with the requirement of Tdp1 action irrespective of the DNA sequence environment. In addition, 
the characteristics of Tdp1 “binding channel” make Tdp1 able to resolve a broad spectrum of 3’-
blocking termini (Figure 14B): 
- 3’-phosphotyrosine/phosphotyrosyl peptide: Tdp1 hydrolyses 3’-tyrosine in a variety of 
DNA structures, including dsDNA with 3’-tyrosine at a nick or a gap and 3’-tyrosine at blunt, 
frayed or tailed ends but with a preference for ssDNA (Raymond et al., 2004; Yang et al., 1996).  
Tdp1 can process 3’-peptides ranging from one to more than 100 aa and DNA fragments consisting 
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of at least 4 nucleotides with a major efficiency for longer oligonucleotides and shorter peptides 
(Debethune et al., 2002; Interthal and Champoux, 2011; Interthal et al., 2005a). The ability of Tdp1 
to hydrolyse 3’-phosphotyrosyl linkage is consistent with a role for the enzyme in protecting cells 
against cytotoxic Top1-associated DNA damage. To be a good substrate for Tdp1, Top1 covalently 
linked to DNA has to be prior denatured or proteolyzed (see section I.5.2.4) (Debethune et al., 
2002; Interthal et al., 2005a). Yeast Tdp1 has been reported to resolve 5’-phosphotyrosyl linkage 
(Nitiss et al., 2006) and recently a similar action has also been characterized in vitro for human 
Tdp1 (Murai et al., 2012) indicating a possible back-up role for Tdp1 in Top2cc repair.   
- 3’-phosphoglycolate: Tdp1 can process 3’-phosphoglycolate ends that are commonly 
produced by oxidative DNA damage or by radiotherapy (El-Khamisy et al., 2007; Inamdar et al., 
2002). 
- 3’-deoxyribose phosphate: The nucleosidase activity of Tdp1 can remove a single 
nucleoside from the 3’ end of DNA or RNA molecules where they are not 3’-phosphorylated 
(Interthal et al., 2005a). This action of Tdp1 results in the generation of one nucleotide shorter 
polymer bearing a 3’-phosphate group. Tdp1 can remove the abasic mimic tetrahydrofuran moiety 
(Interthal et al., 2005a) and the anti-viral and anti-cancer chain-terminating nucleoside analogues 
such as acyclovir, zidovudine and cytarabine (Huang et al., 2013). Tdp1 also processes 3'-
deoxyribose lesions generated by alkylating agents after the apurinic or apyrimidinic lyase 
processing such in the case of methylmethanesulfonate and temozolomide (Alagoz et al., 2014; 
Lebedeva et al., 2011; Murai et al., 2012). 
- 3’-synthetic DNA adducts: Tdp1 can resolve a wide range of 3’-synthetic DNA adducts such 
as biotin and a variety of fluorophores. This Tdp1 property has been used for screening Tdp1 
inhibitors and for mechanistic studies (Antony et al., 2007b; Dexheimer et al., 2010; Rideout et al., 
2004). 
 
To process its substrates, Tdp1 proceeds via a two step-reaction without nucleotide cofactor or 
metal (Interthal et al., 2001; Pommier et al., 2014) (Figure 15). The first step consists in a 
nucleophilic attack of the Top1-DNA phosphotyrosyl bond by H263 of the first HKN motif 
resulting in the liberation of Top1 and in the formation of a Tdp1-DNA covalent intermediate. This 
intermediate is resolved by a hydrolytic reaction driven by H493 of the second HKN motif leading 
to the liberation of Tdp1 and to a 3’-phosphate terminus. 
 
	   	   	   55 	  
	  
Figure 15: Tdp1 catalytic cycle. The nucleophilic attack of the phosphodiester bond Top1-DNA by H263 of Tdp1 results in the 
release of Top1 and the formation of a covalent Tdp1-DNA intermediate. Then, a second nucleophilic attack via an activated H2O 
molecule by H493 of Tdp1 allows the release of Tdp1 and the generation of an unligatable 3’-phosphate (3’-P) end. Adapted from 
(Ashour et al., 2015). 
 
I.6.2.2 Physiological consequences of Tdp1 mutations: SCAN1  
 
Tdp1 is physiologically important since a mutation in the enzyme is responsible for an autosomal 
recessive called spinocerebellar ataxia with axonal neuropathy (SCAN1) (Takashima et al., 2002). 
To date, SCAN1 is restricted to nine patients from a single Saudi Arabian family. Clinically, 
affected individuals suffer from early onset ataxia (≈ 15 years), cerebellum atrophy and peripheral 
neuropathy but without involving cognitive decline (Takashima et al., 2002; Walton et al., 2010). 
SCAN1 patients lack extra-neurological symptoms like chromosomal instability and cancer 
predisposition that are found in individuals affected by other DNA repair-related disorders such as 
ataxia telangiectasia (Rass et al., 2007).  
To date, the only mutation known to be associated with SCAN1 is a homozygous mutation resulting 
in the substitution of histidine by arginine (H493R) within the second HKN motif of the Tdp1 
active site (Takashima et al., 2002). Recombinant mutated Tdp1 is ≈ 25-fold less active of wild-
type (Interthal et al., 2001) and SCAN1 cell extracts display a Tdp1 activity reduced of ≈ 100 fold 
(Interthal et al., 2005b). The greater defect in SCAN1 extracts is likely to reflect the 2-3- fold 
reduction in Tdp1 protein level likely linked to instability of the mutant protein. The H493R 
mutation affects primarily the second step of Tdp1 catalytic reaction (Figure 15) thus leading to the 
liberation of Top1 adducts and the accumulation of Tdp1-DNA covalent intermediates (Interthal et 
al., 2005b). Wild-type Tdp1 can hydrolyse Tdp1-DNA covalent complex, which explains why 
heterozygote carriers for H493R mutation do not display SCAN1 symptoms (Interthal et al., 2005a). 
However, the relative proportion of unprocessed (and therefore Top1-associated) versus partially 
processed (and therefore Tdp1-associated) termini that accumulate in SCAN1 cells is unclear. 
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Consequently, the relative contribution of these covalent complexes to the SCAN1 phenotype is 
unknown.  
Consistently, features of SCAN1 cells are hypersensitivity to CPT and defective repair of CPT-
induced Top1cc associated with accumulation of SSBs, Top1-DNA and Tdp1-DNA covalent 
complexes (Barthelmes et al., 2004; El-Khamisy et al., 2005; Interthal et al., 2005b; Miao et al., 
2006). The deficiencies in the repair of Top1cc have been proposed to be responsible for the 
neurodegenerative phenotype of SCAN1 patients but further studies are necessary to understand the 
molecular mechanism leading to neurodegeneration. 
 
I.6.2.3 Post-translational modification of Tdp1  
 
The action of Tdp1 is tightly regulated by post-translational modifications on its N-terminal 
domain: 
- Phosphorylation: ATM and DNA-PK are able to phosphorylate Tdp1 on S81 (Chiang et al., 
2010; Das et al., 2009). S81 phosphorylation is not required for Tdp1 enzymatic activity (Antony et 
al., 2007b; Chiang et al., 2010) but it promotes Tdp1 stability and controls its subcellular 
distribution (Chiang et al., 2010; Das et al., 2009). In response to CPT and IR, phosphorylated S81-
Tdp1 forms foci that colocalize with γH2AX and with X-ray repair cross-complementing protein 1 
(XRCC1) foci (Das et al., 2009). Indeed, S81 phosphorylation enhances the interaction with DNA 
ligase 3α (Lig3α) and XRCC1 (Chiang et al., 2010; Das et al., 2009) thereby promoting the 
formation of stable Tdp1 complex at Top1-linked damage sites that facilitate Top1cc repair and cell 
survival in response to CPT- and IR-induced DNA damage. The formation of S81-Tdp1 foci 
induced by CPT is prevented by both aphidicolin (APH) and DRB indicating that they are 
dependent on RC-DSBs and TC-DSBs (Das et al., 2009). Yet, it is still unclear whether S81 
phosphorylation impacts both SSB and DSB repair, since the phosphorylation appears to be driven 
by DSB formation. 
- SUMOylation: Tdp1 is SUMOylated at K111 in a DNA damage-independent manner 
(Hudson et al., 2012). K111R mutants do not display defects in Tdp1 catalytic activity and in Lig3α 
interaction but they show accumulation of SSBs and decreasing Tdp1 concentration at sites of DNA 
damage in response to CPT (Das et al., 2014; Hudson et al., 2012). In addition, upon transcription 
inhibition by DRB, the higher level of SSBs in Tdp1 K111R mutants treated with CPT, are 
decreased to a level comparable to wild-type Tdp1 cells (Hudson et al., 2012). These results 
indicate that the function of Tdp1 K111-SUMOylation is to promote Tdp1 accumulation at 
transcription-dependent Top1cc sites, which is consistent with the role of Tdp1 in protecting post-
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mitotic neurons against Top1cc-induced damage. 
- PARylation: PARP1 directly binds the N-terminal domain of Tdp1, and PARylates Tdp1 
without affecting its catalytic activity (Das et al., 2014). The functional role of PARylation is to 
stabilize Tdp1 in response to Top1cc-induced DNA damage and to promote the recruitment of both 
Tdp1 and XRCC1 at Top1cc-induced DNA damage sites (Das et al., 2014). Tdp1 and PARP1 form 
complexes independently of DNA damage. PARP1 activation by Top1cc drives Tdp1 at damage 
sites acting as a molecular switch that channels Top1-DNA covalent complexes to the Tdp1 
pathway, and it might protect DNA from non-specific endonucleolytic cleavage. This role of PARP 
explains the hypersensitization of PARP1 KO and PARP inhibitor-treated cells to CPTs (Bowman 
et al., 2001; Chatterjee et al., 1989; Patel et al., 2012; Zhang et al., 2011) and the absence of 
additional sensitization by Tdp1 depletion (Alagoz et al., 2014; Das et al., 2014). 
 
I.6.2.4 Stepwise repair by Tdp1 pathway  
 
The Tdp1 excision pathway is a sub-pathway of SSBR (SSB Repair) (for review see (Caldecott, 
2008)), in which Tdp1 works with BER factors to carry out the detection, the excision of the 3’-
phosphotyrosyl linkage Top1-DNA and the repair of the damage (Figure 16B).  
Based on recent findings, a working model is that Tdp1 detects Top1-mediated DNA damage 
through PARP1, as Tdp1 and PARP1 form complexes in physiological conditions (Das et al., 2014). 
Once activated by Top1cc-associated SSBs (Bowman et al., 2001; Chatterjee et al., 1989; Das et al., 
2014; Patel et al., 2012; Zhang et al., 2011), PARP1 catalyses PARylation at DNA lesions 
favouring the recruitment of repair complexes (such as XRCC1) and the release of PARP1 from 
DNA to facilitate DNA repair (Das et al., 2014). XRCC1 functions as a loading dock, which 
stabilizes, stimulates and facilitates the accumulation of SSB repair factors. XRCC1 is able to bind 
Tdp1 (Das et al., 2014; El-Khamisy et al., 2005; Plo et al., 2003), PARP1 (Das et al., 2014), PNKP, 
Polymerase β and Lig3α (Caldecott, 2008; El-Khamisy et al., 2005; Whitehouse et al., 2001).  
Tdp1 accumulates at sites of Top1cc-associated damages (Das et al., 2009) and hydrolyses the 
phosphodiester bond Top1-DNA that is exposed after the proteasome-mediated degradation of 
Top1 (Desai et al., 1997; Desai et al., 2003).  Tdp1 generates 3’-phosphate ends that cannot be 
directly religated to the 5’-OH. PNKP converts 3’-phosphate to 3’-OH and also 5’-OH to 5’-
phosphate, making ends compatible for extension by a polymerase or directly for religation with no 
base loss (Yang et al., 1996). The rejoining of the 3’-OH and the 5’-phosphate ends is mainly 
mediated by Lig3α.        
The requirement of end-processing by PNKP after Top1 excision explains why PNKP-defective 
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human cells and SCAN1 cells accrue similar levels of CPT-induced DNA damage (El-Khamisy et 
al., 2005). Multiple mutations in the PNKP gene have been recently identified by genome-wide 
linkage analysis to be tied to the hereditary disease, MCSZ, microcephaly with early-onset, 
intractable seizures and developmental delay (Shen et al., 2010). MCSZ is primarily a 
neurodevelopment disease, highlighting a key role for the DNA processing activity of PNKP in 
non-replicating cells (Reynolds et al., 2012). 
The Tdp1 excision pathway is thought to repair preferentially transcription-mediated Top1cc (El-
Khamisy et al., 2005; Hudson et al., 2012; Miao et al., 2006). First, Tdp1 action requires prior 
proteolysis of Top1 (Debethune et al., 2002) and Top1 proteasomal degradation is dependent on 
transcription and independent on replication (Desai et al., 2003; Sordet et al., 2008b). Second, the 
defective repair of CPT-induced Top1cc in SCAN1 cells is independent on replication whereas 
DRB pre-treatment reduces CPT-induced SSBs in these cells (El-Khamisy et al., 2005; Miao et al., 
2006). These observations suggest that Top1cc accumulated in CPT-treated SCAN1 cells are likely 
to be transcription-associated lesions predominantly (Miao et al., 2006). Finally, Tdp1 exists in 
equilibrium between unmodified (the majority) and a SUMOylated version (a tiny proportion) (see 
section I.6.2.3). This SUMOylated Tdp1 has been shown to be, at least in part, engaged in resolving 
Top1-dependent transcription-blocking lesions (Hudson et al., 2012).  
Tdp1 is an attractive target for cancer therapy. SCAN1 cells (Das et al., 2009; El-Khamisy et al., 
2005; Interthal et al., 2005b; Miao et al., 2006), cancer cells treated with siTdp1 (Das et al., 2009) 
and Tdp1 knockout mice (Hirano et al., 2007; Katyal et al., 2007) are hypersensitive to CPT. In 
addition, the broad spectrum of Tdp1 substrates open the possibility that inactivation of Tdp1 might 
enhance the anticancer effect of IR or chemotherapy. Another reason that makes Tdp1 a good target 
is that Tdp1 knockout mice are viable and they present a mild phenotype suggesting that the 
pharmacological inhibition of Tdp1 may be well tolerated. However, to date any Tdp1 inhibitors 
have progressed to clinical trials because of their poor physiochemical properties (Huang et al., 
2011). 
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Figure 16: Schematic representation of the three main pathways for Top1cc repair. (A) Helicase pathway. Top1cc are reversed 
by 5’ end religation after regression of the replication fork. Fork regression and restart requires helicase activity. (B) Tdp1 excision 
pathway. Top1 is degraded by the proteasome and the phosphodiester bond is cleaved by Tdp1. Tdp1 generates 3’-P ends that are 
processed by PNKP and religated by Lig3α. Tdp1, PNKP and Lig3α are part of the XRCC1 complex. (C) Endonuclease pathway. 
Top1cc are processed by non-specific nucleolitic cleavage of DNA, releasing Top1 and a fragment of DNA. Several endonucleases 
have been implicated. The resulting DNA lesions are likely processed by HR or by NHEJ. Adapted from (Ashour et al., 2015). 
 
I.6.3 Excision by the endonuclease pathway 
 
In addition to Tdp1, Top1-DNA lesions can be excised by 3’-flap endonuclease complexes (Figure 
16C). It is not clear how the pathway choice is determined, but recent evidences highlight a 
possible role of PARP1 in channelling Top1cc repair to the Tdp1 excision pathway (Alagoz et al., 
2014; Das et al., 2014). It is also not clear whether Top1 degradation has a role in the endonucleases 
pathway and in the pathway choice. The activity of the endonucleases is highly dependent on the 
structure of the Top1-associated DNA lesion and usually multiple nucleases are required to excise 
the DNA on the scissile strand to release Top1 and a fragment of DNA.  
The endonuclease pathway has initially emerged from studies using genetically altered yeast strains 
to identify genes that function in CPT repair in the absence of Tdp1 (Deng et al., 2005; Pommier et 
al., 2006; Vance and Wilson, 2002). The budding yeast Tdp1 KO is viable and relatively insensitive 
to CPT (Pouliot et al., 1999) and it acquires CPT sensitivity only in the presence of additional 
mutations in other DNA repair/checkpoint genes or specific endonucleases. Some endonucleases 
identified for the repair of Top1cc in yeast and/or in vertebrates are: 
- XPF/ERCC1 (ortholog of yeast Rad1/Rad10) (Vance and Wilson, 2002): XPF forms a 
heterodimer with its non-catalytic partner ERCC1 (excision repair cross-complementing group 1) to 
generate a structure-specific endonuclease, which cleaves the duplex DNA segment immediately 5’ 
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from the damaged region where the two DNA strands are separated (3’-flap, splayed arm or bubble) 
corresponding at about 3-4 nucleotides away from the 3’ end (Ciccia et al., 2008). XPF/ERCC1 
works in the NER pathway. Inactivation of the XPF/ERCC1 pathway increases the cytotoxicity of 
PARP inhibitors in CPT-treated mammalian cells (Zhang et al., 2011). In addition, siRNA 
downregulation of XPF reduces transcription- and replication-dependent γH2AX foci in response to 
CPT (Zhang et al., 2011). 
- Mus81/Eme1 (ortholog of yeast Mus81-Mms4) (Liu et al., 2002; Vance and Wilson, 2002): 
The heterodimer Mus81/Eme1 cleaves flap or branched DNA intermediates, but typically cleaves 3-
6 base pairs 5’ of the 3’ single strand/duplex transition and requires the presence of a 5’ end of 
DNA at the flap junction (Ciccia et al., 2008). Thereby it preferentially cleaves substrates 
mimicking stalled replication forks and nicked Holliday junctions. Recently it has been shown that 
Mus81/Eme1 is not involved in the direct excision of Top1cc in mammalian cells but rather 
participates in the repair and recovery of Top1cc-induced stalled replication forks (Zhang et al., 
2011). 
- MRN complex (ortholog of yeast MRX complex) (Deng et al., 2005; Liu et al., 2002): The 
nuclease of the MRN complex is Mre11 (see section II.5.1.1) and it preferentially cleaves 3’-single 
strand branched structures and requires a single-strand gap between the 3’ end to be processed and 
the 5’ end of the DNA (D'Amours and Jackson, 2002). The yeast MRX complex has a well-
established role in the nucleolytic removal of Spo11 (Hartsuiker et al., 2009) and it has also been 
implicated in the removal of both trapped Top1 and Top2 from DNA independently of its function 
in DSB repair and meiosis (Hamilton and Maizels, 2010; Hartsuiker et al., 2009).  
- SLX4-SLX1 (ortholog of yeast Slx4-Slx1): The dimeric complex has a strong endonuclease 
activity in 3’ flap and other substrates (Fricke and Brill, 2003). They have been identified in yeast 
as an alternative pathway to the Tdp1 excision pathway for protection against CPT (Deng Brown 
2005). In addition, SLX4 (SLX4 structure-specific endonuclease subunit) is involved in the repair 
of CPT-induced Top1cc in mammalian cells working as a scaffold protein for SLX1 (SLX1 
structure-specific endonuclease subunit), Mus81-Eme1 and XPF (Kim et al., 2013). 
- CtIP (ortholog of yeast Sae2): CtIP (carboxy-terminal binding protein-interacting protein) is 
a 5’ flap endonuclease that recognizes and cleaves branched DNA structures (Makharashvili et al., 
2014). CtIP functions at the 5’ DNA resection during homologous recombination (HR) (Sartori et 
al., 2007) and in the removal of Spo11 with the MRN complex (Hartsuiker et al., 2009). In yeast, 
Sae2 and MRX collaborate to remove Top2cc from DNA (Hartsuiker et al., 2009). In vertebrate, the 
BRCA1-CtIP interaction, which is dispensable for HR, plays a role in the nuclease mediated 
elimination of oligonucleotides covalently bound to polypeptides from DSBs, thus facilitating DSB 
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repair in response to Top1 and Top2 inhibitors (Nakamura et al., 2010). Consistently, CtIP S322A 
mutant DT40 cells deficient for BRCA1 interaction are hypersensitive to CPT (Nakamura et al., 
2010) and CtIP S322A-Tdp1 KO DT40 double mutants have greater than additive sensitivity to 
CPT (Das et al., 2014).  
- FEN1 (the ortholog of yeast Rad27): FEN1 (flap structure-specific endonuclease 1) is a 5’ 
flap endonuclease (Hiraoka et al., 1995). Deletion of yeast Rad27 causes mild sensitivity to CPT 
(Deng et al., 2005; Zheng et al., 2005) and this phenotype is rescued by human FEN1 (Zheng et al., 
2005). The implication of FEN1 in Top1cc removal could be related to FEN1 ability to directly 
cleave stalled replication forks in complex with WRN (Zheng et al., 2005). 
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CHAPTER II: DNA Double-Strand Break and  
DNA Damage Response 
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II.1 Sources of DSBs  
 
DNA is constantly assaulted by endogenous and environmental agents responsible for many 
thousands of DNA damages per cell every day (Lindahl and Barnes, 2000). The most severe form 
of DNA lesions are the double-strand breaks because they do not leave an intact complementary 
strand to be used as a template for DNA repair. A DSB is formed when both strands of the DNA 
duplex are severed by a break in the phosphodiester backbone at opposite sites within 10 bp. If left 
unrepaired, DSBs can lead to mutagenesis, chromosome breakage and rearrangement ultimately 
resulting in developmental defects, neurodegeneration, immunodeficiency, radiosensitivity, sterility, 
and cancer predisposition (Jackson and Bartek, 2009). 
DSBs can be very different from each other since they can have multiple origins.  
 
Endogenous DSBs 
In various specialized contexts, DSBs are programmed by the cell. During meiosis, the Top2-
related enzyme, Spo11 generates DSBs to promote exchange of genetic information between 
parental chromosomes by HR (Neale and Keeney, 2006). During immune system development, 
DSB-induced rearrangements at immunoglobulin genes, in the context of V(D)J recombination and 
CSR, occur in lymphoid cells to generate immunoglobulin and T-cell receptor diversity and for 
antigen-stimulated B-cell differentiation (Bassing and Alt, 2004; Chaudhuri and Alt, 2004). 
Telomeres also possess DNA ends that are sequestrated in the Shelterin complex to prevent them 
from being recognized as DNA damage and from fusions (de Lange, 2005). In addition, 
spontaneous DSBs can arise as a consequence of endogenous processes, such as DNA oxidation, 
generation of ROS, nitrogen species, reactive carbonyl species, oestrogen and cholesterol 
metabolites (Hoeijmakers, 2009). ROS are formed continuously in the cell as products of metabolic 
activities (Bonner et al., 2008; De Bont and van Larebeke, 2004). ROS are estimated to be 
responsible for about 5x103 SSBs per cell per day, about 1% of which may lead to DSBs by the 
close proximity of two SSBs or by replication (Tanaka et al., 2006). The encounter of DNA 
replication fork with unrepaired DNA lesions is the major source of endogenous DSBs. The 
slowing or the stalling of the replication fork progression is defined as replication stress and in cell 
there are several sources of replication stress (reviewed in (Magdalou et al., 2014; Zeman and 
Cimprich, 2014)), including obstacles to fork progression (nicks, gaps, AP sites, DNA secondary 
structures, protein-DNA complexes…) (Lambert and Carr, 2013), interferences between replication 
and transcription (R-loops, early replicating fragile sites, topological stress,…) (Lin and Pasero, 
2012), depletion of nucleotides or replication machinery components (Bester et al., 2011), 
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ribonucleotides misincorporation (Dalgaard, 2012), inappropriate firing of replication origins 
(common fragile sites) (Debatisse et al., 2012) or DNA accessibility (Zeman and Cimprich, 2014). 
The frequency of replication-associated DSBs is so high that the synthesis of both leading- and 
lagging-strand in vivo is considered to be discontinuous (Lehmann and Fuchs, 2006). 
 
Exogenous DSBs 
Exogenous DSBs can be produced directly by physical or chemical agents or as a secondary lesion 
upon collision with replication and transcription or as a by-product of repair. UV light from sun is 
an example of physical source of DNA damage. A single day of sun exposure can induce up to 105 
UV photoproducts per cell to which inflammation-induced ROS damage can be sum up 
(Hoeijmakers, 2009). Another example of physical genotoxics that produce DSBs is ionizing 
radiation (IR) that can result from radioactive decay of naturally radioactive compounds or from 
medical treatment employing X-ray or radiotherapy. Chemical agents used in cancer chemotherapy 
can also produce DSBs. Among them, Top2 inhibitors (etoposide, doxorubicin...) that can produce 
DSBs directly or alkylating agent (methyl methanesulfonate, temozolomide…) and crosslinking 
agents that can produce DSBs indirectly. Today, one of the most prevalent environmental chemical 
than can induce a variety of adducts and ROS-dependent damages is cigarette smoking, on average 
≈ 45-1000 aromatic DNA adducts per cell per day in the lung of smokers (Ciccia and Elledge, 
2010). 
Table 4 and Figure 17 summarize the mechanisms of action and the amount of DSBs produced by 
some exogenous agents.  
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Table 4: Examples of DNA DSB inducing agents, mechanisms and amount of DSB induction 
Agents Characteristics and mechanism of DSB induction Amount of DSBs References 
IR 
γ-Irradiation DNA damage by IR is formed by both direct 
energy deposition on DNA (especially 
particulate IR) and by indirect action in the 
surrounding environment, in particular, 
reactions with diffusible water radicals 
(especially for γ- and x-ray). The biological 
effects of IR arise from the production of 
DSBs and clustered DNA damage (lesions 
within 10 bp separation) randomly on the 
genome. IR generate a mixture of DNA 
lesions, ≈ 4-5% of them are DSBs. 
1 Gy: 1 DSB/0.2x102 bp 
(≈ 30-60 DSBs/cell)a 
(Cedervall et al., 1995; 
Ruiz de Almodóvar et 
al., 1994) 
α-particles, 
heavy ions 
1 Gy: 41-73 DSBs/cell 
using α-particles with 
LET of 110 KeV/µMb or 
nitrogen ions with LET 
80-225 KeV/µMb 
(Claesson et al., 2007; 
Löbrich et al., 1996; 
Radulescu et al., 2004) 
X-ray 1 Gy: 0.8 DSB/0.2x10
2
 
bp (≈ 25 DSB/cell) (Elmroth et al., 2003b) 
UV 
UVA Photons of UV light are in the energy range 
of chemical bond and then alter the 
molecules that absorb energy. UVC (240-290 
nm), UVB (290-230 nm) and UVA (320-400 
nm) predominantly induce pyrimidine 
dimers. UVA and UVB produce SSBs and 
DSBs indirectly by reaction with oxygen 
molecules (generally replication-dependent 
DSBs). 
1 DSB/0.95x106 bp with 
laser 364nm + 
Hoechst33342; 90-180 
DSBs/stripe (equals to 3 
Gy γ-Irradiation) with 
laser 337nm + BrdU. 
Laser generates a high 
number of breaks in a 
small nuclear volume 
(Bekker-Jensen et al., 
2006) (Kruhlak et al., 
2006) 
UVB __ (Peak and Peak, 1990) 
UVC 
UVC through filters 
0.0156: 6-
4photoproducts + 0.05 
cyclobutane pyrimidine 
dimers/10Kb/J/m2. 
Number of DSBs not 
determined. 
(van Hoffen et al., 
1995) 
Drugs 
Radiomimetics 
DNA damage is directly induced by free 
radical attack on deoxyribose moieties in 
both DNA strands. They produce replication-
independent DSBs, SSBs and base damage. 
Examples of radiomimetics are bleomycin, 
neocarzinostatin (NCS), calichemicin, C-
1027, kedarcidin 
Bleomycin: 10% of the 
induced lesions are 
DSBs; NCS: 20% of the 
induced lesions are 
DSBs; calicheamicin: 
30% of the induced 
lesions are DSBs 
(Elmroth et al., 2003a; 
Povirk, 1996) 
Bifunctional 
alkylators 
Bifunctional alkylators have two reactive 
sites and they crosslink DNA with proteins or 
two DNA bases within the same DNA strand 
(intra-strand crosslinks) or on opposite DNA 
strands (inter-strand crosslinks). Examples 
are nitrogen mustard, mitomycin C and 
cisplatin. They can produce DSBs, DNA 
cross-links, replicative lesions and bulky 
adducts. 
__ 
(Helleday et al., 2008) 
(Woods and Turchi, 
2013) 
Replication 
inhibitors 
These inhibitors target DNA synthesis. 
Aphidicolin directly inhibits DNA 
polymerase activity. Hydroxyurea inhibits 
ribonucleotide reductase. They can generate 
DSBs and replicative lesions. 
__ (Saintigny et al., 2001) 
Topoisomerase 
inhibitors 
These inhibitors trap topoisomerases in 
complex with DNA producing DSBs. They 
produce also SSBs and replicative lesions. 
__ 
(Muslimović et al., 
2009) 
aAssuming 6x109 bp x diploid cell 
bLET (Linear	  Energy	  Transfer) is defined as the average energy that an ionizing particle deposits per unit length of track (KeV/µm) 
as it traverses matter 
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Figure 17: DNA damage in endogenous conditions or induced by genotoxic agents. DSBs are detected by γH2AX staining and 
cyclobutane pyrimidine dimers (CPD) are detected by antibody against CPD. (A) Non-treated HeLa cells. (B) U2OS cells 1 h after 
treatment with 10 Gy γ-Irradiation. (C) HeLa cells treated with 25 ng/ml NCS. (D) Human fibroblasts irradiated with UVC through a 
3 µM pore-filter. (E) Human fibroblasts 15 min after carbon ion irradiation. (F) PA-GFP-H2AX in MEFs H2AX KO irradiated with 
344 nm laser followed by Hoechst sensitization. (G) U2OS cells irradiated with 405 nm laser followed by BrdU 
(bromodeoxyuridine) sensitization. (H) Cells irradiated by a 3-photon NIR laser. (I) HeLa cells expressing I-SceI endonuclease. (J) 
Leukemic cells treated with etoposide. (K) Colon cancer cells treated with CPT. (L) Eroded telomeres in ageing cells. Telomeric 
DNA (red) and γH2AX (green) staining. Eroded telomeres display γH2AX foci but are too short to bind telomeric probe. DNA is 
blue for images (A-I and L) and red for images (J, K). γH2AX is green for all images. Adapted from (Nagy and Soutoglou, 2009) 
and (Bonner et al., 2008). 
 
II.2 DDR: sensing DSB and signalling 	  
The DNA damage response (DDR) is the global signalling network set up by cells to maintain 
genome integrity. DDR senses different types of DNA damages to mount a coordinated and 
multifaceted response.	  	  
DDR is most vigorously activated by DSBs. DDR proteins are classically divided in four categories 
according to their role: sensors, mediators, transducers and effectors. However, DDR proteins have 
a broad activity and this classification is for convenience and can vary from author to author. DNA 
damage is detected by sensors proteins. The signals are transmitted to transducers that, aided by the 
!!
(j)          etoposide! (k)    campthotecin! (l)           telomeres!
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mediators, amplify the signal and transmit it to the effectors in numerous downstream pathways 
(Niida and Nakanishi, 2006) (Table 5). These pathways slow down or stop the cell cycle 
progression at critical stages before (G1/S checkpoint) or during (intra-S checkpoint) DNA 
duplication and before cell division (G2/M checkpoint) giving time to the cell for DSB repair before 
replication and mitosis, respectively. In parallel, DDR stimulates the re-localization and the 
transcriptional and post-transcriptional regulation of DNA repair proteins enhancing repair (Harper 
and Elledge, 2007). 	  
If DNA is efficiently repaired, DDR is inactivated and normal cell functioning can be restored. 
Alternatively, maintained DDR signalling activates apoptosis or senescence, both of which have 
potential antitumor functions (Figure 18).  
 
Table 5: Main factors involved in DNA damage signalling 
Functions Class Proteins 
Sensors 
RFC-like Rad17, RFC2 
PCNA-like Rad9-Rad1-Hus1 (9-1-1 complex) 
DSB recognition/repair Mre11-Rad50-Nbs1 (MRN complex), RPA 
Mediators 
BRCT-containing (ATM signalling) BRCA1, 53BP1, MDC1, MCPH1, PTIP 
BRCT-containing (ATR signalling) Top1BP1 
Non-BRCT-containing (ATR signalling) Claspin 
Transducers 
PI3K kinase-like protein ATM, ATR, DNA-PK 
PIKK binding protein kinase ATRIP, Chk1, Chk2 
Effectors 
Transcription factor p53, p21 
Phosphatase Cdc25A,B,C 
Protein kinase Cdks, Cdc7 	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II.3 ATM, ATR and DNA-PKcs: three PI3-Kinases of the DDR 
 
In mammalian cells, the ATM, ATR and DNA-PKcs are the most apical DDR kinases. These 
proteins are members of the phosphatidylinositol-3-kinase-like kinase family (PIKKs). Other 
members of this group are SMG1 (suppressor of mutagenesis in genitalia 1), mTOR (mammalian 
TOR) and TRRAP (transformation/transcription domain-associated protein). 
The PIKKs are large proteins (between 2547 and 4128 amino acids) that share a similar domain 
organization. From the N-terminus to the C-terminus (Lempiäinen and Halazonetis, 2009; Lovejoy 
and Cortez, 2009) (Figure 19): 
- FAT domain: the FRAP-ATR-TRAAP domain consisting of α-helical HEAT repeats (helix-
turn-helix motifs). 
- PI3K-like domain: the serine/threonine kinase domain, preferential phosphorylation of S/T-
Q motifs. 
- PRD domain: the PIKK-regulatory domain, its C-terminal half appears to be a site of post-
translational modifications or protein–protein interactions that enhance PIKK kinase activity. 
- FATC domain: the small (32 amino acids) and highly conserved FAT C-terminus domain 
that is required for PIKK kinase activity. 
Modulation of protein activity, 
stability and interactions 
Translocation of proteins 
and RNA species 
Modulation of 
gene expression 
DNA repair 
Cell survival 
E!ectors
Transducers 
Cell death 
Cell cycle 
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and metabolic pathways 
Activation of cell death or 
senescence pathways 
DSB 
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Mediators 
Figure 18: The DDR cascade. Schematic representation of the signal transduction of checkpoint responses and activation of cell 
survival or cell death pathways ensued. Figure adapted from (Shiloh and Ziv, 2013). 
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Figure 19: Schematic representation of the functional PIKK 
domains showing the locations of the kinase, PRD, FAT, and 
FATC domains (Lovejoy and Cortez, 2009). 
 
 
The large N-terminal region of PIKKs is composed of numerous HEAT repeats with little sequence 
similarity between the kinases and may serve as a protein–protein interaction surface. 
The precise functions of these PIKK domains remain unclear. This is related to the lack of structural 
data because of PIKK’s size that challenges crystallization. However, the crystal structure of DNA-
PKcs was obtained (6.6 Å resolution) (Sibanda et al., 2010). The domain structure of the others 
PIKKs comes principally from electron microscopy studies (Llorca et al., 2003; Unsal-Kaçmaz et 
al., 2002) and superposition of PIKK domains on PI3K three-dimensional structure. 
 
II.3.1 ATM  
 
The gene coding for the ATM kinase is localized to chromosome 11q22-23 and Shiloh and 
colleagues have discovered it in 1995 (Savitsky et al., 1995). ATM gene is mutated in Ataxia-
Telangiectasia (AT), a rare autosomal recessive disorder. AT patients display progressive 
neurodegeneration, telangiectasia, immunodeficiency, extensive problems related to fertility and 
metabolism and increased risk of cancer (for review see (Lavin, 2008)).  
AT cells show increased chromosome instability, premature senescence of cultured primary 
fibroblasts, high sensitivity to DSBs and defective signalling response such as cell cycle checkpoint 
and apoptosis that clearly contribute to cancer predisposition. 
Not surprisingly, ATM is a key player in DDR and it has long been known that its activity is 
enhanced by DSBs (Banin et al., 1998; Canman et al., 1998). However, evidences have 
accumulated showing that ATM is part of many other signalling networks, including cell 
metabolism and growth, oxidative stress, and chromatin remodelling (reviewed in (Cremona and 
Behrens, 2014; Shiloh, 2014; Shiloh and Ziv, 2013; Stracker et al., 2013)). 
 
The three main elements that drive ATM in response to DSBs are: re-localization, activation and 
chromatin retention.  
Activation: In undamaged cells, ATM is present in a dimeric or multimeric configuration that, after 
damage, releases highly active ATM monomers (Bakkenist and Kastan, 2003). During this process, 
ATM undergoes autophosphorylation on at least four sites (S367, S1893, S1981 and S2996) 
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(Kozlov et al., 2006) (Figure 20). Autophosphorylation after DNA damage is required for 
monomerization (Bakkenist and Kastan, 2003) and mutations of the autophosphorylation sites to 
alanine result in defects in ATM-dependent phosphorylation and increased radiosensitivity (Kozlov 
et al., 2006). ATM autophosphorylation at S1981 is widely used as a read-out of ATM activation. 
ATM phosphorylation is regulated by different phosphatases (see Table 6). In particular, inactive 
dimeric ATM associates with protein phosphatase 2A (PP2A). This phosphatase seems to 
constitutively dephosphorylate ATM under physiological conditions (Goodarzi et al., 2004). Upon 
DSB induction, ATM-PP2A interaction is abolished and trans-phosphorylation of ATM ensues. 
Phosphorylation is not the only post-translational modification that modulates ATM activity. Sun et 
al. showed that DSBs induce Tip60 (tat interacting protein, 60kDa) -mediated acetylation of ATM 
at K3016 (near the FATC domain) of ATM (Sun et al., 2005; Sun et al., 2007)  (Figure 20). SiRNA 
depletion of Tip60 causes defects in ATM autophosphorylation and mutations on K3016 inhibit 
monomerization of inactive ATM, prevent the upregulation of ATM activity by DNA damage and 
the ATM-dependent p53 and Chk2 phosphorylation. 
 
Re-localization: Upon DSB induction, the total amount of ATM does not change, but a portion of 
nuclear ATM is rapidly recruited to DSB sites, whereas another portion remains nucleoplasmic. 
Using live cell imaging of fluorescently-tagged ATM, Davis and colleagues showed that in 
response to laser-generated DSBs, ATM localizes at chromatin after 60 seconds reaching its 
maximal level in 10 minutes (Davis et al., 2010). ATM autophosphorylation is required for its 
association to chromatin (Berkovich et al., 2007) but at the same time, ATM recruitment to 
chromatin is an important part of its activation process. Kitagawa et al. showed that Nbs1 (a part of 
the MRN complex) and BRCA1 migrate to the sites of DSBs independently of ATM activation, but 
their presence is required to recruit activated ATM to chromatin (Kitagawa et al., 2004). Berkovich 
et al. showed that Nbs1 is required for ATM autophosphorylation as well as for the association of 
active ATM with chromatin after the induction of endonuclease-generated DSBs (Berkovich et al., 
2007). The MRN complex has been shown by several groups in in vitro and in cellulo studies to be 
absolutely required for the ATM signalling pathway in response to DSBs (Table 6) (Lee and Paull, 
2007). 
 
Retention: The retention of ATM and other DDR proteins on chromatin is a crucial part of DDR 
signalling. Stable binding of single factors of the DDR machinery to chromatin is sufficient to 
induce the DNA damage response in the absence of DSBs (Soutoglou and Misteli, 2008).  
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YFP-tagged ATM is retained for a long-time at the site of laser-generated DSBs. Two hours after 
irradiation, the fluorescence intensity of ATM is still at 60% of its maximal level (Davis et al., 
2010). In this work, the authors suggested that ATM is retained at chromatin to assist in processes 
of chromatin remodelling and to participate to DSB repair. Data showing that ATM is required for 
DSB repair in the heterochromatin by phosphorylating KAP1 (KRAB-associated protein-1) (see 
section II.8) support this hypothesis (Goodarzi et al., 2008). In addition, ATM autophosphorylation 
is shown to be required for sustained retention of ATM to DSBs. In particular, autophosphorylation 
at S1981 promotes ATM retention by allowing its interaction with the mediator protein MDC1. 
 
	  
 
Figure 20: Schematic representation of ATM. The major domains, the sites of PTMs (post-translational modifications) and the 
proteins responsible for these modifications are represented. Figure is adapted from (Shiloh and Ziv, 2013) 
 
Several questions remain opened about the mechanism of ATM activation: the nature of the initial 
signal that activates ATM and promotes its monomerization, the role of ATM recruitment to 
chromatin and the role of different PTMs. A huge amount of literature discusses and debates these 
open questions and sometime experimental results are contradictory depending on models, 
experimental conditions and the nature of the stimulus (reviewed in (Cremona and Behrens, 2014; 
Lavin, 2008; Shiloh, 2006; Shiloh and Ziv, 2013)).  
There is growing agreement that the initial stimulus for ATM activation is a chromatin 
conformational change but the mechanism of action is still unclear. The importance of chromatin 
status is supported by the activation of ATM in response to chromatin changes in the absence of 
DNA damage (Bakkenist and Kastan, 2003). Chloroquine, histone deacetylase inhibitors or 
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hypotonic buffer activate ATM and induce p53 phosphorylation. However, activated ATM by these 
factors does not form nuclear foci and fails to phosphorylate its substrates bound to chromatin.  
The importance of autophosphorylation in the ATM activation process in human cells is also a 
shared issue. On the other hand, studies in other organisms and in vitro have shown that 
autophosphorylation is dispensable for ATM monomerization and activation. For example, the 
expression of a non-phosphorylatable mutant S1987A (the mouse equivalent for S1981A) in ATM 
KO mice yields normal ATM-dependent phosphorylation of substrates and localization and 
retention at DSB sites (Pellegrini et al., 2006). Another report showed that autophosphorylation is 
accessory for the initial recruitment of ATM to DSB sites in Xenopus egg extracts (Dupré et al., 
2006). Furthermore, in vitro studies using purified human components show that activation of ATM 
does not need its autophosphorylation (Lee and Paull, 2005). Despite these differences, it is likely 
that in human cells there are cellular factors that render autophosphorylation essential. Table 6 
summarizes several proteins described to regulate ATM activation. 
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Table 6: Some human cellular factors known to regulate ATM 
Proteins Characteristics ATM regulation Type of DSB References 
Activators 
MRN 
complex 
Mre11-Rad50-
Nbs1 DSB sensor 
complex 
MRN interacts with ATM in response to 
DSBs. Nbs1 is required for activation and 
recruitment of ATM to chromatin 
Endonuclease-
generated 
DSBs, IR, 
NCS 
(Berkovich et al., 
2007; Girard et al., 
2002; Kitagawa et 
al., 2004; Uziel et 
al., 2003) 
Tip60 Histone 
acetyltransferase 
Tip60 interacts constitutively with ATM. 
Tip60 activated by DSBs acetylates ATM 
(K3016) at chromatin in an MRN-dependent 
manner. Role in ATM activation 
 
IR, Bleomycin (Sun et al., 2005; Sun et al., 2007) 
MDC1 DDR mediator protein 
Interaction with phospho-S1981-ATM. Role 
in ATM activation and retention at 
chromatin 
 
IR, laser-
irradiation, γ-
irradiation 
(Mochan et al., 
2003; So et al., 
2009) 
53BP1 DDR mediator protein 
SiRNA against 53BP1 decrease ATM kinase 
activity, the phenotype is more pronounced 
in cells lacking Nbs1 
 
IR 
(DiTullio et al., 
2002; Mochan et 
al., 2003; Wang et 
al., 2002) 
BRCA1 
DDR mediator 
protein, E3 
Ubiquitin ligase 
It is required for ATM localization at 
chromatin and facilitates ATM-mediated 
phosphorylation of some ATM substrates 
 
IR, UV 
(Foray et al., 2003; 
Kitagawa et al., 
2004) 
HMGN1 Nucleosome-binding protein 
It regulates ATM activity by modulating 
histone H3 acetylation 
 
IR (Kim et al., 2009) 
RNF8 
and 
CHFR 
E3 Ubiquitin ligase 
Regulators of ATM activity by synergic 
modulation of histone H4 acetylation 
 
IR (Wu et al., 2011) 
RNF2 
and 
BMI1 
Ubiquitin E3 ligase 
complex 
It promotes the localization of activated 
ATM at chromatin by ubiquitinating H2A(X)  
 
IR 
(Facchino et al., 
2010; Pan et al., 
2011) 
hMOF Histone 
acetyltransferase 
Acetylation of H4. SiRNA against hMOF 
decreases ATM kinase activity 
 
IR (Gupta et al., 2005) 
PARP1 NAD+ ADP-
ribosyltransferase 
PARP1 rybosylates ATM in response to IR. 
ATM rybosylation seems required for ATM 
localization at chromatin but not for its 
autophosphorylation at S1981 
 
IR, γ-
irradiation 
(Aguilar-Quesada 
et al., 2007; Haince 
et al., 2007) 
TIP Negative regulator 
of PP2A 
TIP positively regulates ATM 
autophosphorylation by interaction and 
inhibition of PP2A phosphatase 
 
No DSBs: 
physiological 
conditions 
(McConnell et al., 
2007) 
PP5 Phosphatase 
PP5 interacts with ATM in a DNA damage-
inducible manner and stimulates its 
autophosphorylation 
 
NCS, IR (Ali et al., 2004) 
Inactivators 
PP2A Phosphatase 
It prevents ATM autophosphorylation by 
interacting with ATM under physiological 
conditions. It dissociates upon DSBs 
 
No DSBs: 
Okadaic Acid, 
IR 
(Goodarzi et al., 
2004) 
Wip1 Phosphatase 
ATM activity regulator. Wip1 
dephosphorylates ATM S1981 in response to 
DSBs 
 
IR (Shreeram et al., 2006) 
Cofactors ATMIN ATM cofactor ATM activity regulator in the absence of 
DSBs. It interacts with ATM in response to 
chromatin conformational changes in Nbs1-
independent manner 
 
No DSBs: 
Cloroquine, 
hypotonic 
conditions 
(Kanu and 
Behrens, 2007) 
 
 
 
	   	   	   74 	  
II.3.2 ATR 
 
ATR has been discovered in 1996 in the human genome database as a gene with sequence 
homology to ATM and SpRad3, hence the name ATR (Cimprich et al., 1996). 
ATR deficiency in mice results in early embryonic lethality (Brown and Baltimore, 2000). 
Individuals with hypomorphic mutations of ATR, causing a partial loss of its activity, develop the 
rare Seckel syndrome, which is characterized by microcephaly and growth retardation.  
The primary signal for ATR activation is ssDNA coated with the ssDNA-binding protein RPA. 
ssDNA occurs predominantly at stalled or collapsed replication forks but ssDNA can be produced 
also by the processing of certain DNA lesions, such as pyrimidine dimers or nuclease-mediated 
resection of DSBs. In physiological conditions, the sources of replication stress are abundant. For 
example, in mammals, the rate of sister chromatid exchange suggests that ≈ 10 DSBs form at 
replication forks per cell division (Haber, 1999). The frequency of fork stalling is much higher 
because of the numerous sources of replication stress (see section II.1). This is the reason why, 
unlike ATM, ATR is essential. ATR is probably activated during every S-phase to regulate the 
firing of replication origins, the repair of damaged replication forks and to prevent premature entry 
into mitosis.  
Once RPA-coated ssDNA appears, a canonical ATR signalling pathway is organised in four steps 
(Nam and Cortez, 2011) (Figure 21): 
1) Recruitment of ATR via ATR-interacting protein (ATRIP) to RPA-coated ssDNA: ATRIP 
binds directly RPA to allow ATR recruitment at chromatin.  
2) ATR-independent recruitment of Rad9-Hus1-Rad1 proteins (9-1-1 complex) and 
topoisomerase-binding protein 1 (TOBP1): the junction of ssDNA/dsDNA is recognized by Rad17- 
replication factor C (RFC2) clamp loader that in turn, loads the 9-1-1 clamp at the 5’ primer 
junction. This loading brings the ATR activator, TOBP1 to the damage site through the interaction 
with the phosphorylated Rad9.  
3) TOBP1-mediated activation of ATR: TOBP1 binds and activates ATR in an ATRIP-
dependent manner. The mechanism of ATR activation by TOBP1 is unknown. A proposed model 
envisages that TOPB1 binding to ATR induces a conformational change of ATR that increases its 
kinase activity and/or its affinity for substrates (Mordes and Cortez, 2008).  
4) Phosphorylation of ATR substrates: Chk1 and other ATR effectors are phosphorylated by 
active ATR. Currently, the most common measure of ATR activation is the phosphorylation of 
Chk1 on S317 and S345. ATR is phosphorylated at S428, S435, and T1989 and possibly at S436 
and S437 (Daub et al., 2008; Dephoure et al., 2008; Liu et al., 2011; Nam et al., 2011). However, at 
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present only the phosphorylation at T1989 has been linked to ATR activation (Liu et al., 2011). 
An important feature of the regulation of ATR signalling pathway is the independent recruitment of 
ATR-ATRIP and TOBP1. This characteristic represents a molecular version of the “two-man rule” 
for ATR activation (Cimprich and Cortez, 2008): by requiring multiple complexes to sense the 
problem, inappropriate launching of the checkpoint might be prevented.  
	  
Figure 21: Canonical ATR signalling pathway. ssDNA coated by RPA induces the independent recruitment of ATR-ATRIP and 
TOBP1. TOBP1 activates ATR kinase, which in turn phosphorylates numerous substrates including Chk1 to regulate cellular 
responses to DNA damage and replication stress. Figure adapted from (Cimprich and Cortez, 2008). 
 
Although a good model for ATR activation has emerged from the current body of work, much is 
still unclear. The recruitment of ATR to DNA damage sites and its mechanism of activation are 
poorly understood. In addition, a number of mechanisms of ATR regulation that do not fit into the 
canonical ATR signalling pathways are emerging. For example, DNA alkylating agents seem to 
activate ATR in an RPA-independent and mismatch repair-dependent mode (Yoshioka et al., 2006). 
Similarly, DSBs can induce ATM-dependent ATR activation in S and G2 phases of the cell cycle 
via the ATM and Mre11-mediated DSB-end resection (Jazayeri et al., 2006; Myers and Cortez, 
2006). In addition, Derheimer et al. showed that the ATR pathway is also activated in response to 
transcriptional stress (Derheimer et al., 2007). Stalled elongating RNAPII complexes induce RPA-
dependent ATR activation and accumulation of phosphorylated p53 (S15). The authors 
hypothesized that a region of ssDNA is formed after the blockage of transcription elongation that 
becomes coated with RPA, leading to the recruitment of ATR. 
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II.3.3 DNA-PK 
 
The first clue that cells contain a DNA-activated protein kinase came from the work of Andersons 
and colleagues (Walker et al., 1985) and then DNA-PK was discovered in 1990 as part of the 
transcriptional complex Sp1 (specificity protein 1) (Jackson et al., 1990). Today, the best 
characterized function of DNA-PK is in the response to DSBs and in particular in the non-
homologous end-joining (NHEJ) pathway for DSB repair. However, new cellular roles of DNA-PK 
are emerging in mitosis, transcription, viral infection and telomere maintenance (for review see 
(Goodwin and Knudsen, 2014; Jette and Lees-Miller, 2015)). DNA-PK is a holoenzyme composed 
of a large catalytic subunit (DNA-PKcs) and the DNA-end binding heterodimer Ku. 
 
Ku 
The heterodimer Ku was initially discovered as an auto-antigen, consisting of two subunits of 70 
(Ku70) and 83 (Ku80) kDa (Mimori et al., 1986). Mice deficient for Ku display severe 
immunodeficiency, growth retardation and a hypersensitivity to IR (Manis et al., 1998; 
Nussenzweig et al., 1997). Ku heterodimer is extremely abundant in cells (≈ 4x106 molecules per 
cell) (Woodgett, 1993) and its stability depends on the presence of the two components: the 
depletion of Ku70 leads to Ku80 depletion (Gu et al., 1997) and vice versa (Boubnov et al., 1995). 
Ku shows high affinity for dsDNA ends (Kd ≈ 2.4x10-9 – 5x10-10 M) (Blier et al., 1993) and binds 
DNA in a sequence-independent manner. Ku has a ring structure that encircles DNA for 
approximately two turns of helix (Walker et al., 2001).  
The main function of Ku is to detect DNA free ends and to target DNA-PKcs to them. In addition, 
Ku has a 5’-deoxyribose-5-phosphate/AP lyase activity (excision of 5’-terminal abasic sites) 
(Roberts et al., 2010). This activity is maximal at DSB ends suggesting that Ku may process DSB 
ends for ligation (Strande et al., 2012). 
 
DNA-PKcs 
The cDNA of DNA-PK has been isolated in 1995 by Jackson and colleagues (Hartley et al., 1995). 
The only germline missense mutation of the gene encoding DNA-PK has been described in a RS-
SCID (radiosensitive T-B- severe combined immunodeficiency) patient (van der Burg et al., 2009). 
Like Ku, DNA-PKcs is extremely abundant in human cells (≈ 5x106 molecules per cell) (Woods 
and Turchi, 2013). 
The X-ray structure of DNA-PKcs displays that the protein is composed of a “head” and an 
“arms/palm” domain organized in a pincer-shaped structure surrounding an open, central channel 
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proposed to bind dsDNA (Sibanda et al., 2010) (Figure 22A). Some characteristics of the “arms” 
domain suggest that it may be able to open and close around the central DNA binding channel and 
the phosphorylation of DNA-PKcs may modulate this process.  
In physiological conditions, the activation of the kinase activity of DNA-PKcs requires its 
association with both the Ku heterodimer and a DNA terminus. Once activated, DNA-PKcs can 
phosphorylate different substrates including factors of NHEJ, histone H2AX and DNA-PKcs itself 
(reviewed in (Jette and Lees-Miller, 2015)). 
In vitro, autophosphorylation of DNA-PKcs results in the inactivation of its kinase activity and the 
dissociation of DNA-PKcs from the Ku-DNA complex (Chan and Lees-Miller, 1996). DNA-PKcs 
can be phosphorylated at more than 40 sites in vitro and at 37 sites in vivo (Dobbs et al., 2010) 
(Figure 22B). The most studied DNA-PKcs phosphorylation sites are located in its N-terminal 
domain and have been termed the ABCDE (T2609, S2612, T2620, S2624, T2638, T2647) and PQR 
(S2023, S2029, S2041, S2053, S2056) clusters. These clusters have been studied by generating 
non-phosphorylatable mutants at each site. Ablation of only 1 or 2 sites in either cluster has little or 
no functional effect. However, complete ablation of ABCDE phosphorylation leads to a severe 
radiosensitive phenotype (Ding et al., 2003). In contrast, ablation of PQR phosphorylation imparts 
only a modestly radiosensitive phenotype (Cui et al., 2005). In the two cases, the complete mutation 
of those clusters does not impact the kinase activity but deregulates the end processing. 
Functionally, the two clusters seem to work in an opposite direction: phosphorylation of ABCDE 
promotes end access for NHEJ while phosphorylation of PQR inhibits it (Cui et al., 2005). In 
addition, mutation of the T2609 and S2056 residues leads to the increased stabilization of DNA-
PKcs into DNA that interferes with NHEJ (Uematsu et al., 2007). Together these data support a 
model in which DNA-PKcs phosphorylation facilitates NHEJ by destabilizing the interaction of 
DNA-PKcs with DNA ends and is required for release of DNA-PKcs from damaged DNA in vivo 
(Dobbs et al., 2010) . ABCDE cluster can be also phosphorylated at T2609 and T2647 by ATM in 
vivo (Chen et al., 2007; Jiang et al., 2015).  
Other phosphorylation sites that have functional importance include the JK (T976/S1104) and the N 
(S51/S72) clusters. In addition, phosphorylation of T3950, which is located in the catalytic domain, 
likely modulates the kinase activity (Douglas et al., 2007). 
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Figure 22: Model for structure, domains and trans-activation of DNA-PKcs. (A) Model of DNA-PKcs’ structure: the “head” 
(yellow and purple) and arms/palm (green) with the DNA binding cavity in the center of the molecule before and after 
autophosphorylation. (B) Schematic representation of DNA-PKcs showing the main phosphorylation sites in vivo. A and B are 
adapted from (Wang and Lees-Miller, 2013) (C) Cartoon model of the trans-activation of DNA-PK (Woods and Turchi, 2013). 
 
Activation of DNA-PK 
In response to laser microirradiation fluorescent-tagged DNA-PKcs rapidly localizes to DSBs 
reaching its maximal level in ≈ 10 minutes (Davis et al., 2010). Precisely, how DNA-PKcs is 
recruited to Ku and how this recruitment leads to kinase activation remains unclear, but the binding 
of DNA-PKcs to Ku, enables Ku to translocate inward into the dsDNA allowing DNA-PKcs to bind 
the terminus of a DNA end (Frit et al., 2000).  
A current model of DNA-PK’s activation envisages the following steps (for review see (Meek et al., 
2008)): 
 
1) Ku recognizes and binds the two ends of a DSB. 
2) DNA-PKcs is recruited at each end via Ku. DNA binding induces a conformational change 
in DNA-PKcs that results in closer association of the head and the palm domains. 
3) Two DNA-PK molecules on adjacent sides of the DSB end can interact and form a synaptic 
complex (Figure 22C). These structures likely maintain broken ends in proximity and provide a 
platform for NHEJ factors, blocking access to nucleolytic activities. 
4) Synapses favour the autophosphorylation of DNA-PKcs. It has been shown that 
autophosphorylation within the two major clusters occurs in trans (Meek et al., 2007) but the 
mechanism of all phosphorylation’s events in vivo is still unclear (in trans, in cis or even on both 
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sides of the synapsis). ABCDE autophosphorylation in trans promotes access of DNA ends to end 
modifying factors (including the nuclease Artemis). 
5) End alignment is “sensed” by DNA-PK resulting in PQR autophosphorylation that “locks” 
the two ends in aligned position favouring NHEJ. 
6) Additional autophosphorylation occurs at undefined sites to facilitate the final step in NHEJ 
and to release DNA-PKcs. 
7) After dissociation, DNA-PKcs is dephosphorylated and can be recycled. The question of 
how Ku is removed from the DNA remained unclear. Ku is ubiquitylated in response to DSBs 
(Brown et al., 2015). Hence, it has been suggested that Ku may be ubiquitylated and then degraded 
and/or released from chromatin and degraded (Brown et al., 2015; Feng and Chen, 2012). 
 
II.3.4 Interplay of PIKKs 
 
Although ATM, ATR and DNA-PK have distinct DNA damage specificities, convincing evidences 
are accumulating about their cross talk (Cimprich and Cortez, 2008; Shrivastav et al., 2009; Woods 
and Turchi, 2013). 
PIKKs can regulate each other directly: 
- Decreased expression of DNA-PK is associated with downregulation of ATM protein levels 
in various cellular models (Chan et al., 1998; Gately et al., 1998; Peng et al., 2005).  
- DNA-PK can phosphorylate ATM on S1981 in apoptotic cells (Solier et al., 2009). 
- ATM can phosphorylate DNA-PK on T2609 in response to IR (Chen et al., 2007) and 
during apoptosis (Solier et al., 2009). ATM-mediated DNA-PK phosphorylation is critical 
for the DSB repair activity of DNA-PK and radioresistance (Chen et al., 2007). In particular, 
it regulates end-processing at the step of Artemis recruitment (Jiang et al., 2015).  
- ATR can phosphorylate DNA-PK on T2609 and T2647 in S-phase cells in response to UV 
(Chen et al., 2007; Yajima et al., 2006). However, the impact of these phosphorylations on 
DNA repair has not been evaluated. 
In addition to the direct mechanisms of regulation, PIKKs can regulate each other indirectly by 
activating signalling pathways that in turn activate other PIKKs. For example, DNA-PK contributes 
to sustain ATR signalling in the presence of limited amount of ssDNA (Vidal-Eychenie et al., 2013). 
ATM can also promote the activation of ATR by phosphorylating TOPBP1 (Yoo et al., 2009) and 
by favouring the processing of DSBs to generate RPA-coated ssDNA (Jazayeri et al., 2006). Other 
important evidence of PIKKs’s crosstalk is the overlap in substrates specificity. Most substrates are 
shared by PIKKs, the best example is given by H2AX (see section II.5.3.2.1). 
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II.4 Spatiotemporal dynamics of DDR proteins at DNA break 
 
One important aspect that determines the effectiveness of DDR signalling in mammals is the tight 
spatiotemporal coordination of DDR factors at DSBs: they have to relocate to the right place at the 
right time. Unlike bacteria that activate a global transcriptional program to increase the availability 
of DDR proteins, eukaryotes primarily respond with a local up-concentration of DDR components 
already present in the cell. This local and sequential accumulation of DDR factors at DSBs usually 
leads to the formation of microscopically detectable foci, also referred as IRIF (ionizing radiation 
induced foci), that are widely used as marker of DSB presence and location (Figure 23A) (Lukas et 
al., 2011b).  
The “spatial map” of IRIFs reveals two distinct compartments: the DSB-flanking chromatin and the 
ssDNA micro-compartment (Bekker-Jensen et al., 2006; Bekker-Jensen and Mailand). The proteins 
associated with DSB flanking chromatin, such as γH2AX (for details see Figure 23B), are able to 
spread out for megabases from the initial DSB and they can assemble throughout most of the cell 
cycle. The second compartment is much smaller and cytologically visible like “microfoci”. It 
localizes at RPA-coated ssDNA that forms after resection of the DSB. Accumulation of DDR 
proteins in this compartment is restricted to S- and G2-phases (Figure 23C). There is another group 
of proteins that is able to interact with DNA but the transient nature of this interaction (for example, 
Chk1 and Chk2) or the low concentration at DSBs (DNA-PK, NHEJ factors) technically challenges 
microscopy detection. Recently, Britton and colleagues developed a method, based on combined 
ribonuclease treatment, detergent pre-extraction and high-resolution microscopy, to visualize Ku 
and others NHEJ factors at DSBs (Britton et al., 2013). Interestingly, ATM, ATR and DNA-PK are 
located in distinct compartments: ATM in DSB-flanking chromatin, ATR in ssDNA micro-
compartment and DNA-PK at unprocessed DSB ends.  
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Figure 23: Spatiotemporal properties of DDR. (A) Example of the DDR proteins’ foci organization after DSB induction: 53BP1 
(red), γH2AX (green), DNA (blue) and merge (yellow). Each focus represents at least a DSB. (B) “Spatial map” of DDR proteins 
around DSBs. (C) Cell cycle regulation of DDR foci formation. Efficient foci formation is represented with solid lines and 
weak/undetectable foci are represented by a dashed line. Figure B and C are adapted from (Bekker-Jensen et al., 2006; Polo and 
Jackson, 2011).  
 
II.5 Molecular mechanisms of DDR proteins assembly at DNA break 
 
The mechanisms driving the highly coordinated spatiotemporal recruitment of DDR proteins at 
DSB sites are based on (1) direct recognition of DNA-breaks, (2) protein-protein interaction and (3) 
post-translation modifications. 
 
II.5.1 Direct recognition of DNA-breaks 
 
DDR factors that act as DSB sensors are the first proteins recruited to DSBs. Such proteins are able 
to directly recognize and bind broken DNA in a sequence-independent manner. The Ku heterodimer 
(see section II.3.3), the MRN complex, RPA (see section II.3.2) and the proteins PARP1 and 
PARP2 belong to this category.  
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II.5.1.1 The MRN complex 
 
The MRN complex (Mre11/Rad50/Nbs1) consists of dimers of each subunit and structurally it can 
be divided into distinct “head”, “coil”, “hook” and “flexible adapters” domains (Figure 24) 
(Williams et al., 2010). The “head” is the DNA-binding and processing core of MRN, containing 
two Mre11 molecules and two ATPase domains of Rad50. Mre11 can bind DNA with the specific 
ability to synapse DSB ends and it has endonuclease and 3’→5’ exonuclease activities (the opposite 
polarity from what is required for HR in vivo). Rad50 provides ATPase and adenylate-kinase 
activities and can also bind/unwind DNA. Rad50 also forms an anti-parallel coiled-coil (“coil”) that 
terminates with a zinc hook motif (“hook”) (Hopfner et al., 2002). The “coil” is a flexible structure 
projected away from the DNA that can mediate long-range tethering of two DNA molecules by 
oligomerization via its zinc hook. Nbs1 constitutes the “flexible adapter” domain of MRN 
providing a regulatory and protein-protein interaction module. Nbs1 does not possess a known 
enzymatic activity itself. However, it is essential for the nuclear localization of the MRN complex 
(Desai-Mehta et al., 2001) and stimulates its DNA-binding and its nuclease activities (Paull and 
Gellert, 1999).  
 	  
Figure 24: Scheme of MRN structure and domains. MRN can assemble as a heterohexamer with head, coils, hook and flexible 
adapter domains. 
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The MRN complex plays a role in both signalling and repair of DSBs (reviewed in (Lamarche et al., 
2010; Riches et al., 2008)), in particular it participates to: 
- Very early DSB detection and recruitment of ATM at chromatin 
- Retention of ATM to DSB to achieve signal propagation 
- Activation of ATR by contributing to the early step of end resection at breaks 
- DNA tethering to bridge the ends of broken chromosomes 
These multiple roles in DDR are reflected by human disorders associated with MRN mutations. 
Hypomorphic mutations in the NBS1 gene result in Nijmegen breakage syndrome (NBS), an 
autosomal recessive disorder characterized by microcephaly, immunodeficiency and cancer 
predisposition (Lavin, 2008). Mutations in MRE11 lead to AT-like disorder (ATLD) that resembles 
to the phenotypes of ATM deficiency (Lavin, 2008). Recently, a patient with hypomorphic 
mutation in RAD50 has been described to have a phenotype similar to NBS (NBSLD, NBS-like 
disorder) (Waltes et al., 2009). Cells from NBS, ATLD and NBSLD patients show increased 
radiosensitivity and checkpoint’s defects.  
 
II.5.1.2 PARP 
 
PARP1, PARP2 and PARP3 are the members of the PARP family found to be induced in response 
to DNA damage. PARPs catalyse the polymerization of ADP-ribose units from donor NAD+ 
molecules on Glutamate, Lysine or Aspartate residues of target proteins, resulting in the attachment 
of linear or branched polymers. PARP1 can be activated by different types of damage such as SSBs, 
DSBs, DNA crosslinks and stalled replication forks while currently, PARP2 seems able to detect 
gaps and flap structures and PARP3 DSBs (Beck et al., 2014). Structurally and mechanistically the 
best characterized PARP member is PARP1. PARP1 can act like a DNA damage sensor by virtue of 
its DNA-binding domain, composed of two zinc finger domains (Zn1 and Zn2). A substantial body 
of data suggests a model for PARP recognition of DNA damage and activation (Ali et al., 2012). 
PARP1 is constitutively associated with chromatin likely via the weak interaction of Zn1 with the 
sugar-phosphate backbone and it has a very low basal activity. A discontinuity in the DNA 
backbone allows the binding of Zn2 and the formation of a functional break-recognition module via 
dimerization with a second PARP1 molecule thereby facilitating activation by trans-modification. 
The absence or the inhibition of PARP1 sensitizes cells to chemical drug-inducing DSBs and delays 
their repair (Boulton et al., 1999; Smith et al., 2005). This is in agreement with different key roles 
of PARP1 in DDR: 
- PARylation targets DDR proteins to DNA breaks for DSB signalling 
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- PARP1 responds to collapsed replication fork facilitating HR repair (Bryant et al., 2009)  
- PARP1 operates in the alternative-NHEJ repair pathway (Wang et al., 2006). 
PARylation is negatively regulated by PARG (PAR-glycohydrolase) that hydrolyses the glycosidic 
linkage between the ADP-ribose units producing free ADP-ribose (Kim et al., 2005). 
 
II.5.2 Protein-protein interactions 
 
Downstream from DSB sensors, other DDR factors assemble to damage sites in a highly 
coordinated manner by protein-protein interactions. An example is given by MDC1, which 
constitutes a molecular binding platform for DDR components at DSB sites (see section II.5.3.2.2). 
Similarly, the apical DDR kinases, ATM, ATR and DNA-PK, are recruited to sites of DNA damage 
through analogous mechanisms involving a conserved C-terminal region present in Nbs1, ATRIP 
and Ku80, respectively (Falck et al., 2005). 
 
II.5.3 Post-translational modifications 
 
Along with protein-protein interaction the sequential protein assembly at DNA breaks is achieved 
by post-translational modifications. PTMs regulate recruitment, dissociation and/or retention of 
DDR proteins and drive the DNA damage-induced chromatin responses. 
 
II.5.3.1 Poly(ADP-ribosyl)ation 
 
PARylation (see section II.5.1.2) is one of the earliest modifications detectable at sites of DSBs and 
PAR chains are quickly removed by PARG providing a transient response lasting minutes (Ciccia 
and Elledge, 2010; Schreiber et al., 2006) (Figure 25). In response to DSBs, PARP1 PARylates 
target proteins, including histone H1 and H2B and PARP1 itself. PAR structures act as platforms to 
recruit factors that locally remodel chromatin at DNA damage sites to promote DSB signalling 
and/or repair. For instance, PAR-dependent recruitment of the NuRD (nucleosome remodelling and 
deacetylase) complex, the Polycomb histone-modifying complex and the histone variant macroH2A 
(via APLF, aprataxin-PNK-like factor), promotes transcriptional silencing and chromatin 
compaction around DNA lesions thereby minimizing the probability of encounter between 
transcriptional and repair machineries (Lukas et al., 2011b). In addition, PARylation plays a variety 
of different roles in DSB signalling such as the regulation of the exchange of histone variant H2AX 
with conventional H2A by inhibiting the exchange regulator FACT (facilitates chromatin 
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transcription) (Heo et al., 2008) and the ATM activation in response to IR (Aguilar-Quesada et al., 
2007). Recently, a new mechanism by which PARylated proteins at DNA damage sites coordinate 
the spatiotemporal recruitment of DDR factors has been described (Altmeyer et al., 2015; Hyman et 
al., 2014; Patel et al., 2015). PARylated proteins at damaged sites trigger the rapid accumulation of 
intrinsically disordered proteins that results in the phase separation into liquid droplets (referred to 
as liquid demixing) and in the creation of a liquid-like compartment. This PAR-seeded 
compartment filters the access of DDR proteins to chromatin regulating the early phase of DDR, for 
example MDC1 can penetrate while 53BP1 is excluded.   
 
Figure 25: Poly(ADP-ribosyl)ation 
in response to DSBs. Proteins 
depicted in green determine alteration 
of chromatin status. See text for 
details. Figure from (Lukas et al., 
2011b). 
 
 
II.5.3.2 Phosphorylation 
 
The importance of phosphorylation and dephosphorylation events in DDR is displayed by the large 
number of phosphorylation sites (more than 900 over 700 proteins) identified by mass 
spectrometry-based screens (Bennetzen et al., 2010; Matsuoka et al., 2007). The roles of this PTM 
are to: 
- Directly regulate the activity or the structure of the target proteins 
- Regulate the sequential recruitment of DDR factors having phospho-binding domains such 
as BRCT (breast cancer C-terminal) or FHA (forkhead-associated) domains 
Phosphorylation can also promote the dissociation of proteins from the DSB sites. Examples are 
given by (i) DNA-PKcs autophosphorylation (as discussed before in section II.3.3), which triggers 
its dissociation from Ku (Chan and Lees-Miller, 1996), (ii) KAP1 that is released from 
heterochromatin upon ATM phosphorylation (Goodarzi et al., 2008) (see section II.8) or (iii) Chk1 
and Chk2 that, after ATR or ATM phosphorylation, are able to migrate from chromatin to 
nucleoplasm to phosphorylate their substrates (Lukas et al., 2003; Smits et al., 2006). 
The key role of phosphorylation in DDR is primarily exemplified by H2AX phosphorylation.  
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II.5.3.2.1 Phosphorylation of the histone H2AX: γH2AX 
H2AX is a member of the histone H2A family. In mammalian cells, it comprises 2-25% of the H2A 
pool, depending on organism and cell types (Bonner et al., 2008; Rogakou et al., 1998). It exists as 
a component of the nucleosome core structure, constituted of eight histone proteins, two from each 
of the H2A, H2B, H3 and H4 families, and it is present in every fifth nucleosome on average.  
H2AX consists of 143 amino acids and structurally, it is similar to other H2A species and in general 
to all histone core proteins. It is composed of a central globular highly conserved “histone fold” 
domain containing three α-helices connected by two loops and flanked by terminal “tails” that have 
very little secondary or tertiary structure. The “histone fold” domain is the site of interaction for 
H2A/H2B dimer formation and it provides stability to the nucleosome while, the “tails” protrude 
from the core and possess sites for a variety of post-translational modifications. Respect to the bulk 
H2A species, H2AX has an extended C-terminal tail with an SQEY phosphorylatable motif 
(Fernandez-Capetillo et al., 2004; Li et al., 2005).  
The phosphorylation of the serine 139 (S139) of this motif is an early and key event in the response 
to DSBs. The phosphorylated form of H2AX, referred as γH2AX, appears within minutes after 
DSB induction (Rogakou et al., 1999) and leads to the formation of large foci detectable by 
immunofluorescence. The first studies of the Bonner laboratory (Rogakou et al., 1999; Rogakou et 
al., 1998) and recent studies using chromatin immunoprecipitation of γH2AX around sequence-
specific DSBs (Iacovoni et al., 2010; Savic et al., 2009), provide a quite complete landscape of 
γH2AX distribution around a DSB. H2AX phosphorylation occurs over large domain from 0.5 to 2 
Mb surrounding the DSB and the percentage of H2AX phosphorylated around the break is constant, 
≈ 0.03% in yeast and mammals. Mapping of the γH2AX domains reveals also characteristically 
locus-specific, bidirectional, discontinuous and asymmetric distributions of γH2AX flanking DSB 
sites with a marked depletion in the ≈ 1 Kb proximal to the DSB (Berkovich et al., 2007; Iacovoni 
et al., 2010) (Figure 26). γH2AX propagation is spatially confined by domain boundaries but what 
defines these boundaries is still not completely understood.  
In response to DSBs, ATM, ATR or DNA-PK can phosphorylate H2AX. A rough generalization is 
that H2AX phosphorylation is carried out by ATM and DNA-PK in a partially redundant way (Stiff 
et al., 2004) and by ATR in response to UV radiations or replicative stress (Ward and Chen, 2001). 
The real scenario is likely more complex. In normal cells, H2AX is primarily phosphorylated by 
ATM while in the absence of ATM, DNA-PK appears to be the primary H2AX kinase (Stiff et al., 
2004). Another aspect to consider is the different mechanism of ATM and DNA-PK activation. 
Upon DSB induction, ATM is activated and distributed between soluble and chromatin-bound pools 
(Andegeko et al., 2001). This dynamism might make ATM able to phosphorylate H2AX within 
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large domains. DNA-PKcs, on the other hand, becomes active through its interaction with Ku and 
DNA ends and probably it has a reduced phosphorylation range requiring longer times for H2AX 
phosphorylation at longer distances (Kinner et al., 2008; Savic et al., 2009).   
 
Figure 26: Distribution of the DDR proteins around a DSB. Distribution of γH2AX, ATM and Nbs1 around a I-Ppo-induced DSB 
assessed by ChIP. Nbs1 localizes at the DSB site, whereas γH2AX is depleted at DSB site and accumulates in adjacent regions. ATM 
distribution follows both γH2AX and Nbs1 distributions. From (Berkovich et al., 2007).  
 
γH2AX must be removed to allow the repair and the restoration of pre-lesion chromatin status 
(Chowdhury et al., 2005). Currently, two non-exclusive mechanisms are proposed for γH2AX 
removal: γH2AX dephosphorylation or γH2AX replacement by histone exchange (Heo et al., 2008). 
Dephosphorylation seems to be the predominant mechanism in mammals. γH2AX 
dephosphorylation can take place in chromatin (Chowdhury et al., 2005) and several γH2AX 
phosphatases have been identified, such as PP2A (Chowdhury et al., 2005), PP1 (Nazarov et al., 
2003), PP4 (Chowdhury et al., 2008), PP6 (Douglas et al., 2010) and Wip1 (Moon et al., 2010). 
Another residue is phosphorylated in the C-terminal tail of H2AX, the tyrosine 142 (Y142) (Cook 
et al., 2009). This phosphorylation is deposited by the chromatin-remodelling factor WSTF 
(williams syndrome transcription factor) (Xiao et al., 2009) under basal conditions and it is 
removed by EYA phosphatase (EYA1 and EYA3) in response to DNA damage when the S139 site 
becomes phosphorylated (Cook et al., 2009). Persistent phosphorylation of Y142 promotes an 
apoptotic response over repair. 
The H2AX gene is not essential. H2AX knockout mice survive well in unstressed conditions but 
they have defects in DSB repair, are radiosensitive and present increased chromosomal 
abnormalities (Bassing et al., 2002; Celeste et al., 2002). Similarly, studies in H2AX knockout cells 
show that the key function of γH2AX is to maintain and accumulate DDR components at DSBs 
(such as Nbs1, BRCA1 and 53BP1) while it is dispensable for their initial recruitment (Celeste et al., 
2003).  
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Currently, γH2AX is the most popular DSB marker suitable for measuring induction and repair of 
DSBs in cells exposed to various genotoxic agents. It is accepted that a γH2AX foci represents at 
least a DSB. However, other cellular processes or genotoxic stresses can induce H2AX 
phosphorylation even if usually they do not form a focal pattern. Examples are given by UVC 
radiations that induce a γH2AX pan-nuclear staining in non-S-phase cells (Marti et al., 2006) or by 
apoptosis that can be marked by a γH2AX ring in early phases, followed by a nuclear pan staining 
and apoptotic bodies in late phases (Solier et al., 2009). 
 
II.5.3.2.2 MDC1 
The mediator protein MDC1 is a large protein principally constituted by three distinct interaction-
domains: an N-terminal FHA domain, a central Proline/Serine/Threonine repeat domain (PST 
repeat) and a C-terminal tandem BRCT domain (tBRCT) (Coster and Goldberg, 2010) (Figure 
27A).  
MDC1 can bind several DDR proteins, including γH2AX (Stucki et al., 2005), the MRN complex 
(Chapman and Jackson, 2008), ATM (So et al., 2009), 53BP1 (Eliezer et al., 2009), RNF8 (Huen et 
al., 2007) and DNA-PK (Lou et al., 2004). 
Upon DSB induction, γH2AX acts as a docking site for the tBRCT of MDC1 and this interaction 
protects γH2AX from dephosphorylation and mediates the γH2AX-dependent DDR signal. Since 
MDC1-deficient mice recapitulate many phenotypes of H2AX deficiency (Lou et al., 2003), it is 
proposed that the major role of MDC1 is to promote the γH2AX-dependent chromatin retention of 
DDR factors. In particular, MDC1 is required for the recruitment and the chromatin retention of 
ATM (Lou et al., 2006) and it drives the ATM-mediated spreading of γH2AX. Indeed, MDC1 can 
recruit ATM both directly by binding ATM phosphorylated on S1981 (So et al., 2009) or indirectly 
via Nbs1 (Chapman and Jackson, 2008). MDC1 constitutively interacts with Nbs1 through CK2-
mediated phosphorylation of MDC1 (Chapman and Jackson, 2008). Thus, MDC1-Nbs1 interaction 
brings the recruitment of Nbs1-ATM dimers in regions flanking DSBs thereby triggering H2AX 
phosphorylation in distal regions (Figure 27B).  
In the case of replication stresses, MDC1 promotes also the ATR-dependent spreading of γH2AX 
by recruiting TOBP1 (Wang et al., 2011).  
Moreover, ATM-mediated phosphorylation of MDC1 in TQXF motifs, allows the interaction 
between MDC1 and the ubiquitin E3 ligase RNF8 (Huen et al., 2007), which drives the ubiquitin-
dependent DDR signalling (see section II.5.3.4).  
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Figure 27: Schematic representation of MDC1 and model of MDC1-mediated γH2AX signalling. (A) Organization of MDC1’s 
main domains showing the in vivo phosphorylation sites and MDC1 major partners. Adapted from (Coster and Goldberg, 2010) (B) 
Model of γH2AX recruitment of MDC1 and MDC1-mediated γH2AX spreading (Lukas et al., 2011b). 
 
II.5.3.3 Acetylation 
 
Histone acetylation regulates local chromatin structure on domains contiguous to DSBs, directly by 
modulating chromatin compaction or indirectly by recruiting chromatin-remodelling factors. Lysine 
acetylation facilitates the formation of open chromatin by neutralizing the negative charge on 
lysines and therefore decreasing both histone-DNA and histone-histone interactions within the 
nucleosomes. The formation of localized relaxed chromatin at the break sites may increase the 
accessibility of DNA for signalling and repair (reviewed in (Xu and Price, 2011)).  
Tip60 has been identified has one of the first acetyltrasferases involved in DDR and DSB repair 
(Figure 28). Tip60 is recruited to DSBs via its interaction with the constitutively methylated K9 of 
histone H3 (H3K9me3) (Sun et al., 2009). H3K9me3 is “unmasked” by the transient release of HP1 
(heterochromatin-binding protein 1) following DNA damage (Sun et al., 2009). Once activated, two 
main functions of Tip60 are to (i) acetylate ATM thus promoting its activation (Sun et al., 2005; 
Sun et al., 2007) and (ii) acetylate histones H2A and H4 at DSBs thus promoting chromatin 
relaxation and HR (Bird et al., 2002; Downs et al., 2004; Murr et al., 2006). Chromatin remodelling 
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frequently combines histone acetylation with the use of large motor ATPases to modify the 
chromatin architecture. An example is given by the SWI/SNF DNA-dependent ATPase p400. p400 
is recruited to DSBs where it is required (i) for RNF8-dependent ubiquitination of histones and for 
the subsequent recruitment of 53BP1 and BRCA1 (see section II.5.3.4.2) (Xu et al., 2010) and (ii) 
for HR (Courilleau et al., 2012).  
Histone deacetylases, like HDAC1, HDAC2 (histone deacetylase 1 and 2), SIRT1 and SIRT6 
(sirtuin 1 and 6), also accumulate at chromatin in response to DSBs. HDAC1 and HDAC2 regulate 
deacetylation of histones H3 and H4 stimulating NHEJ (Miller et al., 2010), while SIRT1 and 
SIRT6 stimulate Rad51 foci formation promoting DSB repair by HR (Kaidi et al., 2010; 
Oberdoerffer et al., 2008). 
 
Figure 28: Acetylation in 
response to DSBs. Proteins 
depicted in green determine 
alteration of chromatin 
status. See text for details. 
Figure from (Lukas et al., 
2011b). 	  
 
 
II.5.3.4 Ubiquitylation 
 
Ubiquitylation is the covalent attack of ubiquitin, a highly conserved 76 amino acid polypeptide, to 
a lysine residue on a target protein. It is a three-step process involving an ubiquitin-activating 
enzyme (E1), an ubiquitin-conjugating enzyme (E2) and an ubiquitin ligase (E3) (Figure 29). In 
humans, there are eight known E1s, two of which (UBA1 and UBA6) are specific for ubiquitin 
(Schulman and Harper, 2009), 35 active E2s (van Wijk and Timmers, 2010) and more than 1000 
E3s divided in three major families, RING (really interesting new gene), HECT (homology to 
E6AP C-terminus) and RBR (ring between ring) (Berndsen and Wolberger, 2014). The biological 
outcomes of ubiquitin ligation to a protein are dictated by the fashion in which the ubiquitin chains 
are assembled and attached to the substrate: single ubiquitin monomer (monoubiquitylation), 
multiple ubiquitin monomer (multi-monoubiquitylation) or ubiquitin polymers (polyubiquitylation) 
linked via one of the seven lysines of ubiquitin (K6, K11, K27, K29, K33, K48, K63). The linkage 
specificity is largely determined by the pairing of specific E2s and E3s. 
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In response to DSBs, various protein-ubiquitin conjugates have been detected at DSBs sites 
(reviewed in (Brown and Jackson, 2015; Pinder et al., 2013)). The functions of this modification 
are: 
- Target proteins for proteasomal degradation (usually at least four ubiquitin moiety linked by 
K48 or K11) 
- Create docking sites to recruit DDR proteins (usually monoubiquitylation or K63-chains) 
containing ubiquitin-binding domains (UBDs), like MIU (motifs interacting with ubiquitin 
domain) and UIM (MIU-related ubiquitin-binding domain) domains. 
	  
Figure 29: Schematic representation of ubiquitylation cascade. In an ATP dependent reaction, the E1 enzyme binds the GG-motif 
of ubiquitin (Ub) via its catalytic cysteine forming an E1-Ub intermediate. In the case of UBA1 a second Ub molecule is loaded on 
the E1. An E2 conjugating enzyme recognizes the ubiquitin-charged E1 and Ub is transferred to the catalytic cysteine of the E2. Then, 
the Ub is conjugated to the lysine of the substrate by the concerted action of E2 and E3 enzymes. Ring E3 ligases catalyse the Ub 
transfer from the E2 to the substrate by positioning the Ub moiety for conjugation. In the case of HECT and RBR E3 ligases, Ub is 
transferred from the E2 to the active cysteine of the E3 and then to the substrate. Ubiquitylation can be reversed by deubiquitylating 
enzymes (DUBs). Image from (Brown and Jackson, 2015). 
 
II.5.3.4.1 RNF8/RNF168 ubiquitination cascade 
The major players in ubiquitination cascade are the two E3 ligases RNF8 and RNF168. RNF8 
consists of a N-terminal FHA domain and a C-terminal RING finger motif, while RNF168 
possesses a N-terminal RING finger domain and two ubiquitin-binding domains (MIU1 and MIU2). 
Homozygous or biallelic heterozygous nonsense mutations in RNF168 gene have been identified as 
responsible for the RIDDLE (radiosensitivity, immunodeficiency, dysmorphic features, and 
learning difficulties) syndrome, which is a novel “AT-mimicking syndrome” (Devgan et al., 2011; 
Stewart et al., 2007). Cells from RIDDLE patients display an impaired accumulation of 53BP1 and 
BRCA1 at DSBs. 
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RNF8 binds ATM-phosphorylated MDC1 via RNF8-FHA domain (Huen et al., 2007; Kolas et al., 
2007; Mailand et al., 2007), which allows the recruitment of RNF168 though RNF168-MIU 
domains (Doil et al., 2009; Stewart et al., 2009). The two E3 ligases act in concert to catalyse K63-
ubiquitylation of H2A(X) on K13 and K15 (Gatti et al., 2012; Mattiroli et al., 2012). This 
polyubiquitination is required for focal accumulation of downstream DDR factors such as BRCA1 
and 53BP1 but it does not impact on the formation of γH2AX, MDC1 and Nbs1 foci (Doil et al., 
2009; Huen et al., 2007; Mattiroli et al., 2012). After the discovery of RNF8 and RNF168, the first 
model envisaged that RNF8 initiates the H2A(X) ubiquitylation on chromatin around the break and 
then RNF168 binds and amplifies the ubiquitin conjugates initiated by RNF8 (Bekker-Jensen and 
Mailand; Ciccia and Elledge, 2010; Lukas et al., 2011b; Polo and Jackson, 2011). The work of 
Mattiroli and colleagues challenges this hierarchy (Mattiroli et al., 2012). They show that, although 
the recruitment of RNF168 is dependent on its MIU domains and on RNF8 catalytic activity (Doil 
et al., 2009; Stewart et al., 2009), RNF168 is the priming ubiquitin ligase for histones. Therefore 
RNF8 may allow the ubiquitin-mediated recruitment of RNF168 by ubiquitinating another non-
histone substrate. Even if this protein has not yet been identified, RNF8 is able to ubiquitylate other 
DDR proteins at DSB sites including Nbs1 (Lu et al., 2012), JMJD2A (jumonjii-domain containing 
protein 2A) (Mallette et al., 2012) and BCL10 (B-cell CLL/lymphoma 10) (Zhao et al., 2014). Once 
RNF168 recruited, it initiates H2A(X) ubiquitination on K13 and K15, which leads to K63-
polyubiquitination on these lysines by RNF168 and/or RNF8 (Mattiroli et al., 2012) (Figure 30).  
The others members of the RNF8/RNF168 ubiquitin cascade have also been identified: 
- E1 enzyme: UBA1 (Moudry et al., 2012) 
- E2 enzyme: Ubc13 (ubiquitin-containing enzyme E2N) (Huen et al., 2007; Kolas et al., 
2007; Stewart et al., 2009), which is the only E2 ligase known to exclusively catalyse K63-linked 
ubiquitin chains  
- E3 enzyme: HERC2 (HECT and RLD domain containing E3 ubiquitin protein ligase 2) (in 
addition to RNF8 and RNF168) (Bekker-Jensen et al., 2010). HERC2 is phosphorylated by ATM in 
response to DSBs. Phosphorylated HERC2 interacts with RNF8 and stabilizes RNF8-Ubc13 
association providing specificity to E2-E3 interaction and promoting K63-linked ubiquitin chain 
formation. In addition, HERC2 stabilizes RNF168 protein level. 
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Figure 30: RNF8/RNF168-dependent signalling at DSBs. (A) Proposed model for RNF8/RNF168 ubiquitination cascade at DSBs. 
RNF168 is recruited to DSBs by the activity of RNF8 toward a non-nucleosomal substrate. RNF168 mono-ubiquitinates H2A-type 
histones on K13, K15 and this leads to K63-polyubiquitination on these lysines. Independently, RNF2-BMI1 monoubiquitinates 
H2A/H2AX on K119, K120. Adapted from (Mattiroli et al., 2012).  
 
II.5.3.4.2 Recruitment of BRCA1 and 53BP1 
BRCA1: K63-linked ubiquitin chains on histones surrounding DSBs constitute the specific signal 
for BRCA1 recruitment. BRCA1 is a tumour suppressor protein playing a central role in the 
maintenance of genome integrity (reviewed in (Silver and Livingston, 2012)). BRCA1 is a large 
protein (1863 amino acids) containing a C-terminal tandem BRCT (tBRCT) domain and a N-
terminal RING-finger domain. Mutations in both domains of BRCA1 predispose to cancer 
(Rostagno et al., 2003). 
The cellular levels of BRCA1 fluctuate in a cell cycle-dependent manner. BRCA1 is abundant in S- 
and G2-phase cells while it reaches a low steady-state level in G0/G1 cells. This process is 
regulated by both transcriptional mechanisms and ubiquitin proteasome-dependent degradation 
(Chen et al., 1996; Choudhury et al., 2004). 
BRCA1 forms a stable heterodimer with BARD1 (BRCA1-associated ring domain protein 1) via its 
RING motif. BRCA1-BARD1 heterodimer is a functional ubiquitin E3 ligase, which catalyses the 
formation of K6-ubiquitin chains in complex with E2 UBCH5C (ubiquitin-conjugating enzyme 
E2D 3) (Nishikawa et al., 2004; Wu-Baer et al., 2003). BRCA1 is present in distinct biochemical 
complexes and it localizes at DSBs as member of the BRCA1-A complex (Rap80, 
Abraxas/CCDC98, BRCC36, BRCC45, MERIT40) (Feng et al., 2009; Kim et al., 2007; Wang et al., 
2007). Abraxas interacts specifically with the BRCT domain of BRCA1 bridging it with Rap80. 
Rap80 recognizes and binds K63-ubiquitinated histones via two UIM motifs (Sobhian et al., 2007; 
Wang et al., 2007). Rap80 also binds SUMO at DNA damage sites via SIM motif (SUMO-
interacting motif) (Guzzo et al., 2012) (see paragraph II.5.3.6). Interestingly, BRCC36 
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(BRCA1/BRCA2-containing complex subunit 36) possesses a deubiquitylating activity raising the 
possibility of a dynamic regulation of BRCA1 functions at DSBs (Sobhian et al., 2007). 
53BP1: 53BP1 is a large protein (1972 amino acids) with not apparent enzymatic activity. 53BP1 
functions in maintaining genomic integrity. Mice lacking 53BP1 show similar defects to ATM null 
mice and 53BP1 knockout cells have defects in checkpoint activation (Ward et al., 2003). 
Structurally, 53BP1 contains a C-terminal tBRCT domain, an ubiquitylation-dependent recruitment 
motif (UDR), a tandem Tudor domains (tTudor) and a N-terminal S/T-Q site, which can be 
phosphorylated by ATM (or ATR) (Jowsey et al., 2007). In response to DSBs, 53BP1 accumulates 
at DNA lesions and forms foci (Anderson et al., 2001). γH2AX is dispensable for the initial 
recruitment of 53BP1 but γH2AX-dependent RNF8-RNF168 ubiquitination cascade is necessary 
for its retention (Celeste et al., 2003; Stewart et al., 2009). How 53BP1 is recruited to DSB has been 
a longstanding question. Several studies have provided new insights revealing a mechanism based 
in a specific combination of histone marks at damaged chromatin: 
- Recognition of H4K20: 53BP1 binds H4K20me1 (monomethylated) and H4K20me2 
(dimethylated) via its Tudor domains and this interaction is essential for 53BP1 foci formation 
(Huyen et al., 2004). In undamaged chromatin, H4K20me2 is masked by the Polycomb protein 
L3MBTL1 (lethal(3) malignant brain tumour-like protein 1) and by the demethylase JMJD2A (Lee 
et al., 2008; Min et al., 2007). Upon DSB induction, RNF8/RNF168 are required for 53BP1 
recruitment at chromatin. Ubiquitylation of H2AK15 helps to expose the H4K20me2 mark, 
ubiquitylation of L3MBTL1 allows its eviction from chromatin by p97/VCP (valosin containing 
protein) and ubiquitylation of JMJD2A targets it to proteasome for degradation (Mallette et al., 
2012; Meerang et al., 2011). Increased acetylation of H4K16 decreases the binding of 53BP1 to 
chromatin (Tang et al., 2013). Therefore, 53BP1 recruitment at DSBs is regulated by the 
antagonistic activities of Tip60 and HDAC1/HDAC2 (Hsiao and Mizzen, 2013). 
- Recognition of H2AK15ub: The binding of 53BP1 to H4K20me2 is necessary but not 
sufficient for 53BP1 foci formation. 53BP1 needs to interact with H2AK15ub via its UDR motif 
(Fradet-Turcotte et al., 2013). 
53BP1 only binds nucleosomes that have both H2AK20me2 and H2AK15ub marks.  
 
It is emerging that 53BP1 and BRCA1 have an antagonistic relationship during DSB repair pathway 
choice. 53BP1 promotes NHEJ-mediated DSB repair protecting DSB ends from end-resection 
during G1 phase while BRCA1 favours HR during S and G2 phases probably by evicting 53BP1 
and NHEJ factors (Chapman et al., 2013; Escribano-Diaz et al., 2013) (see also section II.8).  
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II.5.3.4.3 RNF2-BMI1 ubiquitination cascade 
Another E3 ligase participates to DSB response, RNF2 with its co-activator BMI1 (Facchino et al., 
2010; Ismail et al., 2010; Pan et al., 2011). RNF2 and BMI1, together with another E3 ligase, RNF1, 
form the RING domain-containing proteins of the Polycomb repressive complex 1 (PRC1) (Ginjala 
et al., 2011; Ismail et al., 2010). PRC1 ubiquitinates H2A and silences transcription (Wang et al., 
2004).  
The involvement of E3 ligases other than RNF8/RNF168 in H2A(X) ubiquitylation was initially 
suggested by the fact that depletion of RNF8 abrogates γH2AX polyubiquitylation without 
preventing the IR-induced γH2AX monoubiquitylation (Huen et al., 2007). This 
monoubiquitylation of H2AX at K119 and K120 (K118 and K119 in H2A) in response to DSBs is 
catalysed by RNF2–BMI1 (Facchino et al., 2010; Ismail et al., 2010; Pan et al., 2011). RNF2–BMI1 
complex is recruited early (within minutes) at chromatin, forms foci that colocalize with DDR 
proteins and co-immunoprecipitates with DDR factors including H2AX, ATM, Nbs1, MDC1 and 
DNA-PK (Facchino et al., 2010; Ismail et al., 2010; Pan et al., 2011). Blocking the 
monoubiquitination of H2AX by downregulation of one component of RNF2-BMI1 complex or by 
using H2AX K119R/K120R mutants does not affect ATM activation (Pan et al., 2011) but impairs 
the recruitment of activated ATM at DSB sites (Facchino et al., 2010; Pan et al., 2011) and the 
subsequent foci formation of γH2AX and MDC1 (Facchino et al., 2010; Pan et al., 2011) and the 
downstream DDR response (FK2, 53BP1, BRCA1, pChk2) (Ismail et al., 2010). 
Interestingly, BRCA1-BARD1 heterodimer is able to monoubiquitylate H2A in vitro (Xia et al., 
2003). Zhu and co-workers demonstrated that BRCA1 E3 ligase activity is necessary for the 
maintenance of the monoubiquitinated H2A (Ub-H2A) within constitutive heterochromatic regions 
in mouse and human cells (Zhu et al., 2011). To date, it is not known if BRCA1-dependent 
monoubiquitylation of H2A could have a role in the response to DNA damage. However, cells 
lacking BRCA1 E3 ligase activity do not exhibit defects in HR (Reid et al., 2008) but expression of 
constitutive Ub-H2A in BRCA1 null cells is able to rescue about 50% of HR defects measured with 
the HR GFP reporter system after I-SceI expression (Zhu et al., 2011). 
 
II.5.3.4.4 Negative regulation of ubiquitination 
Ubiquitination process in DSB response is also negatively regulated. This opposite activity seems to 
be important in the context of DSB repair and repair pathway choice. Three mechanisms have been 
described to antagonize ubiquitin-dependent signalling at DSBs: 
1) Deubiquitylation: Several deubiquitylating enzymes (DUBs) have been implicated in the 
clearing of DDR signal (for review see (Jacq et al., 2013)), including USP3 (ubiquitin-specific 
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protease 3) which deubiquitylates H2A and H2B (Nicassio et al., 2007), BRCC36 (Shao et al., 
2009) and POH1 (26S proteasome-associated PAD1 homolog 1) that both antagonize RNF8 by 
removing ubiquitin residues induced by RNF8 (Butler et al., 2012). Interestingly, OTUB1 (OTU 
deubiquitinase, ubiquitin aldehyde binding 1), another DUB, opposes DSB-induced ubiquitylation 
by suppressing the activity of RNF168 through interaction and inhibition of Ubc13 rather than by 
using its catalytic activity (Nakada et al., 2010).  
2) Ejection of ubiquitinated proteins: Ubiquitinated proteins can be ejected from chromatin by 
ubiquitin-directed segregases, such as p97/VCP (Meerang et al., 2011) (for review see (Ramadan, 
2012; Vaz et al., 2013)). 
3) Competition: RNF169, a RNF168 paralog, competes with UBD-binding proteins (53BP1 
and Rap80) at DSB sites, thus inhibiting RNF8/RNF168-dependent signalling (Chen et al., 2012; 
Panier et al., 2012; Poulsen et al., 2012). 
 
II.5.3.4.5 Role of proteasome in DDR 
Ubiquitylation is a key component of DDR signalling but polyubiquitin chains (in particular K48 
and K11), when associated with an unfolded protein region, also constitute a signal (also known as 
degron) for proteasomal degradation (for review see (Bhattacharyya et al., 2014)).    
The 26S proteasome comprises a catalytic core particle (20S) containing the proteolytic active sites 
capped by one or two regulatory particle (19S). The 20S forms a compact cylinder composed of 
four stacked rings enclosing the catalytic sites that can be reached only by unfolded proteins 
through a very narrow pore. This pore is generally close in the 20S free particle and can be opened 
after docking of activators to the core particle (Groll et al., 2000). The 19S is a 20S activator 
complex composed by a “lid” working in the poly-Ub substrate recognition, binding and 
deubiquitylation and a “base” harbouring the ATPase function. The large 26S proteasome is 
localized in both the cytoplasm and the nucleus of all eukaryotic cells (Bhattacharyya et al., 2014). 
In addition to 19S cap, others proteasome activators have been identified and can form a complex 
with the 20S core: (i) the 11S cap, also known as PA28 (proteasome activator 28) (Dubiel et al., 
1992), (ii) PA200 (proteasome activator 200) (Ustrell et al., 2002) and (iii) p97/VCP (Barthelme 
and Sauer, 2012; Barthelme and Sauer, 2013).  
The proteasome is involved at different levels in the DSB response. First, the proteasome is 
required indirectly for ubiquitin signalling. Indeed, inhibition of the 20S catalytic activities (such as 
by MG132 or bortezomib) induces the accumulation of poly-Ub proteins, thus preventing the 
recycling of ubiquitin (Dantuma et al., 2006). Accumulation of ubiquitylated substrates coincides 
with the reduction of the nuclear free ubiquitin pool and of the histone-conjugated ubiquitin 
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(Dantuma et al., 2006). Thereby, in the presence of DSBs, the inhibition of the proteasome results 
in persistence of MDC1 foci, impairment of phospho-ATM, FK2, 53BP1 and BRCA1 foci 
formation and inhibition of both HR and NHEJ repair pathways (Butler et al., 2012; Cron et al., 
2013; Galanty et al., 2012; Gudmundsdottir et al., 2007; Jacquemont and Taniguchi, 2007; Mailand 
et al., 2007; Meerang et al., 2011; Murakawa et al., 2007; Takeshita et al., 2009). Consistently, 
introduction of exogenous ubiquitin upon proteasome inhibition is able to rescue the production of 
53BP1 foci in presence of DSBs (Butler et al., 2012). 
The proteasome may also be implicated more directly in DDR, since several studies have revealed 
that 20S and 19S proteasome subunits, PA200, PA28 and p97/VCP accumulate at DSBs created by 
different sources (Ban et al., 2013; Blickwedehl et al., 2008; Blickwedehl et al., 2007; Butler et al., 
2012; Galanty et al., 2012; Levy-Barda et al., 2011; Livingstone et al., 2005; Meerang et al., 2011; 
Ustrell et al., 2002) and can interact with DDR proteins (Brown et al., 2015; Butler et al., 2012; 
Galanty et al., 2012). In addition, some proteasome components are regulated by DDR proteins 
following DNA damage induction: 19S subunit PSMD4 (proteasome 26S subunit, non-ATPase, 4) 
is phosphorylated by the DDR protein kinases ATM and/or ATR (Matsuoka et al., 2007), PA28 is a 
target of ATM (Levy-Barda et al., 2011), DNA-PK activity drives the PA200-associated 
proteasome recruitment at chromatin (Blickwedehl et al., 2008) and p97/VCP can be 
phosphorylated by ATM and/or DNA-PK (Livingstone et al., 2005). The role of proteasome at 
DSBs is not clearly understood but different possibilities are emerging (reviewed in (Stone and 
Morris, 2014)): 
- Degradation of DDR proteins: Degradation of DDR proteins can be part of the DDR 
cascade and DSB repair. For instance, MDC1 turnover is controlled by the proteasome (Luo et al., 
2012), JMJD2 degradation is necessary for 53BP1 recruitment (Mallette et al., 2012) and BRCA1 is 
also degraded by the proteasome (Choudhury et al., 2004). If the proteasome degrades ubiquitylated 
proteins in situ or after their eviction from chromatin by p97/VCP, remains to be established. 
- Restriction of K63-Ub conjugates at DSBs: The 19S deubiquitylating enzyme POH1 
processes K63-Ub conjugates to restrain 53BP1 assembly at DSBs (Butler et al., 2012). 
- Participation in DSB repair: The proteasome could be directly implicated in DSB repair. 
For example, DSS1 (deleted in split hand/split foot protein 1) is a component of the 19S proteasome 
(Wei et al., 2008) and a co-factor of BRCA2 (Marston et al., 1999). DSS1 is recruited to DSBs in a 
POH1-dependent manner (Butler et al., 2012) and the depletion of DSS1 impairs HR (Kristensen et 
al., 2010). 
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II.5.3.5 NEDDylation 
 
NEDD8 (neural precursor cell expressed developmentally downregulated 8) is a member of the 
UBL family. Among the UBLs, NEDD8 is the most highly related to the ubiquitin at sequence and 
secondary structure level (reviewed in (Enchev et al., 2015)). NEDD8 is conjugated to a lysine 
using E1, E2 and E3 enzymes distinct to ubiquitin. The well-described conjugation pathway for 
NEDD8 involves the NAE1 (NEDD8 activating enzyme) as E1 enzyme, UBE2M or UBE2F 
(ubiquitin-conjugating enzyme E2M or E2F) as E2 enzyme and RBX1 or RBX2 (ring box 1 or 2) as 
E3 (Enchev et al., 2015). NEDD8 and neddylation-pathway components rapidly accumulate at DSB 
sites and colocalize with γH2AX (Brown et al., 2015; Ma et al., 2013). The role of neddylation in 
DDR is tightly connected to ubiquitylation. The predominant substrates of NEDD8 are the E3 
ubiquitin ligase cullins. Neddylation of the cullins results in the activation of their ubiquitin transfer 
activity. A recent report from the Jackson’s laboratory shows that neddylation is required for 
ubiquitylation of Ku, probably mediated by cullins, and for the removal of Ku and NHEJ factors 
from DSBs (Brown et al., 2015) (Figure 31). The persistence of NHEJ factors at chromatin after 
completion of DSB repair could be the cause of the hypersensitivity to IR of cells deficient for 
neddylation processes (Brown and Jackson, 2015; Brown et al., 2015). In the last years, several 
non-cullin substrates of neddylation have also been reported including proteins involved in DDR 
such as p53 (Xirodimas et al., 2004), RNF168 (Li et al., 2014) and histone H4 (Ma et al., 2013) and 
H2A (Li et al., 2014). However, the presence of non-cullin substrates in vivo is debated, because of 
the redundancy between neddylation and ubiquitylation that makes the ubiquitin machinery able to 
catalyse neddylation in some experimental conditions (Brown and Jackson, 2015; Enchev et al., 
2015). 
Neddylation is negatively regulated by deneddylase enzymes, among them CSN (COP9 
signalosome) is the predominant (Enchev et al., 2012). In the case of cullins, CAND1 (cullin-
associated NEDD8-dissociated 1) acts also as a negative regulator since it binds deneddylated 
cullins and promotes their dissociation from the substrate (Zheng et al., 2002). 
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Figure 31: Model for neddylation-dependent ubiquitylation and release of Ku from chromatin. After DSB repair by NHEJ, 
cullin proteins are neddylated and ubiquitylate Ku favouring the release of Ku and NHEJ factors from chromatin. Figure from 
(Brown et al., 2015).  
 
II.5.3.6 SUMOylation 
 
SUMOylation reaction consists in the covalent attachment of a SUMO group to a lysine of a target 
protein. Similarly to ubiquitylation, SUMOylation involves a SUMO-activating enzyme (E1), a 
SUMO-conjugating enzyme (E2) and a SUMO-ligase (E3), which is not always required. In 
humans, the only known SUMO E1 and E2 are the heterodimer SAE1-UBA2 (SUMO1 activating 
enzyme subunit 1- ubiquitin-like modifier activating enzyme 2) and Ubc9 (ubiquitin-conjugating 
enzyme E2I), respectively whereas several SUMO E3 ligases exist (Desterro et al., 1999). Unlike 
ubiquitin, at least four SUMO isoforms have been described: SUMO1 is mostly associated with 
mono-SUMOylation, SUMO2/3 (so called because of their sequence similarities) can form poly-
SUMO chains and SUMO4 appears to function in the cytoplasm with tissue-specificities. SUMO-
modified proteins can be recognized by and interact with partners having SIMs motifs. Moreover, 
SUMOylation can be reversed by SUMO-specific proteases (SENPs). 
SUMO1 and SUMO2/3 conjugates accumulate at DSB sites, form foci that colocalize with 53BP1 
and persist at breaks for several hours after damage (Galanty et al., 2009; Morris et al., 2009). 
Similarly, SAE1, Ubc9 and the SUMO E3 ligases PIAS1 and PIAS4 (protein inhibitor of activate 
STAT protein 1 or 4) are also recruited at damaged chromatin and are required for SUMOylation at 
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DSBs. PIAS4 is necessary for 53BP1 SUMOylation and recruitment at DSBs while both PIAS1 and 
PIAS4 SUMOylate BRCA1 and favour BRCA1 focal accumulation (Galanty et al., 2009; Morris et 
al., 2009). The function of 53BP1 SUMOylation remains to be determined while SUMOylation of 
BRCA1 stimulates its E3 ligase activity in vitro (Morris et al., 2009). 
In addition, several evidences suggest that SUMOylation may promote DSB-induced 
ubiquitylation: 
- PIAS4 is needed for effective RNF168-mediated formation of ubiquitin-adducts at site of 
DNA damage (Galanty et al., 2009). 
- HERC2 and RNF168 are DNA damage-dependent SUMOylation targets. SUMOylation of 
HERC2 is required to interact with RNF8 and to stabilize the RNF8-Ubc13 complex (Danielsen et 
al., 2012). 
- RNF4 is an E3 ubiquitin ligase, harbouring SIMs motifs that enable its specific interaction 
with SUMOylated proteins at DSB sites where it functions to ubiquitylate and target proteins for 
removal by proteasome and/or by p97/VCP (Galanty et al., 2012). RNF4 localizes at DSBs sites 
and it is required for proper recruitment of Rap80, BRCA1 and Rad51 and for DSB repair (Galanty 
et al., 2012; Guzzo et al., 2012; Luo et al., 2012; Vyas et al., 2013). RNF4 is also important in 
controlling the turnover of MDC1 (Luo et al., 2012). Indeed, RNF4 ubiquitinates SUMOylated-
MDC1 targeting it for proteasomal degradation, a process that promotes HR (Luo et al., 2012) (see 
also section II.5.3.7 and Figure 32). 
 
II.5.3.7 Methylation 
 
Protein methylation consists in the addition of a methyl group to a lysine (up to three methyl 
groups) or to an arginine (up to two methyl groups) on a target protein. Methylation of a protein can 
promote its recognition by partners having Tudors domains, PDH finger domains or 
chromodomains, or it can modulate its biological activity. In the context of DDR, methylation can 
interest histone and non-histone proteins and it is catalysed by methyltransferases.  
53BP1 and Tip60 give two intriguing examples displaying the importance of methylation in the 
DDR.  
The requirement of H4K20me2 for 53BP1 recruitment has already been described in section 
II.5.3.4.2. H4K20 is constitutively methylated but different methyltrasferases can regulate this 
“mark” in response to DSBs. For instance, MMSET methyltrasferase is phosphorylated by ATM 
and recruited in an MDC1-dependent manner to chromatin where it increases the local H4K20 
methylation and favours 53BP1 recruitment (Pei et al., 2011). Recently, the concerted activities of 
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two others methyltransferases PR-Set7 (PR/SET domain-containing protein 07) and Suv4-20 
(suppressor of variegation 4-20 homolog 1) in catalysing H4K20me2 at DSBs have been identified 
as determinant for 53BP1 focal accumulation and proficient NHEJ repair (Tuzon et al., 2014). 
Tip60 is activated by binding to H3K9me3 when HP1 dissociates from damaged sites (Sun et al., 
2009). A recent work of Ayrapetov et al. shows that Tip60 can be activated upon DSB-induction in 
regions of euchromatin with low H3K9me3 density by a transient increase in H3K9me3 (Ayrapetov 
et al., 2014). They demonstrate that the methyltrasferase suv39h1 (suppressor of variegation 3-9 
homolog 1) in complex with KAP1 and HP1 is rapidly loaded onto chromatin flanking DSBs where 
it catalyses tri-methylation of H3K9. The nascent H3K9me3 in turn recruits additional 
KAP1/HP1/suv39h1 complexes determining the spreading of H3K9me3 around the break. These 
H3K9me3 domains are transient, since they rapidly activate Tip60 and consequently ATM, which 
promote the release of KAP1/HP1/suv39h1 complex by phosphorylating KAP1 (see section II.8). 
The methylation of H3K36 is also emerging as an important histone mark regulating DSB repair. 
The H3K36 di-methylation operated by the methyltransferase Metnase seems facilitate the DSB 
repair by NHEJ (Fnu et al., 2011) while the SET2 (SET domain containing 2)-dependent tri-
methylation may promote DSB resection and HR (Aymard et al., 2014; Pfister et al., 2014).  
Methylation is negatively regulated by demethylases (Mosammaparast and Shi, 2010). An example 
of demethylase functioning in DDR is JMJD1C (jumonji domain containing 1C), which participates 
to MDC1 regulation in response to DNA damage (Lu and Matunis, 2013; Watanabe et al., 2013). 
JMJD1C selectively promotes the recruitment of BRCA1 shuttling DSB repair toward HR pathway 
(Watanabe et al., 2013). Indeed, mechanistically, JMJD1C demethylates MDC1 at K45 thereby 
promoting MDC1-RNF8 interaction. This interaction favours the RNF8-mediated ubiquitylation of 
MDC1 and the recruitment of BRCA1 to the polyubiquitylated MDC1 (Figure 32).  
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Figure 32: Methylation, SUMOylation and ubiquitylation regulate MDC1 and DSB repair pathway choice. Recruitment of 
PIAS1/4 at sites of DSBs leads to MDC1 SUMOylation and recruitment of JMJD1C results in demethylation of MDC1 at K45. 
MDC1 demethylation promotes RNF8-mediated ubiquitylation of MDC1. In addition to RNF8, RNF4 can also ubiquitinate SUMO-
modified MDC1. The RAP80–BRCA1 complex is subsequently recruited through interactions with K63-linked polyubiquitin chains 
attached to MDC1. Alternatively, 53BP1 recruitment to MDC1 leads to NHEJ repair. Figure from (Lu and Matunis, 2013). 
 
II.6 Importance of DDR foci for genome integrity maintenance 
 
Despite the considerable advances in elucidating mechanistic and spatiotemporal regulation of DDR 
foci assembly, the understanding of the functional importance of these structures remains still 
limited. Kinetic modelling suggests that it is unlikely that all the molecules of a given factor 
immobilized near DNA lesions are directly involved in repair (Dinant et al., 2009). However, the 
evolutionary conservation of many proteins and motifs triggering focal assembly and the various 
pathologies associated with defects in DDR proteins (Jackson and Bartek, 2009) suggest a clear 
importance for DDR foci in the maintenance of genome stability. Notably, emerging and proposed 
roles for DDR foci include: 
- Amplify the DNA damage signalling. In support of this idea, local chromatin immobilization 
of DDR factors was shown to be sufficient to trigger, amplify and maintain robust DDR activation 
in a damage-independent fashion (Soutoglou and Misteli, 2008). Amplification of DNA damage 
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signalling may have a particular importance in physiological conditions to efficient checkpoint 
activation at low levels of DSBs.  
- Promote DSB repair in regions where DNA repair is difficult to achieve like 
heterochromatin (Goodarzi et al., 2011; Goodarzi et al., 2008) (see section II.8).  
- Stabilize broken ends and protect them from decay and/or illegitimate resection and repair 
processes. For example, 53BP1 collaborating with Rif1 (rap1-interacting factor 1 homolog) and 
PTIP (PAX transcription activation domain interacting protein 1 like) prevents DSB resection in G1 
(Chapman et al., 2013; Zimmermann et al., 2013). Similarly, the BRCA1-Rap80 complex restricts 
Mre11-CtIP-dependent end resection preventing excessive and deleterious end processing in S/G2 
(Coleman and Greenberg, 2011). 
- DSB storage. A clear example is given by 53BP1 nuclear bodies in G1-phase cells. They 
represent DSBs produced during mitosis by unresolved replication intermediates, particularly 
common at fragile sites that are chromosomal regions prone to breakage upon replication stress. 
Large chromatin domains enriched in 53BP1 sequestrate these DSBs transmitted to daughter cells 
and protect them from nucleases until repair mechanisms become available (Harrigan et al., 2011; 
Lukas et al., 2011a). 
- Coordination of DSB repair with other DNA metabolic activities such as transcription and 
replication. Spreading of histone modifications, such H2A(X) monoubiquitination (Pan et al., 2011) 
and γH2AX (Iacovoni et al., 2010), along the chromatin around the site of break may indirectly 
affect repair by suppressing accidental ‘intrusions’ of advancing RNAPII into the sites of active 
repair. Indeed, transcription is negatively regulated when DSBs occur in expressed genes (see 
section II.9) (Shanbhag et al., 2010). 
 
II.7 Targeting DDR proteins in cancer 
 
Due to the important roles of DDR in maintaining genome stability, it is not surprising that defects 
in this pathway are associated with tumorigenesis. Loss of certain DDR components appears to be 
selected in early stages of tumorigenesis.  
The connection between defects of DDR and tumours is the cornerstone of many anticancer-
therapies. Other than surgery, the most prevalent cancer therapies are radiotherapy and 
chemotherapies that function by generating DNA damage. This implies that tumours with defects in 
DDR may be more vulnerable to genotoxic agents and it opens up the possibility of exploiting 
“synthetic lethality” in oncology. Because different repair pathways can overlap in function, the 
inhibition of the remaining pathway(s) in cancer cells should, in some cases, induces a greater 
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toxicity on the cancer cells compared to normal cells that can still rely on “back-up” pathways 
(Figure 33).  
 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
Figure 33: Synthetic lethality relationship. Normal cells have two DDR pathways, A and B. The elimination of pathway B results 
in genomic instability and eventually in cancer. Inhibition of the pathway B triggers cancer cells to death while normal cells, that still 
retain an active pathway A, survive (Jacq et al., 2013). 
 
A paradigm of synthetic lethality is provided by PARP inhibitors that cause selective killing of 
tumours deficient in BRCA1 or BRCA2 with relatively low toxicity in normal cells (Bryant et al., 
2009; Farmer et al., 2005). Inhibitors of PARP activity block SSB repair and also cause PARP to 
become trapped on DNA repair intermediates, resulting in DNA replication-associated DSBs that 
cannot be repaired correctly by HR in BRCA1/2 defective cells (Helleday, 2011). Similarly, 
inhibiting ATM seems a promising strategy to induce synthetic lethality in cancer having 
deficiencies in the Fanconi Anemia pathway (FA) (Kennedy et al., 2007; Landais et al., 2009). 
Despite these results, specific ATM inhibitors have currently not reached any clinical trials.  
Table 7 illustrates some selected DDR inhibitors undergoing clinical trials (clinical trials 
information come from www.clinicaltrials.gov). 
These therapies based on DDR deficiencies display the importance of understanding the stepwise 
cellular responses to DNA damage and the genotype of a specific tumour (Basu et al., 2012; Biss 
and Xiao, 2012; Jackson and Bartek, 2009; Jacq et al., 2013).  
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Table 7: Examples of DDR inhibitors undergoing or entered in clinical trials (www.clinicaltrials.gov) 
Target Inhibitors Phase Indications 
DNA-
PK/mTOR CC-115 I 
Solid tumours and hematologic malignancies 
DNA-PK 
CC-122 I/II Solid tumours, non-Hodgkin lymphoma, multiple myeloma 
MSC2490484A I Solid tumours and hematologic malignancies 
ATR 
AZD6738 I/II Solid tumours, leukaemia, lymphoma and ATM deficient adenocarcinoma 
VX-970 I/II Solid tumours 
Chk1/Chk2 LY2606368 I/II Solid tumours, ovarian and breast cancer with BRCA1/2 mutations 
Chk1 SCH900776 I/II Leukaemia, lymphoma, solid tumours 
PARP 
Olaparib 
(AZD2281) 
I/II/III and 
FDA/EMA 
Approved 
Approved for advanced ovarian cancers with BRCA1/2 mutations. Clinical 
trials for solid tumours 
Veliparib 
(ABT-888) I/II/III 
Solid tumours, leukaemia, lymphoma. In particular in association with 
germline or sporadic BRCA1/2 mutations 
Rucaparib (AG-
014699) I/II/III 
Advanced solid tumours, breast cancer, ovarian cancer. In particular in 
association with germline or sporadic BRCA1/2 mutations 
Niraparib I/II/III Ovarian cancer, prostate cancer, Ewing sarcoma, breast cancer BRCA1/2 
mutated, Ewing sarcoma 
 
II.8 DSBs repair and influence of DDR signalling on repair 
 
Eukaryotic cells have evolved two main pathways to repair DSBs and thereby suppress genomic 
instability: the NHEJ and the HR. NHEJ promotes direct ligation of broken ends. It primarily 
involves the DNA-PK complex to recognize and tether broken ends and Artemis and other end-
processing factors to prepare ends for ligation by XRCC4-XLF-Lig4 (X-ray repair cross-
complementing protein 4 -	  XRCC4-like factor - ligase 4) complex and a new NHEJ component, 
PAXX (paralog of XRCC4 and XLF) (Ochi et al., 2015). NHEJ represents the major DSB repair 
pathway in mammalian cells. It is active throughout the cell cycle but it is of particular importance 
during G0/G1-phase (reviewed in (Grabarz et al., 2012; Hartlerode and Scully, 2009; Wyman and 
Kanaar, 2006)).  
HR pathway uses a homologous undamaged sequence, such as a sister chromatid, as template. This 
process is normally accurate but requires an available sister chromatid generated by duplication and 
therefore it is generally restricted to cells in S- and G2-phases. HR starts with the resection of DNA 
ends by the concerted action of the helicase BLM and several nucleases (including CtIP, MRN 
complex, Exo1, Dna2) to yield 3’-ssDNA overhangs coated by RPA. The other key steps in HR 
consist in Rad51-mediated displacement of RPA with the help of mediator proteins (including 
BRCA1 and BRCA2), search for homology, DNA pairing and strand exchange (reviewed in 
(Grabarz et al., 2012; Hartlerode and Scully, 2009; Wyman and Kanaar, 2006)). 
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Along with these pathways, other “error-prone” processes have been described. Alt-NHEJ 
(alternative NHEJ) derives from NHEJ and is highly mutagenic and frequently uses micro-
homologies distant from the break (Weinstock et al., 2007). Similarly, a derivative of HR pathway 
is the SSA (single-strand annealing). It always starts with resection but this step is not followed by 
strand invasion. In some cases it can lead to translocations (Richardson and Jasin, 2000). 
An intense objet of current studies is the choice of DSB repair pathway and the molecular 
mechanism regulating this choice (reviewed in (Chapman et al., 2012b)). The major factor 
determining pathway’s choice is the resection, such that long 3’-ssDNA ends become destined for 
HR. The primary mechanism regulating resection is the cell cycle. In particular, a phospho-
dependent switch seems to turn on resection at G1/S transition. For instance, specific cyclin-
dependent kinases (Cdks) are responsible for the phosphorylation and the activation of CtIP (Liu 
and Lee, 2006) and for the recruitment of Dna2 (Chen et al., 2011). CtIP is also degraded by the 
proteasome in G1 (Germani et al., 2003). However, HR and NHEJ coexist in S- and G2-phases 
indicating that other factors participate to the pathway’s choice in addition to cell cycle. For 
example, DSBs’ chromatin context drives the choice of DSB repair pathway, thereby 
transcriptionally active genes rich in H3K36me3 are repaired by HR (Aymard et al., 2014).  
DDR signalling and repair are strictly connected each-other and some examples of DDR signalling 
components also implicated in DSBs repair are discussed below:  
 
ATM is required for DSB repair in heterochromatin regions 
Heterochromatin is a barrier to DSB repair and ATM is necessary to facilitate the repair in these 
regions. Indeed, loss of ATM activity results in persistent DSBs localized at the periphery of 
heterochromatin (Goodarzi et al., 2008). Mechanistically, ATM triggers localized heterochromatin 
relaxation to promote DSB repair by phosphorylating KAP1, a transcriptional co-repressor 
associated with the maintenance of heterochromatin structure. KAP1 is a SUMO E3 ligase, which 
undergoes auto-SUMOylation (Ivanov et al., 2007) and by virtue of this modification, it interacts 
with the SIM domain of CHD3 (chromodomain helicase DNA binding protein 3), a subunit of the 
NuRD complex, promoting ATP-dependent chromatin compaction. Upon DSB induction, ATM is 
activated and phosphorylates KAP1 at S824 (Goodarzi et al., 2011). This phosphorylation event 
interferes with the SUMOylated KAP1-CHD3 interaction and causes the release of CHD3 leading 
to the relaxation of the chromatin surrounding the DSB sites. Formation of phospho-KAP1 foci 
coincides with localized chromatin relaxation (Goodarzi et al., 2011; Noon et al., 2010) (Figure 34).  
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Figure 34: Model of ATM-dependent repair of DSBs in heterochromatin. A DSB in heterochromatin activates ATM. Activated 
ATM phosphorylates KAP1 and determines its dissociation from CHD3. In the absence of CHD3, the chromatin surrounding the 
DSB site relaxes allowing DSB repair by NHEJ or HR (Goodarzi and Jeggo, 2012).  	  
53BP1 and BRCA1 oppositely regulate resection 
53BP1 negatively regulates resection in G1 (Bothmer et al., 2010), while BRCA1 promotes 53BP1 
removal and resection in S/G2 (Bunting et al., 2010). Deletion of 53BP1 restores HR and Rad51 
foci in BRCA1 deficient cells (Bouwman et al., 2010; Bunting et al., 2010) demonstrating that 
53BP1 and BRCA1 oppositely regulate HR. 53BP1 promotes NHEJ with the help of cofactors, 
RIF1 (Chapman et al., 2013; Zimmermann et al., 2013), PTIP (Callen et al., 2013) and the newly 
identified REV7 (REV7 homolog) (Boersma et al., 2015; Xu et al., 2015). The mechanisms by 
which 53BP1 blocks resection have not been elucidated. Super resolution microscopy gives 
architectural information about the antagonistic relationship between 53BP1 and BRCA1 at DSB 
foci (Chapman et al., 2012a). In G1 phase, 53BP1 occupies the core of IRIF probably correlating 
with NHEJ repair, while in S/G2-phase, 53BP1 is pushed to the periphery of the focus and the core 
is filled by BRCA1. The mechanism by which BRCA1 displaces 53BP1 is not known but it is likely 
that phosphorylated CtIP is the key mediator of this processes. BRCA1 can form a complex with 
CtIP and MRN (BRCA1-C complex) and one possibility is that this complex mediates the removal 
of 53BP1 (Daley and Sung, 2014).  
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Ku and DNA-PKcs 
The binding of Ku heterodimer to broken ends represents the first engagement for NHEJ. Binding 
of Ku occurs during all phases of the cell cycle and Ku removal is necessary for resection (Shao et 
al., 2012). DNA-PKcs is also a strong inhibitor of resection since knockdown of DNA-PKcs leads 
to increased ssDNA formation at DSBs sites (Zhou et al., 2014). 
 
II.9 Transcriptional DSBs 
 
Transcriptional DSBs can be defined as DSBs produced in actively transcribed genes and/or by a 
transcription-dependent process. Compared to replication-dependent DSBs, transcriptional DSBs, 
both endogenous and exogenous, are a minority and their contributions to the cytotoxicity of DNA 
damage-inducing agents generally have not been characterized. In addition, the tumour selectivity 
and the cytotoxicity of the majority of chemotherapeutics are associated with replication. Despite 
this apparent minor role, DSBs in transcriptional units that remain unrepaired, or repaired by error-
prone pathways, can have catastrophic consequences for the cell functioning, such as deleterious 
mutations in coding region, aberrant transcripts or prolonged transcription inhibition. For all these 
reasons, the study of the interplay between transcription and DSBs has recently emerged as a 
central topic of interest.  
Knowledge on transcriptional lesions comes primarily from studies focused on UV-induced 
photoproducts and bulky adducts that have led to the identification of the TCR pathway. TCR is a 
sub-pathway of NER that targets DNA alterations interfering with the translocation of RNAP 
through expressed genes (Hanawalt and Spivak, 2008). A number of outcomes are possible 
following RNAPII arrest (Hanawalt and Spivak, 2008): (i) RNAPII can bypass the lesion possibly 
resulting in transcriptional mutagenesis, (ii) RNAPII can be displaced from the lesion (RNAPII 
backtracking), (iii) RNAPII can be ubiquitinated and degraded by the proteasome or (iv) prolonged 
RNAPII arrest can activate cell cycle checkpoints possibly leading to apoptosis.  
However, different mechanisms of transcriptional regulation may exist at bulky adducts and DSBs. 
For instance, IR does not result in RNAPII ubiquitylation, unlike UV-induced damage (Bregman et 
al., 1996). UV damage or bulky adducts directly block RNAPII while the arrest at DSBs sites is 
controlled by DDR proteins, including ATM (Kakarougkas et al., 2014; Kruhlak et al., 2007; 
Shanbhag et al., 2010; Ui et al., 2015), DNA-PK (Pankotai et al., 2012), ATR (Jiang and Sancar, 
2006), and PARP (Chou et al., 2010) and by chromatin modifications (Adam and Polo, 2014; 
Oliveira et al., 2014). Different studies often propose different models of response to transcriptional 
DSBs which might be related to the complexity of lesions, the localization of lesions (promoter or 
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body of the gene), the length of the gene, the transcription rate and the pre-existing transcriptional 
state of chromatin in which the break occurs. In general, transcriptional DSBs result in transient 
transcriptional inhibition in damaged chromatin that may be important to prevent interference 
between transcription and repair (Svejstrup, 2010). However, recent studies show that this 
inhibition does not concern all the transcripts. Indeed small non-coding RNAs are produced at DSB 
sites and regulate DSB signalling and repair; these RNAs are called DDRNA (DNA damage 
response RNAs) (Francia et al., 2012; Wei et al., 2012). 
Some DDR proteins associate with the transcription apparatus, such as DNA-PK and BRCA1. In 
the case of DNA-PK, it has been shown that (i) the Ku heterodimer interacts with the elongating 
RNAPII (Mo and Dynan, 2002) (ii) DNA-PKcs has been initially identified in complex with the 
transcriptional factor Sp1 (Jackson et al., 1990) and (iii) DNA-PKcs efficiently phosphorylates 
RNAPII and the transcription factors TBP (TATA box binding protein) and TFIIB in vitro 
stimulating basal transcription (Chibazakura et al., 1997; Dvir et al., 1992; Maldonado et al., 1996).  
In response to UV exposure, the heterodimer BRCA1-BARD1 ubiquitinates Rpb1 thus, initiating 
the proteasome-dependent RNAPII degradation (Kleiman et al., 2005; Starita et al., 2005). Hence, it 
is tempting to speculate that the association of DDR proteins with the transcriptional machinery 
may help to promote genome stability. When a DSB occurs, the signalling and repair machineries 
are immediately present and alerted to promote transcription arrest and repair.  
 
II.9.1 Induction of transcriptional DSBs  
 
In vivo transcriptional DSBs are produced by generation of site-specific DSBs or by drugs targeting 
transcription: 
 
Site-specific DSBs 
Site-specific nucleases generate DSBs at different and known genomic loci and thus, also in 
transcription units. This field was pioneered with yeast mating-type switch (HO) endonuclease 
(Rudin and Haber, 1988) and translated into mammalian cells by using I-SceI (Jasin, 1996) and I-
PpoI (Berkovich et al., 2007) endonucleases. More recently, Legube’s laboratory has developed a 
mammalian system stably expressing the bacterial AsiSI restriction enzyme that recognizes a 8 bp 
sequence and generates approximately 150 sequence-specific DSBs distributed across the genome 
(Iacovoni et al., 2010). Site-specific DSBs can also be produced by the artificial engineering of site-
specific zinc-finger (ZFNs) or TALEs (transcription activator-like effectors) DNA binding domain 
fused to the non-specific cleavage domain of Fok1 (Shanbhag et al., 2010). 
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Characteristics of these systems are, (i) the exclusive generation of DSBs, (ii) the generation of 
DSBs of the same complexity and (iii) the possibility to create inducible systems. For instance, the 
AsiSI restriction enzyme is fused to a modified oestrogen receptor hormone-binding domain that 
responds to the synthetic analog 4-hydroxy tamoxifen (4OHT). Treatment with 4OHT induces 
nuclear localization of AsiSI-ER enzyme and generate DSBs. Site-specific DSBs can be studied by 
using ChIP, which enables the detection of proteins strictly recruited to DSB ends and not forming 
foci and also enables the study of DDR spreading around a break. A major limit of these systems is 
that they must be turned off to study DSB repair (Aymard et al., 2014).    
 
Drugs targeting transcription 
Transcriptional DSBs can also be produced by drugs through mechanisms implicating transcription 
or through direct targeting of transcriptional machinery components. Drug-induced lesions that can 
be converted in DSBs by transcription usually can be also converted by replication thus, generating 
a mixture of TC- and RC-DSBs in cycling cells. Unlike to site-specific DSBs, drug-induced 
transcriptional DSBs are often not compatible with ChIP analysis, as their genomic localisation is 
not known. Usually the removal of drugs allows the study of DSB repair kinetics. 
Table 8 shows the drugs currently known to produce transcriptional DSBs. 
 
Table 8: Examples of drugs producing transcriptional-DSBs 
Drug 
Type 
of 
DSBs 
DDR Remarks References 
Ecteinascidin 
743 (Et743) 
TC- 
and 
RC-
DSBs 
TC- DSBs induce γH2AX, 
53BP1, Mre11, pATM foci and 
activation of DNA-PK and 
Chk2. γH2AX phosphorylation 
by DNA-PK is required for full 
ATM activation. 
TC-DSBs are dependent on TCR and MRN. 
Et743 induces RNAPII degradation. Et743 is 
an FDA approved drug for treatment of soft 
tissue sarcoma. 
(Aune et al., 2008; 
Erba et al., 2001; 
Guirouilh-Barbat 
et al., 2008) 
Pyridostatin 
TC- 
and 
RC-
DSBs 
DSBs induce γH2AX foci, and 
phosphorylation of KAP1, 
Chk1, RPA and DNA-PK. 
Pyridostatin stabilizes G-quadruplex structures 
at specific genomic loci. Telomeres loci are 
targeted at high concentration and non-
telomere at low concentration. Functionally, 
pyridostatin leads to cell-cycle arrest and 
transcription downregulation of several genes. 
(Rodriguez et al., 
2012) 
Camptothecin 
(CPT) 
TC- 
and 
RC-
DSBs 
TC-DSBs induce γH2AX, 
53BP1, MDC1, pATM foci 
and activation of Chk2 and 
DNA-PK. 
See details in Chapter I. Campthotecin’s 
derivatives are FDA-approved drugs. 
(Huang et al., 
2010; Sakasai et 
al., 2010a; Sordet 
et al., 2009) 
Etoposide 
(VP16) 
TC- 
and 
RC-
DSBs 
DSBs induce γH2AX, pATM, 
MDC1 and RPA foci and 
activation of DNA-PK. Etoposide is an FDA-approved drug. 
(Soubeyrand et al., 
2010; Tammaro et 
al.; Zhang et al., 
2006) 
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II.9.2 γH2AX in active transcribed genes 
 
High-resolution mapping of γH2AX in chromatin surrounding DBSs induced by the restriction 
enzyme AsiSI displays a discontinuous signal, consisting of a series of “peaks” and “holes” 
(Iacovoni et al., 2010). Holes correspond to active genes rich in RNAPII in which transcription 
remains unchanged, indicating that undamaged active coding regions are refractory to γH2AX 
(Figure 35A). These observations agree with immunofluorescence data showing that transcription, 
monitored by in vivo incorporation of 5-bromouridine triphosphate (BrUTP), does not colocalize 
with IR-induced γH2AX foci (Solovjeva et al., 2007). The Legube’s laboratory has also shown that 
cohesin plays an antagonist role to γH2AX spreading (Caron et al., 2012). Cohesin is a multisubunit 
complex that participates in DSB repair and in transcriptional control by connecting the enhancers 
to the promoters of active genes (Kagey et al., 2010). Cohesin may play a role in isolating actively 
transcribed genes from the γH2AX response in the chromatin surrounding-DSBs and a tempting 
model is that cohesin may loop active genes outside of γH2AX foci. Indeed, depletion of the 
cohesin component SCC1 (SCC1 homolog) triggers an accumulation of γH2AX at cohesin-bound 
genes and a reduction of their transcriptional activity (Figure 35B). This protective effect is not 
induced by DSBs but rather the binding of cohesin to active genes seems to be constitutive (Caron 
et al., 2012).  
 
 
Figure 35: Transcription and 
cohesin antagonize γH2AX 
enrichment. (A) γH2AX and RNAPII 
profiling obtained by ChIP 
experiments after DSB induction by 
the endonuclease AsiSI in U2OS (for 
technical details see (Iacovoni et al., 
2010)). The γH2AX/H2AX ratio is 
plotted relatively to transcription start 
site (TSS) from 368 genes located 
within γH2AX domains. RNAPII 
distribution is also plotted in the same 
way. (B) The γH2AX/input signal in 
the same system than (A) is plotted 
relatively to the TSS from 359 genes 
located within γH2AX domains. The 
panel 1 shows the distribution in 
control cells and the panel 2 shows the 
distribution in SCC1 depleted cells 
(for technical details see (Caron et al., 
2012)). 
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II.9.3 Role of PARP 
 
Chou et al described a role of PARP in setting up a repressive chromatin structure to block 
transcription at sites adjacent to DNA breaks in response to UV laser microirradiation (Chou et al., 
2010). Transcriptional silencing is mediated by PARP-dependent recruitment at damaged chromatin 
of Polycomb group and NuRD complexes, which negatively regulate transcription. Indeed, by using 
an anti-7-methylguanosine antibody recognizing the cap structure of nascent RNA, the authors 
displayed the rapid loss of nascent transcripts at sites of γH2AX and this loss was further enhanced 
following PARG inhibition. In addition, elongating RNAPII is also lost at laser microirradiation-
induced “stripe” as consequence of PARG inhibition.  
 
II.9.4 Role of ATM 
 
ATM plays a key role in repressing transcription in response to DSBs (Shanbhag et al., 2010). 
ATM-dependent inhibition of transcription in response to DSBs seems to favour recruitment of 
DSB repair factors and consequent DSB repair (Ui et al., 2015). 
The Greenberg’s laboratory showed that the ATM-dependent transcription silencing spreads for 
kilobases of chromatin in cis to euchromatic DSBs (Shanbhag et al., 2010). They used a single-cell 
assay based in a transcriptional reporter system, which allows the simultaneous visualization of 
DDR and nascent transcription on a contiguous stretch of chromatin. By generating a DSB (induced 
by FokI nuclease) distal to the reporter gene promoter (4-13 kb), the authors found that ATM 
activity is responsible for the spreading of H2A monoubiquitinated at K119 (H2AK119ub) that 
mechanistically leads to the removal of the elongating RNAPII from the transcribed region. The 
reversal of silencing relies on the H2AK119ub deubiquitylating enzyme USP16. DSB induced-H2A 
monoubiquitination at K119 and the consequent transcription silencing are mediated by the 
Polycomb complexes (PRC1 and PRC2) (Kakarougkas et al., 2014; Mattiroli et al., 2012; Ui et al., 
2015) (Figure 36). It is still unclear how ATM promotes Polycomb-mediated H2AK119ub. 
However, two ATM substrates have been recently involved in the ATM-mediated transcriptional 
repression by promoting H2AK119ub: (i) the SWI/SNF chromatin remodelling complex, PBAF 
(Kakarougkas et al., 2014) and (ii) the transcriptional elongation factor ENL (myeloid/lymphoid 
translocated) (Ui et al., 2015). ATM can phosphorylate PBAF (Matsuoka et al., 2007) and ENL (Ui 
et al., 2015) in response to DNA damage. It seems that the ATM-mediated phosphorylation of 
PBAF is responsible for the role of PBAF in transcriptional silencing (Kakarougkas et al., 2014). 
The ATM-dependent phosphorylation of ENL increases the interaction between ENL and PCR1 in 
	   	   	   113 	  
response to DSB, favouring the recruitment of PCR1 at transcriptional DSBs and the ubiquitination 
of H2A (Ui et al., 2015). 
H2B monoubiquitination on K120 (H2BK120ub) is another histone mark associated with 
transcription elongation in unstressed cells and dependent on ATM in response to DSBs (Moyal et 
al., 2011). Monoubiquitination of H2B relies on the ATM-dependent phosphorylation of the E3 
ligase RNF20-RNF140 heterodimer and its recruitment to DSB sites (Moyal et al., 2011). However, 
the primary role of H2BK120ub appears to be in DSB repair (Chernikova et al., 2010; Moyal et al., 
2011; Nakamura et al., 2011) and this process seems to be uncoupled with transcription 
(Chernikova et al., 2010; Moyal et al., 2011; Nakamura et al., 2011; Shiloh et al., 2011). 
Finally, along with the role of ATM in regulating RNAPII, ATM has been also described in 
controlling RNAPI transcription in presence of persistent DSBs within the rDNA (Harding et al., 
2015; Kruhlak et al., 2007). IR- and etoposide-induced DNA damages result in ATM-dependent 
transient inhibition of both the assembly of RNAPI initiation complex and the elongation in the 
nucleolus (Kruhlak et al., 2007). This ATM-dependent transcriptional silencing induces nucleolar 
reorganization and the recognition of rDNA DSBs at the nucleolar periphery by the DDR factors 
(Harding et al., 2015). 
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Figure 36: ATM-dependent DSB-induced silencing in cis. Working model representing how ATM regulates gene silencing: when 
a DSB is introduced at an actively transcribed region, ATM is activated and phosphorylates H2AX. ATM promotes H2A/H2AX 
monoubiquitination in K119 by phosphorylating the remodelling complex PBAF and the transcriptional elongation factor ENL. ENL 
interacts with PCR1 and triggers its recruitment at DSBs. PCR1 and PCR2 Polycomb repressive complexes ubiquitinate H2A. After 
DSB repair or recovery from DNA-damage signal, USP16 deubiquitinates H2A. Adapted from (Huen and Chen, 2010). 
 
II.9.5 Role of DNA-PK 
 
Pankotai et al reported a role for DNA-PK in transcriptional DSBs (Pankotai et al., 2012; Pankotai 
and Soutoglou, 2013). They analysed the impact of a single DSB encountered during RNAPII 
transcriptional elongation. Introduction of a single site-specific DSB in a transcribed gene by the 
meganuclease I-PpoI results in transient transcription arrest followed by re-initiation. In presence of 
a DNA-PK inhibitor, RNAPII remains associated with the promoter and the body of the transcribed 
gene and the same results are obtained by depletion of Ku heterodimer or DNA-PKcs. These data 
demonstrate that in the absence of DNA-PK, RNAPII can bypass the break and continues to 
elongate. Moreover, DNA-PK-dependent RNAPII removal requires the proteasome as proteasome 
inhibition or depletion of PSMD4 (19S subunit), rescues the transcriptional defect similarly to 
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DNA-PK inhibition. The authors speculated that a-yet unidentified protein might undergo DNA-
PK-dependent phosphorylation and proteosomal degradation to remove RNAPII from the DSB site 
thus, preventing the synthesis of a mutant transcript (Pankotai et al., 2012; Pankotai and Soutoglou, 
2013).  
 
II.9.6 Role of histone mobilization 
 
Recently, transcription chaperones, that mobilize histones in and out of chromatin, have been 
shown as key elements in transcription re-initiation after UV damage in human cells. In particular, 
the histone chaperones HIRA (histone regulator A) and FACT have been involved in transcription 
resumption and they are also recruited at DSB sites (Adam et al., 2013; Dinant et al., 2013; Yang et 
al., 2013). HIRA deposits newly synthetized H3.3 histones at sites of UV lesions and HIRA 
downregulation significantly inhibits transcription recovery. Mechanistically, the process is not 
completely understood but H3.3 histones generally carry posttranslational modifications that render 
chromatin permissive to transcription at sites of DNA damage (Adam et al., 2013). At 
endonuclease-induced DSB sites, HIRA is also known to depose H3.3 histones, which in turn 
promotes HR. However, the role of HIRA in transcription restart has not been addressed (Yang et 
al., 2013). 
Similarly to HIRA, FACT is an H2A-H2B chaperone, which accelerates the exchange of H2A and 
H2B and favours transcription restart after DNA repair of the lesions blocking transcription (Dinant 
et al., 2013). In addition, FACT promotes HR-mediated repair of DSBs by localizing RNF20 at 
damaged chromatin (Oliveira et al., 2014) suggesting that FACT may be important for transcription 
resumption also at DSBs. Finally, FACT has an important function in the resolution of R-loop-
mediated transcription-replication conflicts thus protecting cells against transcription-induced DNA 
damage (Herrera-Moyano et al., 2014). 
 
II.9.7 Repair 
 
Different works point up transcribed loci as regions particularly prone to chromosomal 
rearrangements (Gunn et al., 2011; Mathas and Misteli, 2009). Some critical factors that could 
favour chromosomal rearrangements are the incorrect end use during NHEJ repair of multiple DSBs, 
R-loops and exchange between chromosomal loci located in close spatial proximity at the time of 
DSB production (Nikiforova et al., 2000). By using a reporter system for NHEJ repair of multiple 
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DSBs located downstream from an inducible promoter, the Stark’s laboratory showed a higher 
frequency of incorrect end use during end-joining in active transcription units (Gunn et al., 2011).  
Aymard and colleagues demonstrated that DSBs in actively transcribed human genes are 
preferentially repaired by HR. Active transcribed regions are marked by the transcription 
elongation-associated histone modification H3K36me3 that is probably recognized by LEDGF (lens 
epithelium-derived growth factor), which interacts with CtIP and initiates end-resection (Aymard et 
al., 2014). In parallel, two other groups, working on yeast models, have shown the importance of 
H3K36me3 histone mark and the methyltransferase Set2 (SETD2 in humans), responsible for this 
modification, in driving repair pathway choice (Jha and Strahl, 2014; Pai et al., 2014). Interestingly, 
in agreement with literature, Aymard et al. identified about 15% of the DSBs as HR-repaired in G2. 
They also found that XRCC4 depletion does not impair DSB repair at transcribed genes in G1 
suggesting that these transcriptional-DSBs are not processed by NHEJ (Aymard et al., 2014). One 
possibility could be that these DSBs are repaired by HR as cells progress to S-phase. Furthermore, a 
recent work shows that in G0/G1 cells, homologous chromosomes frequently contact each other at 
the sites of DSBs produced by the restriction enzyme I-PpoI in coding regions, but not in intergenic 
regions (Gandhi et al., 2013; Gandhi et al., 2012). The authors suggested that this contact might 
have a role in DSB repair, since it requires ATM kinase activity. They also speculated the 
possibility that it could be a specialized DSB repair pathway operating in active genes that uses a 
homologous chromosome as a repair template and that could involve sequence-specific RNA 
molecules in homology searching. 
In addition, in yeast a novel Rad52-dependent mechanism of DNA repair and HR has been 
characterised, in which endogenous transcript RNA is used as a template for DSB repair (Keskin et 
al., 2014). Human Rad52 can also promote RNA-DNA annealing in vitro raising the possibility that 
transcript-RNA-templated DNA repair could occur in human cells at highly transcribed loci and/or 
in non-dividing cells (Keskin et al., 2014). 
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Top1 removes DNA supercoiling generated during transcription and replication by producing Top1-
DNA cleavage complexes (Top1cc). These transient Top1cc can be stabilized by common DNA 
alterations and by CPT, from which anticancer drugs are derived.  
One of the best-characterized consequences of Top1cc stabilization is the production of DSBs 
during replication. However, stabilized Top1cc are also potent transcription-blocking lesions and 
our understanding regarding the molecular processes resulting from the stalling of transcription 
complexes by Top1cc is currently limited. The laboratory has shown that stabilized Top1cc can lead 
to the production of transcriptional DSBs with activation of the ATM-dependent DDR pathway in 
post-mitotic cells (Sordet et al., 2009).  
Hence, the main objective of my PhD was to characterize those transcriptional DSBs produced as a 
result of Top1cc stabilization. I used primarily serum-starved quiescent cells treated with CPT as a 
model to induce specifically transcription-blocking Top1cc and to determine:  
 
1 – The mechanism of DSB production: The first objective of my PhD has been to decipher how 
stabilized Top1cc lead to DSB production by a transcription-dependent mechanism.  
2 – The DSB signalling: The second objective has been to characterize the DDR signalling pathway 
that is activated by transcriptional DSBs and its role in Top1cc repair and cell survival. 
3 – The cellular relevance of transcriptional DSBs: The third objective has been to investigate if 
transcriptional DSBs are cytotoxic to gain insights into their relevance in the context of (i) 
stabilized Top1cc that accumulate spontaneously in the case of deficiencies in Top1cc repair or 
DSB signalling such as in the neurodegenerative syndromes SCAN1 (Tdp1 deficiency) and AT 
(ATM deficiency) or (ii) Top1cc stabilized by CPT derivatives during chemotherapy. 
4 – The genomic distribution of transcriptional DSBs: Finally, the last objective has been to test 
whether CPT-induced transcriptional DSBs were preferentially produced at specific genomic 
regions or at specific genes across the genome. This work has been initiated in collaboration with 
the groups of William Bonner (NIH, USA) and Giovanni Capranico (University of Bologna, Italy).  
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Ubiquitination triggers DNA double-strand break formation and signalling in 
response to transcription-blocking topoisomerase-I lesions  
 
Agnese Cristini, Joon-Hyung Park, Giovanni Capranico, Gaëlle Legube, Gilles Favre, Olivier 
Sordet 
 
 
Previous work by Sordet and coworkers (Sordet et al., 2009) has shown that stabilized Top1cc 
produce transcription-dependent DSBs that activate the ATM-DDR pathway.  
In this report, we characterize these DSBs by investigating the mechanisms of DSB production and 
signalling. To induce specifically transcription-blocking Top1cc, we used serum-starved quiescent 
cells treated with CPT and we showed that: 
 
1- CPT-induced transcriptional DSBs are generated as a result of defective repair of Top1 
associated SSBs: after Top1 proteolysis and before the action of Tdp1 and PARP. 
2- CPT-induced transcriptional DSBs activate the ATM signalling pathway leading to the 
phosphorylation of ATM substrates such as H2AX and 53BP1. 
3- ATM also activates DNA-PK, which promotes ubiquitination of H2A and H2AX that may 
in turn favour the proper assembly of activated ATM in nuclear foci. DNA-PK also 
promotes Top1cc degradation suggesting that DSB signalling further enhances Top1cc 
repair. 
4- CPT-induced transcriptional DSBs can kill non-replicating cells and inhibition of DDR 
signalling hypersensitizes these cells to CPT. 
 
Our study reveals a new mechanism of DSB production in response to stabilized Top1cc as well as 
a new function of DNA-PK in promoting ubiquitin signalling. These findings should prime further 
investigations on the cellular relevance of those transcriptional DSBs as we show that Tdp1, whose 
deficiency leads to the neurodegenerative syndrome SCAN1 with phenotypic similarities to AT, 
protects non-replicating cells against DSB formation. 
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ABSTRACT  
Although defective repair of DNA double-strand breaks (DSBs) leads to neurodegenerative diseases, 
the processes underlying their production and signaling in non-replicating cells are largely unknown. 
Stabilized topoisomerase-1 cleavage complexes (Top1cc) by natural compounds or common DNA 
alterations are transcription-blocking lesions whose repair depends primarily on Top1 proteolysis and 
excision by tyrosyl-DNA phosphodiesterase-1 (TDP1). We previously reported that stabilized Top1cc 
produce transcription-dependent DSBs that activate ATM in neurons. Here we use camptothecin 
(CPT)-treated quiescent cells to induce transcription-blocking Top1cc and show that those DSBs are 
generated during Top1cc repair from Top1 peptide-linked DNA single-strand breaks generated after 
Top1 proteolysis and before excision by TDP1. Following DSB induction, ATM activates DNA-PK 
whose inhibition suppresses H2AX and H2A ubiquitination and the later assembly of activated ATM 
into nuclear foci. Inhibition of DNA-PK also reduces Top1 proteolysis suggesting that DSB signaling 
further enhances Top1cc repair. Finally, we show that co-transcriptional DSBs kill quiescent cells. 
Together, these new findings reveal that DSB production and signaling by transcription-blocking Top1 
lesions impact on non-replicating cell fate and provide insights on the molecular pathogenesis of 
neurodegenerative diseases such as SCAN1 and AT syndromes, which are caused by TDP1 and 
ATM deficiency, respectively. 
INTRODUCTION 
Topoisomerase I (Top1) is required to remove DNA supercoiling generated during transcription. It 
relaxes DNA by producing transient Top1 cleavage complexes (Top1cc), which are Top1-linked DNA 
single-strand breaks (SSB) (1). After DNA relaxation, Top1cc reverse rapidly, and Top1 is released as 
the DNA religates. The rapid resealing of Top1cc is inhibited by common DNA base alterations, 
carcinogenic adducts, DNA nicks and ribonucleotides misincorporated into DNA (2-4). Top1cc can 
also be trapped selectively by camptothecin (CPT) and its derivatives used to treat cancers, which 
bind at the Top1-DNA interface (1). Stabilized Top1cc are potent transcription-blocking DNA lesions 
(5,6) and their repair (removal) depends primarily on the tyrosyl-DNA phosphodiesterase I (TDP1) 
excision pathway. Top1cc excision by TDP1 requires prior proteolysis of Top1 by the 
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ubiquitin/proteasome system (7-14). Defective repair of Top1cc by inactivating mutation of TDP1 
leads to the hereditary spinocerebellar ataxia with axonal neuropathy-1 (SCAN1) syndrome (15,16), 
indicating the importance of removing transcription-blocking Top1cc in non-replicating cells. A 
consequence of transcription-blocking Top1cc is the production of DSBs. These co-transcriptional 
DSBs have been detected in post-mitotic neurons and lymphocytes as well as in replicating cells out 
of the S-phase (17-19). Their production involves the formation of R-loops, a three-strand nucleic acid 
structure consisting of an RNA:DNA hybrid and displaced single-stranded DNA (20,21). Whether the 
Top1cc repair process is involved in the production of co-transcriptional DSBs is an unresolved 
question.   
DNA double-strand breaks (DSBs) are among the most severe genomic lesions, and their repair 
requires the recruitment of DNA damage response (DDR) proteins in the vicinity of damaged 
chromatin, where they form discrete nuclear foci (22). The serine/threonine kinase ATM is critical for 
DDR (23) and its deficiency leads to the hereditary ataxia telangiectasia (AT) syndrome, which is 
primarily a neurodegenerative disease (15,24). ATM is readily activated by DSBs and phosphorylates 
various DDR proteins at damaged sites such as histone H2AX and MDC1. Phosphorylated H2AX 
(known as γH2AX) binds MDC1, which amplifies the damage signal around the break by recruiting 
additional ATM molecules (23). Accumulating studies indicate that histone ubiquitination regulates 
DDR both upstream and downstream of ATM. Ubiquitination of H2AX by the E3 ligase activity of 
RNF2-BMI1 complex triggers recruitment of activated ATM to DSBs allowing ATM to phosphorylates 
its targets at damaged sites (25,26). Then, ATM-mediated phosphorylation of MDC1 provides a 
binding site for the E3 ligase RNF8, which permits the recruitment of the E3 ligase RNF168. The 
concerted action of RNF8 and RNF168 allows ubiquitination of H2AX and H2A leading to the further 
recruitment of repair proteins such as 53BP1 and the BRCA1 complex (27-32). DNA-PK is also 
rapidly recruited at DSBs where it mediates repair by non-homologous end-joining (NHEJ) (33). 
Although DNA-PK can phosphorylate H2AX in response to DSBs (34), it is not clear whether it 
participates to DDR signaling asides from its role in DSB repair.  
Here, we use serum-starved quiescent cells treated with CPT as a model to induce specifically 
transcription-blocking Top1cc and get molecular insights into the processes underlying both the 
production and signaling of DSBs. We found that those DSBs are produced during Top1cc repair from 
Top1 peptide-linked DNA single-strand breaks generated after Top1 proteolysis and before excision 
by TDP1. These data provide the first demonstration that TDP1, whose deficiency leads to 
neurodegeneration, protects non-cycling cells against the formation of DSBs. Analysis of DSBs 
signaling further reveals a novel function of DNA-PK in promoting protein ubiquitination leading to 
enhancement of Top1 proteolysis in a feedback look as well as to full ATM activity at DSB sites. 
Lastly, we found that those co-transcriptional DSBs kill quiescent cells indicating that the cellular 
response to transcription-blocking Top1 lesions impact on non-proliferative cell fate. Together, these 
findings provide new insights on the molecular pathogenesis of neurodegenerative diseases. 
MATERIAL AND METHODS 
Drugs and chemical reagents 
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BrdU, CPT, FLV, MG132 and Pyr-41 (35) were obtained from Sigma-Aldrich; lactacystin, G5 (36), 
KU55933 (37) and VE-821 (38) from Millipore; bortezomib, veliparib and olaparib from Selleckchem; 
and NU7441 (39) from Tocris.  
 
Cell lines, culture and treatments 
Primary human lung embryonic WI38 fibroblasts immortalized with hTERT were obtained from Estelle 
Nicolas (LBCMCP, Toulouse, France) and Carl Mann (CEA, Gif-sur-Yvette, France) (40). Cells were 
cultured in modified Eagle's medium (MEM) supplemented with 10% (v/v) fetal bovine serum, 1  mM 
sodium pyruvate, 2 mM glutamine and 0.1  mM non-essential amino acids. NHDF cells were isolated 
from healthy patients, as described previously (41), and human primary lung IMR90 fibroblasts were 
from ATCC. NHDF and IMR90 cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 10% (v/v) fetal bovine serum. To induce quiescence, cells were washed twice with 
serum-free medium and cultured for 72 in medium supplemented as described above but with 0.2% 
(v/v) serum instead of 10%. U2OS EV28 cells, stably expressing AsiSI-ER-HA enzyme (Iacovoni et al. 
2010) were grown in DMEM supplemented with 10% (v/v) fetal bovine serum and 1 μg/ml puromycine. 
To induce DSBs, U2OS EV28 cells were treated with 300 nM 4-hydroxitamoxifen (Sigma-Aldrich) for 
4 h. In Figure 3A and B, cells were gamma-irradiated with Gamma-cell Exactor 40 at 0.8 Gy. In all the 
experiments, untreated cells correspond to cells treated with the vehicle only. 
 
Immunofluorescence microscopy, foci quantification and graphical representation 
Cells were seeded in poly-L-lysine-coated Lab-TekTM RS chamber slides (NalgeNunc). After treatment, 
cells were washed twice with PBS and immunofluorescence was carried out as described previously 
(17). Where indicated, cells were pre-extracted with CSK buffer (10 mM Pipes (pH 6.8), 100 mM NaCl, 
300 mM sucrose, 3 mM MgCl2, 0.5% (v/v) Triton X-100) for 3 min at room temperature. Following two 
washes in PBS, cells were fixed with 2% (v/v) formaldehyde for 12 min at room temperature and 
washed three times. Cells were incubated with the primary antibody in PBS with 5% (v/v) fetal bovine 
serum for 1 h. Anti-ubiquityl-H2A antibody was incubated overnight at 4°C. Cells were washed twice 
and incubated with the appropriate secondary antibody coupled to Alexa Fluor 488, 594 or 568 (Life 
Technologies). After three washes, slides were mounted using Mowiol® 4-88 (Millipore) containing 
4’,6’-diamino-2-phenylindole (DAPI). Slides were visualized at room temperature by using a 
fluorescence microscope (Eclipse 90i, Nikon) or an inverted confocal microscope (LSM 710 or LSM 
780; Carl Zeiss). Pictures were analyzed with Photoshop CS3 (Adobe) or ImageJ (version 1.48v). 
Primary antibodies used for microscopy were rabbit anti-53BP1 (NB100-305; Novus), rabbit anti-
53BP1-pS1778 (2675; Cell Signaling), mouse anti-ATM-pS1981 (4526; Cell Signaling), mouse anti-
BrdU (clone B44; BD Biosciences), mouse anti-γH2AX (05-636; Millipore), rabbit anti-γH2AX (NB100-
384; Novus), mouse anti-DNA-PK-pT2609 (ab18356; Abcam), rabbit anti-MDC1 (ab11169; Abcam), 
mouse anti-ubiquityl-H2A (Ub-H2A; 05-678; Millipore), and mouse anti-ubiquitinated proteins (Ub-
proteins; clone FK2, 04-263; Millipore).  
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Nuclear foci were counted manually and for nucleus with more than 20 foci, we set a default value 
of 25 foci. For Figure 4, nuclear foci were counted with imageJ software (version 1.48v). For graphical 
representation of foci distribution, we used box-and-whisker plots using GraphPad Prism 6 software 
with the following settings: boxes: 25-75 percentile range; whiskers: 10-90 percentile range; horizontal 
bars: median number of γH2AX foci. Each dot indicates an individual nucleus that is not in the 10-90 
percentile range.  
 
Cell extracts and Immunoblotting 
Whole-cell extracts were obtained by lysing cells in 1% SDS and 10 mM Tris-HCl (pH 7.4) 
supplemented with protease (Sigma-Aldrich) and phosphatase (Halt phosphatase inhibitor cocktail; 
Thermo Scientific) inhibitors. Viscosity of the samples was reduced by brief sonication. For detection 
of ATM, ATM-pS1981, DNA-PK and DNA-PK-pS2056, cells were lysed for 15 min in buffer containing 
50 mM Tris-HCl (pH 8.0), 300 mM NaCl, 0.4% NP-40, 10 mM MgCl2 and 5 mM DTT, supplemented 
with protease (Sigma-Aldrich) and phosphatase (Halt phosphatase inhibitor cocktail; Thermo 
Scientific) inhibitors. After centrifugation (10,000 x g, 20 min), supernatants were diluted (v/v) in 50 
mM Tris-HCl (pH 8.0), 0.4% NP-40 and 5 mM DTT. Proteins were separated by SDS-PAGE and 
immunoblotted with the following antibodies: anti-actin (MAB1501; Millipore), anti-ATM (sc-23921; 
Santa-Cruz), anti-ATM-pS1981 (ab81292; Abcam), anti-ATR (ab2905; Abcam), anti-caspase-3 (9662; 
Cell Signaling), anti-cleaved caspase-3 (9661; Cell Signaling), anti-Chk2 (2662; Cell Signaling), anti-
Chk2-pT68 (2661; Cell Signaling), anti-cullin 3 (ab108407; Abcam), anti-cullin 4B (A303-863A; Bethyl), 
anti-DNA-PK (NA57; Millipore, or ab18192; Abcam), anti-DNA-PK-pS2056 (ab18192; Abcam), anti-
γH2AX (NB100-384; Novus), anti-H2AX (ab11175; Abcam), anti-histone H3 (ab1791; Abcam), anti-
KAP1 (A300-274A; Bethyl), anti-KAP1-pS824 (A300-767A, Bethyl), anti-PARP (9542; Cell Signaling), 
anti-PSMA6 (2459; Cell Signaling), anti-p53 (DO-7, DakoCytomation), anti-p53-pS15 (9284; Cell 
Signaling), anti-topoisomerase I (ab109374; Abcam), anti-αTubulin (T5168; Sigma-Aldrich), anti-
UBA1 (4890; Cell Signaling), anti-XLF (2854; Cell Signaling) and anti-XRCC4 (from Patrick Calsou, 
IPBS, Toulouse, France). Immunoblotting was revealed by chemiluminescence using autoradiography 
or a ChemiDoc MP System (Bio-Rad). Quantification of protein levels was done by using ImageJ 
(version 1.48v) in Figure 5E and with Image Lab software (version 4.1) in the other figures.  
 
Cellular fractionation 
Chromatin-bound proteins were isolated as described previously (42). Briefly, cells were extracted 
twice by lysis in extraction buffer (50 mM Hepes (pH 7.5), 150 mM NaCl, 1 mM EDTA) containing 
0.1% (v/v) Triton X-100 supplemented with protease (Sigma-Aldrich) and phosphatase (Halt 
phosphatase inhibitor cocktail; Thermo Scientific) inhibitors for 15 min at 4°C followed by 
centrifugation at 14,000 x g for 3 min to separate soluble proteins. The collected supernatant was the 
fraction S1. The pellet was further resuspended in extraction buffer without Triton X-100 
supplemented with 200 μg/ml RNAse A (Roche) for 30 min at 25°C under agitation. The fraction S2 
was collected after centrifugation at 14,000 x g for 3 min. The remaining pellet was resuspended in 
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buffer containing 1% SDS and 10 mM Tris-HCl (pH 7.4) supplemented with protease (Sigma-Aldrich) 
and phosphatase inhibitors (Halt phosphatase inhibitor cocktail; Thermo Scientific) and sonicated. 
 
Comet assays 
Neutral Comet assays were performed according to the manufacturer’s instructions (Trevigen), except 
that electrophoresis was performed at 4°C. Comet tail moments were measured with ImageJ software 
(version 1.48v) using a macro provided by Robert Bagnell 
(https://www.med.unc.edu/microscopy/resources/imagej-plugins-and-macros/comet-assay) or with the 
plugin OpenComet (http://opencomet.org/). 
 
Detection of Top1-DNA cleavage complexes 
Cellular Top1-DNA cleavage complexes (Top1cc) were detected as previously described (43), except 
that immunoblotting was revealed with a rabbit monoclonal anti-Top1 antibody from Abcam 
(ab109374) and with a ChemiDoc MP System (Bio-Rad).  
 
Cell viability assays 
Cell survival in Figure 8A was determined at times and conditions indicated in the text by counting 
adherent cells with Z1 Coulter Counter® (Beckman Coulter).   
 
Chromatin immunoprecipitation (ChIP) 
Chromatin immunoprecipitation was performed as described previously (Iacovoni et al. 2010) using a 
rabbit polyclonal anti-γH2AX antibody (ab81299) or a rabbit nonimmune antibody (control IgG) 
(catalogue number 02-6102, Life Technologies). ChIP were analyzed by real-time QPCR using 
primers proximal to two sites for the restriction enzyme AsiSI located inside genes (chr20:42089225-
42089433: Gene 1-FW: AAAAGTCGCTCCCGGTAAAT, Gene 1-RV: CCGATCAGACTTGGGCTTAG; 
chr17:61847852-61848028: Gene 2-FW: TGCAAGGCATTCGACAATAA, Gene 2-RV: 
ATGGAAGCCATAATGCAAGC) or primers distal to AsiSI sites (chr21:25081874-25082075: Control-
FW: TGGCTGGAACTGCTTTCTTT, Control-RV: GGTGAGTGAATGAGCTGCAA). All samples were 
analyzed in triplicates and data normalized to the maximal recovery in each experiment, which was 
set equal to 1.   
 
Proteasome activity assay 
P2 fractions were isolated as described above (Cellular fractionation). At each step of fractionation, 
the extraction buffer was supplemented with 10% (v/v) glycerol and 50 mM ATP without the addition 
of protease and phosphatases inhibitors. P2 fractions were solubilized in extraction buffer and briefly 
sonicated. Following centrifugation at 14,000 x g for 3 min, 30 μg of the collected supernatant were 
used to perform proteasome activity assay by using the Proteasome Activity Assay Kit (ab107921) 
according to the manufacturer’s protocol. The chymotrypsin-like activity of proteasome was measured 
by the cleavage of a synthetic proteasome substrate linked to methyl coumarin amid (MCA). 
Cleavage of MCA in the presence or absence of the proteasome inhibitor MG132 was detected by 
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fluorescence emission using a SynergyTM2 Multi-Mode Microplate Reader (Bio-Tek). Proteasome 
activity (U/ml) was calculated by subtracting for each sample, the background fluorescence given by 
the presence of the proteasome inhibitor MG132 (except in Supplementary Figure S5H) and by using 
an MCA standard curve.  
 
siRNA transfection 
Cells were transfected with siRNA duplexes using Dharmafect 4 transfection reagent (GE Healthcare) 
for 24 h before inducing quiescence for 72 h. siRNAs used are directed against cullin 3 (Silencer® 
Pre-designed siRNA CUL3, ID#217187, Ambion), cullin 4B (Silencer® Pre-designed siRNA CUL4B, 
ID#13299, Ambion), DNA-PK (M-005030-01, GE Healthcare), TDP1 (M-016112-01, GE Healthcare), 
XLF (5’-CGCUGAUUCGAGAUCGAUUGAdTdT-3’; Eurogentec), XRCC4 (5’-
AUAUGUUGGUGAACUGAGAdTdT-3’; Qiagen) or a nontargeting sequence (SR-CL000-005; 
Eurogentec).  
 
Statistics 
Unless indicated otherwise, experimental differences were tested for significance using one-way 
ANOVA Tukey’s multiple comparisons test with GraphPad Prism 6 software.  
RESULTS 
Top1cc stabilization induces transcription-dependent DSBs in quiescent cells  
To investigate the production and signaling of transcription-dependent DSBs, we used primary human 
WI38 fibroblasts immortalized with hTERT (40). Non transformed cells normally have low genomic 
instability (44) and can be induced in quiescence following serum deprivation (45,46), thus allowing 
the analysis of replication-independent damage produced by stabilized Top1cc. 
Microscopy analysis of bromodeoxyuridine (BrdU) incorporation showed that the percentage of 
WI38 hTERT cells in S-phase decreased from 26% to approximately 3% after a 3-day serum 
deprivation (0.2% serum) (Figure 1A and B), indicating that they efficiently entered quiescence. To 
determine whether CPT can induce replication-independent DSBs in those cells, we examined the 
phosphorylated histone H2AX on S139 (known as γH2AX) and its accumulation in nuclear foci. A 
single γH2AX focus reflects hundreds to thousands of γH2AX proteins that are concentrated around at 
least one DSB (47). We found that CPT induced γH2AX foci within 1 h, with an average of 2 to 10 foci 
per nucleus at CPT concentrations ranging from 1 to 25 µM, respectively (Figure 1C-E). Almost all 
cells formed at least 2 γH2AX foci at concentrations ≥ at 10 µM (Figure 1C and D). Similar results 
were obtained in serum-starved quiescent human IMR90 primary lung fibroblasts (Supplementary 
Figure S1A-D) and in serum-starved quiescent normal human dermal fibroblasts (NHDF) 
(Supplementary Figure S1E-H). These γH2AX foci colocalized with 53BP1, another DDR protein 
(Figure 1F), and a neutral Comet assay provided direct evidence for the presence of DSBs (Figure 1H 
and I). These results indicate that CPT induces replication-independent DSBs in quiescent cells.  
To determine whether these breaks depend on transcription, we used the transcription inhibitor 
flavopiridol (FLV). Figure 1F and G show that FLV suppressed γH2AX and 53BP1 foci in CPT-treated 
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quiescent WI38 hTERT cells. To test whether FLV prevented DSBs or prevented DDR signaling by 
some other mechanisms, we performed neutral Comet assays. The significant decrease in Comet tail 
moment we observed in quiescent cells co-treated with FLV and CPT provides direct evidence for 
DSB suppression (Figure 1H and I). Together these results indicate that CPT induces transcription-
dependent DSBs in quiescent cells, providing a robust model to further study their production and 
their signaling.  
 
The formation of co-transcriptional DSBs requires Top1 proteolysis 
Top1cc-mediated transcription block triggers Top1 degradation by the ubiquitin/proteasome system 
(12,13,48). Hence, we examined whether Top1 degradation would contribute to the formation of 
transcription-dependent DSBs. As expected, inhibition of transcription (FLV), ubiquitin (isopeptidase 
inhibitor G5) or proteasome (MG132) prevented Top1 degradation in CPT-treated quiescent WI38 
hTERT cells (Supplementary Figure S2A-C). Then, we assessed whether inhibiting the 
ubiquitin/proteasome system would prevent DDR signaling. We found that the proteasome inhibitors 
MG132, lactacystin and bortezomib (also called PS-341) (Figure 2A and B) as well as the ubiquitin 
inhibitors G5 and Pyr41 (Figure 2D and E) prevented the induction of γH2AX and 53BP1 foci. Western 
blot analysis confirmed the suppressive effect of MG132 and G5 on γH2AX (Figure 2C and F). 
Importantly, DSB formation was also reduced by MG132, as indicated by a neutral Comet assay 
(Figure 2G and H). These results indicate that the ubiquitin/proteasome system is required for the 
formation of DSBs in CPT-treated quiescent cells.  
Top1 is degraded selectively in response to CPT (1). To evaluate whether defective Top1 
degradation accounts for the lack of DSBs following inhibition of the ubiquitin/proteasome system, we 
inhibited cullin 3 and cullin 4B, which targets Top1 for proteosomal degradation in CPT-treated cells 
(49,50). We observed that siRNA-mediated depletion of cullin 3 and cullin 4B in quiescent WI38 
hTERT cells (Figure 3A) reduced CPT-induced Top1 degradation (Figure 3B) and γH2AX foci (Figure 
3C). To further assess the role of Top1 degradation, we induced DSBs with ionizing radiation (IR) and 
the restriction enzyme AsiSI (51), which do not trigger Top1 degradation (Supplementary Figure S2D 
and E). We found that MG132 did not suppress γH2AX foci induced by IR in quiescent WI38 hTERT 
cells (Figure 3D and E) and by AsiSI in cycling U2OS cells (Figure 3F) indicating that genotoxics that 
do not promote Top1 degradation produce proteasome-independent DSBs. As expected, MG132, 
which causes depletion of free nuclear ubiquitin (52), prevented the ubiquitin-dependent focal 
accumulation of 53BP1 at DSB sites (31) in response to IR (Figure 3D) and AsiSI (Figure 3F). IR and 
AsiSI produce DSBs in both transcribed and non-transcribed regions whereas CPT likely produces 
co-transcriptional DSBs solely in transcribed regions. To assess whether proteasome activity is 
required simply because DSBs are located at transcribed regions, we analyzed γH2AX by chromatin 
immunoprecipitation (ChIP) at AsiSI sites located in genes. We found that MG132 did not suppress 
the induction of γH2AX in the two genes analyzed (Figure 3G). These results suggest that the 
requirement of proteasome activity for CPT-induced co-transcriptional DSBs is not only because 
these breaks are produced at transcribed regions but also because Top1cc are stabilized on 
chromatin. Altogether, these findings strongly suggest that the ubiquitin/proteasome-dependent 
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degradation of Top1 is required for the production of transcription-dependent DSBs following CPT 
treatment.  
 
Co-transcriptional DSBs arise from SSB intermediates generated after Top1 proteolysis and 
before TDP1 action 
Top1 degradation primes the repair of transcription-blocking Top1cc by TDP1. Top1cc excision by 
TDP1 requires prior proteolysis of Top1 to expose the covalent bond between the Top1 catalytic 
tyrosine and the 3’-end of the DNA to be attacked. TDP1 generates a 3’-phosphate, which is 
hydrolyzed by the polynucleotide kinase 3’-phosphatase (PNKP) before religation by ligase III (see 
Supplementary Figure S2F) (8-11,14). Because TDP1 deficient cells accumulate Top1 peptide-linked 
SSBs and causes hypersensitivity to CPTs (9,53,54), we examined whether transcription-dependent 
DSBs would arise from these SSB intermediates generated before TDP1 action.  
We found that depletion of TDP1 with siRNA markedly increased the number of γH2AX and 53BP1 
foci in CPT-treated quiescent WI38 hTERT cells (Figure 4A and B and Supplementary Figure S2G). 
Previous work showed that Top1cc excision by TDP1 requires PARP1 (10,55). PARP1 binds to and 
PARylates TDP1 leading to TDP1 stabilization and its recruitment at Top1cc-induced DNA damage 
sites. We therefore assessed whether inhibition of PARP1 would also increase DSBs in CPT-treated 
quiescent cells. We found that the PARP inhibitors veliparib (also called ABT-888) and olaparib (also 
called AZD-2281), both increased the number of γH2AX and 53BP1 foci (Figure 4C and D and 
Supplementary Figure S2H and I). DSB formation was also increased by veliparib, as indicated by a 
neutral Comet assay (Figure 4E). Inhibition of transcription (FLV) or proteasome (MG132), which 
prevented CPT-induced Top1 degradation (Supplementary Figure S2A and C), also prevented CPT-
induced accumulation of γH2AX and 53BP1 foci following TDP1 depletion (Figure 4A and B) and 
PARP inhibition (Figure 4C and D), indicating that those breaks depend on Top1 degradation. To 
determine whether TDP1 and PARP1 are in the same pathway to prevent DSBs, we compared the 
number of γH2AX foci following co-treatment with CPT and PARP inhibitors when TDP1 is expressed 
or not. Figure 4F shows that TDP1 suppression with siRNA did not further increase the number of 
γH2AX foci in quiescent WI38 hTERT cells exposed to CPT and veliparib or CPT and olaparib, 
indicating that TDP1 and PARP1 are in the same pathway. Together, these results indicate that co-
transcriptional DSBs produced in CPT-treated quiescent cells arise from SSB intermediates 
generated after Top1 proteolysis and before TDP1 action. 
 
Activation of ATM and DNA-PK by co-transcriptional DSBs  
Next, we studied the signaling of these co-transcriptional DSBs to gain insight into their functional 
relevance. To that end, we examined which kinases phosphorylate H2AX. ATM, ATR and DNA-PK 
are the main kinases for H2AX in response to DNA damage (47). To identify which of them induces 
γH2AX, we assessed whether γH2AX foci formation is prevented by specific chemical inhibitors of 
these kinases in CPT-treated quiescent WI38 hTERT cells; the ATM inhibitor (ATMi) KU55933, the 
DNA-PK inhibitor (DNA-PKi) NU7441 and the ATR inhibitor (ATRi) VE-821. We found that ATMi 
completely suppressed γH2AX foci and that DNA-PKi markedly reduced their number and size (Figure 
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5A and B and Supplementary Figure S3A and B). Analysis of DSBs by neutral Comet assays showed 
that ATMi and DNA-PKi did not decrease the Comet tail moment induced by CPT (Figure 5C), which 
exclude the possibility that fewer DSBs account for the reduced γH2AX levels. Similar results were 
obtained in quiescent IMR90 cells (Supplementary Figure S1A-D) and in quiescent NHDF cells 
(Supplementary Figure S1E-H). By contrast, ATRi did not reduce the number of γH2AX foci induced 
by CPT in quiescent WI38 hTERT cells (Figure 5A) under conditions where it prevented 
phosphorylation of the ATR substrate Chk1 in replicating cells (Supplementary Figure S3C). This is 
consistent with ATR being primarily activated by replication stress (56) and that it is expressed at low 
levels in non-cycling cells (Supplementary Figure S3D) (17,57). These data suggest that ATM and 
DNA-PK but not ATR are implicated in the induction of γH2AX in CPT-treated quiescent cells.  
We therefore assessed whether ATM and DNA-PK are activated under conditions where γH2AX is 
induced. ATM autophosphorylation on S1981 (ATM-pS1981) marks activated ATM (58). In quiescent 
WI38 hTERT cells, we found that CPT induced ATM-pS1981 that colocalized with γH2AX foci (Figure 
5D and Supplementary Figure S3E). We also observed phosphorylation of the ATM targets KAP1, 
Chk2 and p53 (Supplementary Figure S3E) (23). Similar to ATM, DNA-PK phosphorylation status 
regulates its activity. DNA-PK autophosphorylation on both S2056 and T2609 is required for the repair 
of DSBs by NHEJ (59,60). We found that CPT induced DNA-PK phosphorylation on both residues in 
quiescent WI38 hTERT cells (Figure 5D and E). Immunofluorescence microscopy further revealed 
that DNA-PK phosphorylated on T2609 formed discreet nuclear foci that colocalized with γH2AX 
(Figure 5D), indicating that similar to ATM, DNA-PK is activated at DSB sites. Previous work showed 
that ATM can phosphorylate DNA-PK on T2609 following IR (61). We found that inhibition of ATM 
prevented CPT-induced DNA-PK phosphorylation on T2609 and also on S2056 in quiescent WI38 
hTERT cells (Figure 5D and E). Together these data suggest that in CPT-treated quiescent cells, 
transcription-dependent DSBs activate ATM, which in turn activates DNA-PK.  
 
DNA-PK promotes the assembly of activated ATM in nuclear foci 
Next, we considered whether cross talk between ATM and DNA-PK is mutual or limited to one 
direction in which ATM activates DNA-PK. To test this, we asked whether inhibiting DNA-PK would 
prevent MDC1 and 53BP1 foci, which depends, at least in part, on ATM (23). Supplementary Figure 
S3F shows that DNA-PKi suppressed CPT-induced MDC1 and 53BP1 foci in quiescent WI38 hTERT 
cells. To test more directly the role of DNA-PK on ATM, we analyzed the impact of DNA-PK inhibition 
on the induction of ATM-pS1981 and on its accumulation in nuclear foci. We found that DNA-PKi only 
slightly reduced CPT-induced ATM-pS1981 levels (Figure 5E), indicating that DNA-PK does not 
markedly contribute to ATM activation. Microscopy analysis confirmed that DNA-PKi did not suppress 
ATM-pS1981 following CPT treatment (Figure 5F, top panels). However, it revealed a pan staining for 
ATM-pS1981 rather than well-defined foci (Figure 5F, top panels), suggesting that activated ATM is 
not localized at damaged sites. Previous work showed that ATM associated with sites of DSBs was 
resistant to detergent extraction while unbound ATM was removed (62). Thus, we treated cells with a 
detergent-based extraction buffer known as cytosqueleton (CSK) buffer (63) before 
immunofluorescence staining for ATM-pS1981. We found that CSK buffer suppressed the pan-
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staining signal for ATM-pS1981 in cells co-treated with DNA-PKi and CPT under conditions where it 
did not affect ATM-pS1981 foci in cells treated with CPT alone (Figure 5F bottom panels and G). 
Together, these data suggest that DNA-PK promotes the assembly of activated ATM into nuclear foci 
in CPT-treated quiescent cells.  
To assess whether the role of DNA-PK on ATM foci formation is related to its function in DSB 
repair, we inhibited XLF and XRCC4, which mediate DNA-PK-dependent NHEJ (33). We found that 
contrary to DNA-PK inhibition, depletion of XLF or XRCC4 with siRNAs did not prevent CPT-induced 
ATM-pS1981 foci in quiescent WI38 hTERT cells (Supplementary Figure S4). These results suggest 
that the role of DNA-PK on ATM foci formation is independent of its function in DSB repair.  
 
DNA-PK promotes ubiquitination of H2AX and H2A at DSB sites  
H2AX and H2A are ubiquitinated in response to DSBs (27-32). Previous work showed that defective 
monoubiquitination of H2AX at K119/K120 in IR-exposed cells impaired the recruitment of ATM-
pS1981 to DSBs and thereby reduced γH2AX and MDC1 foci formation (25,26), effects similar to 
those observed following DNA-PK inhibition in CPT-treated quiescent cells (Figure 5 and 
Supplementary Figure S3F). We therefore tested whether DNA-PK inhibition would prevent CPT-
induced H2AX monoubiquitination in quiescent cells. 
Western blot analysis using an antibody against H2AX showed that CPT did not significantly 
increase global H2AX monoubiquitination in quiescent WI38 hTERT cells (Supplementary Figure 
S5A). We though it might be because H2AX is monoubiquitinated only at damaged sites in response 
to DSBs (26), and CPT induced only few γH2AX foci in quiescent cells (Figure 1). Consistent with this 
hypothesis, detection of H2AX monoubiquitination by Western blot was previously reported at high 
doses of IR, typically 4 to 10 Gy (26,64). To examine specifically H2AX monoubiquitination at DSB 
sites, we analyzed γH2AX monoubiquitination. We found that CPT induced γH2AX monoubiquitination 
in quiescent WI38 hTERT cells, which was prevented by DNA-PKi (Figure 6A). To analyze more 
directly histone monoubiquitination at DSB sites, we performed immunofluorescence microscopy with 
an antibody against H2A monoubiquitinated at K119 (Ub-H2A). We found that CPT induced Ub-H2A 
foci that colocalized with the p53BP1 foci, and that those Ub-H2A foci were completely prevented by 
DNA-PKi (Figure 6B and C). Consistent with these results, CPT also induced DNA-PK-dependent 
FK2 foci (Figure 6D and E), which mark ubiquitinated proteins at DNA damage sites (65). siRNA-
mediated depletion of DNA-PK confirmed the suppressive effect of DNA-PKi on FK2 foci formation 
(Supplementary Figure S5B and C). Altogether, these results indicate that DNA-PK promotes 
monoubiquitination of H2AX and H2A at site of co-transcriptional DSBs in CPT-treated quiescent cells. 
This in turn may favor the recruitment of activated ATM and phosphorylation of its downstream 
substrates. 
 
DNA-PK promotes ubiquitin/proteasome-dependent Top1cc removal  
Based on our results that DNA-PK promotes ubiquitination processes (Figure 6) and the fact that 
transcription-blocking Top1cc are removed following ubiquitination and proteosomal degradation of 
Top1 (Supplementary Figure S2A-C) (12,13,48), we examined the possibility that DNA-PK could 
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promote Top1 degradation. Figure 7A shows that DNA-PKi markedly decreased CPT-induced Top1 
degradation in quiescent WI38 hTERT cells. Similar results were obtained in quiescent IMR90 and 
NHDF cells (Supplementary Figure S5D). Analysis of endogenous Top1cc confirmed that defective 
Top1 degradation following DNA-PK inhibition reflected defective Top1cc removal (Figure 7B). The 
role of DNA-PK in promoting Top1 degradation is unlikely related to its function in NHEJ repair as 
depletion of XRCC4 or XPF with siRNAs did not affect CPT-induced Top1 degradation in quiescent 
WI38 hTERT cells (Supplementary Figure S5E). Because we found that ATM activates DNA-PK 
(Figure 5), we examined whether ATM inhibition would also prevent Top1 degradation. 
Supplementary Figure S5F shows that ATMi also decreased CPT-induced Top1 degradation in 
quiescent WI38 hTERT cells.  
Consistent with the ubiquitin/proteasome-dependent removal of Top1cc, we found that the E1 
ubiquitin ligase UBA1 and the 20S-proteasome subunit PSMA6, which are both involved in DDR 
(66,67), tended to accumulate in chromatin-bound fraction (P2 fraction, see Supplementary Figure 
S5G) in CPT-treated quiescent WI38 hTERT cells (Figure 7C). Under these conditions, the global 
expression of PSMA6 remained unchanged while that of UBA1 slightly increased (Figure 7D). 
Accumulation of UBA1 and PSMA6 in P2 fraction was further associated with an increased activity of 
proteasome (Figure 7E). DNA-PKi suppressed the CPT-induced UBA1 and PSMA6 accumulation and 
proteasome activity in P2 fraction (Figure 7C-E). As a control, we showed that DNA-PKi is not a direct 
proteasome inhibitor (Supplementary Figure S5H). Altogether, these results suggest that DNA-PK 
promotes ubiquitin/proteasome-dependent removal of Top1cc in CPT-treated quiescent cells.  
 
Transcription- and proteasome-dependent apoptosis of quiescent cells by stabilized Top1cc 
To assess whether transcription-dependent DSBs can kill non-replicative cells, we analyzed the 
percentage of quiescent cells that remained attached to the culture flask following CPT treatment. 
Typically, cells detach as they undergo apoptosis. We found that CPT decreased the number of 
quiescent WI38 hTERT cells attached to the culture flask by approximately 70 % after 24 h (Figure 
8A). This was associated with the appearance of biochemical markers of apoptosis such as the 
cleavage of caspase-3 and PARP, and the massive induction of γH2AX, which was reported in cells 
undergoing apoptosis (68) (Figure 8B). All these apoptotic marks were suppressed by the 
transcription inhibitor FLV (Figure 8A and B), suggesting that transcription-dependent DSBs are the 
initiating events for apoptosis induction. Consistent with this hypothesis, inhibition of CPT-induced 
DSBs with lactacystin (Figure 2A and B) also prevented caspase-3 and PARP cleavage and γH2AX 
induction (Figure 8C). By contrast, increased CPT-induced DSBs with veliparib or olaparib (Figure 4C-
F and Supplementary Figure S2H and I) also increased PARP cleavage (Figure 8D).  
To analyze the impact of DDR signaling on CPT-induced apoptosis of quiescent cells, we inhibited 
ATM and DNA-PK. Figure 8E and F shows that ATMi and DNA-PKi, both increased CPT-induced 
caspase-3 and PARP cleavage, indicating that the predominant role of ATM- and DNA-PK-dependent 
signaling is likely to promote cell survival after CPT-induced transcription-dependent DSBs.  
DISCUSSION 
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Although defective repair of DSBs can lead to neurodegenerative diseases, the molecular processes 
of their production and signaling in non-replicating cells are largely unknown. Here we analyzed the 
transcription-dependent DSBs that form in non-replicating cells as a consequence of Top1cc 
stabilization (17). Our data support a model depicted in Figure 9 in which Top1cc stabilization blocks 
transcription elongation, which triggers partial Top1 proteolysis and the generation of a Top1 peptide-
linked SSB, which is a substrate for TDP1. Defective repair of this SSB intermediate by TDP1 can 
give rise to a DSB, which leads to ATM activation and phosphorylation of its substrates such as H2AX 
and 53BP1. ATM also activates DNA-PK, which promotes H2AX and H2A monoubiquitination and the 
assembly of activated ATM into nuclear foci. ATM and DNA-PK also increase Top1 proteolysis 
suggesting that this pathway further enhances Top1cc repair after DSB induction. This is consistent 
with recent work showing that ATM deficiency increases Top1cc levels in CPT-treated quiescent 
astrocytes (69,70). Because we found that Top1 proteolysis primes DSB formation, DNA-PK could 
therefore increases DSB production in a feedback loop. This might be however compensated as 
DNA-PK can also phosphorylate TDP1, which increases its repair activity towards Top1cc (71). 
Nevertheless, we did not find that DNA-PK inhibition reduced the amount of DSBs in CPT-treated 
quiescent cells measured by a neutral Comet assay. DSBs event tend to accumulate, which might be 
related to the function of DNA-PK that we report here in promoting ATM signaling but also on its 
function in NHEJ repair (33). 
Transcription-blocking Top1cc seem primarily repaired by the TDP1 excision pathway. Indeed, our 
study and previous reports indicate that Top1 degradation is transcription dependent following CPT 
exposure (12,13,48) and that TDP1 primarily repairs transcription-blocking Top1cc as compared to 
replication-blocking Top1cc (8,9). Consistent with the involvement of the TDP1 pathway in the repair 
of transcription-blocking Top1cc, Top1 degradation has been suggested to promote resumption of 
RNA synthesis (12). Our findings that DSBs produced in CPT-treated quiescent cells depend both on 
transcription and on Top1 degradation suggest that they arise during the repair of Top1cc. A further 
support to this is that inhibition of TDP1 or PARP1 (which is required for TDP1 activity (10,55)), 
increases transcription-dependent DSBs following Top1cc stabilization. Because TDP1 deficient cells 
accumulate Top1 peptide-linked SSB intermediates (9,53,54), our results suggest that transcription-
dependent DSBs arise from these intermediates if TDP1 fails to repair them. How a Top1 peptide-
linked SSB can give rise to a DSB is still an unresolved question. A DSB may result from two nearby 
SSBs on opposing DNA strands. It is also possible that the second SSB is caused by R-loop 
processing. Indeed, reduced Top1 activity causes R-loop formation (72) and we showed that CPT-
induced R-loops are involved in the formation of transcription-dependent DSBs in post-mitotic cells 
(17). Also, a recent work showed that R-loops formed in response to CPT are cleaved by the 
endonuclease XPG (21).  
It is now well documented that DNA-PK functions in cellular processes other than NHEJ such as 
gene regulation (73,74) and mitosis (75-77). Here we report a novel function of DNA-PK in the 
regulation of protein ubiquitination. Previous work suggested connection between DNA-PK and the 
proteasome. In the presence of DSBs, DNA-PK was reported to induce transcription arrest by a 
mechanism that depends on proteasome activity (78). Also, DNA-PK inhibition prevents the 
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accumulation of the proteasome activator PA200 on chromatin in response to IR (79). 
Phosphorylation is known to regulate protein ubiquitination in two main ways (80). First, substrate 
phosphorylation can create a recognition signal for binding of an E3 ligase. Second, phosphorylation 
of an E3 ligase can stimulate its ubiquitin transfer activity. Hence, it is possible that DNA-PK 
phosphorylates H2AX, H2A and Top1 and/or their respective E3 ligases following CPT treatment. The 
first possibility is plausible as the N-terminal domain of Top1 binds to DNA-PK (81) and possesses a 
potential phosphorylation site for DNA-PK (SQ motif on S10). DNA-PK can also phosphorylate H2AX 
on S139 (γH2AX) (34) but it is unlikely that this is what primes H2AX for ubiquitination because H2A 
lacks S139 but is also ubiquitinated in response to DSBs. Several E3 ubiquitin ligases have been 
reported for H2AX and H2A (RNF2, RNF8, RNF168) (25-31) and for Top1 (Cullin3, Cullin4A, Cullin4B, 
BRCA1) (13,49,50) but it is not known whether they can be phosphorylated by DNA-PK. It is also 
possible that DNA-PK favors the recruitment of the E1 ligase UBA1 at damaged sites as we found 
that DNA-PK inhibition prevented CPT-induced UBA1 accumulation on chromatin. 
Lastly, our analysis demonstrates that co-transcriptional DSBs can kill non-replicating cells 
following CPT treatment. Co-transcriptional DSBs might occur spontaneously in cells as Top1cc are 
stabilized by common alterations of DNA (2-4) and therefore they may have a marked impact on non-
replicating cell fate. Neurodegenerative diseases can arise from defective repair of Top1cc (SCAN1 
caused by TDP1 deficiency) (16) as well as from defective response to DSBs (AT caused by ATM 
deficiency) (24). Neurons might be particularly prone to produce co-transcriptional DSBs as a result of 
high rates of oxygen consumption, which produces reactive oxygen species that can stabilize Top1cc 
(1,3,82). Hence, our findings raise the possibility that accumulation of co-transcriptional DSBs and the 
defective response to those breaks might contribute to the neurodegenerative phenotype of SCAN1 
and AT patients, respectively. 
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FIGURE LEGENDS 
Figure 1. Induction of transcription-dependent DSBs in quiescent WI38 hTERT cells in response to 
CPT. (A,B) Cells were cultured in 10% serum or in 0.2% serum for 3 days to induce quiescence. Cells 
were then exposed to 100 µM BrdU for 30 min before staining for BrdU (green). DNA was 
counterstained with DAPI (blue). (A) Representative images. Bars: 50 µm. (B) Percentages of BrdU-
positive cells from one representative experiment (> 300 cells were analyzed for each treatment) out 
of two. (C-E) Serum-starved cells were treated with the indicated CPT concentrations for 1 h before 
staining for γH2AX (green). DNA was counterstained with DAPI (blue). (C) Representative images. 
Numbers are the percentage of nuclei with at least 2 γH2AX foci (bottom) and the average foci per 
nucleus (top). Bars: 10 µm. (D) Number of γH2AX foci per nucleus. ****, P < 0.0001. (E) Quantification 
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of γH2AX fluorescence intensity per nucleus. Quantifications in panels C to E are from two 
independent experiments (209-246 nuclei were analyzed for each treatment). (F,G) Serum-starved 
cells were treated with FLV (1 µM) for 1 h before the addition of CPT (25 µM) for 1 h and then co-
stained for γH2AX (green) and 53BP1 (red). (F) Representative pictures. Images were merged to 
determine colocalization (yellow). Nuclear contours, identified by DAPI staining (not shown), are 
indicated by dashed lines. Bars: 10 µm. (G) Number of γH2AX foci per nucleus from one 
representative experiment (99-133 nuclei were analyzed for each treatment) out of four. ****, P < 
0.0001. (H,I) Detection of DSBs by neutral Comet assays in serum-starved cells treated with FLV (1 
µM) for 1 h before the addition of CPT (7.5 µM) for 1 h. (H) Representative pictures of nuclei. (I) 
Quantification of neutral Comet tail moments from one representative experiment (101-106 nuclei 
were analyzed for each treatment) out of three. ****, P < 0.0001.   
 
Figure 2. Induction of ubiquitin/proteasome-dependent DSBs in CPT-treated quiescent WI38 hTERT 
cells. (A-F) Serum-starved cells were treated with MG132 (50 µM, 1 h), lactacystin (10 µM, 1 h), 
bortezomib (1 µM, 4 h), G5 (1.5 µM, 0.5 h) or Pyr-41 (9 µM, 0.5 h) before the addition of CPT (25 µM) 
for 1 h and then co-stained for γH2AX (green) and 53BP1 (red) or analyzed by Western blot. (A,D) 
Representative pictures. Nuclear contours, identified by DAPI staining (not shown), are indicated by 
dashed lines. Bars: 10 µm. (B,E) Number of γH2AX foci per nucleus from two independent 
experiments (147-153 nuclei were analyzed for each treatment). ****, P < 0.0001. (C,F) Western blot 
of γH2AX. αTubulin: loading control. Dashed lines indicate that intervening wells have been spliced 
out. The top panels show quantification of γH2AX expression normalized to αTubulin (means ± SEM, 
n = 4 in panel C, n=3 in panel F). ***, P < 0.001; **, P < 0.01. (G,H) Detection of DSBs by neutral 
Comet assays in serum-starved cells treated with MG132 (25 µM) for 1 h before the addition of CPT 
for 1 h (7.5 µM for experiments (Exp) I and II; 5 and 7.5 µM for Exp III). (G) Representative pictures of 
nuclei from Exp I. (H) Quantification of neutral Comet tail moments for three independent experiments 
(95-133 nuclei were analyzed for each treatment in each experiment). ***, P < 0.001; ****, P < 0.0001. 
The untreated and CPT data from Exp I are from the same experiment as that of Figure 1I.  
 
Figure 3. The production of DSBs depends on Top1 degradation in CPT-treated quiescent cells. 
(A-C) Serum-starved WI38 hTERT cells were co-transfected with siRNAs against cullin 3 and cullin 
4B or against a control sequence and then treated with CPT (25 µM) for 1 h. (A,B) Western blotting of 
the indicated proteins. αTubulin: loading control. (C) Number of γH2AX foci per nucleus from one 
representative experiment (246-348 nuclei were analyzed for each treatment) out of three. ***, P < 
0.001. (D,E) Serum-starved WI38 hTERT cells were treated with MG132 (50 µM) for 1 h before 
exposure to 0.8 Gy IR. One hour post-irradiation, cells were co-stained for γH2AX (green) and 53BP1 
(red). (D) Representative pictures. (E) Number of γH2AX foci per nucleus from one representative 
experiment (162-180 nuclei were analyzed for each treatment) out of three. Ns: not significant. (F,G) 
U2OS EV28 cells were treated with MG132 (10 µM) for 1 h before the addition of 300 nM 4-
hydroxitamoxifen (4OHT) for 4 h to express AsiSI in the nucleus (51). (F) Representative pictures of 
cells co-stained for γH2AX (green) and 53BP1 (red). (G) ChIP analysis using an anti-γH2AX antibody 
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(black) or a non-immune antibody (IgG, grey). Enrichment was assessed by QPCR amplification using 
primers proximal to two AsiSI sites located inside two genes (Gene I: SFRS6, Gene II: CCD47) and 
primers distal to an AsiSI site (Control). Enrichment was normalized to the maximum recovery for 
each experiment (means ± SEM, n = 3). Ns: not significant; *, P < 0.05. In the microscopic images, 
nuclear contours, identified by DAPI staining (not shown), are indicated by dashed lines. Bars: 10 µm. 
 
Figure 4. Inhibition of TDP1 or PARP increases CPT-induced DSBs in quiescent WI38 hTERT cells. 
(A,B) Serum-starved cells were transfected with TDP1-targeting or nontargeting (Control) siRNAs and 
then treated with MG312 (25 µM) or FLV (1 µM) for 1 h before the addition of CPT (25 µM) for 1 h. 
Cells were then co-stained for γH2AX (green) and 53BP1 (red). (A) Representative pictures. (B) 
Number of γH2AX foci per nucleus from one representative experiment (152-233 nuclei were 
analyzed for each treatment) out of two to four. ****, P < 0.0001. (C,D) Serum-starved cells were 
treated for 1 h with veliparib (5 µM), either alone or in combination with MG132 (25 µM) or FLV (1 µM), 
before the addition of CPT (25 µM) for 1 h. Cells were then co-stained for γH2AX (green) and 53BP1 
(red). (C) Representative pictures. (D) Number of γH2AX foci per nucleus from one representative 
experiment (120-223 nuclei were analyzed for each treatment) out of two. ****, P < 0.0001. (E) 
Detection of DSBs by neutral Comet assays in serum-starved cells treated with veliparib (5 µM) 
before the addition of CPT (7.5 µM). Data show the quantification of one representative experiment 
(226-249 nuclei were analyzed for each treatment) out of three. ****, P < 0.0001. (F) Serum-starved 
cells were transfected with TDP1-targeting or nontargeting (Control) siRNAs and then treated for 1 h 
with veliparib (5 µM) or olaparib (10 µM) before the addition of CPT (25 µM) for 1 h. Cells were then 
stained for γH2AX. The number of γH2AX foci per nucleus from one representative experiment (105-
215 nuclei were analyzed for each treatment) out of two is shown. ****, P < 0.0001; ns, not significant. 
In the microscopic images, nuclear contours, identified by DAPI staining (not shown), are indicated by 
dashed lines. Bars: 10 µm.  
 
Figure 5. Inhibition of DNA-PK prevents the formation of ATM-pS1981 foci in CPT-treated quiescent 
WI38 hTERT cells. (A,B) Serum-starved cells were treated with ATMi (10 µM), DNA-PKi (10 µM) or 
ATRi (10 µM) for 1 h before the addition of CPT (25 µM) for 1 h. Cells were then stained for γH2AX 
(green) and DNA was counterstained with DAPI (blue). (A) Representative pictures. Numbers are the 
percentage of nuclei with at least 2 γH2AX foci (bottom) and the average number of foci per nuclei 
(top). (B) Number of γH2AX foci per nucleus. Quantifications in panels A and B are from one 
representative experiment (159-306 nuclei were analyzed for each treatment) out of three. ****, P < 
0.0001. (C) Detection of DSBs by neutral Comet assays in serum-starved cells treated with ATMi (10 
µM) or DNA-PKi (10 µM) for 1 h before the addition of CPT (7.5 µM) for 1 h. Data show the 
quantification of one representative experiment out of two for ATMi (226-428 nuclei were analyzed for 
each treatment) and out of four for DNA-PKi (102-120 nuclei were analyzed for each treatment). ****, 
P < 0.0001; *, P < 0.05. The untreated and CPT data from the experiment with ATMi are from the 
same experiment as that of Figure 4E. (D) Right panels: colocalization of ATM-pS1981 foci (red) with 
γH2AX foci (green) in serum-starved cells treated with CPT (25 µM) for 1 h before staining. Similar 
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data were obtained in > 10 independent experiments. Left panels: serum-starved cells were treated 
with DNA-PKi (10 µM) or ATMi (10 µM) for 1 h before the addition of CPT (25 µM) for 1 h and then co-
stained for DNA-PK-pT2609 (red) and γH2AX (green). Similar data were obtained in two independent 
experiments. Images were merged to determine colocalization (yellow). (E) Western blot of ATM-
pS1981 and DNA-PK-pS2056 in serum-starved cells treated as described for panel D. The top panel 
shows quantification of ATM-pS1981 expression (means ± SD, n = 3). **, P < 0.01; ****, P < 0.0001. 
(F) Serum-starved cells were treated with DNA-PKi (10 µM) for 1 h before the addition of CPT (25 µM) 
for 1. Nucleosoluble proteins were then removed (lower panels) or not (top panels) with CSK buffer 
before co-staining for ATM-pS1981 (red) and γH2AX (green). Representative images are shown. The 
zoomed images are x4 magnifications of the main images. The yellow boxes indicate areas of 
magnification. (G) Quantification of ATM-pS1981 fluorescence intensity per nucleus shown in lower 
panel F (means ± SD, n= 3, 70-100 nuclei were analyzed for each treatment in each experiment). ****, 
P < 0.0001. In the microscopic images, nuclear contours, identified by DAPI staining (not shown), are 
indicated by dashed lines. Bars: 10 µm. 
 
Figure 6. Inhibition of DNA-PK prevents monoubiquitination of H2AX and H2A in CPT-treated 
quiescent WI38 hTERT cells. (A-E) Serum-starved cells were treated with DNA-PKi (10 µM) for 1 h 
before the addition of CPT (25 µM) for 1 h. (A) Western blot of γH2AX. +Ub1 indicates γH2AX 
monoubiquitinated. The top panel shows quantification of Ub1-γH2AX expression normalized to 
αTubulin (means ± SEM, n = 4). **, P < 0.01. (B,C) Cells were pre-extracted with CSK buffer before 
co-staining for Ub-H2A (red) and 53BP1 phosphorylated on S1778 (p53BP1) (green). (B) 
Representative pictures. Images were merged to determine colocalization (yellow). The large Ub-
H2AX focus at the periphery of the nuclei of untreated and CPT-treated cells may marks the inactive 
X chromosome as reported (83). (C) Percentages of nuclei with at least 5 Ub-H2A foci (means ± SEM, 
n = 3, 100 nuclei were analyzed for each treatment in each experiment). ***, P < 0.001. (D,E) Cells 
were co-stained for ubiquitinated proteins (FK2, red) and γH2AX (green). (D) Representative pictures. 
Images were merged to determine colocalization (yellow). (E) Number of FK2 foci per nucleus from 
one representative experiment (76-111 nuclei were analyzed for each treatment) out of three. ****, P < 
0.0001. In the microscopic images, nuclear contours, identified by DAPI staining (blue in the merge 
images at bottom), are indicated by dashed lines. Bars: 10 µm.  
 
Figure 7. Inhibition of DNA-PK prevents Top1 degradation and proteasome activity in CPT-treated 
quiescent WI38 hTERT cells. (A-E) Serum-starved cells were treated with DNA-PKi (10 µM) for 1 h 
before the addition of CPT (25 µM) for the indicated times. (A) Western blot of Top1. The top panel 
shows quantification of Top1 expression normalized to αTubulin (means ± SEM, n = 4). **, P < 0.01. 
(B) Detection of Top1-DNA cleavage complexes (Top1cc). Three concentrations of genomic DNA (5, 
2.5, and 1.25 µg) were probed with an anti-Top1 antibody. Dashed lines indicate where panels have 
been reorganized to facilitate reading. (C) Western blot of UBA1, PSMA6 and Top1 in the P2 fraction 
(see Supplementary Figure S5G). Dashed lines in the UBA1 blot indicate that intervening wells have 
been spliced out. The top panel shows quantification of UBA1, PSMA6 and Top1 expression in the P2 
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fraction normalized to histone H3 (mean ± SEM; n = 4 for PSMA6 and Top1, n = 3 for UBA1). (D) 
Western blot of UBA1 (top) and PSMA6 (bottom) in whole cell extracts (WCE). (E) Chymotrypsin-like 
activity assessment in the P2 fraction (means ± SD of triplicates; each time point is representative of 
at least two independent experiments). αTubulin and histone H3 were the loading controls for 
Western blot experiments.  
 
Figure 8. CPT induces transcription- and proteasome-dependent apoptosis in quiescent WI38 hTERT 
cells. (A) Serum-starved cells were treated with FLV (1 µM) for 1 h before the addition of CPT (25 µM) 
for 16 and 24 h. Cell survivals are percentages of cells that remained attached to culture flasks 
(means ± SD of quadruplicates). (B-F) Western blot of the indicated proteins in serum-starved cells 
treated for 1 h with FLV (1 µM) (B), lactacystin (10 µM) (C), veliparib (5 µM) or olaparib (10 µM) (D), 
ATMi (10 µM) (E) or DNA-PKi (10 µM) (F) before the addition of CPT (25 µM) for the indicated times. 
Data shown are representatives from two to three experiments. PARPCL: cleaved PARP. H2AX and 
αTubulin were the loading controls  
 
Figure 9. Proposed molecular pathways for the production and signaling of DSBs by transcription-
blocking Top1 lesions. “Y” is the catalytic tyrosine of Top1 covalently bound to the 3’-end of the 
broken DNA. Asterisks indicate proteins whose deficiency induces neurodegenerative diseases 
(TDP1 deficiency: SCAN1 syndrome; ATM deficiency: AT syndrome).  
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SUPPLEMENTARY FIGURE LEGENDS 
Figure S1. ATM- and DNA-PK-dependent induction of γH2AX in quiescent IMR90 and NHDF 
cells in response to CPT. Data in IMR90 cells are shown in panels A-D and data in NHFD cells are 
shown in panels E-H. (A,E) Cells cultured in 10% or 0.2% serum for 3 days were exposed to 100 µM 
BrdU for 30 min before staining for BrdU. Percentage of BrdU positive cells (> 300 cells were analyzed 
for each treatment). (B-D, F-H) Serum-starved cells were treated with ATMi (10 µM) or DNA-PKi (10 
µM) for 1 h before the addition of CPT (25 µM) for 1 h. Cells were then stained for γH2AX (green) and 
DNA was counterstained with DAPI (blue). (B,F) Representative pictures. Numbers indicate the 
average number of foci per nucleus. Bars: 10 µM. (C,G) Number of γH2AX foci per nucleus (122-167 
nuclei were analyzed for each treatment in panel C and 111-169 in panel G); ****, P < 0.0001. (D,H) 
Quantification of γH2AX fluorescence intensity per nucleus (means ± SD, 182-209 cells were 
examined per condition in panel D and 208-267 in panel H).  
 
Figure S2. Top1 is degraded in response to CPT but not IR or AsiSI, and PARP inhibition 
increases γH2AX/53BP1 foci in CPT-treated quiescent cells. (A-C) Western blot of Top1 in serum-
starved WI38 hTERT cells treated with FLV (1 µM, 1 h), G5 (1.5 µM, 0.5 h) or MG132 (10 µM, 1 h) 
before the addition of CPT (25 µM) for the indicated times in panels A and C or for 4 h in panel B. (D) 
Western blot of Top1 in serum-starved WI38 hTERT cells 4 and 6 h post-irradiation with 0.8 Gy IR. (E) 
Western blot of Top1 in U2OS EV28 cells treated with 300 nM 4OHT for the indicated times. (F) 
Schematic representation of the repair of a Top1cc. Top1 is partially proteolyzed by the 
ubiquitin/proteasome system to expose the covalent bond between the Top1 catalytic tyrosine and the 
3’-end of the DNA to be attacked by TDP1. Top1cc excision by TDP1 requires PARP1. TDP1 
generates a 3’-phosphate, which is hydrolyzed by PNKP before religation by ligase III. (G) Western 
blot of TDP1 in serum-starved WI38 hTERT cells transfected with TDP1-targeting or nontargeting 
(Control) siRNAs. αTubulin: loading control. (H,I) Serum-starved WI38 hTERT cells were treated for 1 
h with olaparib (10 µM) before the addition of CPT (25 µM) for 1 h. Cells were then co-stained for 
γH2AX (green) and 53BP1 (red). (H) Representative pictures. Nuclear contours, identified by DAPI 
staining (not shown), are indicated by dashed lines. Bars: 10 µm. (I) Number of γH2AX foci per 
nucleus from one representative experiment (131-151 nuclei were analyzed for each treatment) out of 
two; ****, P < 0.0001. 
 
Figure S3. Activation of ATM signaling and its prevention following DNA-PK inhibition in CPT-
treated quiescent WI38 hTERT cells. (A,B) Serum-starved WI38 hTERT cells were treated with 
ATMi (10 µM) or DNA-PKi (10 µM) for 1 h before the addition of CPT (25 µM) for 1 h and stained for 
γH2AX (green). Representative pictures are shown in Figure 5A. (A) Quantification of γH2AX 
fluorescence intensity per nucleus (means ± SD, 172-307 nuclei were examined for each treatment). 
(B) Size of γH2AX foci (means ± SD, n = 3, > 320 foci from 50-70 cells were analyzed for each 
treatment in each experiment).**, P < 0.01; t-test. (C) Western blot of Chk1 phosphorylated on S345 
(Chk1-pS345) and total Chk1 in replicating WI38 hTERT cells treated with ATRi (10 µM) for 1 h before 
the addition of CPT (25 µM) for the indicated times. (D) Western blot of ATM, DNA-PK and ATR in 
WI38 hTERT cells cultured in 10% serum or in 0.2 % serum for 3 days. (E) Phosphorylation of ATM on 
S1981 (ATM-pS1981), KAP1 on S824 (KAP1-pS824), Chk2 on T68 (Chk2-pT68) and p53 on S15 
(p53-pS15) was determined by Western blot in serum-starved WI38 hTERT cells treated with the 
indicated concentrations of CPT for 1 h. Total ATM, KAP1, Chk2 and p53 were examined in parallel. 
(F) Serum-starved WI38 hTERT cells were treated with DNA-PKi (10 µM) for 1 h before the addition of 
CPT (25 µM) for 1 h and stained for 53BP1, 53BP1 phosphorylated on S1778 (p53BP1) or MDC1. 
Representative pictures from one experiment out of two. Nuclear contours, identified by DAPI staining 
(not shown), are indicated by dashed lines. Bars: 10 µm.   
 Figure S4. Inhibition of XLF or XRCC4 does not prevent the formation of ATM-pS1981 and 
γH2AX foci in CPT-treated quiescent WI38 hTERT cells. (A,B) Serum-starved WI38 hTERT cells 
were transfected with XLF-targeting or nontargeting (Control) siRNAs. (A) Western blot showing the 
efficiency of XLF silencing. Actin: loading control. (B) siRNA-transfected cells were treated with CPT 
(25 µM) for 1 h and pre-extracted with CSK buffer before co-staining for ATM-pS1981 (red) and 
γH2AX (green). Representative pictures. Nuclear contours, identified by DAPI staining (not shown), 
are indicated by dashed lines. Bars: 10 µm. (C,D) Similar experiments were performed following 
siRNA-mediated depletion of XRCC4.  
 
Figure S5. Inhibition of DNA-PK or ATM but not XLF or XRCC4 prevents CPT-induced Top1 
degradation in quiescent cells. (A) Western blot of H2AX in serum-starved WI38 hTERT cells 
treated with CPT (25 µM) for 1 h. +Ub1 indicates monoubiquitinated H2AX. (B,C) Serum-starved WI38 
hTERT cells were transfected with DNA-PK-targeting or nontargeting (Control) siRNAs. (B) Western 
blot showing DNA-PK silencing. αTubulin: loading control. (C) siRNA-transfected cells were treated 
with CPT (25 µM) for 1 h before staining for ubiquitinated proteins (FK2). Number of FK2 foci per 
nucleus from two experiments (156-171 nuclei were analyzed for each treatment). ****, P < 0.0001, t-
test. (D) Western blot of Top1 in serum-starved IMR90 cells (top) and serum-starved NHDF cells 
(bottom) treated with DNA-PKi (10 µM) for 1 h before the addition of CPT (25 µM) for the indicated 
times. αTubulin: loading control. (E) Western blot of Top1, XLF and XRCC4 in serum-starved WI38 
hTERT cells transfected with siRNAs against XLF, XRCC4 or a nontargeting sequence (Control) 
before treatment with CPT (25 µM) for 6 h. Actin: loading control. (F) Western blot of Top1 in serum-
starved WI38 hTERT cells treated with ATMi (10 µM) for 1 h before the addition of CPT (25 µM) for 
the indicated times. αTubulin: loading control. (G) Serum-starved WI38 hTERT cells were subjected to 
fractionation and proteins from whole cell extracts (WCE), 150 mM NaCl/0.1% Triton X-100 
supernatant (S1), 150 mM NaCl/RNAse A supernatant (S2) and pellets (P2) were analyzed by 
Western blot. αTubulin and histone H3 control the S1 and P2 fractions, respectively. (H) DNA-PKi (10 
µM) or MG132 (10 µM) were incubated with the P2 fraction of serum-starved WI38 hTERT cells and 
proteasome chymotrypsin-like activity was measured  (means ± SEM, n = 3).  
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Supplementary Results 
 
We have previously shown that transcriptional DSBs can arise during the repair of Top1 trapped 
into chromatin by CPT in serum-starved quiescent cells. We have proposed that Top1cc 
stabilization by CPT blocks transcription elongation, which triggers partial Top1 proteolysis and the 
generation of a Top1 peptide-linked SSB which is a substrate for Tdp1. Defective repair of this SSB 
intermediate by Tdp1 can give rise to a DSB (see Figure 9, paper). The unresolved question is how 
this SSB can be converted into a DSB in the absence of replication. To address this question, we are 
currently investigating the following points:  
- Determine whether transcriptional DSBs that are produced during the repair of Top1cc arise 
specifically from Top1 peptide-linked SSBs or also by the other SSBs generated downstream of 
Tdp1 action (see the Top1cc repair pathway in Figure S2F, paper). 
- Determine whether the second SSB is created by an endonuclease. 
- Determine whether transcriptional DSBs are produced at hot-spot regions across the genome 
to gain insight into the mechanism of their production and signalling. 
- Determine whether the mechanism of DSB production that we identified in serum-starved 
quiescent cells can be extended to replicating cells outside of S-phase. If so, that will allow the use 
of genetically modified cell lines that cannot be induced in quiescence for further studies.  
 
Transcriptional DSBs arise from SSB intermediates generated during Top1cc repair by the 
Tdp1 excision pathway  
To gain mechanistic insights in the production of transcriptional DSBs, we asked whether the nature 
of the SSB intermediate is important for DSB production. Indeed, DSBs may arise specifically from 
the Top1 peptide-linked SSBs or also from the other SSBs generated downstream from Tdp1. 
Following Tdp1 action, the Top1 peptide-linked SSB is converted into a 3’-phosphate SSB, which 
is hydrolysed by PNKP to generate a 3’-hydroxyl SSB, which is a substrate for LIG3 (Figure S2F, 
paper). To answer this point, we measured γH2AX foci upon inhibition of PNKP and LIG3, which 
increases the amount of 3’-phosphate- and 3’-hydroxyl-SSB intermediates, respectively, in CPT-
treated cells. We found that depletion of PNKP or LIG3 with siRNAs increased the number of 
γH2AX foci in CPT-treated quiescent WI38 hTERT cells (Figure IC and D), under conditions 
where they also increased the amount of SSBs measured by alkaline comet assay (Figure IE and 
F). These results indicate that co-transcriptional DSBs produced in CPT-treated quiescent cells arise 
from SSB intermediates generated during Top1cc repair, independently of the nature of the SSB. 
The production of transcriptional DSBs requires the endonuclease XPF  
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It has been previously reported that transcriptional DSBs are produced by a mechanism dependent 
on R-loops in post-mitotic cells treated by CPT (Sordet et al., 2009). More recently, it has been 
reported that R-loops can be cleaved by the TCR endonucleases XPF and XPG (Sollier et al., 2014). 
We therefore tested the possibility that XPF-dependent cleavage of R-loops could be implicated in 
the generation of the second SSB on the opposite strand to the first SSB produced by Top1cc repair 
then, leading to the production of a DSB.  
We found that depletion of XPF with siRNA significantly decreased the number of γH2AX and 
53BP1 foci in CPT-treated quiescent WI38 hTERT cells (Figure IIA-C). To get additional 
evidence of the role of XPF in the production of transcription-dependent DSBs, we assessed 
whether its depletion also reduced CPT-induced DSBs under conditions where Tdp1 or PARP are 
inhibited. Figure IIB-E show that XPF depletion with siRNA reduced the number of γH2AX and 
53BP1 foci induced by CPT in quiescent WI38 hTERT cells where Tdp1 was depleted with siRNA 
or PARP was inhibited with olaparib. Together, these results indicate that XPF contributes to the 
production of transcription-dependent DSBs in CPT-treated cells and further raise the possibility 
that it could mediate a SSB in the R-loop at the proximity of a SSB generated during Top1cc repair 
on the opposing DNA strand.  
 
Transcriptional DSBs are preferentially formed at subtelomeric regions  
To get insights into the mechanism of production of CPT-induced transcriptional DSBs, we 
wondered if it would be possible to identify some loci or regions where transcription-dependent 
DSBs are preferentially produced. To map the genomic localization of CPT-induced transcriptional 
DSBs, we analysed the distribution of γH2AX in post-mitotic human lymphocytes and serum-
starved WI38 hTERT fibroblasts treated with CPT. As subtelomeric regions are highly rich in 
transcribed genes and have G-rich sequences that may be prone to R-loop formation (Duquette et al., 
2004), we tested the hypothesis that the production of transcriptional DSBs could be favoured at 
subtelomeres. By using immunocytochemistry staining followed by DNA fluorescence in situ 
hybridization (ICC/DNA-FISH) to simultaneously visualize γH2AX and telomeres, in collaboration 
with William Bonner’s group (NIH, USA), we found that approximately 70% of γH2AX foci were 
localized in proximity of telomeres in post-mitotic human lymphocytes treated with CPT (Figure 
IIIA and B). In the same conditions, only 25% of γH2AX foci localized near telomeres in 
lymphocytes exposed to IR at a dose that induced approximately 2 γH2AX foci per cell (as 25 µM 
of CPT in those cells). As a control, we showed that γH2AX foci did not localize near centromeres 
in lymphocytes treated with CPT. Then, we confirmed these observations by assessing γH2AX 
enrichment by ChIP in CPT-treated lymphocytes. We found that γH2AX was enriched at 
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subtelomeres (Actin β, SMARCA2, Telomere I), while it was not enriched at centromeres (TTF2, 
CCT6A, IKZF1) (Figure IIIC). In addition, γH2AX enrichment at subtelomeric regions was 
dependent on transcription since it was completely suppressed by the transcription inhibitor 
flavopiridol (Figure IIIC). 
Then, we investigated whether the CPT-induced transcriptional DSBs were preferentially formed at 
subtelomeres also in serum-starved quiescent fibroblasts. By co-staining γH2AX foci with the 
telomeric markers TRF1 or TRF2 (telomeric-binding protein 1 or 2) as described (Rodriguez et al., 
2012) or with the centromeric marker CENPA, we found that approximately 60-70% of γH2AX 
foci formed in proximity of telomeres (Figure IIIF and G). The specificity of the immunostaining 
and the percentage of foci that colocalized by chance were evaluated by co-staining CENPA with 
TRF2 and TRF1 with TRF2 (Figure IIID and E). Taken together, these results suggest that 
transcriptional-DSBs induced by CPT are not randomly distributed across the genome and give a 
rational to determine more precisely where they are formed for example by using ChIP-sequencing 
analyses of γH2AX. 
 
The production of transcriptional DSBs in G1- and G2-phase cells requires Top1 proteolysis  
It has been reported that CPT-induced transcriptional DSBs are also produced in EdU-negative 
replicating cells (Regairaz et al., 2011; Sordet et al., 2009; Zhang et al., 2011). We wondered 
whether transcriptional DSBs are produced by the same mechanism in replicating cells outside of S-
phase than in serum-starved quiescent cells. To answer this point, at first, we analysed the 
production of transcriptional DSBs in G1- and G2- phase cells treated with CPT. We showed the 
production of DSBs by analysing the induction of γH2AX and p53BP1 foci in response to CPT in 
asynchronously growing WI38 hTERT cells (Figure IVA and B). In response to CPT, G1- and G2- 
phase cells can be distinguished from S-phase cells by a dotted instead of a pan-nuclear γH2AX 
staining as described (Bonner et al., 2008). Then, G2 cells can be distinguished from G1 cells 
because they are positive for CENP-F staining and they have a high DAPI signal compared to G1 
cells as described (Beucher et al., 2009). To determine if DSBs are produced by the same 
mechanism in replicating cells outside of S-phase than in quiescent cells, we checked whether 
inhibiting Top1 proteolysis by the inhibition of the ubiquitin/proteasome system would prevent 
DDR signalling. We found that the proteasome inhibitor MG132, prevented the induction of 
γH2AX foci in G1- and G2- cells and decreased γH2AX signal in S-phase cells (Figure IVC). 
Inhibition of ubiquitination by G5 also decreased CPT-induced γH2AX signal analysed by western 
blot (Figure IVE), under conditions where it prevented Top1 degradation (Figure IVD). These 
results indicate that the ubiquitin/proteasome system is required for the formation of DSBs in CPT-
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treated cells outside of S-phase and strongly suggest that CPT-induced transcriptional DSBs are 
produced by a general mechanism that is not limited to serum-starved quiescent cells. These 
findings also give the rational for the use of genetically modified cell lines that cannot be induced in 
quiescence by serum-starvation for further mechanistic studies.  
 
FIGURE LEGENDS 
 
Figure I. Inhibition of PNKP or LIG3 increases CPT-induced DSBs in quiescent WI38 
hTERT cells. (A-F) Serum-starved cells were transfected with PNKP- or LIG3-targeting or 
nontargeting (Ctrl) siRNAs and then treated with CPT (25 µM) for 1 h. (A,B) Western blotting of 
the indicated proteins. αTubulin or KAP1: loading control. (C,D) Detection of SSBs by alkaline 
comet assays. (C) Representative pictures of nuclei. (D) Quantification of alkaline comet tail 
moments from one representative experiment (60-249 nuclei were analysed for each treatment) out 
of three. ***, P < 0.001; ****, P < 0.0001. (E,F) Co-staining of γH2AX (green) and 53BP1 (red). 
(E) Representative pictures. (F) Number of γH2AX foci per nucleus from one representative 
experiment (152-233 nuclei were analysed for each treatment) out of three. ****, P < 0.0001. In the 
microscopic images, nuclear contours, identified by DAPI staining (not shown), are indicated by 
dashed lines. Bars: 10 µm. 
 
Figure II. Inhibition of XPF decreases CPT-induced DSBs in quiescent WI38 hTERT cells. 
(A) Serum-starved cells were transfected with XPF-targeting or nontargeting (Ctrl) siRNAs. 
Western blotting of XPF. αTubulin: loading control. (B,C) Serum-starved cells were transfected 
with XPF- and/or Tdp1- targeting or nontargeting (Ctrl) siRNAs, treated with CPT (25 µM) for 1 h 
and then co-stained for γH2AX (green) and 53BP1 (red). (B) Representative pictures. (C) Number 
of γH2AX foci per nucleus from one experiment (113-300 nuclei were analysed for each treatment) 
out of one to four. ****, P < 0.0001. (D,E) Serum-starved cells were transfected with XPF-
targeting or nontargeting (Ctrl) siRNAs and treated for 1 h with olaparib (10 µM) before the 
addition of CPT (25 µM) for 1 h. Cells were then co-stained for γH2AX (green) and 53BP1 (red). 
(D) Representative pictures. (E) Number of γH2AX foci per nucleus from one experiment (116-439 
nuclei were analysed for each treatment). ****, P < 0.0001. In the microscopic images, nuclear 
contours, identified by DAPI staining (not shown), are indicated by dashed lines. Bars: 10 µm. 
 
Figure III. Preferential formation of γH2AX foci at subtelomeric regions after CPT treatment 
in post-mitotic human lymphocytes and serum-starved quiescent human cells. (A) Left and 
middle panels: representative confocal microscopy images of immunostaining of γH2AX (green) 
and fluorescence in situ hybridization of telomeres (red) in lymphocytes after treatment with CPT 
(25 µM, 1 h) or after ionizing radiation (IR: 0.2 Gy, 30 min). DNA was counterstained with DAPI 
(blue). Both treatments induce the production of approximately 2 γH2AX foci per nucleus. Images 
show the preferential localization of γH2AX foci at the proximity of telomeres in response to CPT 
but not in response to IR. Right panel: co-staining of CPT-treated lymphocytes (25 µM, 1 h) for 
γH2AX (green) and CENPA (red, centromeric marker) show that γH2AX foci do not form at the 
proximity of centromeric regions. (B) Percentages of γH2AX foci that form at the proximity 
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(proximal, black bars) or at distance (distal, grey bars) of telomeres (Telomeric-FISH) or 
centromeres (CENPA). The data show the average of two independent experiments ± SD, 30-40 
cells were counted for each experiment. (C) Lymphocytes treated or not with flavopiridol (FLV, 1 
µM) for 1 h before the addition of CPT (25 µM, 1 h) were sonicated to generate long chromatin 
fragments (> 1 Kb with high variability) and then immunoprecipitated by using an anti-γH2AX 
antibody. γH2AX enrichment was assessed by qPCR amplification using primers localized in 
subtelomeric (Actβ, SMARCA2, Telomere I) or pericentromeric (TTF2, CCT6A, IKZF1) regions. 
DNA recovery is calculated by setting untreated samples to 1. Data show the average ± SD of 
triplicates. ChIP analysis was performed in parallel by using a non-immune antibody (IgG) as 
negative control and an anti-H3 antibody as positive control (data not shown). For qPCR 
amplification, primers recognizing α-satellite regions at centromere were also used as negative 
control (data not shown). (D-G) Serum-starved WI38 hTERT cells were treated with CPT (10 µM, 
1 h) before staining for the indicated proteins. DNA was counterstained with DAPI (blue). Bars: 10 
µm. (D) Representative confocal microscopy images of immunostaining of CENPA (green, 
centromeric marker, left panel) or TRF1 (green, telomeric marker, right panel) with TRF2 (red, 
telomeric marker). Images show the specificity of antibody staining, CENPA and TRF2 do not 
colocalize while TRF1 and TRF2 perfectly merged (yellow). (E) Percentages of TRF2 foci that 
form at the proximity (proximal, black bars) or at distance (distal, grey bars) of centromeres 
(CENPA) or telomeres (TRF1). The percentage of TRF2 foci proximal to CENPA gives a measure 
of colocalization by chance. Data show the average of TRF2 foci per cell ± s.e.m. , 181-265 TRF2 
foci were counted per condition. (F) Representative confocal microscopy images of 
immunostaining of γH2AX (green) whit TRF1 (red, left panel) or TRF2 (red, middle panel) or 
CENPA (red, right panel). Images show that γH2AX foci form preferentially at the proximity of 
telomeric regions. (G) Percentages of γH2AX foci that form at the proximity (proximal, black bars) 
or at distance (distal, grey bars) of centromeres (CENPA) or telomeres (TRF1 and TRF2). Data 
show the average of γH2AX foci per cell ± s.e.m. , 201-365 γH2AX foci were counted per 
condition. 
 
Figure IV. The production of CPT-induced DSBs is dependent on proteasome activity in 
replicating WI38 hTERT cells in G1 and G2 phases. (A) Identification of the cell cycle phases in 
WI38 cells treated with CPT (25 µM) for 1 h and then co-stained for γH2AX (green) and CENP-F 
(red). DNA is counter-stained with DAPI (blue). S-phase cells are CENP-F positive and exhibited a 
pan-nuclear staining of γH2AX. G1- and G2-phase cells were distinguished from S-phase cells by 
their dotted γH2AX staining. G1 cells are negative for CENP-F and have a low DAPI content. G2 
cells are positive for CENP-F and have high DAPI content. (B) Representative pictures of co-
staining with γH2AX (green) and 53BP1 phosphorylated on S1778 (p53BP1) (red). DNA is 
counter-stained with DAPI (blue). Images were merged to determine colocalization (yellow). (C) 
Representative pictures of replicating WI38 cells treated with MG132 (50 µM, 1 h) before the 
addition of CPT (25 µM) for 1 h and then co-stained with γH2AX (green) and CENP-F (red). DNA 
is counter-stained with DAPI (blue). (D) Replicating WI38 cells were treated with G5 (1.5 µM, 0.5 
h) before the addition of CPT (25 µM) for 1 h and then analysed by western blotting for the 
indicated proteins. αTubulin: loading control. In the microscopic images, nuclear contours, 
identified by DAPI staining are indicated by dashed lines. Bars: 10 µm. 
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DISCUSSION AND PERSPECTIVES 
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My PhD’s work has been focused on the study of DSBs produced by CPT-induced transcription-
blocking Top1cc in the aim of uncovering their mechanisms of production and signalling. These 
DSBs are particular because: 
- They are generated by Top1 covalently linked to DNA 
- They are accompanied by an inhibition of the enzymatic activity of Top1, which results 
from Top1 trapping 
- They are transcriptional DSBs: their production is dependent on transcription and they likely 
occur in actively transcribed regions.  
The interest in characterizing these co-transcriptional DSBs is linked to the fact that they can be 
produced (i) endogenously as a result of Top1cc trapping by common DNA alterations or (ii) during 
chemotherapy as a result of selective Top1cc trapping by CPT derivatives. Our work reveals a new 
mechanism and a preferential genomic location of DSB production in response to stabilized Top1cc 
as well as a new function of DNA-PK in promoting ubiquitin signalling.  
In the following section, we will discuss the main findings of this work in the context of literature, 
the open questions, the perspectives arising from this work and the possible relevance of 
transcriptional DSBs produced endogenously or during chemotherapy from transcription-blocking 
Top1cc. 
 
1. The choice of quiescent cells as cellular model  
 
To overcome the replication-related consequences of CPT treatment, we have chosen to use human 
primary WI38 fibroblasts immortalized with hTERT induced in quiescence by serum deprivation 
(Figure 1A and B, paper). Firstly, we have chosen primary cells because they have low genomic 
instability (Lobrich et al., 2010). Second, working in G1- and G2-phase cells requires the use of 
synchronization protocols that can potentially induce DNA damage or the use of cell cycle markers 
in asynchronously growing cells (Figure IVA) that are compatible with microscopy analyses (albeit 
not with multiple co-staining) but not with western blot experiments. Finally, post-mitotic cells also 
constitute a good model to study transcriptional DSBs (Sordet et al., 2009) but the available 
material is limited since they cannot be grown in culture. Another good model in complement to 
serum-starved quiescent cells for further experiments could be the SH-SY5Y neuroblastoma cell 
line. Different protocols can be used to differentiate SH-SY5Y in neuron-like cells that arrest to 
proliferate, form long neurites, express neuronal markers (Dwane et al., 2013) and behave like 
neurons in response to CPT (Tian et al., 2009).  
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2. Correlations between γH2AX foci and DSBs  
 
γH2AX foci are the most common and used marker to detect DSBs, however the use of γH2AX has 
been debated as γH2AX can also reveal damage other than DSBs (Bonner et al., 2008; Lobrich et 
al., 2010). In our study we clearly demonstrated that CPT induces DSBs in non-cycling cells as (i) 
γH2AX foci colocalize with the other DDR proteins 53BP1 and MDC1 foci, (ii) neutral comet tail 
moment is increased, and (iii) ATM, DNA-PK and the downstream DDR pathway are activated. 
In agreement with the literature (Sakai et al., 2012; Sakasai et al., 2010a; Sordet et al., 2009; Tian et 
al., 2009), TC-DSBs associate with large γH2AX and 53BP1 foci (Figure 1F, paper) compared 
with RC-DSBs or AsiSi-induced DSBs (Figure 3F, paper). A number of studies have shown a 
nearly one-to-one correlation between γH2AX foci and DSBs (Kinner et al., 2008; Lobrich et al., 
2010). However, in our model few DSBs (≈3-5 foci/cells with 5-7.5 µM CPT, respectively) are able 
to increase the tail moment in neutral comet assay (Figure 1I, paper). This was unexpected as the 
limit of sensitivity of the neutral comet assay has been estimated to approximately 12.5-50 
DSBs/cell depending on the cellular type (Olive and Banath, 2006; Redon et al., 2009; Wang et al., 
2013). A tempting hypothesis might be that one large transcription-dependent γH2AX focus 
contains more than one DSB. For instance, multiple DSBs might occur simultaneously in a 
transcription factory as in the case of etoposide-induced DSBs (Cowell et al., 2012). To test 
whether one γH2AX focus corresponds to more than one DSB, it would be interesting to analyse 
the CPT-induced Ku and/or XRCC4 foci in serum-starved quiescent cells and determine how many 
Ku or XRCC4 foci are present in a single γH2AX focus as described (Britton et al., 2013). 
Detection of Ku foci would also be of interest in the context of DDR inhibition to directly visualize 
DSBs in the absence of γH2AX foci. Indeed, neutral comet assay shows an increase in DSBs in 
response to CPT upon ATM or DNA-PK inhibition (Figure 5C, paper) that cannot be studied by 
analysing DDR foci. 
 
3. How are CPT-induced transcriptional DSBs produced?  
 
Our results show that CPT-induced transcriptional DSBs produced in serum-starved quiescent cells 
arise from SSB intermediates generated during Top1cc repair by the Tdp1 excision pathway, 
independently of the nature of the SSBs (Figure 2 and 4, paper and Figure IE and F). Our model 
is consistent with previous works showing that: (i) CPT-induced Top1 downregulation is 
transcription and proteasome-dependent (Desai et al., 2001; Desai et al., 2003), (ii) Tdp1 primarily 
repairs transcription-blocking Top1cc (El-Khamisy et al., 2005; Miao et al., 2006) and requires 
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prior Top1 proteolysis (Debethune et al., 2002), (iii) proteasome inhibition prevents the activation 
of ATM in CPT-treated quiescent cells (Lin et al., 2008), and (iv) PARP inhibition or Tdp1 
depletion increases the number of γH2AX and 53BP1 foci in response to CPT in post-mitotic and 
cycling cells (Katyal et al., 2014; Sakai et al., 2012; Zhang et al., 2011). 
We have shown that similar to quiescent cells, CPT induces proteasome-dependent γH2AX foci in 
both G1- and G2-phase cells (Figure IVA and B). These observations strongly suggest that in 
replicating cells, transcriptional DSBs are produced during Top1cc repair by the same mechanism 
identified for quiescent cells. The results of Zhang et al. also support this possibility as PARP 
inhibition increases the number of γH2AX foci in response to CPT in the EdU negative population 
of replicating cells (Zhang et al., 2011). It would be interesting to further confirm the role of 
Top1cc repair in DSB production by analysing CPT-induced γH2AX foci in G1- and G2-phases in 
presence or not of transcription or proteasome inhibitors in genetically modified cell lines deficient 
for component of the Tdp1-excision pathway such as Tdp1 KO, PARP1 KO and Tdp1/PARP1 KO 
DT40 cells (Das et al., 2014; Murai et al., 2012) and PNKP shRNA human cells (Rasouli-Nia et al., 
2004). 
 
How to pass from a SSB to a DSB in the absence of replication?  
 
 
How a SSB can give rise to a DSB in the absence of replication is still an unresolved question. 
Many scenarios are possible but our data clearly indicate that a required step for DSB production is 
the generation of a SSB during the repair of Top1cc and after Top1 proteolysis. Different 
hypothesis could be envisaged for DSB production: 
- A Top1-linked SSB opposite to a nicked DNA 
It has been shown that a DSB can arise by a CPT-induced Top1cc opposite to nicks or short gaps at 
positions -1/+1 or between the position +2/+6 from the Top1cc on the nonscissile strand (Pourquier 
et al., 1997a). Given the high rate of DNA damage per cell per day (Lindahl and Barnes, 2000), one 
possibility is that a DSB is generated by a nick or a gap in proximity of a Top1cc located in the 
opposite strand (Figure 37A). 
- Two nearby Top1cc 
A DSB may result from two nearby Top1cc-dependent SSBs within 10 bp (Pommier et al., 2014; 
Pourquier et al., 1997a; Wu and Liu, 1997) on opposing DNA strands. At least three possible 
configurations can be envisaged (Figure 37B-D): (i) two opposite SSBs generated after Top1 
proteolysis (Figure 37B), (ii) one SSB generated after Top1 proteolysis and one SSB generated by 
an endonuclease (either to excise a Top1cc or not) (Figure 37D) (iii) one SSB generated after Top1 
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proteolysis and one unprocessed Top1cc (non-degraded Top1-linked SSB) (Figure 37C). The 
hypothesis that two Top1cc could be close to each other on opposing DNA strands is plausible 
because Top1 nicking-closing activity is increased in transcribed regions. It is also possible that two 
Top1cc on opposing DNA strands result from convergent transcription. To get insights into these 
hypotheses, it would be very helpful to determine where CPT-induced transcriptional DSBs are 
produced across the genome.  
- R-loop-dependent mechanism 
The second SSB may be caused by R-loop processing. A number of evidences support a 
participation of R-loops in the production of CPT-induced transcriptional DSBs: (i) Reduced Top1 
activity causes R-loop formation (Drolet et al., 1994; Drolet et al., 1995; Tuduri et al., 2009) and 
CPT treatment increases R-loops in vivo (Groh et al., 2014; Marinello et al., 2013; Powell et al., 
2013), (ii) RNaseH1 overexpression significantly reduces CPT-induced γH2AX signal in post-
mitotic cells (Sordet et al., 2009) and (iii) R-loops formed in response to CPT are cleaved by the 
endonuclease XPG in replicating cells (Sollier et al., 2014).  
To test if R-loops are implicated in DSB production in CPT-treated quiescent cells, we tried to 
overexpress RNaseH1 and analyse γH2AX. Unfortunately, we failed to overexpress RNaseH1 
probably because of low transfection rate and/or low transcriptional rate of quiescent cells. 
Experiments are ongoing in the laboratory to deplete RNaseH1 by using siRNA as described (Groh 
et al., 2014; Tresini et al., 2015) and analyse the impact of RNAseH1 depletion in CPT-induced 
γH2AX foci in quiescent cells. In addition, it should be interesting to determine whether R-loops 
are in the same pathway of Top1cc’s repair in the production of DSBs. 
As the mechanism of DSB production seems to be the same in replicating cells outside of S-phase, 
we are planning to analyse the role of R-loops in cycling cells by using an ArrayScan Operetta. This 
could enable to avoid the employ of a cell-phase marker by using DAPI intensity to discriminate 
cell cycle phases. We could overexpress RNAseH1 in replicating cells and/or use cell lines 
inducible for WT or mutated RNAseH1 (Britton et al., 2014).  
If R-loops are responsible for the production of the second SSB, the arising question is: how this 
second SSB is produced in the R-loop? 
The ssDNA that is exposed during R-loop formation is particularly vulnerable to nucleases and 
other enzymes. The TCR flap endonucleases, XPF and XPG, have been recently identified as 
factors able to cleave R-loops (Sollier et al., 2014) (Figure 37E and F). Preliminary experiments in 
CPT-treated quiescent cells show that depletion of XPF significantly reduces the number of γH2AX 
foci (Figure IIB and C). Tdp1-excision pathway and XPF processing seem to contribute to DSB 
production by a common pathway, as XPF depletion decreases CPT-induced γH2AX foci in 
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quiescent cells depleted for Tdp1 or treated with PARP inhibitors (Figure IIB-E). Currently, we 
did not find consistent results for XPG depletion (data not shown). It will be interesting to confirm 
these observations by using other siRNA targeting XPF or XPG, by depleting ERCC1, the non-
catalytic partner of XPF, and by using XPG- and XPF-deficient fibroblasts complemented with the 
wild type or the nuclease-dead proteins (as described (Sollier et al., 2014)) after serum-starvation.  
However, in addition to the TCR pathway to process R-loop structures (Sollier et al., 2014), XPF 
can also work in the nuclease excision pathway to repair Top1cc (Vance and Wilson, 2002). It 
would be interesting to investigate the role of these cellular pathways in DSB production as both 
could account for the contribution of XPF to transcriptional DSBs that we observed (Figure 37D 
and E). To test the potential participation of TCR in CPT-induced transcriptional DSB, we could 
analyse the impact of CSB depletion in CPT-induced γH2AX foci, as CSB is also required for R-
loop processing (Sollier et al., 2014). The work of Sakai et al. shows that CSB depletion partially 
decreases the number of transcriptional 53BP1 foci in response to CPT (Sakai et al., 2012) 
supporting this  possibility. To investigate whether the role of XPF in CPT-induced transcriptional 
DSB depends on its role in Top1cc repair, we could analyse the impact of XPF depletion on Top1cc 
repair directly by measuring Top1cc levels or indirectly by measuring transcription resumption.   
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Figure 37: Possible mechanisms for generation of CPT-induced transcriptional-DSBs from a Top1cc. Formation of a DSB by a 
Top1cc-associated SSB and a second SSB created by (A) a pre-existing nick in the opposite strand, (B-D) another Top1cc in the 
opposite strand (see text for details), (E) the processing of the ssDNA exposed in a R-loop by the endonuclease XPF or (F) XPG or 
(G) by the deamination of a cytidine by an APOBEC protein followed by the generation of an AP site by UNG and the cleavage by 
the endonuclease APE1 or Mre11. Top1 is shown not proteolysed (full circle) or partially proteolysed (crescent-shaped). Red arrows 
indicate the cleavage of endonucleases and asterisk indicates the processing of a cytidine residue by the AID-UNG-APE1/Mre11 
pathway. 
 
In addition to TCR endonucleases, the ssDNA on the R-loop might be “attacked” by a cytidine 
deaminase member of the APOBEC (apolipoprotein B mRNA editing enzyme, catalytic 
polypeptide) family, of which AID (activation-induced cytidine deaminase) is a member. During 
CSR, AID promotes the conversion of cytidine to uracil specifically on ssDNA in co-transcriptional 
R-loops formed over the S (switch) regions at the Ig locus (Yu et al., 2003). Deamynated cytidine is 
deglycosylated by uracil-DNA glycosylase UNG with the subsequent creation of an abasic site, 
which can be converted in SSB by APE1 (apurinic-apirimidic endonuclease) or Mre11 
endonucleases. In B-lymphocytes, AID can initiate DSBs in a small subset of non-Ig genes (Chiarle 
et al., 2011). It has been proposed that other APOBEC members might act in a similar manner in 
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cells that do not express AID (Burns et al., 2013; Sollier and Cimprich, 2015). Hence, we may 
consider also a possible participation of this mechanism to transcriptional DSBs (Figure 37G). 
- Other factors 
We can’t exclude the participation of other factors, in particular nucleases that might cleave the 
opposite strand to Top1cc. Indeed, in post mitotic cells RNaseH1 overexpression only partially 
prevents γH2AX signal (about ≈50%) (Sordet et al., 2009) suggesting that other mechanisms in 
addition to R-loops should contribute to DSB formation. Similarly, XPF depletion does not 
completely prevent CPT-induced γH2AX foci in serum-starved quiescent cells. Therefore, it would 
be interesting to perform a siRNA screening to identify potential other factors implicated in DSB 
production.   
 
4. Genomic localization of CPT-induced transcriptional DSBs 
 
Our results show that transcriptional DSBs induced by CPT tend to form at subtelomeric regions in 
post-mitotic lymphocytes and quiescent WI38 fibroblasts (Figure III). Why CPT-induced 
transcriptional DSBs should be produced preferentially at subtelomeres? 
Subtelomeric regions can be defined as the terminal 500 Kb of each euchromatic chromosome arm 
and they are highly enriched in transcripts (Riethman et al., 2005). Thus, one possibility is that 
CPT-induced transcriptional DSBs could be preferentially localized at those regions simply because 
of the high transcriptional rate that increases the probability of collisions of stabilized Top1cc with 
ongoing RNAPII.  
Another possibility is that the sequence’s characteristics of these regions may promote CPT-
induced transcriptional DSBs. For instance, telomeric repeats may constitute a high concentration 
of nested Top1 cleavage sites, as each telomeric repeat represents a potential Top1 cleavage site in 
vivo (Kang et al., 2004). Indeed, Top1 can cleaves efficiently 5’-TT*AGGG-3’ (cleavage site 
marked by *) telomeric repeats in the presence of CPT in vitro and Top1cc have also been detected 
at telomeric repeats in vivo in CPT-treated cells (Kang et al., 2004). Subtelomeric regions are 
enriched about 25-fold in (TTAGGG)n repeats compared to elsewhere in the genome (Riethman et 
al., 2005). Subtelomeres are also G-rich regions (Riethman et al., 2005) and G clusters and G 
density are two factors that promote the formation and the stabilization of R-loops (Roy et al., 
2010). As R-loops are involved in DSBs production (Sordet et al., 2009), regions prone to R-loops 
formation may be enriched in DSBs.  
A third possibility is that transcription-associated DSBs induced by Top1cc tend to form not 
generically at subtelomeric regions but at some specific genes localized at subtelomeric regions. 
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Consistently with this hypothesis, γH2AX foci have been found enriched at IgH locus, which is 
known to form R-loops during CSR, in unstimulated splenocytes treated with CPT (Sordet et al., 
2010). The IgH genes constitute one of the subtelomeric gene families (Riethman et al., 2005).  
The precise identification of some genes or regions where transcriptional-DSBs are produced across 
the genome should be extremely useful to understand the mechanism of DSB production and 
signalling: 
- The analysis of the loci where DSBs are preferentially formed should give precious 
mechanistic information such as, for example, if DSBs are produced at convergent transcription 
units.  
- DSB localization will allow the use of ChIP or ICC/DNA-FISH at specific sites. For 
instance, it should allow the mapping of the position of RNAPII and Top1cc relatively to the DSB. 
According to the “collision model”, TC-DSBs have been predicted to occur in the 5’ region of 
actively transcribed gene not far from the promoter (Wu and Liu, 1997) as Top1cc arrests RNAPII 
early in transcription (Khobta et al., 2006). Interestingly, nucleases XPF and XPG are enriched at 
promoter of particular genes, where they induce DNA breaks, DNA demethylation and the 
establishment of active chromatin marks required for gene expression (Le May et al., 2012). Thus, 
it should be interesting to analyse directly by ChIP at a single site, factors that mechanistically may 
promote DSB production from a transcription-blocking Top1cc.  
- DNA sequence’s characteristics should give insights about the correlation between DSB 
formation and the presence of R-loops or alternative DNA structures (such as G-quadruplex). The 
availability of antibodies against anti DNA-RNA hybrids (S9.6) (Boguslawski et al., 1986) or anti 
G-quadruplex (Biffi et al., 2013; Henderson et al., 2014), should then allow the direct detection of 
those structures at sites where γH2AX is enriched after CPT-treatment by ChIP/DNA or 
immunofluorescence experiments.  
Experiments are ongoing in the laboratory to map transcriptional DSBs based on γH2AX genomic 
distribution in CPT-treated quiescent cells by using ChIP-sequencing approach. 
 
5. What are the components of the ubiquitin-proteasome system that degrade Top1? 
 
As already described in literature (Desai et al., 2003), we confirmed that CPT induces proteasomal 
degradation of Top1 in a transcription-dependent manner (Figure S2A-C, paper). Deciphering the 
ubiquitination cascade and the component of the UPS (ubiquitin-proteasome system) involved in 
Top1 downregulation is important in understanding the response of cancer cells to CPTs as 
deficient Top1 downregulation is a feature of many cancers and hypersensitizes cells to CPT (Desai 
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et al., 2001). We found that CPT treatment triggers accumulation of the E1-activating enzyme 
UBA1 (Figure 7C, paper) at chromatin supporting a role of UBA1 in catalysing Top1 
ubiquitylation as previously suggested by defects in Top1 degradation in ts85 cells (Ban et al., 
2013; Desai et al., 1997). While E2-ubiquitin conjugating enzymes for Top1 are not known, several 
E3 ligases have been implicated such as Cul3 (Lin et al., 2009; Zhang et al., 2004), Cul4A and 
Cul4B (Kerzendorfer et al., 2010). Our data confirmed that depletion of Cul3 and Cul4B prevents 
Top1 downregulation, but the effect is only partial (Figure 3A and B, paper) suggesting that other 
E3s may regulate Top1 ubiquitylation in addition to cullins. To evaluate the implication of cullins 
versus non-cullins E3-ligases, a new approach could be the use of the neddylation inhibitor 
MLN4924, which inhibits cullins’ activity (Soucy et al., 2009). siRNA or shRNA-based approaches 
do not inhibit cullins’ activity to a level comparable with MLN4924 (Brown et al., 2015). This 
could also explain the moderate effect in the prevention of Top1 degradation and γH2AX induction 
that we found with siRNA against Cul3 and Cul4B (Figure 3A-C, paper). If MLN4924 does not 
completely prevent Top1 degradation, it should mean that non-cullin E3 ligases might also directly 
ubiquitylate Top1. Accordingly with this possibility, BRCA1 depletion impairs Top1 
downregulation (Sordet et al., 2008b) and BARD1 can interact with Top1 (Trzcinska et al., 2002). 
Similarly, we observe that siRNA against RNF2 prevent Top1 degradation of the same extent than 
that one found upon cullin’s depletion (data not shown). Moreover, RNF2 can interact with Top1 
(Cao et al., 2014). BMI-RNF1, that work in the same complex of RNF2 (PCR1) (Ismail et al., 
2010), have also been described to ubiquitylate and to induce the degradation of Top2α in response 
to teniposide (Alchanati et al., 2009). Further studies should directly analyse whether 
BRCA1/BARD1 or RNF2/BMI1/RNF1 ubiquitinate Top1 in response to CPT in vivo. As 
alternative to siRNA approaches, PRT4165, an inhibitor of RNF1 and RNF2 recently described 
(Alchanati et al., 2009), could be used.  
We also report for the first time the enrichment in the chromatin fraction of the 20S proteasomal 
subunit PSMA6 and of the proteasomal activity in response to CPT (Figure 7C and 7E, paper). It 
has already been described in literature that proteasome is recruited to chromatin in response to 
DSBs (Blickwedehl et al., 2007; Butler et al., 2012; Galanty et al., 2012; Levy-Barda et al., 2011). 
Proteasome subunits also accumulate at chromatin in response to etoposide and it has been 
proposed that this recruitment is dependent on Top2cc (Ban et al., 2013). Hence, the recruitment of 
proteasome at chromatin in response to CPT may be triggered by DSB production or it may depend 
on trapped Top1cc. We tried to analyse by immunofluorescence microscopy after detergent 
extraction the co-staining of PSMA6 and γH2AX. Although PSMA6 and γH2AX colocalize into 
laser “strip” (Levy-Barda et al., 2011), we were not able to detect a signal for PSMA6 in response 
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to CPT. Then, given the low level of DSBs in our system compared to laser microirradiation and 
given the massive Top1 degradation triggered by CPT, it can be speculated that the observed 
enrichment of proteasome at chromatin may be driven by Top1 trapping rather than by DSBs.  
Proteasome accumulation at chromatin together with the requirement of Top1 proteolysis for Tdp1 
to cleave the covalent bond between the Top1 catalytic tyrosine and the 3’ end of the DNA support 
a model in which Top1 is degraded, at least in part, directly at chromatin. However, it should be 
interesting to evaluate whether the p97/VCP segregase also participates to Top1 downregulation by 
extracting Top1cc from chromatin and delivering them to the proteasome. Indeed, recently 
p97/VCP has been reported to extract Cul3/Cul4B K48-polyubiquitylated substrates from 
chromatin at UV lesion sites (Puumalainen et al., 2014). Thereby, Top1cc could be a potential 
p97/VCP substrate and the interaction between Top1 and p97/VCP has been already described (Yu 
et al., 2013). Interestingly, p97/VCP can also interact with BRCA1 (Zhang et al., 2000) and WRN 
(Indig et al., 2004) and can be phosphorylated by DNA-PK in response to DNA damage 
(Livingstone et al., 2005), all factors that control Top1 degradation (Christmann et al., 2008; Sordet 
et al., 2008b) (Figure 7A and B, paper). 
 
6. DDR signalling of CPT-induced transcriptional DSBs  
 
To study the DDR signalling activated by CPT-induced transcriptional DSBs, we analysed the three 
main kinases involved in H2AX phosphorylation, ATM, ATR and DNA-PK (Bonner et al., 2008). 
We found that ATR is not implicated in the formation of γH2AX foci in response to CPT in 
quiescent cells (Figure 5A, paper). This is consistent with ATR being expressed at low levels in 
non-cycling cells (Sordet et al., 2009) (Figure S3D, paper). In addition, although it has been 
reported that ATR can be activated by a transcriptional stress (Derheimer et al., 2007), the main role 
of ATR is in the response to replication stress (Cimprich and Cortez, 2008; Zeman and Cimprich, 
2014).  
By contrast, CPT activates both ATM and DNA-PK and their inhibition impairs γH2AX foci 
formation without preventing DSB induction as measured by neutral comet assay (Figure 5A-E, 
paper). In agreement with previous findings in post-mitotic cells, ATM is the main transducer of 
TC-DSBs (Katyal et al., 2014; Sordet et al., 2009). Although ATM and DNA-PK function 
redundantly to phosphorylate H2AX (Stiff et al., 2004), in post-mitotic cells, DNA-PK is activated 
but it does not impact γH2AX foci in response to CPT (Katyal et al., 2014; Sordet et al., 2009) 
suggesting that its role may be different in serum-starved quiescent cells versus post-mitotic cells. 
However, after CPT removal, the maintaining of γH2AX foci is dependent on DNA-PK activity in 
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quiescent astrocytes (Katyal et al., 2014) indicating that DNA-PK may be implicated in DDR also 
in post-mitotic cells.  
The functional relationship between ATM and DNA-PK in the DSB response is complex. 
ATM can phosphorylate DNA-PK in T2609 (ABCDE cluster) in response to IR (Chen et al., 2007) 
and during apoptosis (Solier et al., 2009). In post-mitotic cells (Sordet et al., 2009) and in serum-
starved quiescent cells (Figure 5D and E, paper) the activation of DNA-PK is dependent on ATM. 
We found that, in serum-starved quiescent cells, ATMi also blocks S2056 phosphorylation (Figure 
5E, paper). By contrast, we found that CPT induces DNA-PK phosphorylation on S2056 in cycling 
WI38 hTERT cells in the presence of ATMi (data not shown), as already described in HeLa cells 
(Sakasai et al., 2010b). 
The crosstalk between ATM and DNA-PK is mutual. Indeed, it has been described that depletion of 
DNA-PKcs triggers downregulation of ATM protein level (Chan et al., 1998; Gately et al., 1998; 
Peng et al., 2005). DNA-PK can also phosphorylate ATM on S1981 in apoptotic cells (Solier et al., 
2009). Moreover, we describe a new role of DNA-PK in promoting ATM localization at chromatin 
in response to CPT (Figure 5F-G, paper). DNA-PK activity is not required for ATM activation in 
response to CPT (Figure 5E, paper), but it is required for the assembly of activated ATM into 
nuclear foci and for the phosphorylation of ATM substrates (Figure 5F-G and S3F, paper). This 
role of DNA-PK is independent of its function in NHEJ (Figure S4, paper) and it is likely related 
to the function of DNA-PK in promoting H2AX and H2A ubiquitylation (Figure 6, paper), which 
is required for ATM foci formation (Facchino et al., 2010; Pan et al., 2011). 
Furthers studies are needed to clarify the complex interplay between ATM and DNA-PK and the 
differences in their reciprocal regulation in quiescent cells versus replicating cells. 
 
7. A new function of DNA-PK in promoting ubiquitylation 
 
To our knowledge, our work describes for the first time a function of DNA-PK in promoting 
ubiquitylation. We found that in response to CPT, DNA-PK activity stimulates ubiquitylation of 
histones H2A, H2AX (Figure 6A-C, paper) and Top1 proteolysis (Figure 7A and B, paper) and 
in addition, it favours the accumulation of ubiquitin-proteasome components and proteasome 
activity at chromatin (Figure 7C and E, paper). Previous studies have already suggested a possible 
connection between DNA-PK and proteasome. DNA-PK arrests transcription when the RNAPII 
machinery comes across a single DSB by a mechanism dependent on proteasome activity (Pankotai 
et al., 2012). DNA-PK activity is also required to recruit the coactivator PA200 and the 20S subunit 
of proteasome in response to high doses of IR (Blickwedehl et al., 2008). Furthermore, the 
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inhibition of proteasome by bortezomib has been reported to inhibit the formation of ATM foci in 
response to IR without blocking ATM activation (Jacquemont and Taniguchi, 2007), the same 
phenotype that we observe upon DNA-PK inhibition (Figure 5E-G, paper). This could be 
explained by a depletion of nuclear free ubiquitin pool driven by proteasome inhibition (Dantuma et 
al., 2006) that consequently leads to the loss of H2A and H2AX monoubiquitination on K119/K120 
necessary for the assembly of activated ATM into foci (Facchino et al., 2010; Pan et al., 2011). 
Some works show that the absence of H2A(X) monoubiquitination impairs foci formation of early 
DDR proteins such as γH2AX and MDC1 (Facchino et al., 2010; Pan et al., 2011) while others 
show the detection of these early markers (Ismail et al., 2010). Pan et al. explain this apparent 
discrepancy by showing that in the absence of H2A(X) monoubiquitination, the kinetic of γH2AX 
foci is just delayed after IR since at later time points (also 1 hour) H2AX is phosphorylated in a 
DNA-PK-dependent manner (Pan et al., 2011). This is consistent with our experiments: in presence 
of DNA-PKi, H2A and H2AX are not ubiquitylated, activated ATM fails to accumulate to 
chromatin and to phosphorylate H2AX and inhibited DNA-PK cannot compensate for H2AX 
phosphorylation resulting in a defect in γH2AX foci (Figure 5A-C, paper). By contrary, although 
proteasome inhibition leads to a defect in H2A(X) monoubiquitination (Dantuma et al., 2006), it 
does not impact γH2AX foci formation in response to IR and to AsiSI (Figure 3D-G, paper) as 
DNA-PK may compensate for the defect of ATM activity. 
 
How DNA-PK promotes ubiquitylation in response to CPT? 
 
It would be interesting to determine how DNA-PK regulates protein ubiquitylation. 
Phosphorylation is known to regulate protein ubiquitylation mainly in two ways (Hunter, 2007): 
- Regulation of E3 ubiquitin-ligase activity 
Phosphorylation of E3 ligases positively or negatively regulates their ubiquitin transfer activity. 
Several E3 ubiquitin ligases have been implicated in the ubiquitylation of H2AX and H2A (RNF2, 
RNF8, RNF168, BRCA1) (Doil et al., 2009; Huen et al., 2007; Pan et al., 2011; Zhu et al., 2011) 
and of Top1 (Cul3, Cul4A, Cul4B, BRCA1) (Kerzendorfer et al., 2010; Sordet et al., 2008b; Zhang 
et al., 2004). Our preliminary results show also a possible implication of RNF2 in Top1 degradation 
(data not shown). To our knowledge, it is not known whether these ligases can be phosphorylated 
by DNA-PK in vivo. One attractive hypothesis is that DNA-PK by phosphorylating RNF2 and/or 
BRCA1 may positively regulate their activity and then, these E3 ligases may ubiquitinate H2A 
and/or Top1. Some evidences in literature could support this scenario: 
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(i) RNF2 and BRCA1 can form an E3-ligase complex (RNF2-BMI1 and BARD1-BRCA1) 
(Ismail et al., 2010; Nishikawa et al., 2004), participate to DSB response and are 
recruited to chromatin (Ismail et al., 2010; Wang et al., 2007). 
(ii) RNF2 and BRCA1 can catalyse monoubiquitylation of H2A(X) (Pan et al., 2011; Zhu et 
al., 2011) and promote Top1 downregulation (data not shown) (Sordet et al., 2008b) 
(iii) RNF2 (Cao et al., 2014) and BARD1 (Trzcinska et al., 2002) can interact with Top1 
(analysed by using BioGRID v3.4 database, http://thebiogrid.org/) 
(iv) BMI1 co-purify with DNA-PK (Facchino et al., 2010). In addition, RNF2 contains three 
putative phosphorylation sites for DNA-PK in its N-terminal region (S2, T10, S20)  
(predicted by using NetPhosK v1.0, http://www.cbs.dtu.dk/services/NetPhosK/). 
BRCA1 interacts with DNA-PK via its tBRCT domains (Davis et al., 2014) and it can 
be phosphorylated by DNA-PK in vitro on S1387 and S1466 (Kim et al., 1999).  
Hence, it should be interesting to investigate whether DNA-PK can phosphorylate BRCA1 and 
RNF2 in vitro and in vivo and then, the eventual role of these phosphorylations in H2A and Top1 
ubiquitination in response to CPT. 
- Regulation of E3 ubiquitin-ligase substrate selection: creation of a phosphodegron 
Phosphorylation itself can create a recognition signal for binding of an E3 ligase thereby it is 
possible that DNA-PK phosphorylates H2A(X) and Top1 targeting them for ubiquitylation. 
Effectively, DNA-PK can phosphorylate H2AX (Stiff et al., 2004) but it is unlikely that this is what 
primes H2AX for ubiquitination because H2A lacks S139 but is also ubiquitinated in response to 
DSBs (Mosammaparast et al., 2013). By contrast this scenario is plausible for Top1. Firstly, Top1 
phosphorylation has been reported in vitro and in vivo and it seems to interest the first N-terminal 
amino acids of Top1 (Durban et al., 1985; Pommier et al., 1990). Secondly, DNA-PK interacts with 
the N-terminal domain of Top1 (Czubaty et al., 2005), which presents a potential phosphorylation 
site for DNA-PK (SQ motif on S10) (predicted by using NetPhosK v1.0). Top1 overexpressing 
cells are characterized by a lack of additional sensitivity compared to control cells and by the 
elimination of the hyperphosphorylated form of Top1 (St-Amant et al., 2006). As Top1 degradation 
is a potential mechanism of CPT resistance (Desai et al., 2001), one hypothesis is that 
phosphorylated Top1 might be targeted to degradation leading to CPT resistance. Further studies 
should be done to elucidate the role and the potential relevance of Top1 phosphorylation. Indeed, 
Top1 immunoprecipitation in presence or not of DNA-PKi and immunoblotting with an antibody 
recognizing phosphorylated serine should give a first information about the implication of DNA-PK 
in Top1 phosphorylation. If DNA-PK inhibition decreases the phosphorylation of Top1, it could be 
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interesting to generate a Top1 mutant non-phosphorylatable on S10 and analyse its ubiquitylation 
and its degradation in response to CPT. 
 
These two mechanisms of regulation are both plausible and they are not mutually exclusive. 
Furthermore, other scenarios cannot be excluded: 
- Phosphorylation can also regulates ubiquitination by regulating substrate/ligase interaction at the 
level of subcellular localization. For example, phosphorylation of p27Kip1 on S10 triggers nuclear 
export, allowing p27Kip1 to be degraded by cytoplasmic E3 ligases (Besson et al., 2006).  
- E1 and/or E2 enzyme may also be regulated by DNA-PK phosphorylation or recruited by 
phosphorylation of the substrates, as we found that DNA-PK favours the recruitment of UBA1 at 
chromatin in response to CPT (Figure 7C, paper). As the specificity of ubiquitylation reaction is 
given by E3 ligases while few E1 and E2 enzymes regulate more substrates, the DNA-PK 
dependent regulation of an E1 or an E2 should mean that DNA-PK regulates ubiquitination of many 
cellular substrates by a general mechanism.  
- Finally, phosphorylation may regulate the activity of DUBs (Villamil et al., 2012). Indeed, large-
scale phosphoproteomic analyses of human DUBs have revealed that 37 of 55 USPs are 
phosphorylated (Olsen et al., 2006).  
 
Does DNA-PK regulate the fate of stalled RNAPII at transcriptional DSBs produced by CPT? 
 
DNA-PK might also regulate RNAPII turnover in the presence of transcription-blocking DSBs. One 
possible hypothesis is that DNA-PK phosphorylates RNAPII blocked by a CPT-induced TC-DSB 
targeting it for degradation. This possibility is compatible with data of Pankotai et al. showing that 
DNA-PK controls transcription inhibition in the presence of a single endonuclease-generated 
transcriptional DSB by a proteasome-dependent mechanism (Pankotai et al., 2012). Furthermore, 
DNA-PK is able to phosphorylate RNAPII in vitro (Dvir et al., 1992). RNAPII is also rapidly 
hyperphosphorylated in response to CPT on S5 (Sordet et al., 2008b) and S2 (Dutertre et al., 2010) 
and modestly degraded at later time point (6 h) (Desai et al., 2003). As expected, our preliminary 
observations confirm that 1 h of CPT treatment induces an increase of the hyperphosphorylated 
form of RNAPII and of the S5 phosphorylation. Hyperphosphorylation of both total RNAPII and 
S5 are decreased in presence of the DNA-PK inhibitor (data not shown). However, in response to 
UV, S5 phosphorylation of the CTD blocks RNAPII ubiquitination, whereas S2 phosphorylation 
promotes its ubiquitination (Somesh et al., 2005). Hence, it should be interesting to analyse the 
effect of DNA-PK inhibition on S2 phosphorylation in response to CPT. Further studies should 
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elucidate the fate of RNAPII stalling at CPT-induced transcriptional DSBs and the mechanism of 
RNAPII degradation induced at later time points. In particular, the identification of a site where a 
CPT-induced DSB is preferentially produced may be helpful in determining where and when 
RNAPII is degraded in response to CPT and whether degradation is controlled by DNA-PK 
dependent phosphorylation.   
 
8. Caveats in studying the role of DNA-PK in the signalling of transcriptional-DSBs  
 
To study the role of DNA-PK in DDR signalling of CPT-induced transcriptional DSBs in our 
system we used NU7441, a specific inhibitor of the DNA-PK kinase activity (Leahy et al., 2004). 
DNA-PKcs autophosphorylation is required for releasing DNA-PKcs from chromatin (Uematsu et 
al., 2007). Consistently, DNA-PKi leads to strong persistence of IR-induced Ku foci (Britton et al., 
2013). During our work, we wondered whether the function of DNA-PK in CPT-induced DDR was 
related to the physical persistence of DNA-PK at DSBs as result of DNA-PK inhibition. However, 
it is not easy to answer to this point. We tried to deplete DNA-PKcs (Figure S5B, paper) or Ku70 
(data not shown) by siRNAs. In both case, given the extremely abundance of these two proteins in 
cells, siRNAs downregulate protein level only at a little extent (approximately of 40-50%). 
Furthermore, consistently with literature (Peng et al., 2005), siRNAs against DNA-PK strongly 
decrease ATM protein level making difficult to decouple ATM- and DNA-PK-dependent DDR 
signalling (data not shown). The same problem is given by the use of DNA-PK deficient cells, like 
MO59J cells (Gately et al., 1998). A good possibility will be to use DNA-PK kinase dead (KD) 
cells to confirm the results obtained by using DNA-PKi. CHO and MEFs DNA-PK-KD are 
available (Jiang et al., 2015; Shrivastav et al., 2009). Furthermore, MEFs can be induced in 
quiescence by serum-starvation (Lin et al., 2008; Lin et al., 2013).  
 
9. The cytotoxicity of CPT-induced transcriptional-DSBs 
 
Our results show that CPT-induced DSBs can kill quiescent cells by apoptosis (Figure 8, paper). 
Our findings are consistent with published studies showing that CPT induces apoptosis in a 
transcription-dependent manner in neurons (Morris and Geller, 1996; Morris et al., 2001; Stefanis et 
al., 1999). We showed for the first time that this cytotoxicity is due to transcriptional DSBs. Indeed, 
by modulating the amount of DSBs it was possible to modulate the induction of apoptosis: blocking 
DSB production by inhibiting transcription or proteasome completely prevented apoptosis (Figure 
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7A-C, paper), while increasing the number of DSBs by inhibiting PARP enhanced apoptosis 
(Figure 7D, paper). 
We also found that the main function of CPT-induced transcriptional DSB signalling is likely to 
promote cells survival as ATM or DNA-PK inhibition increases apoptosis (Figure 7E and F, 
paper). Interestingly, ATM-dependent signalling in quiescent cells has the same function in 
promoting cell survival than in G1-phase cycling cells (Sakasai et al., 2010a) while in neurons 
ATM promotes cell-cycle re-entry and apoptosis (Tian et al., 2009).  
 
Speculations about the possible implication of our findings in neurodegenerative syndromes  
 
Transcriptional DSBs might occur spontaneously in cells as Top1cc are stabilized by common DNA 
alterations such as DNA nicks, gaps, mismatches, abasic sites or misincorporated ribonucleotides 
(Kim et al., 2011; Pourquier and Pommier, 2001). Therefore, stabilized Top1cc may have a marked 
impact on non-replicating cell fate. Hence, it could be speculated that defective repair of Top1cc 
could lead to the accumulation of transcriptional DSBs that may be involved in neuronal death in 
AT (ATM deficiency) and SCAN1 (Tdp1 deficiency) patients. Indeed, these syndromes are both 
characterized by neurodegeneration and apparition of neurological defects relatively late, in 
childhood for AT and in the teenage years for SCAN1 patients (Rass et al., 2007). Neurons may be 
more relying on Top1cc-repair by the Tdp1 excision pathway compared to replicating cells and they 
may have particular tissue-specific features that increase the probability of Top1 trapping, such as 
(i) the high oxygen consumption that results in the high level of oxidative stress that can stabilize 
Top1, (ii) the high transcriptional rate which may increase the conversion of reversible Top1cc into 
suicide complex and (iii) the lack of replication that may impede to repair Top1cc by other repair 
pathways during replication such as helicase pathway, HR or NHEJ (Rass et al., 2007). We can 
speculate that AT and SCAN1 patients might accumulate unrepaired Top1cc trapped by 
endogenous DNA alterations that may be converted at very low frequencies into cytotoxic 
transcriptional-DSBs that accumulate over years.  
This hypothesis is consistent with our data showing that Tdp1 depletion increases the induction of 
transcriptional DSBs produced by stabilized Top1cc (Figure 4A and B, paper) and that few DSBs 
are able to kill quiescent cells (Figure 8, paper). Evidences in literature could also be consistent 
with this possibility, (i) both Tdp1 and ATM participate to Top1cc repair (Alagoz et al., 2013; El-
Khamisy et al., 2005) (ii) Tdp1 or ATM deficient neural tissues accumulate endogenous Top1cc 
compared to control tissues (Katyal et al., 2014), (iii) AT cells have higher endogenous level of 
Top1cc that are dependent on both transcription and ROS (Alagoz et al., 2013), (iv) ATM regulates 
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the level of ROS (Guo et al., 2010; Ito et al., 2004) and (v) DSBs in neurons can physiologically be 
produced as result of brain activity (Suberbielle et al., 2013). 
Hence, it will be interesting to test the possible involvement of transcriptional DSBs in AT and 
SCAN1 pathologies by using neurons, neurons-like cells or astrocytes as cellular model.  
 
Speculations about the possible implication of our findings in cancer therapy  
 
In highly proliferative cancer cells, replication-induced DSBs are the primary cytotoxic mechanism 
of Top1 inhibitors (Holm et al., 1989; Horwitz and Horwitz, 1973). Hence, at clinical 
concentrations it is unlikely that transcriptional DSBs per se contribute to CPTs cytotoxicity in 
cancer cells (Borovitskaya and D'Arpa, 1998). Furthermore, the RC-DSBs-dependent cytotoxicity 
of CPT allows a S-phase-selective targeting of highly replicating tumour cells limiting side effects 
on slow-cycling nontransformed cells. Nevertheless, transcriptional implications associated with 
CPT-induced Top1 trapping may be relevant in cancer therapy:  
- Top1 proteolysis: As already discussed, CPT-induced Top1 degradation is a mechanism of 
CPT resistance (Desai et al., 2001). Cancer cells are often deficient in Top1 degradation and more 
sensible to Top1 inhibitors (Desai et al., 2001). Deficiencies in Top1 degradation pathway should 
trigger a hypersensitivity to CPTs. For instance, CPT treatment may likely be beneficial in tumour 
with deficiencies in ATM or DNA-PK activity, not only because of the role of ATM and DNA-PK 
in DSB signalling and repair but also for their possible role in Top1 downregulation. Thus, it should 
be interesting to test whether ATM or DNA-PK depletion prevents Top1 downregulation in 
replicating cells such as in quiescent cells (Figure 7A and B, S5D and F, paper) (Alagoz et al., 
2013; Katyal et al., 2014).  
- Transcriptional-DSBs: The proteasome inhibitor bortezomib (Velcade) is approved in 
therapy for the treatment of multiple myeloma and lymphoma. Proteasome inhibition by bortezomib 
potentiates specifically CPT- (or irinotecan-) induced S-phase cytotoxicity (Zhang et al., 2004). By 
contrast, we show that proteasome inhibition blocks CPT-induced apoptosis in quiescent fibroblasts 
(Figure 8C, paper). It should be speculated that combining bortezomib with CPT derivatives might 
kill more tumours cells increasing CPT selectivity. A number of clinical trials have been done or are 
ongoing for this combination in different types of tumours (clinicaltrials.gov). It would be also 
interesting to test the combination of bortezomib, CPTs and olaparib, a PARP inhibitor recently 
approved in cancer therapy. PARP inhibitors (PARPi) potentiate the cytotoxicity of CPT in cancer 
cells (Zhang et al., 2011). We show that PARP inhibition also enhances CPT-dependent apoptosis 
in quiescent cells (Figure 8D, paper) by increasing the amount of transcriptional-DSBs (Figure 4C 
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and D, paper) and our preliminary experiments suggest that DSBs could be produced by the same 
mechanism in G1- and G2-phase cells (Figure IVC-E). Inhibiting proteasome may prevent CPT 
and PARPi cytotoxicity in non-S-phase cells thereby leading to enhanced cell killing specifically in 
S-phase.   
- CPT-induced transcriptional-SSBs during replication: It could be also possible that some 
replication-coupled DSBs produced in response to CPT are dependent on transcription. 
Transcriptional-SSBs generated during Tdp1-excision pathway could be converted in DSBs during 
replication. This scenario is consistent with evidences in literature: (i) Tdp1 deficiency or PARP 
inhibition results in CPT hypersensitivity in replicating cells (Interthal et al., 2005b; Miao et al., 
2006; Zhang et al., 2011), (ii) deficient Top1 proteolysis decreases the induction of RC-DSBs and 
γH2AX signal in response to CPT in replicating cells (Lin et al., 2009) (Figure IVC-E) and (iii) 
transcription-dependent activation of ATM activates the G1/S checkpoint in response to CPT likely 
to avoid the conversion of transcriptional-SSBs carried over from G1 to S-phase in DSBs during 
replication (Sakasai et al., 2010a). Furthermore, cells depleted for Top1 accumulate DSBs in 
particular in actively transcribed genes as a result of the frequent interference between replication 
and transcription (Tuduri et al., 2009). 
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3. ABSTRACT  
 
Topoisomerase I-DNA-cleavage complexes (Top1cc) stabilized by camptothecin (CPT) have 
specific effects at transcriptional levels. We recently reported that Top1cc increase antisense 
transcript levels (aRNAs) at bidirectional CpG-island promoters (CGI) and, transiently, DNA/RNA 
hybrids (R-loop) in nuclear and mitochondrial genomes of colon cancer HCT116 cells. However, 
the relationship between R-loops and aRNAs was not established. Here, we show that aRNAs can 
form R-loops under physiological conditions in HCT116 cells, and that Top1cc stabilize promoter-
associated R-loops immediately upon cell exposure to CPT. In contrast, persistent Top1cc reduce 
the majority of R-loops suggesting that CPT-accumulated aRNAs are not commonly involved in R-
loops. The enhancement of aRNAs by Top1ccs is present both in human colon cancer HCT116 cells  
and WI38 fibroblasts suggesting a common response of cancer and normal cells. Although Top1ccs 
lead to DSB and DDR activation, we do not reveal a correlation between aRNA accumulation and 
ATM or DNAPK activity. Moreover, the cell response to persistent Top1cc can involve an 
impairment of aRNA turnover rather than a higher synthesis rate. Finally, a genome-wide analysis 
shows that persistent Top1cc also determine an accumulation of sense transcripts at 5’-end gene 
regions suggesting an increased occurrence of truncated transcripts. Taken together, these results 
indicate that Top1 may regulate transcription initiation by modulating RNA polymerase-generated 
negative supercoils, which can in turn favor R-loop formation at promoters, and that transcript 
accumulation at TSS is a response to persistent transcriptional stress by Top1 poisoning. 
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5. INTRODUCTION 
 
Topoisomerase I (Top1) is a fundamental enzyme regulating DNA superhelicity, and its activity is 
required for a proper progression of transcription and replication machineries in mammalian cells. 
Enzyme activity can essentially be divided in four steps: substrate binding, DNA cleavage, 
controlled rotation of the cut strand around the other one, and DNA resealing. Top1 poisons, such 
as camptothecin (CPT), inhibit Top1 by binding at the interface of a Top1-DNA complex forming a 
ternary structure (Top1cc) in which the drug molecule prevents DNA resealing and leaves Top1 
covalently bound to a DNA strand (Pommier, 2006). Top1cc can lead to irreversible DNA damage 
when a collision occurs with replication forks or elongating RNA polymerases (RNA Pol) 
(Capranico et al., 2010; Pommier et al., 2006). The replication-dependent irreversible DNA damage 
is commonly considered the molecular mechanisms of CPT cytotoxicity and hence antitumor 
activity, as it can act as a potent inducer of apoptosis of cancer cells (Li and Liu, 2001).  
 In addition to the cell killing activity, Top1 poisons have specific effects at transcriptional 
levels that may impact gene expression profiles of normal and/or cancer cells contributing to drug 
therapeutic outcomes (Baranello et al., 2009; Capranico et al., 2010; Marinello et al., 2013; Solier et 
al., 2013; Sordet et al., 2008; Veloso et al., 2013). Recently, treatments with Top1 poisons have 
been shown to de-repress the paternal Ube3A allele in an Angelman disease murine model (Huang 
et al., 2011) providing an interesting case in which CPT derivatives can permanently change the 
expression of a specific gene in mammalian cells. Thus, understanding the mechanisms of Top1 
regulation of gene expression and the interference of Top1 inhibitors with them can provide 
significant insights to discover new anticancer therapeutics. 
 Top1 is a very active enzyme at transcribed regions (Champoux, 2001; Khobta et al., 2006; 
Wang, 2002). Recently, it has been reported that Top1 mainly regulates DNA superhelicity at 
intermediately-active genes as its inhibition by CPT increased local negative supercoils at their 
promoters (Kouzine et al., 2013). Interestingly, we have demonstrated that CPT impacts 
transcription regulation with characteristic and specific effects on RNA Pol II recruitment and 
pausing, nucleosome density and promoter-associated antisense RNA levels (Baranello et al., 2009; 
Bertozzi et al., 2011; Capranico et al., 2010). In particular, a genome-wide analysis revealed that 
CPT increases antisense transcripts levels at active divergent CpG-island promoters (CGI) in a 
manner dependent on Top1cc formation at the promoter (Marinello et al., 2013). Whether the 
increase in negative DNA supercoils at promoters is mechanistically linked to the specific effects on 
RNA PolII and antisense transcripts was left to be defined. 
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 Top1 silencing is known to increase non-B DNA structures, such as R loops, that are prone to 
DNA damage and genome instability (Costantino and Koshland, 2015; El Hage et al., 2010; Groh 
and Gromak, 2014). R loops are three-strand structures constituted by a DNA-RNA hybrid duplex 
and a displaced DNA strand. Stable R-loops exist in living prokaryotic and eukaryotic cells at origin 
of replication where they have a role in the regulation of replication initiation (Lombrana et al., 
2015; Sollier and Cimprich, 2015; Stuckey et al., 2015). R loops also constitute a necessary step of 
the immunoglobulin recombination mechanism as they form at IgG class switch regions where they 
can extend over a kilobase (Roy et al., 2008; Yu et al., 2003). Moreover, differential stabilization of 
R-loops could influence gene expression in many organisms. For instance, R-loop structures allow 
the presence of the substrate for a single-strand DNA binding protein that represses the expression 
of COOLAIR ncRNA in Arabidopsis (Sun et al., 2013). In addition, R-loops can be enriched over 
human CGI and involved in maintaining their hypomethylated state (Ginno et al., 2012). Gene 
mutations affecting nucleic acid degradation have recently been shown to cause global DNA 
hypomethylation and R-loop accumulation in fibroblasts of patients with autoimmune disorders 
(Lim et al., 2015). Interestingly, Top1 poisoning by CPT can induce specific double-stranded DNA 
cleavage in post-mitotic cells that can be suppressed by the overexpression of RNaseH1, suggesting 
the involvement of transcriptionally-linked R loops in CPT induction of DNA damage (Sordet et 
al., 2009). Increased R-loop levels by CPT have been shown at specific loci such as Angelman 
imprinting locus and Fragile X syndrome site (Groh et al., 2014; Powell et al., 2013). With a time 
course analysis in human colon cancer cells by confocal cell microscopy, we showed that CPT 
effects on R-loops are highly dynamic as it triggers a transient increase of global R-loops in the 
nuclear and mitochondrial genomes (Marinello et al., 2013). However, the genomic location of such 
dynamic R-loop structures and their relationships with aRNA have not been established yet.  
 Therefore, we have here asked whether CPT-increased antisense transcripts can form R loops 
with DNA template at promoters. Our findings show that Top1 inhibition by CPT specifically 
impacts on RNA Pol II activity at promoters by affecting R-loop formation and that antisense and 
sense transcripts are likely accumulated by persistent Top1ccs due to the inhibition of their 
degradation.  
 
 
 
 
 
 
 6 
6. MATERIALS AND METHODS 
 
Cell Lines. The cancer cell lines HCT116 and N-Tera-2 cl.D1 were purchased from ATCC (LGC 
Standards S.r.l., Milan, Italy) and were grown in DMEM medium with 10% fetal bovine serum 
(Carlo Erba, Milan, Italy). Cells were maintained at 37° C in a humidified incubator containing 
20% O2 and 5% CO2. Cell line identity was certified with Cell ID System (Promega) by BMR 
Genomics Srl (Padova, Italy). Immortalized WI-38 human embryonic fibroblasts (WI-38hTERT) 
were obtained from Carl Mann (CEA, Gif-sur-Yvette, France) and Estelle Nicolas (Université de 
Toulouse, Toulouse, France) (Jeanblanc et al., 2012).  WI-38hTERT cells were cultured in modified 
Eagle's medium (MEM) supplemented with 10% fetal bovine serum, 1 mM sodium pyruvate, 2 mM 
L-glutamine and 0.1 mM MEM non-essential amino acids (Life Technologies). For quiescence 
induction, cells were washed twice with serum-free medium and grown in MEM with 0.2% serum 
for 72 h.  
 
Drugs and cell treatments. CPT and flavopiridol were purchased from Sigma-Aldrich. ATM 
inhibitor (KU55933) and DNA-PK inhibitor (NU7441) were obtained from Calbiochem and Tocris 
respectively. Serum-starved or exponentially growing cells were exposed to 10 μM CPT for the 
indicated time at 37° C, unless specified otherwise. In case of co-treatments, cells were previously 
incubated with various inhibitors for 1 h before the addition of CPT to the medium for further 4 
hours. 
 
RNA extraction and cDNA preparation. Total cellular RNA was purified with the acid phenol 
method  (Bertozzi et al., 2011; Bertozzi et al., 2013) and quantified by UV absorbance. After 
verifying its quality on a 1% agarose gel, 1 µg of total RNA was used to prepare cDNA using 
SuperScript III (Invitrogen) following the manufacturer’s instruction. Random (N6) and poly(T) 
primers were used for total RNA retrotranscription. Reactions included a 25°C pre-annealing step 
for 5 min, and then retrotranscription was performed at 50°C for 50 min. 
 
Quantitative Real-Time PCR. Real-time PCR were performed using Applied Biosystems StepOne 
and SYBR Select Master Mix for CFX (Applied Biosystems). Quantification and melting curve 
analyses were performed using StepOne Software v2.2.3 as indicated by the supplier. Specificity of 
PCR products was routinely controlled by melting curve analysis and agarose gel electrophoresis. 
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Expression and purification of MBP-RNAse H1 (D145N). Protocol was obtained from Ginno et al 
2012 (Ginno et al., 2012) and the plasmid expressing a mutated and inactive RNAseH1 was kindly 
provided by F. Chedin (University of California, DAVIS). In particular, transformed Rosetta 
2(DE3) cells of  E. coli were inoculated in LB medium  supplemented with 2 g/L of glucose, 100 
μg/mL of ampicillin, and 30 μg/mL of chloramphenicol. After induction for 4 hours with IPTG, 
cells were pelletted and lysed using for 80 ml of cell culture, 1.2 ml of lysis buffer [200 mM NaCl; 
20 mM Tris-HCl (pH 7.5); 1 mM EDTA; 10 mM DTT; Aprotinin 2 μg/ml; Leupeptin 1 μg/ml; 
Pepstatin 1 μg/ml; PMSF 1 mM and Lysozym 200 μg/ml]. Lysate was sonicated for 10 min with 30 
sec on/off cycles and finally centrifuged at 4°C, 14000g for 20’. The isolation of MBP-fusion 
protein was performed with Amylose Magnetic Beads (New England Biolabs). In particular 100 µl 
of beads suspension were equilibrated twice with 500 µl of MBP column buffer [200 mM NaCl; 20 
mM Tris-HCl (pH 7.4); 1 mM EDTA and 1 mM DTT] thus incubated with 500 µl of cell culture 
supernatant at 4° C with agitation for 1 hour. Supernatant was discarded and beads washed three 
times with 500 µl of MBP column buffer. The purified MBP-RNAse H1 (D145N) was eluted from 
the beads twice with 50 µl of MBP column buffer containing 10 mM maltose for 10 minutes at 4° C 
with agitation. Alternatively MBP-RNAse H1 (D145N) was purified using Amylose Resin (New 
England Biolabs). In particular, 1 ml resin was poured in a column and washed with 5 column 
volumes of MBP column buffer. Crude extract was loaded after 1:1 dilution with MBP column 
buffer and the resin was washed with 12 column volumes of MBP column buffer. Elution of the 
fusion protein was performed with 5 volumes MBP column buffer containing 10 mM maltose. 
Purified protein was concentrated with a centrifugal filter unit (Millipore). 
 
DRIVE (DNA:RNA In Vitro Enrichment). The procedure was performed as in Ginno et al (Ginno 
et al., 2012). In particular, lysis of ~4x106 NTera-2 cl.D1 cells was performed with 1.6 ml TE-SDS 
Lysis Buffer  [10 mM Tris-HCl (pH 8.0); 1mM EDTA and 0.5% SDS] at 37° C for 5 min. 
Proteinase K was then added (125 ng/µl) and samples incubated for 5 h at 37° C. An equal volume 
of phenol (pH 8.0) was added and the samples were mixed gently, thus centrifuged at 3000g for 2 
min. The upper phase was collected and an equal volume of chloroform/isoamylic alcohol (24:1) 
was added to it, then mixed gently and centrifuged again at 3000g for 2 min. Genomic DNA was 
precipitated with 2.5 volumes of ethanol 100% and 1/10 volume of NaOAc 3M (pH 5.2), in 
presence of glycogen. Using a hooked glass rod, DNA were spooled out and washed several times 
with 70% EtOH. Genomic DNA was resuspended in 500µl of TE buffer [10 mM Tris-HCl (pH 
8.0); 1 mM EDTA] avoiding vortexing to preserve RNA/DNA hybrids. Genomic DNA was then 
digested O/N at 37° C in TANGO BUFFER 2X with 2 mM Spermidine and a cocktail of restriction 
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enzymes: 20 U EcoRI; 20 U Xbal; 20 U Hind III; 20 U SspI and 20 U BsrG1 (ThermoFisher 
Scientific). Each sample was thus splitted in three: 1,5 µg were used as input, 1,5 µg were incubated 
for 2 hours at 37° C with 10U of RNAse H and 1,5 µg were incubated for 2 hours at 37° C without 
RNAse H (Life Technologies). Samples incubated with or without RNAseH were added of 50 µl of 
Binding Buffer 10x [100 mM Na2PO4 (pH 7.0); 1.4 M NaCl; 0.5% Triton X-100], MBP-RNAse H 
D145N (w/w ratio according titration) and TE buffer (pH 7.4) to final volume of 500 µl. RNAse H 
D145N was allowed to bind specifically for 2 hours at 4° C on agitation. 50 µl/sample Amylose 
Magnetic Beads (New England Biolabs) were equilibrated twice with 500 µl of MBP column buffer 
[200 mM NaCl; 20 mM Tris-HCl (pH 7.4); 1 mM EDTA and 1 mM DTT], then incubated with 500 
µl of reaction mix at 4° C with agitation for 75 min. Supernatant was discarded and beads washed 
three times with 500 µl of MBP column buffer.  The purified MBP-RNAse H1 (D145N) bound to 
RNA/DNA hybrid was eluted from the beads twice with 100 µl of MBP column buffer containing 
10 mM maltose for 10 minutes at 4° C with agitation. TE (pH 7.4) and SDS (final concentration 
0.5%) were added to a final volume of 250 µl. 140 µg of Proteinase K were added  and samples 
incubated at 55° C for 45 min. Samples, included inputs, were thus brought to 300 µl final volume 
with BDW and phenol/chloroform extraction was performed. To allow precipitation 2,5 volumes of 
ethanol 100%, 1/10 volume of NaOAc 3M (pH 5.2) and glycogen were added and samples were 
incubated O/N at -20° C. For data analysis, RNA/DNA hybrid enrichment of each sample is 
calculated as “% of Input” after subtracting the background signal, as determined by the same 
sample treated with RNAseH1 before DRIVE precipitation. Then the enrichment value is 
normalized against the 2-min CPT sample of the RPL13A amplicon of the same experiment. 
 
Bioinformatics analysis. Due to update versions of specific softwares for RNA-Seq analysis, we re-
align raw data of previous published experiments (Marinello et al., 2013) to improve revious 
results. Then, we checked the quality of each sequenced sample using FastQC 
(http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). Low-quality sequenced bases were 
filtered out using Trimmomatic v0.33 (Bolger et al., 2014). The bisulfite-treated paired reads were 
then mapped twice to the hg19 human genome assembly in which all the cytosines were mutated in 
thymines (CT-hg19) or all the guanine in adenine (GA-hg19) to identify the strand originating the 
sequence fragment. Sequences coming from positive strand transcripts align to the CT-hg19, 
whereas negative strand transcripts align to the GA-hg19. The read alignment was carried out with 
Bowtie2 v2.2.0 (Langmead and Salzberg, 2012) and TopHat v2.0.10 (Kim et al., 2013; Trapnell et 
al., 2009) to identify known transcripts. For each of the four experiments, reads that aligned to both 
CT-hg19 and GA-hg19 were discarded. Cufflinks package v2.2.0 (Trapnell et al., 2010) was used to 
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assemble and identify novel transcripts, using modified reference genomes (CT-hg19 and GA-
hg19). Gene expression levels were estimated in FPKM units (expected number of Fragments Per 
Kilobase of transcript sequence per Millions of sequenced nucleotides) using Cufflinks. Sense tags 
distribution, along non-overlapping Refseq genes, were analyzed in a region from 2000 bases 
upstream the TSS (Transcription Start Site) to 2000 bases downstream the TES using NGSplot 
software v2.41 (Shen et al., 2014).  
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7. RESULTS 
 
Increased antisense transcripts form R-loops in untreated cells. Both immunofluorescence 
imaging and RNAseH1 overexpression experiments have previously demonstrated that CPT-
trapped Top1ccs induce a significant increase of R-loop structures that likely mediate drug-induced 
genome instability (Marinello et al., 2013; Sordet et al., 2009). However, the genomic sites of such 
R-loops are not known. Here, we used the DRIVE technique (Ginno et al., 2013; Ginno et al., 2012) 
to determine whether or not R-loops form under physiological conditions at divergent promoters in 
human NTERA-2 cells. First of all, we analyzed previously-published R-loop positive and negative 
loci (Ginno et al., 2012) to check the DRIVE method. Figure 1A (white bars) shows we could 
clearly discriminate between regions known to form (RPL13A, BTBD19 and MYADM) and those 
depleted of (SNRPN and a-Sat) R-loops as a significant recovery is shown at the former rather than 
the latter loci. Moreover, we determined R-loop levels at the D-loop region of mitochondrial 
genome (mtDNA), where a well-known and stable R-loop is implicated in replication priming of 
mtDNA (Xu and Clayton, 1996). Of the three selected regions, the RB31-R3 amplicon corresponds 
exactly to the R-loop-forming site while 1A-1B and 4A-4B amplicons correspond to the D-loop and 
a more distant region, respectively (Figure1B, map). The two non R-loop-forming regions show a 
recovery significantly lower as compared with RB31-R3 (Figure 1B). Overall, the data showed that 
we can accurately detect R-loops with the DRIVE technique in mitochondrial and nuclear genomes. 
Next, we asked whether divergent promoters might form R-loops under physiological 
conditions in untreated NTERA-2 cells. To that purpose, promoters were selected on the basis of 
their ability to show increase of antisense transcripts after Top1 inhibition by CPT, as reported in 
Fig. 1C. Therefore, we investigated 8 promoters (TAF4, POLR2K, SP2, GPC1, MDM2, PCIF1, 
ATF1, SMARCA4) showing an increase of aRNA and one negative promoter (TNIK) with no 
aRNA increase (Fig. 1C)(Marinello et al., 2013). The results show that we can detect R-loops in 
untreated cells at all positive promoters, though at different levels, whereas no signal was present at 
the TNIK promoter (Fig. 1A). Even though DNA enrichment values for the 8 promoter regions are 
lower than mtDNA sites and other positive controls (RPL13A, BTBD19 and MYADM), they are 
consistently higher than negative controls (SNRPN, a-Sat and TNIK). We may notice that the 
studied sites correspond to promoter regions upstream to the TSS (Transcription Start Site) where 
we detected antisense transcripts in control untreated cells, the levels of which are marked lower 
than mRNAs (Marinello et al., 2013). In contrast, the RPL13A, BTBD19 and MYADM control 
regions correspond to the first intron of transcribed genes, hence, in the latter case R-loops are at 
regions of higher transcription rates. As these R-loops are likely associated with the transcription 
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process (Ginno et al., 2012), the results may suggest that R-loop formation rate correlates with 
transcription levels in the studied regions. 
Taken together, the results show that antisense transcripts of the studied divergent promoters 
are able to form R-loops in untreated cells that are likely in the opposite orientation as compared 
with mRNAs transcription. 
 
Promoter-associated antisense R loops can be transiently increased by CPT and then 
markedly reduced with longer treatment times. Next, we have investigated whether Top1 inhibition 
by CPT increases R-loop levels at the studied promoters and control regions. We found that the R-
loop signal increases after 2-10 minutes from drug addition, and R-loops are maintained up to 4 
hours of CPT treatment at the mitochondrial replication origin (Fig. 2A). Mitochondrial non-R-
loop-forming regions show recoveries unchanged by CPT and significantly lower than the R-loop-
forming region. Therefore, the R loop at the mitochondrial replication origin is substantially stable 
in the presence of a Top1 poison, which can even increase its level at short treatment times. 
A different pattern was observed for R-loops at the transcribed RPL13A, BTBD19 and 
MYADM nuclear loci. Here, R-loops are maintained, or slightly increased, after short times (2 and 
10 minutes), whereas they are markedly reduced after longer time of treatment (4 hours) (Figure 
2A). Similarly, antisense R-loops at the studied divergent promoters show an increase of their levels 
after short treatment time whereas they are completely lost after 4 hours of treatment, with the 
exception of TAF4 promoter (Fig. 2A). Thus, Top1 inhibition by CPT can stabilize antisense and 
sense R-loops at active divergent promoters but only for a short time. 
We next wondered whether CPT treatment could affect the length of the DNA-RNA hybrid. 
Thus, we investigated close regions at two of the studied promoters: TAF4 and PCIF1 (Figure 2B). 
These two gene promoters were chosen as they also present GC skew segments that can be prone to 
R-loop formation (Ginno et al., 2013). Interestingly, at short times of treatment, CPT determines an 
extension of R loops or formation of new R-loops, as after 2 minutes the R-loop signal was also 
detected in TAF4(4) and PCIF1(2) amplicons (Figure 2B). Therefore, CPT can likely modulate R-
loops length at these two promoters. Taken together, our findings show that following a short time 
of treatments, CPT can modify R-loops present in untreated cells while longer CPT treatments 
almost fully abolish R-loops at the studied transcribed genes. The results thus suggest that Top1 
may modulate R-loop levels by controlling the levels of negative supercoils at promoter regions 
(Kouzine et al., 2013). 
Therefore, all the above results show that Top1ccs likely stabilize and extend antisense R-
loops for a very short time at the studied divergent promoters. With persistent Top1ccs, the majority 
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of R-loops are mostly reduced at these loci suggesting that the accumulated antisense transcripts are 
not generally involved in R-loop structures. As CPT inhibits transcription elongation with high 
efficacy and R loops are formed by newly synthesized RNAs, the marked reduction of R loops at 
active regions is likely due to persistent inhibition of transcription by CPT. Interestingly, our data 
show exceptions to that as R-loops can persist for long times of CPT treatment at certain genomic 
loci (TAF4 and mtDNA). 
 
Antisense transcripts are increased by CPT in human resting normal WI38 cells and are 
dependent on ongoing transcription. Next, we further characterized aRNAs. In particular we asked 
if their induction was dependent or not on transcription and specific of cancer vs normal cells, and 
finally if their increase was dependent on Top1cc DSBs formation. To understand whether ongoing 
transcription is critical for increased levels of promoter-associated antisense RNAs, we have 
investigated CPT effects in resting cells and in the presence of flavopiridol (FLV), a specific 
inhibitor of cdk9 and RNA PolII transcription. As Top1ccs specifically increase antisense 
transcripts upstream to the TSS of divergent CGI promoters in human colon cancer HTC116 cells 
(Marinello et al., 2013), here we extended the study to human fibroblast-like embryonic cells 
(WI38) at genomic loci selected on previous findings (Marinello et al., 2013). Treatments with 10 
µM CPT in replicating WI38 cells stimulates antisense accumulation in four out of seven of the 
selected loci (Fig 3), showing that CPT stimulates antisense transcription in non-cancer cells as 
well. However, the promoter pattern of antisense accumulation is different between the two cell 
lines, and the CPT effects are lower in WI38 than HCT116 cells at the selected loci. 
To evaluate the role of replication on drug effects, we studied the CPT response in serum-
starved quiescent WI38 cells (Figure 3, quiescent WI38). Among the studied loci, ATF1 gene 
promoter accumulates antisense transcripts at the highest levels in both proliferating and resting 
cells. As in resting cells the enhancement of antisense transcript levels was partially reduced and 
this reduction could be due to a lower transcription rate in quiescent as compared with replicating 
cells, we suggest that the CPT effect may be independent from DNA replication. In serum-starved 
quiescent WI38 cells, we performed a drug dose-response after 1 and 4 hours of treatment 
(Supplementary Figure 1) showing some increase over time. To determine the role of transcription 
on CPT effects, we pretreated for 1 hour quiescent WI38 cells with FLV. Under these conditions, 
no increase of antisense transcript could be detected at the selected loci (Supplementary Figure 2), 
showing that the drug effect is highly dependent on active transcription in resting human cells. 
As transcription-blocking Top1ccs produce DSBs and activate ATM in post-mitotic neurons 
and lymphocytes (Sordet et al., 2010; Sordet et al., 2009), we next investigated if accumulation of 
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antisense RNAs could potentially be due to activation of selected kinases (DNA-PK and ATM) of 
the DNA damage response (DDR) after Top1cc interference with transcription. Cells were first 
exposed to ATM inhibitor or DNAPK inhibitor for 1 hour, and then CPT was added to the medium 
for additional 4 hours, in both HCT116 and WI38 cell lines. In all tested conditions, inhibition of 
the studied DDR kinases did not significantly alter CPT effects on antisense accumulation 
(Supplementary Figure 3). Therefore, the data suggest that ATM or DNA-PK activation is not 
apparently required for CPT effects. The data did not allow us to establish a direct connection 
between increased antisense RNAs and DDR pathways, however, we cannot exclude that other 
DDR proteins are involved or that the studied kinases act redundantly in the mechanisms of 
antisense accumulation. 
To determine if CPT actively modify the turnover of antisense RNAs, we treated HCT116 
cell with CPT for 4 hours, and then determine the levels of the studied transcripts at different times 
to evaluate their degradation rates. The experiments were performed adding FLV at the end of the 4 
hour period of CPT treatment to block transcription. Under these conditions, the degradation rates 
of TDG and TAF4 antisense transcripts (Fig. 4) and others (see Supplementary figure 5) are lower 
in the presence of CPT and the transcripts are lost faster in drug-free medium (Supplementary 
figure 4). Thus, the data clearly show that CPT seems to stabilize antisense RNAs, likely preventing 
their fast removal and degradation. 
 
CPT determines the accumulation of truncated sense transcripts at 5’-end regions of 
intermediately active genes. The above findings show that persistent Top1 inhibition by CPT 
promotes the stabilization of antisense transcripts upstream to the TSS and a general reduction of 
antisense R-loops at those loci after long treatment time. As R-loops have been shown to form also 
downstream the TSS (Ginno et al., 2013; Ginno et al., 2012) (see also Fig 1A), we have then 
investigated whether CPT induced the accumulation of sense transcripts at the 5’-end of genes as 
well. We have then mapped paired sequence tags obtained from total cellular RNA depleted of 
ribosomal RNAs and treated with bisulfite to maintain the information of strand direction 
(Marinello et al., 2013). Non overlapping genes were grouped depending on their FPKM in four 
categories from low to high expression levels, and we focused on gene regions from -2000 bases 
upstream the TSS to +2000 bases downstream the TES (transcription end site) in both CPT-treated 
and control HCT116 cells. Then we plotted the distribution of the sense reads along these genes. 
Sense tag levels of all non-overlapping genes were clearly dependent on gene expression 
levels, however they were similar among expressed gene sets (Supplementary Figs. 6 and 7). Tag 
distribution of control cells almost overlapped with that of CPT-treated cells with the exception of 
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the region immediately downstream to the TSS in HCT116 cells (Supplementary Fig. 6). In 
particular, sense tags were increased at the 5’-end of genes of the two intermediate expression 
categories following CPT treatment (Supplementary Fig. 6). The increased was lower in HCT116-
shRNATop1 cells indicating that it was dependent on the cellular level of Top1 in response to CPT 
(Supplementary Fig. 7).  
Thus, as the intermediately active genes show such a drug effect, we selected genes showing 
an increase of sense reads within the first 1000 bases downstream the TSS as well as reduced or 
equal levels of sense reads 1000 bases upstream the TES (Figure 5). For these genes we observed a 
marked and specific increase of sense tags (Figure 5) in the two gene sets that was clearly 
dependent on Top1 as in HCT116-shRNATop1 CPT had a lower effect (Fig. 5). The specific 
accumulation of sense tags at 5’-end regions was then confirmed at specific loci by rtqPCR 
(Supplementary Figures 8 and 9). Gene ontology analyses of the two gene sets did not reveal any 
significant gene attribute enriched in the studied groups (splice variants were enriched but with a 
low p-value), suggesting the lack of a simple common functional or structural characteristic among 
them. 
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8. DISCUSSION 
A fine regulation of Top1 activity at active genes is essential to maintain a proper transcription 
process as Top1 deficient cells show impaired transcriptional processes and accumulate abortive 
transcripts by RNA PolI (El Hage et al., 2010). We have previously demonstrated that Top1 
inhibition by CPT leads to unbalanced sense/antisense transcript levels at bidirectional CpG-island 
promoters (Marinello et al., 2013). The newly-identified antisense transcripts, with a median size of 
about 800 bases, are accumulated during drug treatment in a Top1-dependent manner mainly at 
promoters of intermediate activity. In the present work, we aimed to better characterize these aRNA 
and to establish a relationship between them and R-loop formation at divergent promoters. Our data 
show that aRNAs can form antisense R-loops at promoters in unperturbed NTERA-2 cells and that, 
immediately after Top1 inhibition by CPT, the physiological R-loops can be extended in size or 
new R-loops can be formed at active TSS. In contrast, persistent CPT inhibition of Top1 markedly 
reduces R-loop structures and accumulates truncated sense transcripts at 5’ ends of intermediately 
active genes. Thus, the findings indicate that Top1 may regulate transcription initiation by 
regulating RNA Pol II-generated negative supercoils, which in turn can favor R loop formation at 
promoters, and that transcript accumulation at TSS is a transcriptional response to persistent Top1 
poisoning. The proposed role of Top1 at promoters is in agreement with previous findings on the 
effects of Top1 deletion (El Hage et al., 2010; Kouzine et al., 2013). 
 As R-loops can either trigger genome instability or mediate transcription regulation (Ginno 
et al., 2012; Sollier and Cimprich, 2015), we have defined whether or not transcriptional stress 
induced by Top1 inhibition could be mediated by formation of R-loops at active regions. The results 
show that R-loop can likely form in the antisense orientation at the studied divergent CGI promoters 
in untreated cells. Interestingly, CPT perturbs R-loops immediately upon addition to the growth 
medium as short CPT treatments (2-10 minutes) extend or generate new R-loops at the studied 
promoters whereas the Top1 poison completely abolishes R-loops at most of the studied promoters 
following longer treatment times. Therefore, it is likely that Top1 inhibition has a direct and rapid 
effect on R loop formation favored by excess negative supercoils behind elongating RNA Pol II, 
which has not be relieved by Top1. This increase is indeed transient as other homeostatic control of 
DNA superhelicity (for instance, by other DNA topoisomerases) can likely restore default levels of 
template supercoils. This is in agreement with a recent paper (Kouzine et al., 2013) showing that 
Top1 is most efficiently recruited at promoters of intermediate activity and that a short CPT 
treatment determines increased negative supercoils upstream and immediately adjacent to the TSS. 
Such an increase of negative supercoiling of the DNA template would likely favor both stabilization 
and extention of R-loop structures at active promoters.  
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 Our findings also show that when Top1 is persistently inhibited by CPT then R-loop 
formation is also reduced at promoters of active genes. As R-loop levels are dependent on active 
transcription, then persistent CPT treatments, which are known to strongly inhibit transcription 
elongation (Capranico et al., 2007), may preclude the formation of R loops. Nevertheless, CPT may 
have more dynamic effects on R loops in relation to their genomic location, as we observed that R 
loops persistent even after 4 hour of CPT treatment at mitochondrial replication origin and at TAF4 
promoter. In postmitotic neurons, persistent CPT treatments have been shown to affect cell viability 
(Morris and Geller, 1996) and induce transcriptional DSBs in an R-loop-dependent manner (Sordet 
et al., 2009). Thus, it can be speculated that R-loops formed at specific genomic location may be 
stabilized by CPT leading to irreversible double-strand breakage and apoptosis. Here, we have 
attempted to evaluate if the increase of antisense RNAs at promoters is downstream to DDR 
pathway activated by CPT, and our findings show that antisense transcript increase is not simply 
related to either ATM or DNAPK activation in HCT116 and WI38 human cells. However, it 
remains to be established whether DSBs themselves or other DDR proteins or a combination of 
both may be implicated in aRNA induction in response to CPT. 
The increase of antisense and sense transcripts may in principle be originated by an 
enhanced  synthesis and/or a reduced degradation of them. We previously reported that CPT still 
determines a similar increase rate of promoter-associated transcripts when transcription was 
inhibited by DRB as compared with the absence of DRB (Marinello et al., 2013), suggesting that an 
enhanced synthesis of antisense RNA is unlikely even if we cannot rule out completely this 
possibility. In agreement with these data, the present findings show that CPT impairs degradation of 
antisense transcripts. As exosome silencing has been shown to increase the levels of cryptic 
antisense RNA at promoters (Preker et al., 2011), our findings suggest that exosome activity may be 
somewhat reduced in cells treated with CPT. 
The present findings have established that antisense transcripts can form antisense R-loops 
at the studied divergent promoters, and that Top1 inhibition by CPT have dynamic and site-specific 
effects on them. In particular, immediately upon addition, CPT can favor R-loop formation 
whereas, at longer time of treatment, CPT markedly reduces R-loop levels. Interestingly, R-loops 
persist at certain active promoters and other genomic loci along with a more general induction of 
truncated sense and antisense RNAs at active TSS. The findings define new aspects of the specific 
CPT effects at transcriptional levels in human cancer and normal cells. 
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13. FIGURE LEGENDS 
 
Figure 1. R-loop formation  at the studied genomic and mitochondrial regions in untreated control 
NTERA-2 cl.D1 cells. DNA enrichment of each sample is subtracted of the enrichment value of the 
same sample treated with RNAseH1 before DRIVE precipitation. Then the enrichment value is 
normalized against the 2-min CPT sample (see figure 2) of the RPL13A amplicon of the same 
experiment. Values are means ±SEM of two to four independent experiments. The data show a 
higher SEM than commonly published as we report median values of several experiments and not a 
single representative one. (A) DRIVE assay was performed to determine R-loop levels downstream 
TSS (white bars) and upstream TSS (black bars). Three negative loci for R-loop formation are also 
reported (SNRPN, a-SAT, TNIK). (B) Mitochondrial DNA was analyzed with DRIVE assay. Three 
regions of interest were selected: red for the r-loop forming region (RB31-R3), green for the D-loop 
region (1A-1B) and blue for the non-D-loop region (4A-4B). Map on the right of the panel shows 
the heavy (H) and the light (L) strands of mitochondrial DNA, with the three Conserved Sequence 
Blocks (CSB) and the studied regions (in red, green and blue respectively). (C) Antisense 
transcription after CPT treatment in NTERA-2 cl.D1 cells. Promoter-associated antisense 
transcripts were evaluated by rtqPCR after 4 hours CPT treatment at 10 µM. PCR determinations 
were normalized to cytochrome b mRNA and to untreated cells (dotted line). Values are means +/− 
SEM of two determinations from at least two independent experiments. 
 
Figure 2. R-loops are transiently stabilized and extended by Top1 inhibition by CPT. DNA 
enrichment of each sample is subtracted of the enrichment value of the same sample treated with 
RNAseH1 before DRIVE precipitation. Then the enrichment value is normalized against the 2-min 
CPT sample of the RPL13A amplicon of the same experiment. Values are means ±SEM of two to 
four independent experiments. (A) DRIVE assay was performed to determine R-loop levels at 
genomic regions (on the left) and at mitochondrial regions (on the right) respectively after 2 min, 10 
min and 4 hours with 10 µM CPT. Control cells are reported from Figs. 1A and 1B to better 
appreciate any variation after drug treatment. (B) Scan by DRIVE assay of R-loop formation around 
transcription start site of TAF4 and PCIF1 genes after a time course treatment with CPT. Genome 
browser view show the genomic localization of the analyzed regions (right panel). The pattern of 
enzyme digestion used for DRIVE experiment guarantee the regions are properly separated during 
r-loop recovery and are therefore reported for clearness on the maps. One representative experiment 
for each locus is here reported. 
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Figure 3. Antisense transcript levels induced by CPT in replicating HCT116 and WI38, and in 
quiescent WI38 cells. Promoter-associated antisense transcripts were evaluated by rtqPCR after 4 
hours CPT treatment at 10 µM. PCR determinations were normalized to cytochrome b mRNA and 
to untreated cells (dotted line). Values are means +/− SEM of two determinations from at least two 
independent experiments.  
 
Figure 4. Turnover of aRNAs is influenced by CPT. Cells where firstly stimulated for antisense 
accumulation by a 4 hours treatment with CPT. Then FLV was added to block transcription in 
absence (solid lines) and in presence (dotted lines) of CPT, and antisense transcript levels 
determined by rtqPCR after additional 20, 40 and 60 minutes. PCR determinations were normalized 
to cytochrome b mRNA and to aRNAs levels before FLV addition (time 0). A representative 
experiment is here reported. 
 
Figure 5. Sense tags distribution, along non-overlapping Refseq genes of HCT116 cells and 
HCT116-shRNATop1 cells, were analyzed in a region from 2000 bases upstream the TSS to 2000 
bases downstream the TES using NGSplot software. Here, genes have been divided in two groups 
based on their FPKM. These genes have been selected for an accumulation of sense reads in the 5’ 
region (CPT-reads minus Control-reads: 10 ≥ 100) and a reduction of sense reads at the 3’ region 
(CPT-reads minus Control-reads: ≤ 5). Furthermore, genes selected have a fold change above 2 and 
a minimum number of sense reads above 5 in the 5’ region of CPT treated sample. Reads were 
normalized to the length of each region (1000 bp). Control reads are reported in gray dotted line and 
CPT reads in black line. Black arrows indicate an accumulation of reads at 5’ level after CPT 
treatment (10 µM for 4 hours). 
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Supplementary Figure 1: Time course and dose response in quiescent WI38 cells. Promoter-
associated antisense transcripts were evaluated by rtqPCR after 1 and 4 hours of CPT treatment at 
different doses (2, 5 and 10 µM). PCR determinations were normalized to cytochrome b mRNA and 
to untreated cells (dotted line). Values are means +/− SEM of at two determinations of at least two 
independent experiments. 
 
 
 
 
 
  
Supplementary Figure 2: Effect of FLV treatment on antisense transcription. Promoter-associated 
antisense transcripts were evaluated by rtqPCR after 4 hours of CPT treatment (10 µM) in presence 
of FLV (gray bars). PCR determinations were normalized to cytochrome b mRNA and to untreated 
cells (dotted line). Values are means +/− SEM of at two determinations of at least two independent 
experiments. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Supplementary Figure 3: DDR activation effect on antisense transcription. Promoter-associated 
antisense transcripts were evaluated by rtqPCR after 4 hours of CPT treatment (10 µM) in presence 
of ATM (gray bars) and DNAPK (white bars) inhibitors. PCR determinations were normalized to 
cytochrome b mRNA and to untreated cells (dotted line). Values are means +/− SEM of at two 
determinations of at least two independent experiments. 
 Supplementary Figure 4: Degradation rates of aRNAs. Cells where firstly stimulated for antisense 
accumulation by a 4 hours treatment with CPT. Then the drug was removed (blu lines) or 
maintained (red lines) for additional 60 minutes, and antisense transcript levels determined by 
rtqPCR. PCR determinations were normalized to cytochrome b mRNA and to aRNAs levels at time 
0. A representative experiment is here reported. 
 Supplementary Figure 5: Degradation rates of aRNAs. Cells where firstly stimulated for antisense 
accumulation by a 4 hours treatment with CPT. Then FLV was added to block transcription in 
absence (blu lines) and in presence (red lines) of CPT, and antisense transcript levels determined by 
rtqPCR after additional 20, 40 and 60 minutes. PCR determinations were normalized to cytochrome 
b mRNA and to aRNAs levels before FLV addition (time 0). A representative experiment is here 
reported. 
  
 
Supplementary Figure 6: Sense tags distribution, along non-overlapping Refseq genes of HCT116 
cells, were analyzed in a region from 2000 bases upstream the TSS to 2000 bases downstream the 
TES using NGSplot software. Here are reported genes whose FPKM value is below 0,3 up to 500 
divided in four groups. Control reads are reported in gray dotted line and CPT reads in black line. 
Black arrows indicate an accumulation or not of reads in the 5’ region after CPT treatment (10 µM 
for 4h). 
 
 
  
Supplementary Figure 7: Sense tags distribution, along non-overlapping Refseq genes of HCT116-
shRNATop1 cells, were analyzed in a region from 2000 bases upstream the TSS to 2000 bases 
downstream the TES using NGSplot software. Here are reported genes whose FPKM value is below 
0,3 up to 500 divided in four groups. Control reads are reported in gray dotted line and CPT reads in 
black line. Black arrows indicate an accumulation or not of reads in the 5’ region after CPT 
treatment (10 µM for 4h). 
 
 
  
 
Supplementary Figure 8: The accumulation of sense transcripts in the 5’ region and the reduction of 
sense transcripts in 3’ region of selected genes were determined by rtPCR in the HCT116 cells and 
were evaluated after treatment of the indicated cell lines with CPT 10 µM for 4h. The selected 
genes showed a CPT-increased in the 5’ region and a reduction in the 3’ region tag clusters as 
determined with RNA-seq data, with the exception of KLHL22 gene that had a sense transcript 
reduced by CPT. PCR determinations were normalized to cytochrome b mRNA and to untreated 
cells (dotted line). Values are means ± SEM of at least four determinations of six independent 
experiments for each panel. 
 
 
 
 
 
 
 
 
  
Supplementary Figure 9: The accumulation of sense transcripts in the 5’ region and the reduction of 
sense transcripts in 3’ region of selected genes were determined by rtPCR in the HCT116-
shRNATop1 cells and were evaluated after treatment of the indicated cell line with CPT 10 µM for 
4h. The selected genes showed a lower CPT-increased in the 5’ region and a lower reduction in the 
3’ region tag clusters as determined with RNA-seq data, with the exception of AEN gene that had a 
higher sense transcript increased by CPT, taking into account the HCT116 cells line. PCR 
determinations were normalized to cytochrome b mRNA and to untreated cells (dotted line).Values 
are means ± SEM of at least four determinations of two independent experiments. 
 
RhoB Promotes H2AX Dephosphorylation and DNA Double-Strand
Break Repair
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de Cancérologie Gustave Roussy, Université Paris XI, Villejuif, Francec
Unlike other Rho GTPases, RhoB is rapidly induced by DNA damage, and its expression level decreases during cancer progres-
sion. Because inefficient repair of DNA double-strand breaks (DSBs) can lead to cancer, we investigated whether camptothecin,
an anticancer drug that produces DSBs, induces RhoB expression and examined its role in the camptothecin-induced DNA dam-
age response. We show that in camptothecin-treated cells, DSBs induce RhoB expression by a mechanism that depends notably
on Chk2 and its substrate HuR, which binds to RhoBmRNA and protects it against degradation. RhoB-deficient cells fail to de-
phosphorylate H2AX following camptothecin removal and show reduced efficiency of DSB repair by homologous recombina-
tion. These cells also show decreased activity of protein phosphatase 2A (PP2A), a phosphatase for H2AX and other DNA dam-
age and repair proteins. Thus, we propose that DSBs activate a Chk2-HuR-RhoB pathway that promotes PP2A-mediated
dephosphorylation of H2AX and DSB repair. Finally, we show that RhoB-deficient cells accumulate endogenous H2AX and
chromosomal abnormalities, suggesting that RhoB loss increases DSB-mediated genomic instability and tumor progression.
RhoB is a small GTPase from the Rho family of proteins impli-cated in various intracellular functions, including actin cyto-
skeletal organization (1). Besides its well-established roles, RhoB
emerged as an early DNA damage-inducible gene. RhoB is readily
induced in response to various genotoxic agents, including UV
and cisplatin (2, 3), although the molecular mechanisms of induc-
tion and functional relevance remain unclear. RhoB also differs
from other Rho proteins, as it possesses tumor suppressor func-
tions. The RhoB expression level decreases during the progression
of various tumors, and loss of RhoB promotes cell proliferation,
invasion, and metastasis (4–8).
DNA double-strand breaks (DSBs) are among the most severe
lesions, and their inefficient repair can initiate genomic instability,
ultimately leading to cancer (9–11). DSB repair requires the re-
cruitment of DNA damage response (DDR) proteins in the vicin-
ity of damaged chromatin (12). The serine/threonine kinases
ATM, ATR, and DNA-dependent protein kinase (DNA-PK) are
readily activated by DSBs and phosphorylate various DDR pro-
teins, including histone H2AX and checkpoint kinase 2 (Chk2).
Phosphorylation of these proteins is critical for efficient DDR and
repair (10, 13). These phosphorylations are reversible and re-
moved by specific serine/threonine phosphatases, including pro-
tein phosphatase 2A (PP2A), PP4, PP1, PP6, and Wip1 (14). Ac-
cumulating studies indicate that the timely dephosphorylation of
DDR proteins is required for DSB repair (15–17).
Topoisomerase I (Top1) removes DNA torsional stress gener-
ated during replication and transcription. It relaxes DNA by pro-
ducing transient Top1-DNA cleavage complexes (Top1cc), which
are Top1-linked DNA single-strand breaks (18). The rapid reseal-
ing of Top1cc is inhibited by camptothecin (CPT) and its deriva-
tives, which are used to treat cancers and which bind selectively at
the Top1-DNA interface (18). Stabilized Top1cc interfere with the
progression of replication and transcription complexes, which re-
sults in the production of DSBs (19–21). CPT is a sharp tool to
dissect the cellular response to DSBs, as it has no other target
besides Top1. CPT also has the advantage of trapping Top1cc
reversibly. Indeed, Top1cc reverse fully within minutes after
washing out CPT (18). Here we used CPT to determine whether
DSBs induce RhoB and examined both the mechanisms of induc-
tion and its functional relevance.
MATERIALS AND METHODS
Drugs, chemical reagents, and cell culture.CPT, okadaic acid, fostriecin,
and the DNA-PK inhibitor NU7026 were obtained from Sigma-Aldrich.
Human osteosarcoma (U2OS) and colon carcinoma (HCT116 and
HCT15) cells were obtained from the American Type Culture Collection
(ATCC). HCT15 cells stably expressing wild-type Chk2 (Chk2-WT) or a
kinase-dead Chk2 D347A mutant (Chk2-KD) were obtained from Yves
Pommier (NIH, Bethesda, MD) (22, 23). WT and RhoB/ E6-immor-
talized mouse embryonic fibroblast (MEF) cells were established in the
laboratory from SV129 mice obtained from G. C. Prendergast (Lankenau
Institute for Medical Research) by using a protocol described previously
(24). WT and RhoB/ primary mouse dermal fibroblast (MDF) cells
were isolated from SKH1 mice (established in the laboratory from SV129
mice), as described previously (25), and cultured for a maximum of 9
passages. The subline RG37, containing the homologous recombination
substrate (pDR-GFP), was made as described previously (26). The subline
GC92, containing the nonhomologous end joining (NHEJ) substrate
(pCOH-CD4), was made as described previously (27). All of the above-
described cells were cultured in Dulbecco’s modified Eagle’s medium sup-
plemented with 10% fetal bovine serum.
Western blotting. Whole-cell extracts were obtained by lysing cells in
buffer (1% SDS, 10 mM Tris-HCl [pH 7.4]) supplemented with protease
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(Complete; Roche Diagnostics) and phosphatase (Cocktail 3; Sigma-Al-
drich) inhibitors. Viscosity of the samples was reduced by brief sonica-
tion, and proteins were separated by SDS-PAGE and immunoblotted with
the following antibodies: anti-Chk2 (catalog number 2662; Cell Signal-
ing), anti-Chk2-pS516 (catalog number 2669; Cell Signaling), anti-Chk2-
pT68 (catalog number 2661; Cell Signaling), anti-H2AX (catalog number
ab11175; Abcam), anti-H2AX (catalog number 05-636; Millipore), anti-
HuR (catalog number sc-5261; Santa Cruz), anti-PP2A(C) (catalog num-
ber 1512-1; Epitomics), anti-Rad51 (catalog number PC-130; Millipore),
anti-RhoA (catalog number sc-418; Santa Cruz), anti-RhoB (catalog
number sc-180; Santa Cruz), and anti--tubulin (catalog number T5168;
Sigma-Aldrich). Immunoblotting was revealed by chemiluminescence
using autoradiography or a ChemiDoc MP system (Bio-Rad). Quantifi-
cation of protein levels was done by using ImageJ (version 1.40g) in Fig. 1E
and 3F and with Image Lab software (version 4.1) in Fig. 3L and 5D.
RNA immunoprecipitation (RIP). Immunoprecipitation of HuR-as-
sociated RNAs was done as described previously (28), with minor modi-
fications. Forty million cells were lysed for 30 min at 4°C in 750 l buffer
containing 25 mM Tris-HCl (pH 7.4), 150 mM KCl, 0.5% NP-40, 2 mM
EDTA, 1 mM NaF, and 0.5 mM dithiothreitol (DTT), supplemented with
0.2 U RNasin (Promega) and protease inhibitors (Complete; Roche Di-
agnostics). After centrifugation at 10,000  g for 10 min, supernatants
were precleared for 30 min at 4°C with 20l of protein A/G-agarose beads
(Sigma-Aldrich) previously blocked for 5 h at 4°C in washing buffer (300
mM KCl, 50 mM Tris-HCl [pH 7.4], 1 mM MgCl2, 0.1% NP-40) contain-
ing 5 g/l yeast tRNA (Invitrogen), 1 g/l acetylated bovine serum
albumin (BSA; Sigma-Aldrich), and protease inhibitors (Complete;
Roche Diagnostics). Beads (20 l) were coupled with 15 g of mouse
anti-HuR antibody (catalog number sc-5261; Santa Cruz) or 15 g of
mouse nonimmune antibody (control IgG) (catalog number 02-6502;
Invitrogen) for 4 h at 4°C and incubated with 2 mg precleared cell lysate
overnight at 4°C. After several washes in washing buffer and proteinase K
(Roche Diagnostics) treatment, immunoprecipitated RNAs were ex-
tracted by using TRIzol LS reagent (Invitrogen) and treated with Turbo
DNase (Ambion) before quantitative reverse transcription-PCR (RT-
qPCR) experiments.
Quantitative reverse transcription-PCR. Total RNAs (MasterPure
RNA purification kit; Epicentre) were subjected to RT by using the iScript
cDNA synthesis kit (Bio-Rad). qPCR analyses were performed on a
CFX96 real-time system device (Bio-Rad) by using IQ SYBR green Super-
mix (Bio-Rad) according to the manufacturer’s instructions. All samples
were analyzed in triplicate, and-actin mRNA was used as an endogenous
control in the CT analysis. The primer pairs used were RhoA-FW (5=-
TGG AAG ATG GCA TAA CCT GTC-3=) and RhoA-RV (5=-AAC TGG
TGG CTC CTC TGG-3=), RhoB-FW (5=-TTG TGC CTG TCC TAG AAG
TG-3=) and RhoB-RV (5=-CAA GTG TGG TCA GAA TGC TAC-3=),
RhoC-FW (5=-TGT CAT CCT CAT GTG CTT CTC-3=) and RhoC-RV
(5=-GTG CTC GTC TTG CCT CAG-3=), RhoE-FW (5=-CCT GCT CCT
CTC GCT CTC-3=) and RhoE-RV (5=-TCT GGC TGG CTC TTC TCT
C-3=), and -actin-FW (5=-TCC CTG GAG AGG AGC TAC GA-3=) and
-actin-RV (5=-AGG AAG GAA GGC TGG AAG AG-3=).
Cell transfection (siRNAs and plasmids). For cell transfection with
small interfering RNAs (siRNAs), cells were transfected with HuR-,
Rad51-, or RhoB-targeting siRNAs or nontargeting siRNAs (Eurogentec)
by using Oligofectamine transfection reagent (Invitrogen) according to
the manufacturer’s protocol. Target DNA sequences were 5=-GAG GCA
ATT ACC AGT TTC A-3= for HuR, 5=-GAA GCT ATG TTC GCC ATT
A-3= for Rad51, 5=-GGC ATT CTC TAA AGC TAT G-3= for siRNA
RhoB#1, 5=-GTC CAA GAA ACT GAT GTT A-3= for siRNA RhoB#2,
5=-GCT AAG ATG GTG TTA TTT A-3= for siRNA RhoB#3, and 5=-GAC
GTG GGA CTG AAG GGG T-3= for nontargeting siRNA. Experiments
were performed 48 h after transfection. siRNA RhoB#1 was used in Fig. 4B
and G, siRNA RhoB#2 was used in Fig. 4B to E and G and 5D, and siRNA
RhoB#3 was used in Fig. 3G and H. For cell transfection with plasmids,
cells were transfected with a plasmid encoding hemagglutinin (HA)-RhoB
(29) by using jetPEI DNA transfection reagent (Polyplus transfection)
according to the manufacturer’s protocol. Experiments were performed
24 h after transfection.
Neutral Comet assays. Neutral Comet assays were performed accord-
ing to the manufacturer’s instructions (Trevigen), except that electropho-
resis was performed at 4°C. Comet tail moments were measured by using
ImageJ (version 1.47v) using a macro provided by Robert Bagnell (https:
//www.med.unc.edu/microscopy/resources/imagej-plugins-and-macros
/comet-assay).
DSB repair assays. RG37 and GC92 cells, for homologous recombi-
nation and end joining assays, respectively, were plated at 5 105 cells per
well into six-well plates and transfected after 24 h with nontargeting or
RhoB-targeting siRNAs. Forty-eight hours after siRNA transfection, cells
were transfected with 1g of an I-SceI-encoding plasmid (pBASCe-ISceI)
by using JetPEI reagent. Cells were collected 72 h later with phosphate-
buffered saline (PBS)–50 mM EDTA and fixed in PBS–2% paraformalde-
hyde for 15 min at room temperature. Green fluorescent protein (GFP)-
positive RG37 cells were detected by flow cytometry using a FACSCalibur
instrument. For NHEJ assays, GC92 cells were incubated with PBS and 2%
(wt/vol) BSA and then stained for 15 min with 1 l of anti-CD4-phyco-
erythrin (PE) (Miltenyi Biotech) in PBS–1% (wt/vol) BSA. The cells were
washed in PBS before fluorescence-activated cell sorter (FACS) analysis.
WST-1 cell viability assays. WT and RhoB/MEF cells were seeded
in triplicate into 96-well microplates at a density of 1,000 cells per well.
Twenty-four hours after plating, cells were treated with various concen-
trations of CPT (from 1.6 nM to 50M) and cultured for 72 h. The WST-1
reagent (Roche Diagnostics) was then applied for 1 h at 37°C. The formazan
dye was quantified at 450 nm by using a plate reader (LabSystems Multiskan).
Data are expressed as the percentage of cell survival (mean	 standard devi-
ation [SD] of treated cells normalized to the mean	 SD of untreated cells,
which was set to 100%).
Protein phosphatase 2A activity assays. Protein phosphatase 2A
(PP2A) activity was assayed by using a PP2A immunoprecipitation phos-
phatase assay kit (Upstate) according to the manufacturer’s protocol.
Briefly, cells were lysed on ice in phosphatase extraction buffer (20 mM
imidazole-HCl [pH 7.0], 2 mM EDTA, 2 mM EGTA) supplemented with
a protease inhibitor cocktail (Sigma-Aldrich). The cell lysate (500g) was
incubated for 2 h at 4°C with protein A-agarose beads coupled with 4 g
of mouse anti-PP2A(C) antibody (clone 1D6; Upstate) or mouse nonim-
mune antibody (control IgG) (catalog number 02-6502; Invitrogen).
Phosphatase activity was assayed by incubating the immunoprecipitated
proteins with the synthetic threonine phosphopeptide K-R-pT-I-R-R at
30°C for 10 min prior to detection with malachite green phosphate detec-
tion solution. After 15 min, free phosphate was quantified by measuring
the absorbance at 620 nm in a microplate reader. Phosphatase activity was
calculated by using a phosphate standard curve. All samples were analyzed
in triplicate.
Detection of Top1-DNA cleavage complexes. Cellular Top1-DNA
cleavage complexes (Top1cc) were detected as previously described (30),
except that immunoblotting was revealed with a rabbit monoclonal anti-
Top1 antibody from Abcam (ab109374) and by chemiluminescence using
autoradiography or a ChemiDoc MP system (Bio-Rad). Quantification
for Fig. 3L was performed by using Image Lab software (version 4.1).
Immunofluorescence microscopy. Immunofluorescence micros-
copy of H2AX was performed, as described previously (20), with an
anti-H2AX antibody from Millipore (catalog number 05-636). Immu-
nofluorescence microscopy of Rad51 was performed as described previ-
ously (31) by using an anti-Rad51 antibody from Millipore (catalog num-
ber PC-130), except that cells were fixed/permeabilized with ice-cold
methanol for 15 min at 4°C and further permeabilized with 0.5% Triton
X-100 for 5 min at room temperature. Slides were visualized by using a
fluorescence microscope (Eclipse 90i; Nikon), and pictures were analyzed
with Photoshop CS3 (Adobe).
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DNAextraction and comparative genomic hybridization (CGH) ar-
rays. Genomic DNA was extracted from WT and RhoB/ primary MDF
cells by using the QIAamp DNA kit (Qiagen). DNA from WT and
RhoB/ cells was labeled with Cy3 and Cy5 (Dual color labeling kit;
Roche-Nimblegen), respectively, before hybridization on 720K whole-
genome tiling arrays (Roche-Nimblegen). Slides were scanned by using
the MS200 scanner (Tecan), and images were analyzed by using DEVA 2.1
software (Roche-Nimblegen) with segmentation and background correc-
tion. Amplification and deletion were considered significant events when
at least 5 consecutive probes had a log2 value of0.3 (amplification) or a
log2 value of 0.4 (deletion). We determined the genomic instability
index with the formula (number of deletions 
 number of amplifica-
tions)2/number of altered chromosomes, as previously described (32).
Sexual chromosomes were excluded from the analysis.
RhoB and RhoA activity assays. The Rho binding domain (RBD) of
rhotekin, an effector of Rho proteins that selectively binds to the GTP-
loaded form, was expressed as a recombinant fusion with glutathione
S-transferase (GST) in Escherichia coli and purified through binding to
glutathione (GSH)-Sepharose beads. Cells (8 106) were lysed on ice in
800 l lysis buffer (50 mM Tris-HCl [pH 7.5], 500 mM NaCl, 10 mM
MgCl2, 1% Triton X-100, 10 mM DTT) supplemented with a protease
inhibitor cocktail (Sigma-Aldrich) and phosphatase inhibitors (Halt
phosphatase inhibitor cocktail; Thermo Scientific). GST-RBD beads (30
l) were incubated with the cell lysate for 30 min at 4°C. An aliquot from
each lysate was removed as a control for equivalent input for the assay.
After three washes in ice-cold washing buffer (50 mM Tris-HCl [pH 7.5],
500 mM NaCl, 10 mM MgCl2, 1% Triton X-100), bound Rho proteins
were eluted from the beads with SDS-PAGE sample buffer at 95°C and ana-
lyzed by Western blotting with anti-RhoB (catalog number sc-180; Santa
Cruz) or anti-RhoA (catalog number sc-418; Santa Cruz) antibodies.
RhoB promoter activity. U2OS cells were cotransfected with a plas-
mid encoding the RhoB promoter linked to the firefly luciferase reporter
gene and a plasmid encoding the cytomegalovirus (CMV) promoter
linked to the Renilla luciferase reporter gene (internal control), as de-
scribed previously (2). Luciferase activities were measured 48 h after
transfection by using the Dual Luciferase assay system (Promega), and
results were expressed as the ratio of the activity of the firefly luciferase to
the activity of the Renilla luciferase.
BrdU incorporation assays. Cells were incubated with 30 M bro-
modeoxyuridine (BrdU; Sigma-Aldrich) for 30 min and labeled with anti-
BrdU antibody according to the manufacturer’s protocol (clone B44; BD
Biosciences). Cells were analyzed on a Becton, Dickinson FACScan flow
cytometer (BD Biosciences).
RESULTS
RhoB is rapidly and selectively induced in response to DSBs.
Exposure of human cancer cells to 25 M CPT revealed a 2-fold
increase of the RhoB mRNA level within 30 min (Fig. 1A). At this
CPT concentration, the levels of RhoB mRNA reached a maxi-
mum 5-fold increase after 2 h (Fig. 1A). To investigate whether the
induction of RhoB mRNA was dose dependent, cells were treated
for 4 h with increasing CPT concentrations. RhoB induction was
clearly detected at 1 M and increased with increasing CPT con-
centrations (Fig. 1B). In contrast, the two RhoB homologs RhoA
and RhoC were not induced after short exposures to CPT (Fig.
1C). RhoE, another member of the Rho family, has been identified
as a p53-inducible gene in response to genotoxic agents (33). The
authors of that study focused on upregulation of RhoE mRNA
after long exposures to genotoxic agents, typically 12 h or longer.
Figure 1C shows no increase in the RhoE mRNA level after short
exposures to CPT in p53 wild-type U2OS cells under conditions
where RhoB mRNA levels reached a maximum increase.
The increase in the RhoB mRNA level was associated with an
increase in the RhoB protein level that was detectable 1 h after CPT
FIG1 Rapid and selective increase of RhoB by CPT-induced DSBs. (A and B) RhoB mRNA was analyzed by RT-qPCR in cells treated for the indicated times with
25M CPT (U2OS cells) (A) and with the indicated CPT concentrations for 4 h (HCT15/Chk2-WT cells) (B). Data shown are means	 SD for triplicate samples.
(C) The indicated transcripts were analyzed by RT-qPCR in U2OS cells treated with 25M CPT (means	 SD for three independent experiments). (D) Western
blotting of RhoB, RhoA, and H2AX in U2OS cells treated with 25 M CPT. -Tubulin was the loading control. (E) Quantification of RhoB and RhoA protein
levels by Western blotting in U2OS cells treated with CPT (25 M for 4.5 h). Data shown are the means	 SD for three independent experiments. **, P 0.01
by t test. (F) Active (GTP-bound) Rho proteins were pulled down with GST-rhotekin-RBD (Rho binding domain) beads in extracts from U2OS cells treated with
25M CPT for 4 h. The active forms of RhoB and RhoA were detected by Western blotting with antibodies against RhoB and RhoA, respectively. Total RhoB and
RhoA protein levels were examined in the extracts before pulldown (input). (G) HCT15/Chk2-WT cells were treated with the replication inhibitor aphidicolin
(APH) (1 M for 15 min) before the addition of CPT (1 M for 2 h). (Top) RT-qPCR analysis of RhoB mRNA. Data shown are means 	 SD for three
independent experiments. The asterisk denotes a significant difference from CPT-treated cells without APH (P 0.05 by t test). (Bottom) Western blotting of
H2AX and H2AX.
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treatment (Fig. 1D and E). Pulldown of active (GTP-bound) Rho
proteins followed by immunoblotting with an anti-RhoB anti-
body indicated that CPT induced both total and active RhoB pro-
teins (Fig. 1F), although it is still unclear whether these two events
are connected. Under these conditions, the levels of total and ac-
tive RhoA remained unchanged (Fig. 1D to F), which is consistent
with the lack of induction of RhoA mRNA after CPT treatment
(Fig. 1C).
Because DSBs are readily produced in CPT-treated cells (18),
we tested whether they could be the initiating events for RhoB
induction. Figure 1D shows that the increase in the level of RhoB
protein coincided with the phosphorylation of H2AX at Ser139
(referred to as H2AX), a marker for DSBs (9). To assess more
directly the role of DSBs, we prevented their production in CPT-
treated cells. DSBs are primarily produced during DNA replica-
tion at low concentrations (1 M) of CPT (18). As expected
(19), inhibition of replication with aphidicolin prevented the in-
duction of H2AX in response to CPT (Fig. 1G, bottom). Under
these conditions, aphidicolin also prevented the induction of
RhoB mRNA (Fig. 1G, top). These results suggest that DSBs pro-
mote RhoB upregulation.
Although RhoB can be induced in cells undergoing apoptosis
(34), it is unlikely that the early increase in the level of RhoB
induced by CPT resulted from the activation of apoptotic path-
ways. The increase of the RhoB level preceded the caspase-depen-
dent cleavage of poly(ADP-ribose) polymerase (PARP) by sev-
eral hours and was not prevented by the pancaspase inhibitor
benzyloxycarbonyl-Val-Ala-DL-Asp(OMe)-fluoromethyl ketone
(zVAD-fmk) (data not shown). Together, these results indicate
that RhoB is induced rapidly and selectively in response to CPT-
induced DSBs prior to and independently of apoptosis.
HuR-dependent stabilization of RhoB mRNA in CPT-
treated cells. Increases of both transcription and transcript stabil-
ity have been involved in the upregulation of RhoB mRNA in
UV-exposed cells (2, 35). To examine RhoB transcription, we
linked its promoter to a luciferase reporter gene. Figure 2A shows
that CPT did not increase luciferase activity in cells transfected
with this construct, indicating that transcription is unlikely to
account for the upregulation of RhoB mRNA. Next, we compared
the stability of RhoB mRNA between untreated and CPT-treated
cells. Experiments performed in the presence of the transcription
inhibitor flavopiridol revealed that the half-life of RhoB mRNA
was greatly prolonged in CPT-treated cells (Fig. 2B).
The RNA binding protein HuR is known to bind to and stabi-
lize target mRNAs (36). RhoB mRNA contains a HuR binding site
in its 3= untranslated region (UTR) (28), and a constitutive HuR-
RhoB mRNA interaction has been found by RNA immunopre-
cipitation coupled with microarray analyses (RIP-chip) (37, 38).
To test the potential role of HuR in the enhanced stability of RhoB
mRNA, we tested whether HuR inhibition affected CPT-induced
RhoB mRNA. Figure 2C shows that siRNA-mediated depletion of
HuR decreased the induction of RhoB mRNA. To further impli-
cate HuR, we examined its binding to RhoB mRNA by RIP exper-
iments. Endogenous HuR was immunoprecipitated, and the levels
of coimmunoprecipitated RhoB mRNA were analyzed by RT-
qPCR. In untreated cells, RhoB transcripts were enriched in HuR
immunoprecipitates compared with those in control IgG immu-
noprecipitates (Fig. 2D), indicating that HuR binds to RhoB
mRNA under normal conditions, as expected (37, 38). Cellular
exposure to CPT resulted in a further enrichment of RhoB mRNA
in HuR immunoprecipitates, which was detected within 30 min
and increased with the time of CPT exposure (Fig. 2D). A similar
increase in HuR-RhoB mRNA interactions has been observed af-
ter short exposures to UV (35), suggesting that HuR-dependent
stabilization of RhoB mRNA is a common mechanism for the
early induction of RhoB by genotoxic agents.
Chk2-dependent HuR-RhoBmRNA interaction in response
to DSBs. Chk2 is a serine/threonine kinase readily activated by
DSBs (39). Active Chk2 phosphorylates HuR with RNA recogni-
tion motifs and modulates HuR binding to target mRNAs (37,
40–42). As expected (43), CPT induced rapid phosphorylation of
Chk2 at Thr68 (Fig. 2E), which reflects its activation (44). Chk2
Thr68 phosphorylation was detected 30 min after CPT treatment
(Fig. 2E) and coincided with the increased association of HuR
with RhoB mRNA (Fig. 2D).
To assess directly the involvement of Chk2, we used HCT15
cells (Chk2 deficient) stably expressing wild-type Chk2 (Chk2-
WT) or kinase-dead Chk2 (Chk2-KD). The levels of HuR protein
were comparable in Chk2-WT and Chk2-KD cells and were un-
affected by CPT treatment (Fig. 2H). Figure 2F shows that HuR
binding to RhoB mRNA was reduced in Chk2-KD cells compared
to Chk2-WT cells in response to CPT. These results led us to test
whether the level of CPT-induced RhoB was also reduced in
Chk2-KD cells. The induction of RhoB mRNA (Fig. 2G) and pro-
tein (Fig. 2H) was defective in Chk2-KD cells treated with CPT. As
a control, parental HCT15 cells (Chk2 deficient) exhibited a sim-
ilar induction defect in RhoB mRNA (data not shown) as that of
Chk2-KD cells (Fig. 2G). Both WT and Chk2-KD cells showed
identical induction of H2AX in response to CPT (Fig. 2H), indi-
cating that the defective response of Chk2-KD cells is not caused
by a decreased amount of DSBs.
RhoB facilitates H2AX dephosphorylation in CPT-treated
cells. To assess the potential role of RhoB in the cellular response
to CPT, we compared survival of WT and RhoB-deficient
(RhoB/) E6-immortalized MEF cells after CPT treatment. Cells
were treated with increasing concentrations of CPT, and CPT sen-
sitivity was assessed by WST-1 survival assays. Figure 3A shows
that RhoB/ cells are more sensitive to CPT than are WT cells,
indicating that RhoB participates in the cellular response to CPT.
Because the cytotoxicity of CPT depends on Top1-linked DNA
single-strand break (Top1cc)-induced DSBs (18), we analyzed the
influence of RhoB on both the formation of Top1cc and the pro-
duction of DSBs. Primary cells (WT and RhoB/) were used, as
they normally have low background levels of H2AX (45). Our
results indicated that CPT-induced Top1cc (Fig. 3B) and H2AX
(Fig. 3C) levels were similar in WT and RhoB/ cells.
We therefore hypothesized that the hypersensitivity of
RhoB/ cells could instead result from a defect in the repair of
these DSBs. To determine the kinetics of DSB repair, we analyzed
the kinetics of H2AX dephosphorylation (45). WT and RhoB/
cells were exposed to CPT for 1 h and washed, and H2AX de-
phosphorylation was monitored post-CPT treatment (release)
(Fig. 3D). Unlike continuous exposure to CPT, this protocol al-
lows the study of DSB repair, as Top1cc reverse fully within min-
utes after washing out CPT (18), and DSBs are then no longer
produced. After termination of the CPT treatment, H2AX levels
decreased by approximately 70% within 7 h in WT cells (Fig. 3E
and F), which is consistent with the kinetics and magnitude of
H2AX focus loss after exposure to ionizing radiation (46). Under
these conditions, H2AX levels were not significantly reduced in
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RhoB/ cells (Fig. 3E and F). Immunofluorescence microscopy
confirmed the pronounced defect of H2AX dephosphorylation
in RhoB/ cells after removal of CPT (data not shown). In addi-
tion, siRNA-mediated depletion of RhoB in human HCT116 cells
(Fig. 3G) also resulted in a marked reduction of H2AX dephos-
phorylation after removal of CPT (Fig. 3H). Neutral Comet assays
confirmed that the persistence of H2AX in RhoB-deficient cells
post-CPT treatment corresponded to unrepaired DSBs (Fig. 3I
and J). Analysis of endogenous Top1cc showed that they reversed
efficiently in both WT and RhoB/ cells after removal of CPT
(Fig. 3K and L). Thus, it is unlikely that the persistent H2AX
signal in RhoB/ cells resulted simply from the further produc-
tion of DSBs after termination of the CPT treatment. These results
indicate that RhoB promotes H2AX dephosphorylation and
DSB repair.
RhoB promotes DSB repair by homologous recombination.
Homologous recombination and nonhomologous end joining
(NHEJ) are the prevalent pathways for the repair of DSBs (47). To
assess directly the involvement of RhoB in DSB repair, we used
human RG37 fibroblast cells that contain a single chromosomally
FIG 2 Chk2- and HuR-dependent stabilization of RhoB mRNA in response to CPT. (A) RhoB promoter activity was determined after transfection of U2OS cells
with a RhoB promoter-luciferase reporter gene construct before treatment with 25 M CPT. Data shown are means	 SD for three independent experiments.
The positive control (
) was cells treated with trichostatin A (1 M for 15 h). (B) U2OS cells were left untreated (Ctrl) or were treated with CPT (25 M for 2
h) before the addition of the transcription inhibitor flavopiridol (FLV) (1 M). RhoB mRNA was analyzed by RT-qPCR and normalized to the level at the time
of flavopiridol addition, which was set to 100% (averages of data from two independent experiments). The half-life (t1/2) of RhoB mRNA is indicated. (C)
HCT116 cells were transfected with HuR-targeting or nontargeting (control) siRNAs before treatment with CPT (25 M for 6 h). (Top) RT-qPCR analysis of
RhoB mRNA (means	 SD for triplicate samples). (Bottom) Western blotting showing the efficiency of HuR silencing. -Tubulin was the loading control. (D)
Increased HuR-RhoB mRNA interaction upon CPT treatment. HuR was immunoprecipitated (IP) from HCT15/Chk2-WT cells treated with 25 M CPT. The
control was immunoprecipitation with nonimmune IgG. Coimmunoprecipitated RhoB mRNA was analyzed by RT-qPCR relative to-actin mRNA levels in the
input samples (means	 SD for triplicate samples). (E) Phosphorylation of Chk2 on Thr68 was examined by Western blotting in HCT15/Chk2-WT cells treated
with 25M CPT. Chk2 and HuR were examined in parallel. (F) Chk2-dependent binding of HuR to RhoB mRNA. HCT15/Chk2-WT and HCT15/Chk2-KD cells
were treated with 25 M CPT for 4 h, and RhoB mRNA was analyzed in HuR immunoprecipitations, as described above for panel D. (G and H) HCT15/
Chk2-WT and HCT15/Chk2-KD cells were treated with 25 M CPT. (G) RhoB mRNA was analyzed by RT-qPCR (means 	 SD for triplicate samples). (H)
Western blotting of the indicated proteins. Phosphorylation of Chk2 on Ser516, which is an autophosphorylation site in response to DNA damage (64), was used
to control Chk2 kinase activity in cells expressing WT or kinase-dead Chk2.
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FIG 3 RhoB-deficient cells are defective for H2AX dephosphorylation after CPT removal. (A) WT and RhoB/ MEF cells were treated with the indicated
concentrations of CPT for 72 h, and cell survival was analyzed by a WST-1 assay (means 	 SD for triplicate samples). (B) Detection of Top1-DNA cleavage
complexes (Top1cc) in WT and RhoB/ primary mouse dermal fibroblast (MDF) cells treated with CPT (25M for 1 h). Different amounts of genomic DNA
(5, 2.5, and 1.25 g) were probed with an anti-Top1 antibody. (C) Western blotting of H2AX and H2AX in WT and RhoB/ primary MDF cells treated with
CPT (25 M for 1 h). (D) Cell treatment protocol for the study of H2AX dephosphorylation (E to H), DSB repair (I and J), and Top1cc reversal (K and L) in
response to CPT. Cells were treated with CPT for 1 h and washed (W) and cultured in CPT-free medium (release) for the indicated times. (E and F) Western
blotting ofH2AX and H2AX in WT and RhoB/primary MDF cells (CPT, 25M). (E) Representative experiment. (F) Quantification ofH2AX protein levels
(means 	 SD for three independent experiments). *, P  0.05; ***, P  0.001 (by t test). (G and H) HCT116 cells were transfected with RhoB-targeting or
nontargeting (control) siRNAs. (G) Western blotting showing the efficiency of RhoB silencing in two independent experiments. -Tubulin was the loading
control. (H) Western blotting of H2AX and H2AX (CPT, 1M; release, 6 h). Lines indicate that intervening wells have been spliced out. (I and J) Detection of
DSBs by a neutral Comet assay in WT and RhoB/ primary MDF cells (CPT, 25 M; release, 1 h). (I) Representative pictures of nuclei. (J) Quantification of
Comet tail moment (averages	 standard errors of the means). Sixty cells were examined per group. (K and L) Detection of Top1cc in MEF cells treated with 25
M CPT for 1 h. R30= and R60= indicate cells harvested 30 and 60 min after CPT removal, respectively. Different amounts of genomic DNA (5, 2.5, and 1.25g)
were probed with an anti-Top1 antibody. (K) Representative experiment. Dashed lines indicate where panels have been reorganized to facilitate reading. (L)
Quantification of Top1cc normalized to values for CPT-treated cells (means	 SD for three independent experiments). The dashed line indicates Top1cc levels
in WT untreated cells.
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FIG 4 RhoB-deficient cells are defective for DSB repair by homologous recombination. (A) Substrate and strategy used to measure DSB-induced homologous
recombination (26, 48). The pDR-GFP substrate contains two inactive genes coding for GFP under the control of a promoter (P). The 5= gene is inactive because
of the insertion of a cleavage site for I-SceI. The 3= gene is inactive because it is deleted in both the 5= and 3= directions. When a DSB is produced by I-SceI,
recombination between these two inactive genes (specifically gene conversion) restores a functional GFP coding sequence by either intrachromatid homologous
recombination (represented) or unequal sister chromatid exchange (not represented). (B) RG37 cells stably expressing the pDR-GFP substrate were transfected
with RhoB-targeting or nontargeting (control) siRNAs for 2 days and then transfected with an I-SceI plasmid for an additional 3 days. Cells transfected with
Rad51-targeting siRNAs were used as a control for the pDR-GFP substrate. “No I-SceI” corresponds to cells transfected with an empty plasmid for 3 days. (Top)
Percentages of GFP-positive recombinant cells determined by flow cytometry and normalized to the level of cells cotransfected with control siRNAs and I-SceI,
which was set to a value of 1. Data shown are means	 standard errors of the means for five (with RhoB#1 siRNA) or three (with RhoB#2 and Rad51 siRNAs)
independent experiments. ***, P 0.001; **, P 0.01 (by t test). (Bottom) Western blotting of RhoB and Rad51. -Tubulin was the loading control. (C and D)
HCT15/Chk2-WT cells were transfected with RhoB-targeting or nontargeting (control) siRNAs and left untreated or were treated with 1M CPT for 1 h. Rad51
foci were analyzed by immunofluorescence microscopy at 6 h post-CPT treatment (Release) (see protocol described in the legend to Fig. 3D). (C) Representative
images. DAPI, 4=,6-diamidino-2-phenylindole. Bar, 10 m. (D) Percentages of cells with at least five Rad51 foci. At least 200 cells were analyzed in each group
(means	 standard errors of the means). (E) HCT15/Chk2-WT cells were transfected with RhoB-targeting or nontargeting (control) siRNAs, labeled with 30M
BrdU for 30 min, and analyzed by flow cytometry. Numbers indicate percentages of BrdU-positive cells (means	 SD for three experiments). Unlabeled cells were
used as negative controls for anti-BrdU staining. PI, propidium iodide. (F) Substrate and strategy used to measure DSB-induced end joining (49). The
pCOH-CD4 substrate contains genes coding for the membrane antigens H2Kd, CD8, and CD4. The only expressed gene is H2Kd. CD8 is not expressed because
it is in an inverted orientation, and CD4 is not expressed because it is too far from the promoter (P). Two cleavage sites for I-SceI are present in noncoding
sequences, which are in direct orientation generating cohesive ends between the two sites. When two DSBs are produced by I-SceI, the internal fragment
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integrated copy of the pDR-GFP substrate (26) (Fig. 4A). This
substrate allows the monitoring of homologous recombination,
specifically gene conversion, induced by a DSB produced by the
nuclease I-SceI (48). Plasmid pDR-GFP consists of a tandem re-
peat of two inactive GFP genes, one of them containing a cleavage
site for I-SceI. Transient expression of I-SceI produces a DSB in
the chromosomal recombination substrate, which can induce ho-
mologous recombination and recreates a functional GFP (Fig.
4A). The recombinant cells become fluorescent and can be de-
tected by flow cytometry. In RG37 cells, siRNA-mediated deple-
tion of RhoB decreased the induction of GFP-positive recombi-
nant cells in response to I-SceI expression (Fig. 4B). In agreement
with these results, siRNA-mediated depletion of RhoB also pre-
vented the formation of Rad51 foci post-CPT treatment (Fig. 4C
and D), a key protein in homologous recombination that is re-
cruited at DSB sites (47). Flow cytometry analysis of BrdU incor-
poration versus DNA content showed that the percentages of
S-phase cells were similar in cells transfected with control and
RhoB-targeting siRNAs (Fig. 4E) as well as in WT and RhoB/
MEF cells (WT cells, 46.3%	 2%; RhoB/ cells 45.0%	 0.7%)
(data not shown). Thus, RhoB deficiency did not result in a lower
proportion of S-phase cells, which excludes the possibility that
fewer cells in S phase account for the reduced DSB repair by ho-
mologous recombination.
To assess the potential involvement of RhoB in NHEJ repair,
we used human GC92 fibroblast cells stably expressing the pCOH-
CD4 substrate (27, 49, 50) (Fig. 4F). This substrate contains genes
encoding the membrane antigens H2Kd, CD8, and CD4. Before
expression of I-SceI, neither CD8 nor CD4 is expressed. I-SceI
expression produces the excision of the H2Kd/CD8 fragment, and
rejoining of the DNA ends leads to the expression of the CD4 gene
(Fig. 4F). Cells expressing CD4 at the plasma membrane can be
detected by flow cytometry using an anti-CD4 antibody. Figure
4G shows that siRNA-mediated depletion of RhoB did not signif-
icantly affect the induction of CD4-positive cells in response to
I-SceI expression. Together, these results indicate that RhoB is
involved in DSB repair primarily by homologous recombination.
RhoB-deficient cells are defective for PP2A activity. Inhibi-
tion of PP2A is known to impair DSB repair by homologous re-
combination (16). In addition, although several serine/threonine
phosphatases (PP2A, PP4, PP1, PP6, and Wip1) can dephosphor-
ylate H2AX (14), PP2A seems to be the main phosphatase for
H2AX in response to CPT (15). PP2A inhibition induces persis-
tent H2AX and DSBs in CPT-treated cells and increases cellular
sensitivity to CPT (15), effects similar to those observed in RhoB-
deficient cells (Fig. 3). We therefore examined whether RhoB in-
hibition could affect PP2A activity.
Consistent with the prevalent role of PP2A in removing
H2AX in CPT-treated cells (15), inhibition of PP2A with fostrie-
cin or okadaic acid completely prevented H2AX dephosphory-
lation following removal of CPT (Fig. 5A). Next, we measured
PP2A activity in WT, RhoB/, and RhoB/ cells complemented
with HA-RhoB. The levels of PP2A(C) protein were similar in all
cell populations (Fig. 5B). Figure 5C shows that PP2A activity was
reduced in RhoB/ cells compared to WT and RhoB/ cells
complemented with HA-RhoB. To determine whether RhoB and
PP2A are in the same pathway to dephosphorylate H2AX, we
compared the levels of H2AX post-CPT treatment when RhoB is
expressed or not under conditions where PP2A activity is inhib-
ited. Figure 5D shows that RhoB suppression with siRNA did not
further increase the level of H2AX in cells exposed to okadaic
acid post-CPT treatment. From these results, we propose that
RhoB promotes PP2A activity and DSB repair.
RhoB-deficient cells reveal endogenous H2AX foci and
genomic instability. Because we found that RhoB promotes DSB
repair, we examined whether RhoB-deficient cells would accumu-
H2Kd/CD8 is excised, and rejoining of the DNA ends leads to the expression of the CD4 gene. (G) GC92 cells stably expressing the pCOH-CD4 substrate were
transfected as described above for panel B, and percentages of CD4-positive cells were determined by flow cytometry using an anti-CD4 antibody. Nontargeting-
siRNA-transfected cells treated with the DNA-PK inhibitor NU7026 (DNA-PKi) (10 M) at the time of transfection with the I-SceI plasmid were used as a
control for the pCOH-CD4 substrate. Data shown are means	 standard errors of the means for seven (with siRNA RhoB#1) or three (with siRNA RhoB#2 and
the siRNA control plus the DNA-PK inhibitor) independent experiments. ns, nonsignificant (P  0.15 [with siRNA RhoB#1] and P  0.14 [with siRNA
RhoB#2]); ***, P 0.001 (by t test).
FIG 5 RhoB-deficient cells are defective for PP2A activity. (A) Western blot-
ting of H2AX and H2AX in HCT15/Chk2-WT cells treated with 1 M CPT
for 1 h and washed and cultured in CPT-free medium for 5 h (release). Okadaic
acid (OA) (100 nM) (lane 4) and fostriecin (100 nM) (lane 5) were added
immediately after CPT removal (washes). See also the treatment protocol de-
scribed in the legend of Fig. 3D. (B and C) Primary MDF cells of each genotype
were analyzed for RhoB and PP2A(C) expression by Western blotting (B) and
for PP2A activity after PP2A(C) immunoprecipitation (IP) using the Thr
phosphopeptide K-R-pT-I-R-R as a substrate (C). Data shown are means 	
SD for three independent experiments. *, P 0.05; ***, P 0.001 (by t test).
IB, immunoblotting. (D) HCT15/Chk2-WT cells were transfected with RhoB-
targeting or nontargeting (control) siRNAs before treatment, as described
above for panel A. Western blotting of H2AX and H2AX. The top panel
shows quantification of H2AX expression normalized to the expression level
of H2AX, shown at the bottom.
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late endogenous DSBs. We analyzed H2AX nuclear foci by im-
munofluorescence microcopy in WT and RhoB/ cells in the
absence of treatment. This technique is much more sensitive than
Western blotting, as it can detect a single DSB focus per cell (9).
Figure 6A reveals increased numbers of H2AX foci in RhoB/
cells compared to WT cells. Quantitative analyses of the micros-
copy images showed that approximately 25% of RhoB/ nuclei
formed15 H2AX foci, compared to 3% in WT cells (Fig. 6B).
Inefficient repair of DSBs can initiate genomic instability (9,
10). To evaluate genomic instability in RhoB/ cells, we per-
formed comparative genomic hybridization (CGH) whole-ge-
nome tiling arrays. Genomic DNA of primary mouse dermal fi-
broblast (MDF) cells from RhoB/mice was compared to a pool
of genomic DNA of MDF cells from four WT syngeneic mice. As a
control for genomic alterations due to interindividual variability,
genomic DNA of MDF cells from a WT mouse was compared to
the pool of WT genomic DNA (Fig. 6C). The three RhoB/mice
analyzed revealed an increased number of chromosomal amplifi-
cation and deletion events compared to the WT mouse (Fig. 6D).
A representative chromosome is shown in Fig. 6E. In accordance
with these results, the total length of chromosomal alterations and
the genomic instability index, which reflects the number of alter-
ations per chromosome (32), were also higher in RhoB/ mice
(Fig. 6D). Together, these experiments suggest that RhoB loss in-
creases the number of endogenous DSBs and genomic instability.
DISCUSSION
Here we identify RhoB as the first GTPase involved in the signaling
and repair of DSBs. Our data support a model in which DSBs
activate a Chk2-HuR-RhoB pathway that promotes PP2A-medi-
ated dephosphorylation of H2AX and repair (Fig. 7). DSBs are
likely the initiating events for RhoB upregulation, as inhibition of
CPT-induced DSBs by blocking of replication suppressed the in-
duction of RhoB mRNA (Fig. 1G). Also, the induction of RhoB
depends on Chk2 (Fig. 2), a checkpoint kinase readily activated by
DSBs (39). Other parallel pathways besides Chk2 probably also
FIG 6 RhoB loss is accompanied by increased H2AX levels and chromosomal abnormalities. (A) Representative images of WT and RhoB/ primary MDF
cells after staining forH2AX. DNA was counterstained with DAPI (blue). Bar, 10m. (B) Quantification of the number ofH2AX foci per nucleus. A minimum
of 500 nuclei was analyzed per cell type (means	 SD for three independent experiments). (C) Design of the CGH array analysis. Genomic DNA of RhoB/MDF
cells was compared to a pool of genomic DNA of MDF cells from four different WT syngeneic mice. As a control, to determine the number of genomic alterations
due to interindividual variability, genomic DNA of WT MDF cells was compared to the pool of genomic DNA from WT mice. (D) Table showing whole-genome
chromosomal amplification and deletion events as well as the total length (in kbp) of chromosomal alterations in RhoB/MDF cells compared to WT MDF cells
analyzed by CGH arrays. The genomic instability index was calculated with the formula (number of deletions
 number of amplifications)2/number of altered
chromosomes, as previously described (32). (E) Chromosome plots for chromosome 15 of RhoB/MDF cells from mouse 2 compared to the pool of WT MDF
cells, as determined by a CGH array. This chromosome is representative of the mean numbers of amplification and deletion events in RhoB/ MDF cells.
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contribute to RhoB induction, as Chk2-KD cells are not com-
pletely defective for HuR-RhoB mRNA interaction (Fig. 2F) and
RhoB induction in response to CPT (Fig. 2G and H). The Chk2-
independent induction of RhoB (Fig. 7) may be sufficient to pro-
mote H2AX dephosphorylation, as Chk2-KD cells dephosphor-
ylate H2AX with an efficiency similar to that of Chk2-WT cells 5
h after CPT removal (data not shown). Moreover, because Chk2 is
a major player in DSB repair (it phosphorylates/activates Brca1,
p53, and PP2A) (39), these results also raise the possibility that
Chk2-KD cells have evolved and compensate by increasing Chk2-
independent pathways to repair DSBs. Such pathways may impli-
cate Chk1. Indeed, CPT is known to activate the ATR-Chk1 path-
way (18, 19), and Chk1 can promote HuR-dependent stabilization
of mRNAs by inhibiting Cdk1-mediated phosphorylation of HuR
(51, 52). Moreover, Chk1 can also promote DSB repair by phos-
phorylating the repair factor Rad51 (53). In addition, the effect of
Chk2 loss seems to be less pronounced on HuR-RhoB mRNA
interactions than on RhoB mRNA levels after CPT treatment, which
raises the possibility that other pathways besides HuR also participate
in the induction of RhoB mRNA by Chk2. Further support for the
role of DSBs is provided by independent studies showing that RhoB is
also upregulated early in response to UV and cisplatin (2, 3), which
can produce DSBs in replicating cells (54–56).
RhoB appears to be implicated in the repair of DSBs from
different origins. Indeed, RhoB-deficient cells maintain elevated
H2AX levels in response to CPT (Fig. 3), which produces DSBs
indirectly during replication (19) and transcription (20) as well as
in response to endogenous DSBs (Fig. 6). RhoB-deficient cells are
also defective in the repair of DSBs that are produced directly by
the endonuclease I-SceI (Fig. 4). DSBs are potentially lethal DNA
lesions if not repaired (9). In agreement with the involvement of
RhoB in DSB repair, RhoB-deficient cells are hypersensitive to
CPT (Fig. 3A) and other genotoxic agents that can also induce
DSBs, such as ionizing radiation (57) and UV (2).
It is now well documented that inhibition of PP2A activity
impairs DSB repair (15–17). Hence, our finding that RhoB-defi-
cient cells are defective for PP2A activity (Fig. 5) links RhoB ex-
pression to DSB repair. Although RhoB can bind PP2A(C) (58), it
is not known whether this interaction is important for PP2A ac-
tivity. PP2A may stimulate DSB repair by the timely dephosphor-
ylation of H2AX (15). Our analysis showing that RhoB-deficient
cells are defective for DSB repair by homologous recombination
but not for DSB repair by end joining (Fig. 4) further suggests that
H2AX dephosphorylation might be specifically required for ho-
mologous recombination. In line with this possibility, it has been
reported that H2AX dephosphorylation (removal) is required
for efficient DNA end resection, which is a prerequisite for homol-
ogy-mediated DSB repair (59). Besides RhoB promoting DSB re-
pair by PP2A-mediated H2AX dephosphorylation (Fig. 7), it is
possible that RhoB also promotes DSB repair by PP2A-indepen-
dent pathways, which may in turn further increase PP2A-medi-
ated H2AX dephosphorylation. PP2A may also stimulate DSB
repair by homologous recombination by dephosphorylating non-
DDR proteins such as Akt1 (60). Indeed, phosphorylated/active
Akt1 has been reported to inhibit homologous recombination by
inducing cytoplasmic retention of Brca1 and Rad51 (61). It is
therefore possible that RhoB inhibition prevents DSB repair by
inhibiting the PP2A-dependent dephosphorylation of Akt1. This
hypothesis is concordant with our previous and current findings
that the loss of RhoB expression promotes the activation of Akt1
(7) and prevents DSB repair by homologous recombination (Fig.
4). Besides H2AX (and Akt), it is likely that RhoB loss affected
other PP2A substrates, as RhoB loss decreased the global activity
of PP2A, which was measured by using a nonspecific threonine
phosphopeptide (Fig. 5C). Although PP2A can also promote DSB
repair by NHEJ by dephosphorylating Ku70, Ku80, and DNA-
PKcs (17), RhoB downregulation did not significantly affect end-
joining-repair events (Fig. 4). Hence, the predominant role of
RhoB-dependent PP2A activity is likely to promote DSB repair by
homologous recombination. Besides PP2A, it is possible that
RhoB loss also decrease a PP4 activity. Indeed, PP4 loss is primar-
ily involved in the basal increase in the level of H2AX (62), and
we found that RhoB-deficient cells have elevated endogenous
H2AX levels (Fig. 6).
RhoB expression commonly decreases during tumor progres-
sion (4–8), and RhoB knockout (KO) mice are more susceptible to
tumor formation and/or progression in response to UVB (63) and
7,12-dimethylbenz[a]anthracene (DMBA), whose metabolites in-
duce DNA damage (24). However, very little is known about the
molecular mechanisms by which the loss of RhoB promotes tu-
mor progression. We show here that RhoB-deficient cells are de-
fective for DSB repair (Fig. 3 and 4) and that, consistent with this,
they have elevated endogenous H2AX levels and chromosomal
abnormalities (Fig. 6). We recently reported that RhoB-deficient
human skin tumors also have elevated H2AX levels compared to
RhoB-proficient tumors (63). Hence, our findings suggest that
loss of RhoB could promote oncogenesis by increasing DSB-me-
diated genomic instability.
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FIG 7 Proposed molecular pathways for the role of RhoB in the DDR and
repair. The gray box indicates that PP2A promotes DSB repair by dephosphor-
ylating H2AX ([1]) and/or non-DDR proteins ([2]) (see Discussion).
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RhoB Promotes Cancer Initiation by Protecting
Keratinocytes from UVB-Induced Apoptosis but
Limits Tumor Aggressiveness
Nicolas Meyer1,2,3,7, Alexis Peyret-Lacombe1,2,7, Bruno Canguilhem1,2, Claire Me´dale-Giamarchi1,2,
Kenza Mamouni1,2, Agnese Cristini1,2, Sylvie Monferran1,2, Laurence Lamant1,2,4, Thomas Filleron5,
Anne Pradines1,2,6, Olivier Sordet1,2 and Gilles Favre1,2,6
The role of UVB-induced apoptosis in the formation of squamous cell carcinoma (SCC) is recognized. We
previously identified the small RhoB (Ras homolog gene family, member B) GTPase, an early response gene to
cellular stress, as a critical protein controlling apoptosis of human keratinocytes after UVB exposure. Here we
generated SKH1 (hairless immunocompetent mouse) mice invalidated for RhoB to evaluate its role in UVB-
induced skin carcinogenesis in vivo. We show that rhob / mice have a lower risk of developing UVB-induced
keratotic tumors and actinic keratosis that is associated with a higher sensitivity of UVB-exposed keratinocytes to
apoptosis. We extend this observation to primary cultures of normal human keratinocytes in which RhoB was
downregulated with small interfering RNA (siRNA) and further show that the hypersensitivity to apoptosis
depends on B-cell lymphoma 2 (Bcl-2) downregulation. In rhob / mice, the UVB-induced tumors were
preferentially undifferentiated and highly proliferative. Finally, we show in humans an almost constant loss of
RhoB expression in undifferentiated SCCs. These undifferentiated and RhoB-deficient tumors have elevated
phosphorylated histone H2AX (gH2AX) and 53BP1, two markers of DNA double-strand breaks. Together, our
results indicate that UVB-induced RhoB expression participates in in vivo SCC initiation by increasing
keratinocyte survival. Conversely, RhoB may limit tumor aggressiveness as loss of RhoB expression in tumor
cells is associated with tumor progression.
Journal of Investigative Dermatology (2014) 134, 203–212; doi:10.1038/jid.2013.278; published online 18 July 2013
INTRODUCTION
Cutaneous squamous cell carcinomas (SCCs) represent one of
the most common human cancer type (Madan et al., 2010).
Approximately 85% of SCCs are cured by surgery, whereas the
remaining 15% display poor prognosis. Currently, there are no
specific markers to predict tumor aggressiveness and risk of
recurrence in patients.
It is largely admitted that UVB plays a crucial role in the
development of SCC (Goodwin et al., 2004). The response of
keratinocytes to UVB is complex and depends upon a
balance between cell death and survival pathways.
Deregulation of genes controlling this balance is considered
as a key factor in the early phases of photocarcinogenesis
(De Gruijl and Voskamp, 2009). We previously identified
the GTPase RhoB (Ras homolog gene family, member B)
as a key regulator of the apoptotic response of human
HaCaT keratinocytes to UVB. We demonstrated that RhoB is
critical for EGFR-induced cell survival after UVB exposure
through regulation of Ak thymoma (AKT) phosphorylation
(Canguilhem et al., 2005).
RhoB belongs to the Rho GTPase family, a group of proteins
controlling many cellular functions such as cell survival and
migration, the deregulation of which are implicated in cancer
initiation and progression (Karlsson et al., 2009). rhob is an
early inducible gene activated by cellular stress including
hypoxia (Skuli et al., 2006), ionizing radiation (Milia et al.,
2005; Monferran et al., 2008), cytotoxic agents (Liu et al.,
2001), and UV irradiation (Fritz and Kaina, 2001; Canguilhem
et al., 2005). When activated, RhoB triggers a signaling
cascade promoting the activation of AKT and NF-kB survival
pathways (Mazie`res et al., 2005). Moreover, RhoB displays
tumor-suppressor gene functions in many cell types as well
as in mouse models (Chen et al., 2000; Liu et al., 2001;
Prendergast, 2001; Jiang et al., 2004). RhoB expression
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decreases during the progression of various tumors. Loss of
RhoB expression was shown to promote cell proliferation,
invasion, and metastasis.
Here, we develop hairless immunocompetent mice
(SKH1) invalidated for rhob to study its in vivo role in
UVB-induced photocarcinogenesis in mice. We also
evaluated the relevance of RhoB in humans using primary
cultures of human keratinocytes and human SCC tumor
samples. Altogether, our work emphasizes the critical
role of RhoB in both the initiation and the progression of
skin SCC.
RESULTS
rhob / mice experience a lower incidence of SCC precursor
tumors following chronic exposure to UVB
To evaluate in vivo the influence of RhoB on UVB-induced
skin carcinogenesis, we crossed the SKH1 mouse that mimics
UVB-induced photocarcinogenesis in humans (De Gruijl and
Forbes, 1995; Benavides et al., 2009; Sharma et al., 2011)
with rhob knockout (rhob / ) mice (Liu et al., 2001). The
SKH1 mice rhob / , rhobþ / , and rhobþ /þ were
exposed daily to 0.1 J cm 2 UVB, corresponding to one
minimal erythemal dose. Animals started to develop actinic
keratosis (AK)–like lesions after 12 weeks of chronic UVB
exposure and all mice exhibited at least one AK at 24 weeks.
AKs are precursors of SCC (Salasche, 2000). Mice also
developed small keratotic and large ulcerated tumors that
have a similar appearance to human SCC (De Gruijl and
Forbes, 1995). Notably, the relative distribution of AKs and
tumors varied, with mice developing primarily numerous AKs
together with a prevalence of small keratotic tumors, whereas
others only few AKs with primarily large ulcerated tumors
(Supplementary Figure S1 online).
The primary assessment of the extent of AKs in mice was
performed after 17 weeks of daily UVB exposure. Animals
were categorized as highly sensitive to UVB-induced photo-
carcinogenesis if they had AKs covering 450% of the dorsal
skin (group A). Animals experiencing o50% of their dorsal
skin covered by AKs were included in the low sensitivity
(group B; Figure 1a and Supplementary Figure S1 online; also
see Materials and Methods). Figure 1b shows that the mice
with high sensitivity to UVB-induced photocarcinogenesis
were almost exclusively the þ /þ and þ / rhob mice,
whereas mice presenting lower sensitivity were mainly
rhob / . In rhob / mice, the lower occurrence of AKs
was associated with a reduced total number of skin tumors
(Figure 1c and Supplementary Figure S2 online). These results
were confirmed in a second set of experiments (Supple-
mentary Figure S3a and b online). Analysis of the tumor type
revealed that small keratotic tumors were less prevalent in
rhob / mice (Figure 1d and Supplementary Figure S4a
online), whereas the prevalence of large ulcerated tumors was
not significantly different in rhobþ /þ and rhob / mice
(Figure 1e). We concluded that the absence of RhoB is
associated with a reduction in the occurrence of AKs and
small keratotic tumors upon chronic exposure to UVB without
significantly affecting the induction of large ulcerated tumors
(Supplementary Figure S4b online).
UVB irradiation induces RhoB expression in normal human skin
tissues
Because SCCs develop from the stratum spinosum in response
to UVB (Ratushny et al., 2012), we analyzed RhoB expression in
the human epidermis. After surgical excision, human skin tissues
from two healthy donors were left untreated or exposed to
0.4 J cm2 UVB. At 8hours after irradiation, expression of RhoB
was analyzed by immunohistochemistry (Figure 2a and b and
Supplementary Figure S5 online). In the absence of treatment,
RhoB was expressed at very low levels at the suprabasal layers
of the epidermis and was mostly detected at the basal layer
(Figure 2a and b). Keratinocytes from the basal layer are the
replicating cells ensuring renewal of suprabasal layers. Follow-
ing UVB exposure, RhoB expression was markedly increased at
the suprabasal layers of the epidermis (Figure 2b). Altogether,
these results suggest that the induction of RhoB at the suprabasal
layers of the epidermis in response to UVB may be involved in
the development of AKs and small keratotic tumors.
Keratinocytes of rhob / mice are hypersensitive to
UVB-induced apoptosis
To gain insight into the mechanism of RhoB-induced skin
carcinogenesis, we analyzed the role of RhoB in the apoptotic
response to UVB. Apoptosis is a major anticancer
barrier (Lowe and Lin, 2000; Wong, 2011). We have
previously shown that knocking down RhoB in human
HaCaT cells confers hypersensitivity to UVB-induced apop-
tosis (Canguilhem et al., 2005). It is also clearly demonstrated
that RhoB is involved in the apoptotic response to genotoxics,
including ionizing radiation (Fritz and Kaina, 2001; Liu et al.,
2001; Jiang et al., 2004; Milia et al., 2005). To test whether
the reduced number of AKs and small keratotic tumors in
rhob / mice could be related to an excess of apoptosis,
we compared UVB-induced apoptosis of rhobþ /þ and
rhob / mice keratinocytes. Mice were exposed to
0.2 J cm2 UVB and apoptotic DNA fragmentation was
assessed 24 hours later by TUNEL assay (Samejima and
Earnshaw, 2005) on formalin-fixed, paraffin-embedded
(FFPE) skin samples by microscopy. Figure 3a shows that
the percentage of TUNEL-positive keratinocytes was signifi-
cantly higher in rhob / mice than in rhobþ /þ mice.
We also tested whether tumoral keratinocytes of rhob /
mice were more sensitive to UVB-induced apoptosis. All FFPE
tumor samples collected after chronic UVB exposure of
rhobþ /þ (n¼17) and rhob / (n¼23) mice were
assessed for apoptosis by cleaved caspase-3 immunostaining
(Supplementary Figure S6 online). A significantly higher
proportion of cleaved caspase-3-positive keratinocytes was
found in rhob / mice tumors compared with rhobþ /þ
mice tumors (Figure 3b). Together, these results indicate that
RhoB deficiency confers hypersensitivity of both normal and
tumoral keratinocytes to UVB-induced apoptosis, which could
protect rhob / mice against UVB-induced tumor initiation.
RhoB protects human keratinocytes from UVB-induced
apoptosis through Bax/Bcl-2 ratio modulation
To determine whether these results could be extended to
humans, we isolated normal human keratinocytes (NHKs)
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from healthy donors. RhoB expression was downregulated by
transient transfection with small interfering RNA (siRNA)
duplexes. Then, cells were exposed to 0.4 J cm 2 UVB and
apoptosis was assessed after 24 hours. The siRNA-mediated
depletion of RhoB in human NHK (Supplementary Figure S7
online) resulted in marked increase of cleaved caspase-3
(Figure 3c), caspase-3-dependent cleavage of poly (ADP-
ribose) polymerase (Figure 3d), and apoptotic DNA fragmen-
tation (Figure 3e).
It has been demonstrated that the Bax/B-cell lymphoma 2
(Bcl-2) ratio, a critical element determining cell death
or cell survival, increases after UVB exposure in HaCaT
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(Reagan-Shaw et al., 2006) and NHK cells (Afaq et al., 2007).
UVB irradiation (0.4 J cm2) of NHKs increased Bax expres-
sion and decreased Bcl-2 expression, causing a 3-fold increase
in the Bax/Bcl-2 ratio after 24 hours (Figure 4a and b).
Under these conditions, RhoB downregulation with siRNA
further decreased Bcl-2 expression without changing Bax
expression (Figure 4a and b), leading to a 15-fold increase
in the Bax/Bcl-2 ratio.
Because Bcl-2 expression can be regulated by many
survival proteins including AKT (Maddika et al., 2007), we
investigated the role of RhoB on AKT phosphorylation/
activation in NHKs exposed to UVB. Figure 4c shows that
RhoB downregulation with siRNA prevented UVB-induced
AKT phosphorylation on serine 473 after 4 and 8 hours.
This was associated with a reduction of Bcl-2 expression
(Figure 4c). These data suggest that RhoB favors NHK survival
after UVB through upregulation of the AKT/Bcl-2 pathway,
leading to a decrease in the Bax/Bcl-2 ratio. It is unlikely that
the protective effect of RhoB on apoptosis could be related to
p53 because its expression was not affected in both
RhoB-deficient cells (Supplementary Figure S8a online) and
RhoB- deficient mouse tumors (Supplementary Figure S8b
online). Moreover, p53 and RhoB expressions were not
correlated in human tumors (Supplementary Table S1 online).
RhoB loss is associated with the preferential induction of
undifferentiated tumors
Tumor differentiation is inversely related to tumor progression
and metastatic potential. Undifferentiated tumors frequently
display a higher proliferative and invasive potential (Spector
et al., 2011). To evaluate the levels of differentiation of
individual tumors from rhobþ /þ and rhob / mice, all
FFPE tumor samples collected after chronic exposure were
divided into two categories as exemplified in Figure 5a: mild-
to-well-differentiated tumors were defined as tumors with
organoid differentiation without significant cytokeratin-8
expression, whereas low-differentiated to undifferentiated
tumors were tumors without organoid differentiation and
without significant cytokeratin-1 expression. Figure 5b
shows that the proportion of low-to-undifferentiated
tumors was higher in rhob / than in rhobþ /þ mice.
Tumors from rhob / mice showed a higher proportion of
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Figure 2. RhoB (Ras homolog gene family, member B) is induced in human healthy skin explants after UVB exposure. (a) RhoB immunostaining on human
healthy skin explant. The expression of RhoB is weak and mainly localized in basal layer keratinocytes. (b) RhoB immunostaining on human skin explants from
two healthy donors (scale¼ 20mm), unirradiated or 8 hours after 0.4 J cm2 UVB irradiation. The expression of RhoB is markedly increased and detectable in the
entire epidermis.
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cells positive for the proliferation marker Ki67 (Figure 5c)
(Batinac et al., 2006). These results are in agreement with
rhob / mice developing less small keratotic tumors
(Figure 1d), which are normally more differentiated than
ulcerated tumors, and suggest that RhoB deficiency increases
tumor aggressiveness.
We then analyzed RhoB expression in individual tumors
from rhobþ /þ mice, depending on their differentiation
grade. Reverse transcriptase–quantitative PCR analyses
revealed that levels of RhoB transcripts were markedly
reduced in mildly differentiated tumors as compared with
well-differentiated tumors (Figure 5d), suggesting that RhoB
expression decreases during progression of skin tumors upon
chronic UVB exposure. Although we demonstrated that
oncogenic ras mutants downregulated RhoB expression in
lung tumors (Bousquet et al., 2009), we did not find
any mutations in H-ras, N-ras, and K-ras genes in rhobþ /þ
and rhob / mice SCCs.
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RhoB loss is associated with increased levels of DNA
double-strand breaks
To determine whether these results could be extended to
humans, we analyzed RhoB expression on human invasive
SCC by immunohistochemistry and microscopy. A total of
80 tumor samples were selected according to their level of
differentiation (as described above for mice tumors) in the
tumor bank of Toulouse-Purpan Hospital. Two groups were
constituted: the first group with 40 well-differentiated SCCs,
and the second one with 40 undifferentiated SCCs. We
observed that almost all undifferentiated human SCCs did not
express RhoB (Figure 6a and Supplementary Figure S9 online).
On these human tumor samples, we also analyzed the
expression of phosphorylated histone H2AX (referred to as
gH2AX), a marker for DNA double-strand breaks (DSBs)
(Bonner et al., 2008). DSBs are severe lesions and their
inefficient/inaccurate repair can contribute to genomic
instability and cancer progression (Bonner et al., 2008).
Figure 6b shows that the undifferentiated and RhoB-deficient
human skin tumors have elevated gH2AX expression; RhoB
and gH2AX expression were inversely correlated (Spearman’s
r ¼ 0.50; 95% confidence interval: 0.77 to  0.06).
Besides gH2AX, we analyzed p53 binding protein 1 (53BP1),
another DNA damage response protein that accumulates at
sites of DSBs (Lukas et al., 2011). Figure 6c shows that
undifferentiated human skin tumors have elevated expression
of 53BP1. Consistent with these results, tumors from
rhob / mice show elevated gH2AX- and 53BP1-positive
cells compared with tumors from rhobþ /þ mice (Figure 6d
and 6e and Supplementary Figure S10a, b online). These
results suggest that loss of RhoB expression increases the levels
of endogenous DSBs. To test more directly this hypothesis, we
compared gH2AX expression of rhobþ /þ and rhob /
basal layer keratinocytes from normal skin tissues. We
observed a significant increase of gH2AX labeling in kerati-
nocytes from rhob / mice (Figure 6f and Supplementary
Figure S10c online). Immunofluorescence microscopy experi-
ments further show that gH2AX-positive cells from rhob /
skin tissues were also positive for 53BP1 (Figure 6g). Because
rhobþ /þ and rhob / cells have similar proliferation rate
(Supplementary Figure S11 online), it is unlikely that the
increase of gH2AX in rhob / skin tissues simply resulted
from increased DNA replication. Together, these results
indicate that RhoB deficiency is accompanied with increased
levels of DSBs, suggesting that loss of RhoB expression might
contribute to genomic instability and skin tumor progression.
DISCUSSION
This study provides insights, which to our knowledge are
previously unreported, in the understanding of UVB-induced
keratinocyte carcinogenesis in vivo, emphasizing the role of
RhoB. We demonstrate that UVB-induced RhoB expression
participates in maintaining cell survival, thus favoring the
development of SCCs. Our data clearly show that keratino-
cytes from RhoB-deficient mice are more sensitive to UVB-
induced apoptosis and that these mice develop fewer AKs and
keratotic tumors than the wild-type counterparts. These results
are consistent with our previous work showing that RhoB
downregulation sensitized HaCaT immortalized keratinocytes
to UVB-induced apoptosis (Canguilhem et al., 2005). We
further extended these observations to human keratinocytes
isolated from the skin of healthy donors. In addition, we show
that basal expression of RhoB in human skin is almost only
detectable in keratinocytes from the basal layer, and that UVB
exposure induces a strong holoepidermic expression of RhoB.
Together, these observations support the possibility that UVB-
induced RhoB expression protects UVB-exposed keratino-
cytes from apoptosis, thereby promoting the initiation of
carcinogenesis. RhoB may protect keratinocytes from UVB-
induced apoptosis by activating cell survival pathways.
Indeed, we have previously demonstrated that UVB-induced
EGFR survival pathway depends on RhoB in HaCaT cells
through regulation of AKT phosphorylation (Canguilhem et al.,
2005). Increased Bcl-2 expression has been reported to favor
photocarcinogenesis by preventing apoptosis (Nakagawa
et al., 1994; Delehedde et al., 1999). We demonstrate here
that RhoB is a critical determinant for Bcl-2 expression after
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UVB exposure (Figure 4) and therefore suggest that the RhoB/
Bcl-2 axis is involved in early phase of UVB-induced
carcinogenesis.
RhoB also participates in the control of skin tumor
progression. This is supported by three lines of evidence: (1)
rhob / mice are prone to the development of UVB-
induced aggressive SCCs, (2) in rhobþ /þ mice exposed to
UVB, RhoB expression is downregulated in poorly differen-
tiated and thereby aggressive SCCs (Figure 5d), and (3) RhoB
expression is also selectively lost in undifferentiated human
skin tumors (Figure 6a). Moreover, because the number of
ulcerated tumors is similar in the rhobþ /þ and rhob /
genotypes (Figure 1e), it is likely that RhoB does not prevent
the occurrence of undifferentiated tumors. This is in agreement
with our hypothesis that tumor progression requires loss of
RhoB expression. These results are in agreement with our
previous work on lung cancer showing that loss of RhoB
occurs in the most aggressive tumors (Mazieres et al., 2004)
and promotes invasion of human bronchial cancer cells
(Bousquet et al., 2009). Consistently, Adnane et al (2002).
reported loss of RhoB expression in invasive human SCCs of
the head and neck. Although the tumor-suppressor role of
RhoB is now well documented, its mechanism remains to be
elucidated. Our experiments indicate that RhoB-deficient cells
have elevated endogenous DSBs (Figure 6), and therefore
suggest that loss of RhoB expression during progression of skin
tumors (this study) and potentially the above-mentioned
tumors (Adnane et al., 2002; Mazieres et al., 2004;
Bousquet et al., 2009) could promote oncogenesis by
increasing DSB-mediated genomic instability. Further studies
will be required to determine the molecular mechanisms by
which loss of RhoB enhances endogenous DSBs.
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Our results support the hypothesis that RhoB plays a
double-edged role in oncogenesis. Beside its role as a
negative regulator of tumor progression, we report here
a new aspect of the role of RhoB in skin oncogenesis in
promoting tumor initiation through survival of UVB-exposed
cells. RhoB could favor early stages of oncogenesis but
at the same time could limit tumor aggressiveness. In this
model, alteration of gene expression leading to RhoB down-
regulation would then become necessary for tumor progres-
sion. These results are in agreement with our previous
report on lung cancer (Mazieres et al., 2004), in which we
observed the expression of RhoB in in situ carcinoma of
the lung and subsequent loss of RhoB expression in invasive
cancers.
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Understanding the role of RhoB in photocarcinogenesis
could help to find novel strategies into routine clinical
practice for the 15% of human SCCs displaying poor
prognosis. Indeed, our results suggest that loss of RhoB
may be considered a negative prognostic marker of
human SCCs of the skin. Further studies are needed
to assess the prognostic value of RhoB expression on large
cohorts of patients with SCCs. Deciphering the RhoB
pathway involved in the control of skin photocarcinogenesis
may help the development of new therapeutic strategies
against SCCs.
In conclusion, our results show that RhoB is a critical
determinant for SCC initiation and that loss of RhoB
expression in SCCs may predict tumor aggressiveness.
MATERIALS AND METHODS
Mice
SKH1 mice (Charles River, L’Arbresle, France) were crossed with
Sv129/rhob / mice (Supplementary Figure S1 online) (Liu et al.,
2001). The Claudius Regaud Institute animal ethic committee
approval (no. ICR-2009-016) was obtained for the use of the animal
model and the study protocols.
UV exposure
Protocols of mice and cells UVB exposure are described in
Supplementary Materials and Methods online.
Definition of the UV-induced phenotypes
A clinical evaluation of the mice at week 17 was performed on
standardized photographs. Mice were separated in two groups
according to the extent (4 or o50%) of UV-induced AK on the
dorsal skin defined as the skin between the base of the neck and the
base of the tail (Figure 1a and Supplementary Figure S1 online). The
17-week UVB exposure end point for assessment of the effect of UVB
on the occurrence of SCC precursors was chosen as the latest time at
which all mice were alive. No consensus definition exists on the
severity categorization of AK in humans or mice. The threshold of
50% for AK coverage of the dorsal skin of mice was chosen as an
indicator of high UVB-induced skin damage.
NHK culture and siRNA transfection
NHK primary cultures were prepared from skin explants from patients
undergoing mammary plastic surgery (see Supplementary Materials
and Methods online). Transfection of NHKs by siRNAs (10 nM)
(described in Canguilhem et al., 2005) was performed using
Oligofectamine (Life Technologies SAS, Saint Aubin, France) in
keratinocyte serum-free medium according to the manufacturer’s
instructions on cells at 30–50% confluence in 60-mm cell culture
dishes and seeded 24 hours before experiments.
Immunoblot analysis
Immunoblot analysis of RhoB was performed as previously described
(Canguilhem et al., 2005), see Supplementary Materials and Methods
online.
Pathological examination of the tumors
FFPE mouse tumor samples were cut in 4-mm-thick sections. Sections
were incubated at 100 1C for 15 minutes and then deparaffinized with
xylene and rehydrated. Sections were stained with hematoxylin and
eosin, and read by a trained dermatopathologist.
Human SCCs of the skin
A total of 80 FFPE human SCCs were obtained from the tumor bank of
the department of pathology (Toulouse-Purpan Hospital, France) after
written informed consent. The specimens consisted of 40 mild-to-
well-differentiated and 40 low-to-undifferentiated invasive SCCs of
the skin.
Immunostaining of tissues
Immunostainings were performed as described in Supplementary
Materials and Methods online.
Immunofluorescent staining of tissues
Sections of cryoconserved tumor samples were fixed in 3% paraf-
ormaldehyde and permeabilized with 0.1% Triton X-100. After a
saturation step in 3% BSA/phosphate-buffered saline, cells were
incubated with mAb against gH2AX (9718, Cell Signaling, Danvers,
MA) and then with Alexa Fluor 488 antibody (Life Technologies SAS).
Coverslips were mounted on slides with Mowiol solution containing
40,6-diamidino-2-phenylindole. Staining was detected by fluores-
cence microscopy.
Flow cytometry analyses of cleaved caspase-3 in NHKs
The phycoerythrin-conjugated Polyclonal Active Caspase-3 Antibody
Apoptosis Kit (BD Pharmingen, Franklin Lakes, NJ) was used accord-
ing to the manufacturer’s instructions. Fluorescence was analyzed by
flow cytometry on a BD-FACS Calibur (Le Pont de Claix, France).
Quantitative reverse transcribed–PCR
Flash-frozen tissue (50 mg) was homogenized in a TissueLyser system
(Qiagen, Courtaboeuf, France). RNA was isolated using miRNeasy kit
following the manufacturer’s instructions (Qiagen) and reverse tran-
scribed using iScript cDNA Synthesis kit (Bio-Rad, Hercules, CA).
Quantitative PCR was performed with a CFx-96 real-time system
(Bio-Rad). The specific murine primer pairs are described in
Supplementary Materials and Methods online.
Statistical analysis
Comparisons of percentages were made using the w2 test. For mean
comparisons between groups the two-sample t-test and the Mann–
Whitney test were used as appropriate. The Kaplan–Meier method
was used to estimate the distribution time taken to reach 10 tumors or
5 keratotic tumors, and differences among the groups were tested by
the log-rank test. All tests were two sided with an a risk of 5%.
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TITLE: DNA double-strand break formation and signalling in response to transcription-blocking 
topoisomerase I complexes  
 
Summary 
 
Topoisomerase I (Top1) removes DNA supercoiling generated during transcription by producing Top1-DNA 
cleavage complexes (Top1cc). These transient Top1cc can be stabilized by camptothecins, from which 
anticancer drugs are derived, and by common DNA alterations. Although stabilized Top1cc are potent 
transcription-blocking lesions, our understanding regarding the molecular processes resulting from the 
stalling of transcription complexes by Top1cc is currently limited. Previous work showed that stabilized 
Top1cc produce transcription-dependent DNA double-strand breaks (DSBs) that activate ATM signalling. In 
this project, we used camptothecin-treated quiescent cells to induce transcription-blocking Top1cc and study 
the mechanisms of DSB production and signalling. We show that DSBs form preferentially at subtelomeric 
regions during the repair of transcription-blocking Top1cc from DNA single-strand breaks generated after 
Top1 proteolysis and before Tdp1 action. Analysis of DSB signalling reveals a novel function of DNA-PK in 
promoting protein ubiquitination leading (i) to full ATM activity at DSB sites by promoting H2AX and H2A 
ubiquitination, and (ii) to enhancement of Top1cc repair by promoting Top1 proteolysis. Finally, we show 
that co-transcriptional DSBs kill quiescent cells. Together, these findings provide new insights into the 
cellular responses to camptothecins and further suggest that DSBs arising from transcription-blocking 
Top1cc may contribute to the pathogenesis of the neurodegenerative SCAN1 syndrome, which is caused by 
Tdp1 deficiency. 
 
TITRE: Formation et signalisation des cassures double-brin de l’ADN lors d’un blocage de la 
transcription par les complexes topoisomerase I-ADN 
 
Résumé  
 
La topoisomérase I (Top1) élimine les surenroulements de l’ADN générés lors de la transcription en 
produisant transitoirement des complexes de clivage Top1-ADN (Top1cc). Ces Top1cc transitoires peuvent 
être stabilisés par les camptothécines, dont sont dérivés des agents anticancéreux, et par les fréquentes 
altérations de l’ADN. Bien que les Top1cc stabilisés soient des lésions qui bloquent efficacement la 
transcription, la compréhension des processus moléculaires qui résultent du blocage des complexes 
transcriptionnels par les Top1cc est encore limitée. Des travaux précédents ont montré que les Top1cc 
stabilisés produisent des cassures double-brin (DSBs) de l’ADN dépendantes de la transcription qui activent 
ATM. Dans ce projet, nous avons utilisé des cellules quiescentes traitées avec la camptothécine pour induire 
des Top1cc bloquant la transcription et nous avons étudié les mécanismes de la production et de la 
signalisation des DSBs. Nous montrons que les DSBs sont produites préférentiellement dans les régions sub-
télomériques lors de la réparation des Top1cc bloquant la transcription par les cassures simple-brin de 
l’ADN générées après la protéolyse de la Top1 et avant l’action de Tdp1. L’analyse de la signalisation de ces 
DSBs révèle une nouvelle fonction de DNA-PK  dans la promotion de l’ubiquitinylation conduisant (i) à 
l’activité complète d’ATM aux sites des DSBs en favorisant l’ubiquitination d’H2AX et H2A, et (ii) à 
l’augmentation de la réparation des Top1cc en favorisant la protéolyse de la Top1. Enfin, nous montrons que 
les DSBs co-transcriptionnelles induisent la mort des cellules quiescentes. L’ensemble de ces résultats  
apportent un nouvel aperçu des réponses cellulaires aux camptothécines, et suggèrent que les DSBs qui 
résultent des Top1cc bloquant la transcription puissent contribuer à la pathogénèse du syndrome 
neurodégénératif SCAN1, qui est causé par une déficience en Tdp1.  
 
 
Keywords: Topoisomerase, double-strand breaks, DNA-PK, ubiquitin, camptothecin, transcription, Tdp1, 
DNA damage 
 
